var images_info;if (!images_info) images_info =[]; images_info["51"]={"51000":{"type":"graphic_table","displayName":"Darrows solution","title":"Darrow's solution (full strength) for intravenous rehydration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Darrow's solution (full strength) for intravenous rehydration</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Injection solution (full strength)*<sup>&#182;</sup></td> </tr> <tr> <td>Potassium 35 mmol/L (35 mEq)</td> </tr> <tr> <td>Sodium 121 mmol/L (121 mEq)</td> </tr> <tr> <td>Chloride 103 mmol/L (103 mEq)</td> </tr> <tr> <td>Lactate 53 mmol/L (53 mEq)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">When intravenous rehydration is indicated for children with severe malnutrition, Darrow's solution is administered at half-strength by diluting with an equal amount of 5 percent dextrose water (see \"Severe malnutrition in children in developing countries: Treatment\").</div><div class=\"graphic_footnotes\">* The osmolarity of full-strength Darrow's solution is 312 mOsm/L.<br />&para; The composition of individual Darrow's solutions may vary slightly; check local product information for details.</div><div class=\"graphic_reference\">Data from: Darrow's solution (pharmacopeial). Martindale: The Complete Drug Reference [online]. Sweetman S (Ed). Pharmaceutical Press, London.</div><div id=\"graphicVersion\">Graphic 51000 Version 4.0</div></div></div>"},"51001":{"type":"graphic_diagnosticimage","displayName":"Multiseptated cervicothoracic hydrosyringomyelia","title":"Multiseptated cervicothoracic hydrosyringomyelia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Multiseptated cervicothoracic hydrosyringomyelia</div><div class=\"cntnt\"><img style=\"width:504px; height:504px;\" src=\"images/PEDS/51001_Multiseptated_hydrosyringom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiseptated hydrosyringomyelia spanning multiple cervicothoracic segments (asterisks) demonstrated on on T1 sagittal magnetic resonance imaging (MRI). The patient has Crouzon syndrome (craniofacial dysostosis type I).</div><div class=\"graphic_reference\">Courtesy of Chaouki El-Khoury, BS, MD.</div><div id=\"graphicVersion\">Graphic 51001 Version 6.0</div></div></div>"},"51003":{"type":"graphic_table","displayName":"Uses of pancreatic stents","title":"Settings in which pancreatic stents are being used","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Settings in which pancreatic stents are being used</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Pancreatic ductal strictures</td> </tr> <tr> <td class=\"sublist1\">Benign</td> </tr> <tr> <td class=\"sublist1\">Malignant</td> </tr> <tr> <td>Unextractable pancreatic ductal stones</td> </tr> <tr> <td class=\"sublist1_start\">Pancreatic pseudocysts and duct disruptions</td> </tr> <tr> <td class=\"sublist1\">Transpapillary</td> </tr> <tr> <td class=\"sublist1\">Transmural (duodenal/gastric)</td> </tr> <tr> <td class=\"sublist1_start\">Papillary stenosis</td> </tr> <tr> <td class=\"sublist1\">Minor (pancreas divisum)</td> </tr> <tr> <td class=\"sublist1\">Major</td> </tr> <tr> <td>Prevention of procedure-induced pancreatitis</td> </tr> <tr> <td class=\"sublist1_start\">Facilitating&nbsp;bile duct cannulation</td> </tr> <tr> <td class=\"sublist1_start\">Guide for sphincterotomy</td> </tr> <tr> <td class=\"sublist1\">Biliary</td> </tr> <tr> <td class=\"sublist1\">Pancreatic</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51003 Version 2.0</div></div></div>"},"51004":{"type":"graphic_picture","displayName":"Hookworm ovum in stool","title":"Hookworm ovum in stool","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hookworm ovum in stool</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/ID/51004_Hookworm_ovum_in_stool.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A wet mount of stool (x400) shows an ovum of hookworm. The eggs of the two species of hookworm, <EM>Necator americanus </EM>and <EM>Ancylostoma duodenale</EM>, are indistinguishable in wet mounts.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 51004 Version 2.0</div></div></div>"},"51005":{"type":"graphic_picture","displayName":"Tularemia eschar","title":"Tularemia eschar","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tularemia eschar</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/51005_Tularemia_eschar.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Todd M Pollack, MD.</div><div id=\"graphicVersion\">Graphic 51005 Version 2.0</div></div></div>"},"51006":{"type":"graphic_table","displayName":"Comparison PD solutions","title":"Comparison of different peritoneal dialysis solutions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of different peritoneal dialysis solutions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Dextrose</td> <td class=\"subtitle1\" rowspan=\"2\">Amino acid</td> <td class=\"subtitle1\" rowspan=\"2\">Icodextrin</td> </tr> <tr> <td class=\"subtitle2\">Low Ca++</td> <td class=\"subtitle2\">High Ca++</td> </tr> <tr> <td>Osmolality (mOsm/kg)</td> <td>346, 396, and 485</td> <td>346, 396, and 485</td> <td>365</td> <td>282</td> </tr> <tr> <td>Molecular weight (Dalton)</td> <td>182</td> <td>182</td> <td>100 to 200</td> <td>20,000</td> </tr> <tr> <td>Advantages</td> <td> <p>Well studied</p> <p>Most commonly used for a long time</p> <p>Side-effect profile well known to most of the nephrologists</p> <p>Allow the use of oral calcium-containing phosphate binders</p> </td> <td>Same as low-calcium solutions except it may help bringing up serum calcium in patients with low calcium levels</td> <td>Can improve nutritional status in malnourished diabetic and/or patients with recurrent peritonitis</td> <td> <p>Sustained ultrafiltration for many hours</p> <p>Decreased solute absorption</p> </td> </tr> <tr> <td>Disadvantages</td> <td> <p>Short-lived ultrafiltration</p> <p>Metabolic complications like hyperinsulinemia, hyperglycemia, hyperlipidemia, and weight gain</p> <p>Can lead to low serum calcium and bone disease</p> </td> <td>Same as low calcium except it can limit the use of calcium-containing oral phosphate binders</td> <td> <p>Expensive</p> <p>May increase nitrogen waste product in blood</p> <p>May cause/worsen acidosis</p> </td> <td>Increases serum levels of maltose, maltotriose, and oligopolysacharides</td> </tr> <tr> <td>Indications</td> <td> <p>Commonly used, first-line&nbsp;PD solution in all patients unless special circumstances exist</p> <p>High serum phosphorus and normal to high serum calcium</p> </td> <td>Used in patients who have low calcium levels with low calcium-containing dialysis solutions</td> <td> <p>Malnourished diabetic patients or</p> <p>Malnourished patients with recurrent peritonitis</p> </td> <td> <p>Patients who lose ultrafiltration</p> <p>In patients with automated PD situation during the dry day to achieve sustained UF and increased solute and fluid removal</p> <p>In diabetic patients</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PD: peritoneal dialysis; UF: ultrafiltration.</div><div class=\"graphic_reference\">Courtesy of Dinesh Chatoth, MD.</div><div id=\"graphicVersion\">Graphic 51006 Version 3.0</div></div></div>"},"51010":{"type":"graphic_figure","displayName":"Gene map fibrinogen","title":"Exon gene map of the human fibrinogen chains","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Exon gene map of the human fibrinogen chains</div><div class=\"cntnt\"><img style=\"width:479px; height:434px;\" src=\"images/HEME/51010_Gene_map_fibrinogen.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The reported mutations (or mutated initiation sites) are represented by triangles for patients with dysfibrinogenemias and by ovals for those with a- or hypo-fibrinogenemias. Scale for the total exon region and mutation localization is respected. Sites of important fibrinogen functions are identified.</div><div class=\"graphic_reference\">Reproduced with permission from: Hanss, M, Biot, F. A database for human fibrinogen variants. Ann NY Acad Sci 2001; 936:89. Copyright &#169; 2001 New York Academy of Sciences.</div><div id=\"graphicVersion\">Graphic 51010 Version 1.0</div></div></div>"},"51011":{"type":"graphic_table","displayName":"Egg content of vaccines","title":"Egg content of vaccines (subject to change - check package inserts)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Egg content of vaccines (subject to change - check package inserts)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Vaccine </td> <td class=\"subtitle1\">Grown in </td> <td class=\"subtitle1\">Egg protein content </td> <td class=\"subtitle1\">Approach in egg-allergic patient </td> </tr> <tr> <td>Measles and mumps</td> <td>Chick embryo fibroblast cell cultures</td> <td>Picograms to nanograms</td> <td>Administer in usual manner</td> </tr> <tr> <td>Purified chick embryo rabies</td> <td>Chick embryo fibroblast cell cultures</td> <td>Picograms to nanograms</td> <td>Administer in usual manner</td> </tr> <tr> <td>Influenza (killed injected and live attenuated nasal)</td> <td>Chick extra-embryonic allantoic fluid</td> <td>&#60;1 microgram</td> <td>*</td> </tr> <tr> <td>Yellow fever</td> <td>Chick embryos</td> <td>Micrograms</td> <td>Skin test with vaccine prior to administration</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Discussed in the&nbsp;UpToDate topic on&nbsp;influenza vaccination in individuals with egg allergy.</div><div id=\"graphicVersion\">Graphic 51011 Version 4.0</div></div></div>"},"51012":{"type":"graphic_table","displayName":"Romhilt Estes point score","title":"Romhilt-Estes point score system for ECG diagnosis of LVH","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Romhilt-Estes point score system for ECG diagnosis of LVH</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"85%\"></colgroup><colgroup width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Criterion</td> <td class=\"subtitle1\">Points</td> </tr> <tr> <td class=\"sublist1_start\">Any limb R wave or S wave &#8805;2.0 mV (20 mm)</td> <td class=\"centered divider_bottom\" rowspan=\"3\">3</td> </tr> <tr> <td class=\"sublist1\"><strong>OR</strong> S in V1 or S in V2 &#8805;3.0 mV (30 mm)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\"><strong>OR</strong> R in V5 or R in V6 &#8805;3.0 mV (30 mm)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">ST-T wave changes typical of LVH</td> </tr> <tr> <td class=\"sublist1\">Taking digitalis</td> <td class=\"sublist_other_centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">Not taking digitalis</td> <td class=\"sublist_other_centered\">3</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Left atrial abnormality</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">P terminal force in V1 is 1 mm or more in depth with a duration 40 ms (0.04 sec)</td> <td class=\"sublist_other_centered\">3</td> </tr> <tr class=\"divider_bottom\"> <td>Left axis deviation &#8805;&ndash;30&#176;</td> <td class=\"centered\">2</td> </tr> <tr class=\"divider_bottom\"> <td>QRS duration &#8805;90 ms</td> <td class=\"centered\">1</td> </tr> <tr> <td>Intrinsicoid deflection in V5 or V6 &#8805;50 ms (0.05 sec)*</td> <td class=\"centered\">1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A score of 5 or more indicates \"definite\" LVH; a score of 4 indicates \"probable\" LVH.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram; LVH: left ventricular hypertrophy.<br />* Intrinsicoid deflection is defined as interval between beginning of QRS interval and the peak of the R wave.</div><div id=\"graphicVersion\">Graphic 51012 Version 4.0</div></div></div>"},"51014":{"type":"graphic_figure","displayName":"Alendronate after PTH","title":"PTH (1-84) followed by placebo or alendronate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">PTH (1-84) followed by placebo or alendronate</div><div class=\"cntnt\"><img style=\"width:432px; height:302px;\" src=\"images/ENDO/51014_Alendronate_after_PTH_edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean changes (percent) in volumetric trabecular spine BMD as measured by QCT over 24 months of treatment in PTH placebo group (blue line with squares) and PTH followed by alendronate group (dashed red line with circles).</div><div class=\"graphic_footnotes\">PTH: parathyroid hormone; ALN: alendronate; PLB: placebo; BMD: bone mineral density; QCT: quantitative computed tomography.</div><div class=\"graphic_reference\">Data from: Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005; 353:555.</div><div id=\"graphicVersion\">Graphic 51014 Version 3.0</div></div></div>"},"51015":{"type":"graphic_algorithm","displayName":"Ampullary carcinoma algorithm","title":"Ampullary carcinoma algorithm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ampullary carcinoma algorithm</div><div class=\"cntnt\"><img style=\"width:382px; height:467px;\" src=\"images/GAST/51015_Ampullary_carcinoma_algorit.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51015 Version 1.0</div></div></div>"},"51018":{"type":"graphic_figure","displayName":"Male cystectomy PI","title":"Surgery to treat bladder cancer in men (cystectomy)","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Surgery to treat bladder cancer in men (cystectomy)</div><div class=\"cntnt\"><img style=\"width:464px; height:652px;\" src=\"images/PI/51018_Male_cystectomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Some people with bladder cancer must have surgery to remove the bladder and nearby organs. In men, the surgeon removes the bladder, the prostate gland, and the seminal vesicles (shown inside the dotted line). The prostate gland and the seminal vesicles each make some of the fluid that makes up semen.</div><div id=\"graphicVersion\">Graphic 51018 Version 3.0</div></div></div>"},"51020":{"type":"graphic_table","displayName":"Using powder inhalers PI I","title":"Technique for use of various dry powder inhalers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Technique for use of various dry powder inhalers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\"><span style=\"color: black;\">Diskhaler</span></td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Remove the mouthpiece cover and pull tray out from device. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Place disk on wheel with numbers facing up. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Rotate the disk by sliding tray out and in. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Lift the back of the lid until fully upright, so the needle pierces both sides of the&nbsp;blister. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Keep the device level while inhaling the dose with a rapid and steady flow. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Breathe in rapidly and steadily, as deeply as possible, then&nbsp;hold your breath. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Remove the device from your&nbsp;mouth and exhale outside the device. </span></li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Brush off any powder remaining within&nbsp;the device&nbsp;once every week. Store the&nbsp;device in a&nbsp;cool, dry place. </span></li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\"><span style=\"color: black;\">Diskus</span></td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Open the device and slide the lever until it clicks. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Keep the device level while inhaling the dose. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Breathe in rapidly and steadily, as deeply as possible, then&nbsp;hold your breath. </span></li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Remove the&nbsp;device from your mouth and exhale outside device. Store the device in a&nbsp;cool, dry place. </span></li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\"><span style=\"color: black;\">HandiHaler</span></td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Capsules should be stored in sealed blisters and only removed immediately before use. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Peel back the foil using the tab until one capsule is fully visible. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Open the dust cap by pulling it upwards, then open the mouthpiece. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Place the capsule in the center chamber. (It does not matter which end of the capsule is placed in the chamber.) </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Close the mouthpiece firmly until you hear a click, leaving the dust cap open. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Hold the HandiHaler with the mouthpiece upwards, then press the piercing button completely in 1 time and release. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Breathe out completely. Do not breathe into the mouthpiece at any time. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Close your lips tightly around the mouthpiece. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Breathe in rapidly and steadily, as deeply as possible, then&nbsp;hold your breath. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">To ensure you get the full dose, repeat the inhalation from the HandiHaler as described. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">After the dose, open the mouthpiece, tip out the used capsule, and throw it away. Do not handle used capsules. </span></li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Close the mouthpiece and dust cap for storage. Store the&nbsp;device in a&nbsp;cool, dry place. </span></li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\"><span style=\"color: black;\">Pressair/Genuair</span></td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Remove the cap by gently squeezing the arrows on each side of cap. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Hold the inhaler with the green button pointing up. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Before you put the inhaler in your mouth, press the&nbsp;green button all the way down 1 time and release it. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Look at the small window above the mouthpiece to see if the color changed from red to green. If it is still red, press and release green button again. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Breathe out completely. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Close your lips tightly around the mouthpiece. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Breathe in rapidly and as deeply as possible. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">You will hear a click. This means you are inhaling correctly. Do not stop breathing until your lungs are full. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Remove the&nbsp;inhaler from your mouth, and hold your breath for as long as is comfortable. </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">The window above the mouthpiece should now be red. (If window is still green, you might not have inhaled correctly or might have forgotten to release the green button. Close your lips tightly around the mouthpiece and take another rapid, deep breath. Now the window should be red.) </span></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"color: black;\">Once the window has turned red, replace the cap. </span></li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51020 Version 6.0</div></div></div>"},"51021":{"type":"graphic_figure","displayName":"Faces pain scale children","title":"Wong-Baker FACES pain rating scale","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Wong-Baker FACES pain rating scale</div><div class=\"cntnt\"><img style=\"width:479px; height:163px;\" src=\"images/PEDS/51021_Faces_pain_scale_children.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Explain to the child that each face is for a person who feels happy because he has no pain (hurt) or sad because he has some or a lot of pain. Face 0 is very happy because he doesn't hurt at all. Face 1 hurts just a little bit. Face 2 hurts a little more. Face 3 hurts even more. Face 4 hurts a whole lot. Face 5 hurts as much as you can imagine, although you don't have to be crying to feel this bad. Ask the child to choose the face that best describes how he is feeling. Rating scale is recommended for persons age three years and older. Point to each face using the words to describe the pain intensity. Ask the child to choose the face that best describes own pain and record the appropriate number.</div><div class=\"graphic_reference\">Reproduced with permission from: Wong DL, Hockenberry-Eaton M, Wilson D, et al. Wong's Essentials of Pediatric Nursing, 6th ed. Mosby, St. Louis, 2001. p.301. Copyright &#169; 2001 Elsevier.</div><div id=\"graphicVersion\">Graphic 51021 Version 4.0</div></div></div>"},"51022":{"type":"graphic_picture","displayName":"Poststrep GN high power","title":"Poststrep GN high power","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Poststrep GN high power</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/PEDS/51022_Poststrep_GN_high_power.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute postinfectious glomerulonephritis. The glomeruli show global intracapillary hypercellularity with large numbers of polymorphonuclear leukocytes in the glomerular capillary lumina (hematoxylin and eosin stain, x400). (Courtesy of Peter Degrell, University of P&eacute;cs Faculty of Medicine, Nephrological Center, P&eacute;cs, Hungary.)</div><div class=\"graphic_reference\">Reproduced with permission from: Knoers NV, Monnens LA. Nephrogenic diabetes insipidus. In: Pediatric Nephrology, 5th ed, Avner ED, Harmon WE, Niaudet P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Nine V.A.M. Knoers.</div><div id=\"graphicVersion\">Graphic 51022 Version 3.0</div></div></div>"},"51023":{"type":"graphic_figure","displayName":"Patch test control diagram","title":"Patch test control diagram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patch test control diagram</div><div class=\"cntnt\"><img style=\"width:373px; height:394px;\" src=\"images/ID/51023_Patch_test_control_diagram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Petrolatum and Excipient control.</div><div class=\"graphic_reference\">Courtesy of Dr. Elizabeth J Phillips.</div><div id=\"graphicVersion\">Graphic 51023 Version 1.0</div></div></div>"},"51024":{"type":"graphic_table","displayName":"Causes LV outflow obstruction","title":"Distinguishing characteristics of the causes of left ventricular outflow tract obstruction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinguishing characteristics of the causes of left ventricular outflow tract obstruction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Valvular</td> <td class=\"subtitle1\">Supravalvular</td> <td class=\"subtitle1\">Discrete subvalvular</td> <td class=\"subtitle1\">Obstructive hypertrophic cardiomyopathy</td> </tr> <tr> <td><strong>Pulse pressure after ventricular premature beat</strong></td> <td>Increased</td> <td>Increased</td> <td>Increased</td> <td>Decreased</td> </tr> <tr> <td><strong>Valsalva effect on systolic murmur</strong></td> <td>Decreased</td> <td>Decreased</td> <td>Decreased</td> <td>Increased</td> </tr> <tr> <td><strong>Murmur of aortic regurgitation</strong></td> <td>Common after age 40</td> <td>Rare</td> <td>Sometimes</td> <td>No</td> </tr> <tr> <td><strong>Fourth heart sound (S4)</strong></td> <td>If severe</td> <td>Uncommon</td> <td>Uncommon</td> <td>Common</td> </tr> <tr> <td><strong>Paradoxic splitting</strong></td> <td>Sometimes*</td> <td>No</td> <td>No</td> <td>Common*</td> </tr> <tr> <td><strong>Ejection click</strong></td> <td>Most (unless valve calcified)</td> <td>No</td> <td>No</td> <td>Uncommon or none</td> </tr> <tr> <td><strong>Maximal thrill and murmur</strong></td> <td>Second RIS</td> <td> <p>First RIS</p> Suprasternal notch</td> <td>Second RIS</td> <td>Fourth LIS</td> </tr> <tr> <td><strong>Carotid pulse</strong></td> <td>Normal to anacrotic* (parvus et tardus)</td> <td>Unequal</td> <td>Normal to anacrotic</td> <td>Brisk, jerky, systolic rebound</td> </tr> <tr> <td><strong>Valve calcification</strong></td> <td>Common after age 40</td> <td>No</td> <td>No</td> <td>No</td> </tr> <tr> <td><strong>Dilated ascending aorta</strong></td> <td>Common after age 40</td> <td>Rare</td> <td>Rare</td> <td>Rare</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LIS: left intercostal space; RIS: right intercostal space.<br />* Depends upon severity.</div><div class=\"graphic_reference\">Adapted from: Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.</div><div id=\"graphicVersion\">Graphic 51024 Version 4.0</div></div></div>"},"51026":{"type":"graphic_table","displayName":"Miscellaneous cutaneous tox chemotherapy","title":"Miscellaneous cutaneous reactions associated with chemotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Miscellaneous cutaneous reactions associated with chemotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition </td> <td class=\"subtitle1\">Drugs </td> </tr> <tr> <td>Blistering disorder characterized as a paraneoplastic pemphigus-like phenomenon</td> <td>Fludarabine</td> </tr> <tr> <td>Raynaud's phenomenon</td> <td>Bleomycin, vinblastine, vincristine, BEP, PVB, MOPP, ABVD</td> </tr> <tr> <td>Dermatomyositis-like reaction</td> <td>Hydroxyurea (chronic), tamoxifen, tegafur</td> </tr> <tr> <td>Folliculitis</td> <td>Dactinomycin, fluorouracil, methotrexate</td> </tr> <tr> <td>Porphyria</td> <td>Busulfan, chlorambucil, cisplatin, cyclophosphamide, methotrexate</td> </tr> <tr> <td>Telangiectasia</td> <td>Carmustine (topical), hydroxyurea</td> </tr> <tr> <td>Lichenoid eruption</td> <td>Hydroxyurea, tegafur</td> </tr> <tr> <td>Inflammation of benign lesions</td> <td>Cisplatin, dacarbazine, dactinomycin, doxorubicin, fluorouracil, vincristine, capecitabine</td> </tr> <tr> <td>Reactivation of varicella-zoster infection</td> <td>Bortezomib</td> </tr> <tr> <td>Eosinophilic cellulitis</td> <td>Cladribine</td> </tr> <tr> <td>Histiocytic dermatosis</td> <td>Cytarabine, methotrexate</td> </tr> <tr> <td>Leg ulcers</td> <td>Hydroxyurea</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BEP: bleomycin, etoposide, cisplatin; PVB: cisplatin, vinblastine, bleomycin; MOPP: mechlorethamine, vincristine, procarbazine, prednisone; ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine.</div><div class=\"graphic_reference\">Modified from:<br /><OL>&#xD;&#xA;<LI>Susser WS, Whitaker-Worth DL, Grant-Kels JM, et al. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40:367.</LI>&#xD;&#xA;<LI>Rossini MS, de Souza EM, Cintra ML, et al. Cutaneous adverse reaction to 2-chlorodeoxyadenosine with histological flame figures in patients with chronic lymphocytic leukaemia. Journal of the European Academy of Dermatology &amp; Venereology 2004; 18:538.</LI>&#xD;&#xA;<LI>Boyd AS. Histiocyte-rich dermatoses in two patients with acute lymphocytic leukaemia treated with cytarabine. Histopathology 2004; 45:194.</LI></OL></div><div id=\"graphicVersion\">Graphic 51026 Version 4.0</div></div></div>"},"51027":{"type":"graphic_algorithm","displayName":"Glutaric aciduria type 1","title":"Metabolic defect in glutaric aciduria type 1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metabolic defect in glutaric aciduria type 1</div><div class=\"cntnt\"><img style=\"width:207px; height:313px;\" src=\"images/PEDS/51027_Glutaric_aciduria_type_1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GA1: glutaric aciduria type 1.</div><div id=\"graphicVersion\">Graphic 51027 Version 2.0</div></div></div>"},"51028":{"type":"graphic_figure","displayName":"Normal primary tooth eruption","title":"Age and variability of normal primary tooth eruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Age and variability of normal primary tooth eruption</div><div class=\"cntnt\"><img style=\"width:424px; height:274px;\" src=\"images/PEDS/51028_Norm_prim_tooth_eruptn_ed1.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Wright JT. Normal formation and development defects of the human dentition. Pediatr Clin North Am 2000; 47:975. Copyright © 2000 WB Saunders.</div><div id=\"graphicVersion\">Graphic 51028 Version 6.0</div></div></div>"},"51029":{"type":"graphic_diagnosticimage","displayName":"Indeterminate thyroid nodule scan II","title":"Indeterminate thyroid scan: Appearance on thyroid scintigraphy","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Indeterminate thyroid scan: Appearance on thyroid scintigraphy</div><div class=\"cntnt\"><img style=\"width:712px; height:563px;\" src=\"images/ENDO/51029_IndtrmthrdndlscnII.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">123-I thyroid scan obtained to assess a palpable left thyroid nodule. The function of the nodule could not be determined.</div><div class=\"graphic_footnotes\">SSN: suprasternal notch; 123-I: iodine-123.</div><div class=\"graphic_reference\">Courtesy of Douglas Ross, MD.</div><div id=\"graphicVersion\">Graphic 51029 Version 5.0</div></div></div>"},"51030":{"type":"graphic_table","displayName":"VIT schedule 1","title":"Typical conventional dosing schedule for venom immunotherapy: Schedule 1","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical conventional dosing schedule for venom immunotherapy: Schedule 1</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Week</td> <td class=\"subtitle1\">Concentration, micrograms/mL</td> <td class=\"subtitle1\">Volume, mL</td> </tr> <tr> <td>1</td> <td>1</td> <td>0.05</td> </tr> <tr> <td>2</td> <td>1</td> <td>0.1</td> </tr> <tr> <td>3</td> <td>1</td> <td>0.2</td> </tr> <tr> <td>4</td> <td>1</td> <td>0.4</td> </tr> <tr> <td>5</td> <td>10</td> <td>0.05</td> </tr> <tr> <td>6</td> <td>10</td> <td>0.1</td> </tr> <tr> <td>7</td> <td>10</td> <td>0.2</td> </tr> <tr> <td>8</td> <td>10</td> <td>0.4</td> </tr> <tr> <td>9</td> <td>100</td> <td>0.05</td> </tr> <tr> <td>10</td> <td>100</td> <td>0.1</td> </tr> <tr> <td>11</td> <td>100</td> <td>0.2</td> </tr> <tr> <td>12</td> <td>100</td> <td>0.4</td> </tr> <tr> <td>13</td> <td>100</td> <td>0.6</td> </tr> <tr> <td>14</td> <td>100</td> <td>0.8</td> </tr> <tr> <td>15</td> <td>100</td> <td>1</td> </tr> <tr> <td>16</td> <td>100</td> <td>1</td> </tr> <tr> <td>18</td> <td>100</td> <td>1</td> </tr> <tr> <td>21</td> <td>100</td> <td>1</td> </tr> <tr> <td>Monthly</td> <td>100</td> <td>1</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">1</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=1528&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">Injections are generally given weekly. The maintenance dose is achieved in most patients at week 15, after which the interval between injections is extended from weekly to every two weeks and then to monthly. This schedule is based upon the package insert for Hollister-Stier venom extracts (Spokane, WA).</div><div class=\"graphic_reference\">Original figure modified for this publication. Reproduced with permission from: Golden DBK. Insect Allergy. In: Middleton's Allergy: Principles &amp; Practice, 7th ed, Adkinson NF Jr, Bochner BS, Busse WW, et al (Eds), Mosby Elsevier, Philadelphia 2009. Illustrations used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 51030 Version 6.0</div></div></div>"},"51032":{"type":"graphic_table","displayName":"Acute porphyrias features","title":"Comparison of the major features of the four acute porphyrias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of the major features of the four acute porphyrias</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Deficient enzyme<br /> (step in heme synthesis)</td> <td class=\"subtitle1\">Inheritance</td> <td class=\"subtitle1\">Neurovisceral manifestations</td> <td class=\"subtitle1\">Blistering skin lesions</td> </tr> <tr> <td><strong>ALA dehydratase porphyria (ADP)</strong></td> <td>ALA dehydratase (2)</td> <td>Autosomal recessive</td> <td>Yes</td> <td>No</td> </tr> <tr> <td><strong>Acute intermittent porphyria (AIP)</strong></td> <td>PBG deaminase (3)</td> <td>Autosomal dominant, variable penetrance</td> <td>Yes</td> <td>No*</td> </tr> <tr> <td><strong>Hereditary coproporphyria (HCP)</strong></td> <td>Coproporphyrinogen oxidase (6)</td> <td>Autosomal dominant</td> <td>Yes</td> <td>Uncommon</td> </tr> <tr> <td><strong>Variegate porphyria (VP)</strong></td> <td>Protoporphyrinogen oxidase (7)</td> <td>Autosomal dominant</td> <td>Yes</td> <td>Common</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALA: 5-aminolevulinic acid (delta-aminolevulinic acid); PBG: porphobilinogen.<br />* A rare exception is patients with advanced renal failure, who may develop elevations in plasma porphyrins that produce blistering skin lesions.</div><div id=\"graphicVersion\">Graphic 51032 Version 5.0</div></div></div>"},"51033":{"type":"graphic_table","displayName":"CHD likelihood with chest pain","title":"Likelihood of acute coronary syndrome secondary to coronary heart disease in patients without ST-segment elevation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Likelihood of acute coronary syndrome secondary to coronary heart disease in patients without ST-segment elevation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">High likelihood</td> </tr> <tr> <td class=\"sublist1_start\">Any of the following features:</td> </tr> <tr> <td class=\"sublist1\">Primary symptom is pain or discomfort in chest or left arm <strong>AND</strong> current pain is similar to pain of prior documented angina/MI</td> </tr> <tr> <td class=\"sublist1\">Patient has known CHD <strong>OR</strong> MI</td> </tr> <tr> <td class=\"sublist1\">Transient mitral regurgitation <strong>OR</strong> hypotension <strong>OR</strong> diaphoresis <strong>OR</strong> pulmonary edema <strong>OR</strong> rales</td> </tr> <tr> <td class=\"sublist1\">New (or presumably new) transient ST deviation (&#8805;1 mm)</td> </tr> <tr> <td class=\"sublist1\">New T-wave inversion in multiple precordial leads</td> </tr> <tr> <td class=\"sublist1\">Elevated cardiac troponin </td> </tr> <tr> <td class=\"subtitle1_single\">Intermediate likelihood</td> </tr> <tr> <td class=\"sublist1_start\">Absence of high-likelihood features, a normal cardiac troponin,&nbsp;and presence of any of the following:</td> </tr> <tr> <td class=\"sublist1\">Primary symptom is pain or discomfort in chest or left arm</td> </tr> <tr> <td class=\"sublist1\">Older than 70 years of age</td> </tr> <tr> <td class=\"sublist1\">Male</td> </tr> <tr> <td class=\"sublist1\">Diabetes mellitus</td> </tr> <tr> <td class=\"sublist1\">Extracardiac vascular disease</td> </tr> <tr> <td class=\"sublist1\">Fixed Q waves</td> </tr> <tr> <td class=\"sublist1\">ST depression 0.5 to 1 mm or T-wave inversion &#62;1 mm</td> </tr> <tr> <td class=\"subtitle1_single\">Low likelihood</td> </tr> <tr> <td class=\"sublist1_start\">Absence of high- or intermediate-likelihood features and a normal cardiac troponin. May have any of the following and still be low likelihood:</td> </tr> <tr> <td class=\"sublist1\">History of symptoms that are probably ischemic</td> </tr> <tr> <td class=\"sublist1\">Recent use of cocaine</td> </tr> <tr> <td class=\"sublist1\">T-wave flattening or inversion &#60;1 mm</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note: T-wave inversion refers to a T-wave with opposite polarity to the dominant QRS in that lead.</div><div class=\"graphic_footnotes\">MI: myocardial infarction; CHD: coronary heart disease; CK-MB: creatine kinase MB fraction.</div><div class=\"graphic_reference\">Adapted from: Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation).</div><div id=\"graphicVersion\">Graphic 51033 Version 6.0</div></div></div>"},"51035":{"type":"graphic_diagnosticimage","displayName":"Paclitaxel pneumonitis","title":"CT appearance of paclitaxel pulmonary toxicity","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">CT appearance of paclitaxel pulmonary toxicity</div><div class=\"cntnt\"><img style=\"width:504px; height:252px;\" src=\"images/PULM/51035_Paclitaxel_pneumonitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two views of a CT scan from a female patient receiving adjuvant chemotherapy for breast cancer. She had received four cycles of doxorubicin and cyclophosphamide and had just completed her first dose of paclitaxel 10 days before this scan. She presented with dry cough, dyspnea, and malaise. Bronchoscopic/BAL cultures were negative, and radiographic opacities resolved with glucocorticoid therapy.</div><div class=\"graphic_footnotes\">CT: computed tomography; BAL: bronchoalveolar lavage.</div><div class=\"graphic_reference\">Courtesy of James R Jett, MD.</div><div id=\"graphicVersion\">Graphic 51035 Version 5.0</div></div></div>"},"51036":{"type":"graphic_figure","displayName":"Sagittal view of the layers of the abdominal wall","title":"Sagittal view of the layers of the abdominal wall","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Sagittal view of the layers of the abdominal wall</div><div class=\"cntnt\"><img style=\"width:593px; height:554px;\" src=\"images/SURG/51036_Layersabdwallsaggview.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Snell RS. The Abdomen: Part I - The Abdominal Wall. In: Clinical Anatomy by Regions, 8th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 51036 Version 12.0</div></div></div>"},"51037":{"type":"graphic_picture","displayName":"Erythema multiforme atypical","title":"Atypical target lesions in erythema multiforme","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atypical target lesions in erythema multiforme</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/51037_Erythema_multiforme_atypica.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A larger lesion is surrounded by multiple, oval atypical target lesions of erythema multiforme. Note the presence of only two zones of color change.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51037 Version 6.0</div></div></div>"},"51038":{"type":"graphic_figure","displayName":"Functional anatomy of the finger","title":"Functional anatomy of the finger","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Functional anatomy of the finger</div><div class=\"cntnt\"><img style=\"width:591px; height:750px;\" src=\"images/EM/51038_Finger_functl_anat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dorsal \"hood\" and extensor expansion of the third digit. Lateral (A) and posterior (B) views of the dorsal \"hood\" and extensor expansion. Observe the interosseous muscles inserted in part into the base of the proximal phalanx and in part into the extensor expansion and the lumbrical muscle, which inserts into the radial side of the extensor expansion. (C-D) Lateral views of the extensor expansion in extension. The extensor expansion is a delicate fibrous band that runs from the proximal phalanx and fibrous digital sheath obliquely across the middle phalanx and two interphalangeal joints to join the dorsal \"hood\" to the distal phalanx. (E) Lateral view of the finger in flexion. On flexing the distal interphalangeal joint (C), the extensor expansion (particularly its lateral bands) becomes taut, pulling the proximal joint into flexion (E). Similarly, on flexing the metacarpophalangeal joint, the proximal and distal joints are pulled by the extensor expansions (lateral bands) into nearly complete extension.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, PhD, FRSM, FIAC &amp; Dalley AF II, PhD. Clinical Oriented Anatomy (4th ed). Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright © 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51038 Version 3.0</div></div></div>"},"51041":{"type":"graphic_figure","displayName":"ACST any stroke death","title":"Any type of stroke or perioperative death in the Asymptomatic Carotid Surgery Trial","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Any type of stroke or perioperative death in the Asymptomatic Carotid Surgery Trial</div><div class=\"cntnt\"><img style=\"width:447px; height:271px;\" src=\"images/NEURO/51041_ACST_any_stroke_death_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Risk of any stroke and perioperative death in ACST. The net five-year risk for all strokes or perioperative death in the CEA group was reduced by nearly half compared with the CEA deferral group.</div><div class=\"graphic_footnotes\">ACST: Asymptomatic Carotid Surgery Trial; CEA: carotid endarterectomy.</div><div class=\"graphic_reference\">Reproduced with permission from: MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004; 363:1491. Copyright &copy; 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 51041 Version 7.0</div></div></div>"},"51044":{"type":"graphic_table","displayName":"Nutrition risk chronic disease","title":"Nutritional risk factors associated with selected childhood conditions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nutritional risk factors associated with selected childhood conditions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Weight</td> <td class=\"subtitle1\">Height</td> <td class=\"subtitle1\">Energy needs</td> <td class=\"subtitle1\">Feeding problems</td> <td class=\"subtitle1\">Chronic medications</td> </tr> <tr> <td>Autism</td> <td>decreased</td> <td>-</td> <td>-</td> <td>*</td> <td>*</td> </tr> <tr> <td>Chronic lung disease</td> <td>decreased</td> <td>-</td> <td>increased</td> <td>-</td> <td>*</td> </tr> <tr> <td>Cerebral palsy</td> <td>increased or decreased</td> <td>decreased</td> <td>increased or decreased</td> <td>*</td> <td>*</td> </tr> <tr> <td>Cystic fibrosis</td> <td>decreased</td> <td>decreased</td> <td>increased</td> <td>-</td> <td>*</td> </tr> <tr> <td>Down syndrome</td> <td>increased</td> <td>decreased</td> <td>decreased</td> <td>*</td> <td>*</td> </tr> <tr> <td>Fetal alcohol syndrome</td> <td>decreased</td> <td>decreased</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Congenital heart disease</td> <td>decreased</td> <td>decreased</td> <td>increased</td> <td>*</td> <td>*</td> </tr> <tr> <td>HIV/AIDS</td> <td>decreased</td> <td>-</td> <td>increased</td> <td>-</td> <td>*</td> </tr> <tr> <td>Prader-Willi syndrome</td> <td>increased</td> <td>decreased</td> <td>decreased</td> <td>-</td> <td>-</td> </tr> <tr> <td>Prematurity</td> <td>decreased</td> <td>decreased</td> <td>increased</td> <td>*</td> <td>*</td> </tr> <tr> <td>Seizure disorder</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>*</td> </tr> <tr> <td>Spina bifida</td> <td>increased or decreased</td> <td>decreased</td> <td>decreased</td> <td>-</td> <td>*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* May be present.</div><div class=\"graphic_reference\">Adapted from: Baer MT, Harris A. Pediatric nutrition assessment: identifying children at risk. J Am Diet Assoc 1997; 97 (10 Suppl 2):S107.</div><div id=\"graphicVersion\">Graphic 51044 Version 5.0</div></div></div>"},"51045":{"type":"graphic_figure","displayName":"Ileocolic anastomosis - Transverse enterostomies","title":"Ileocolic anastomosis - Transverse enterostomies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ileocolic anastomosis - Transverse enterostomies</div><div class=\"cntnt\"><img style=\"width:377px; height:370px;\" src=\"images/SURG/51045_Ileocolic-anast-transverse-enterostomies.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51045 Version 1.0</div></div></div>"},"51046":{"type":"graphic_figure","displayName":"Posterior compartment forearm muscles  ","title":"Muscles of the posterior compartment of the forearm","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Muscles of the posterior compartment of the forearm</div><div class=\"cntnt\"><img style=\"width:558px; height:678px;\" src=\"images/EM/51046_Forearmmusclespostpict.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The diagrams above show the location of the muscles of the forearm's posterior compartment. Red represents a muscle's origin and blue a muscle's insertion.</div><div class=\"graphic_footnotes\">* Outcropping muscles of deep layer.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 51046 Version 12.0</div></div></div>"},"51047":{"type":"graphic_figure","displayName":"Insulin receptor subunits","title":"Structure of the insulin receptor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Structure of the insulin receptor</div><div class=\"cntnt\"><img style=\"width:392px; height:306px;\" src=\"images/ENDO/51047_Insulin_receptor_subunits.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the structure of the insulin receptor showing both the insulin binding and tyrosine kinase domains. See text for details of the function of each of these sites.</div><div id=\"graphicVersion\">Graphic 51047 Version 1.0</div></div></div>"},"51050":{"type":"graphic_picture","displayName":"H pylori in gastric pits","title":"Helicobacter pylori in gastric pits","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Helicobacter pylori in gastric pits</div><div class=\"cntnt\"><img style=\"width:269px; height:281px;\" src=\"images/GAST/51050_H_pylori_in_gastric_pits.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dieterle's silver strain (x200).</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy III, MD.</div><div id=\"graphicVersion\">Graphic 51050 Version 1.0</div></div></div>"},"51055":{"type":"graphic_diagnosticimage","displayName":"Fused umbilical arteries","title":"Fused umbilical arteries","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Fused umbilical arteries</div><div class=\"cntnt\"><img style=\"width:528px; height:577px;\" src=\"images/OBGYN/51055_US_fused_umbil_arteries.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panels A, B, and C) Fused umbilical arteries.<br> (Panel A) Simultaneous view of an umbilical cord with a fused umbilical artery. The segment closest to the placenta shows a two-vessel cord, while the segment closest to the fetus shows the normal three-vessel cord.<br> (Panel B) Dual view of the umbilical cord in a fetus with fused umbilical arteries shows a segment with three vessels (left) and two vessels (right). At delivery, the exact site at which the arteries fused is shown. The Wharton's jelly was removed after fixation with formalin.<br> (Panels D and E) Dual view of the umbilical cord from a fetus with fused umbilical cord. The umbilical cord has two vessels. However, the normal two intra-abdominal arteries are depicted with Color Doppler ultrasound.</div><div class=\"graphic_footnotes\">A: umbilical artery; V: umbilical vein.</div><div class=\"graphic_reference\">Panels A, B, and C reproduced with permission from: Sepulveda W, Dezerega V, Carstens E, Gutierrez J. Fused umbilical arteries. Prenatal sonographic diagnosis and clinical significance. J Ultrasound Med 2001; 20:59. Copyright &#169; 2001 American Institute of Ultrasound in Medicine.<br></div><div id=\"graphicVersion\">Graphic 51055 Version 3.0</div></div></div>"},"51056":{"type":"graphic_diagnosticimage","displayName":"T2-weighted MRI Canavan disease","title":"T2-weighted MRI, Canavan disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">T2-weighted MRI, Canavan disease</div><div class=\"cntnt\"><img style=\"width:400px; height:345px;\" src=\"images/NEURO/51056_MRI_Canavan_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spongy degeneration of cerebral white matter (Canavan disease). Magnetic resonance imaging study. T2-weighted axial views show a marked increase in signal in the white matter that is most evident in the posterior portions of the hemispheres.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Dr. Franklin G Moser, Division of Neuroradiology, Cedars-Sinai Medical Center, Los Angeles, CA. Reproduced from: Menkes JH. Heredodegenerative Diseases. In: Child Neurology, 6th Edition, Menkes JH, Sarnat HB, Maria BL (Eds), Philadelphia, Lippincott Williams &amp; Wilkins, 2006.</div><div id=\"graphicVersion\">Graphic 51056 Version 3.0</div></div></div>"},"51058":{"type":"graphic_picture","displayName":"Diphtheritic membrane","title":"Diphtheritic membrane","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diphtheritic membrane</div><div class=\"cntnt\"><img style=\"width:333px; height:330px;\" src=\"images/ID/51058_Diphtheritic_membrane.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diphtheritic membrane extending from uvula to pharyngeal wall and neck edema in 47-year-old female patient.</div><div class=\"graphic_reference\">Reproduced with permission from: Kadirova R, Kartoglu HU, Strebel PM. Clinical characteristics and management of 676 hospitalized diphtheria cases, Kyrgyz Republic, 1995. J Infect Dis 2000; 181:S110. Copyright © 2000 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 51058 Version 3.0</div></div></div>"},"51062":{"type":"graphic_waveform","displayName":"CW doppler of MR V wave cut","title":"Continuous wave Doppler of the mitral regurgitation jet demonstrating the 'V-wave cutoff' configuration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Continuous wave Doppler of the mitral regurgitation jet demonstrating the 'V-wave cutoff' configuration</div><div class=\"cntnt\"><img style=\"width:432px; height:425px;\" src=\"images/CARD/51062_CW_doppler_of_MR_V_wave_cut.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This configuration is characterized by an abrupt deceleration from peak velocity and reflects the abrupt drop in gradient between ventricle and atrium resulting from regurgitant V-wave.</div><div class=\"graphic_reference\">Courtesy of Xiushui Ren, MD</div><div id=\"graphicVersion\">Graphic 51062 Version 2.0</div></div></div>"},"51063":{"type":"graphic_diagnosticimage","displayName":"Trapezoid edema T1 MRI","title":"Trapezoid edema on T1 MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trapezoid edema on T1 MRI</div><div class=\"cntnt\"><img style=\"width:324px; height:215px;\" src=\"images/EM/51063_Trapezoid_edema_MRI_T1_axia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This T1-weighted, axial magnetic resonance image of the wrist shows decreased signal intensity throughout the trapezoid, when compared to the strength of the signal from the trapezium (Tm), capitate (C), and hamate (H) bones. This suggests the presence of edema consistent with microtrabecular injury. The trapezoid is the dark-appearing bone between the trapezium and capitate.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 51063 Version 5.0</div></div></div>"},"51065":{"type":"graphic_table","displayName":"TR isoform-specific actions","title":"TR isoform-specific actions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">TR isoform-specific actions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Thyroid hormone target</td> <td class=\"subtitle1\">Mediating receptor</td> </tr> <tr> <td>TSH suppression</td> <td>TR-beta-2</td> </tr> <tr> <td>Bone development</td> <td>TR-alpha</td> </tr> <tr> <td>Neural differentiation</td> <td>TR-alpha</td> </tr> <tr> <td>Cochlear and cone development</td> <td>TR-beta/TR-beta-2</td> </tr> <tr> <td>Cardiac gene expression and heart rate</td> <td>TR-alpha&#62;TR-beta</td> </tr> <tr> <td>Hepatic gene expression</td> <td>TR-beta&#62;TR-alpha</td> </tr> <tr> <td>Catecholamine potentiation</td> <td>TR-alpha</td> </tr> <tr> <td>UCP1 stimulation</td> <td>TR-beta</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TR: thyroid hormone receptor; TSH: thyroid-stimulating hormone; UCP1: uncoupling protein 1.</div><div id=\"graphicVersion\">Graphic 51065 Version 2.0</div></div></div>"},"51066":{"type":"graphic_picture","displayName":"Contact dermatitis allergic 1","title":"Acute allergic contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute allergic contact dermatitis</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/51066_Contactdermatitisaller1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Discrete and confluent, red, scaly, weepy, crusted papules and plaques. A 25-year-old woman consulted a dermatologist for an acute, eczematous dermatitis on her head, neck, and shoulders. The eruption appeared five days after she had black hair dye applied to her hair at the hairdresser. Patch tests were positive for paraphenylenediamine. Paraphenylenediamine is a dark dye used in almost all permanent hair dyes and some semipermanent hair coloring. It is a potent allergen&nbsp;that triggers severe acute contact dermatitis in sensitized individuals.</div><div class=\"graphic_reference\">Copyright © Eric Ehrsam, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 51066 Version 8.0</div></div></div>"},"51067":{"type":"graphic_figure","displayName":"Extended right colectomy for malignancy","title":"Extended right colectomy for malignancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extended right colectomy for malignancy</div><div class=\"cntnt\"><img style=\"width:426px; height:534px;\" src=\"images/SURG/51067_Extended_right_colectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the boundaries of an extended right hemicolectomy, which includes the resection of the distal transverse colon and sometimes the splenic flexure, and, for cancer, involves ligating the ileocolic, right colic, and middle colic vessels at their origin.</div><div id=\"graphicVersion\">Graphic 51067 Version 2.0</div></div></div>"},"51068":{"type":"graphic_figure","displayName":"Ant superior iliac spine","title":"Anterior superior iliac spine","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Anterior superior iliac spine</div><div class=\"cntnt\"><img style=\"width:476px; height:439px;\" src=\"images/HEME/51068_Ant_superior_iliac_spine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Artist's drawing of the pelvis (right anterior view), showing the position of the anterior superior iliac spine, a bony prominence easily felt in most patients at the anterior-most portion of the iliac crest (C). The bone marrow needle should be inserted in the position marked by the asterisk (*).</div><div id=\"graphicVersion\">Graphic 51068 Version 1.0</div></div></div>"},"51069":{"type":"graphic_diagnosticimage","displayName":"Absent nasal bone","title":"Absent nasal bone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Absent nasal bone</div><div class=\"cntnt\"><img style=\"width:432px; height:296px;\" src=\"images/OBGYN/51069_Absent_nasal_bone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Profile of a second trimester Down Syndrome fetus with absent nasal bone ossification.</div><div class=\"graphic_reference\">Courtesy of Beryl R Benacerraf, MD.</div><div id=\"graphicVersion\">Graphic 51069 Version 2.0</div></div></div>"},"51070":{"type":"graphic_figure","displayName":"Inflatable implant PI","title":"Inflatable implant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflatable implant</div><div class=\"cntnt\"><img style=\"width:231px; height:275px;\" src=\"images/PI/51070_Inflatable_implant_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With an inflatable implant, erection is produced by squeezing a small pump (a) implanted in the scrotum. The pump causes fluid to flow from a reservoir (b) residing in the lower pelvis to two cylinders (c) residing in the penis. The cylinders expand to create the erection.</div><div id=\"graphicVersion\">Graphic 51070 Version 1.0</div></div></div>"},"51071":{"type":"graphic_table","displayName":"Genetics and clinical features NPD","title":"Genetics and clinical features of Niemann-Pick disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetics and clinical features of Niemann-Pick disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">OMIM</td> <td class=\"subtitle1\">Gene (chromosome); all are autosomal recessive</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td rowspan=\"3\">Niemann-Pick disease type A</td> <td rowspan=\"3\">257200</td> <td rowspan=\"3\">SMPD1 (11p15.4-p15.1)</td> <td>Onset in first months of life; hepatosplenomegaly, interstitial lung disease, feeding difficulty, loss of early motor skills, rapidly progressive loss of neurologic function, peripheral neuropathy, macular cherry red spot.</td> </tr> <tr> <td>Death, typically from respiratory failure, occurs by age two or three years.</td> </tr> <tr> <td>Diagnosis confirmed when residual acid sphingomyelinase activity is &#60;10 percent of control.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Niemann-Pick disease type B</td> <td rowspan=\"3\">607616</td> <td rowspan=\"3\">SMPD1 (11p15.4-p15.1)</td> <td>Onset in infancy or childhood; hepatosplenomegaly, thrombocytopenia, short stature with delayed skeletal maturation, interstitial lung disease, hyperlipidemia, ocular abnormalities. Neurologic abnormalities (cerebellar signs, nystagmus, extrapyramidal involvement, mental retardation, psychiatric disorders, and peripheral neuropathy) occur in about 30 percent.</td> </tr> <tr> <td>Generally less severe than NPD-A, with most affected patients surviving into adulthood.</td> </tr> <tr> <td>Diagnosis confirmed when residual acid sphingomyelinase activity is &#60;10 percent of control.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Niemann-Pick disease type C</td> <td rowspan=\"6\"> <p>257220</p> 607625</td> <td rowspan=\"6\"> <p>NPC1 (18q11-q12)</p> NPC2 (14q24.3)</td> <td class=\"sublist1_start\">Wide phenotypic spectrum. Onset ranges from in utero to infancy, childhood, or adulthood.</td> </tr> <tr> <td class=\"sublist1\">&#8226; Antenatal cases present with fetal ascites.</td> </tr> <tr> <td class=\"sublist1\">&#8226; Neonatal onset occurs with severe hepatic disease and/or respiratory failure; other neonates have hypotonia and developmental delay with little or no hepatic and pulmonary involvement.</td> </tr> <tr> <td class=\"sublist1\">&#8226; Most cases have onset in middle to late childhood after normal early development. Neurologic manifestations are cerebellar involvement (clumsiness, gait problems, eventual frank ataxia), vertical supranuclear ophthalmoplegia, and slowly progressive cognitive deterioration. Dystonia, dysarthria, dysphagia and seizures are common. Death typically occurs from aspiration pneumonia in the second or third decade of life.</td> </tr> <tr> <td class=\"sublist1\">&#8226; Adult onset is usually similar to juvenile/childhood cases but with slower progression. Adult cases may also present with cognitive dysfunction or psychiatric disturbances.</td> </tr> <tr> <td>Diagnosis confirmed by impaired LDL cholesterol esterification and positive filipin staining in cultured skin fibroblasts.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51071 Version 3.0</div></div></div>"},"51073":{"type":"graphic_figure","displayName":"Patient satisfaction post LVRS","title":"Postoperative patient overall satisfaction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postoperative patient overall satisfaction</div><div class=\"cntnt\"><img style=\"width:448px; height:294px;\" src=\"images/PULM/51073_Patient_satisfaction_post_L.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Ciccone, AM, Meyers, BF, Guthrie, TJ, et al. Long-term outcome of bilateral lung volume reduction in 250 consecutive patients with emphysema. J Thor Card Surg 2003; 125:513.</div><div id=\"graphicVersion\">Graphic 51073 Version 1.0</div></div></div>"},"51074":{"type":"graphic_picture","displayName":"Dry tongue in SS","title":"Severe xerostomia with dry tongue and angular chelitis in Sjögren's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe xerostomia with dry tongue and angular chelitis in Sj&#246;gren's syndrome</div><div class=\"cntnt\"><img style=\"width:360px; height:252px;\" src=\"images/RHEUM/51074_Dry_tongue_in_SS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient with Sj&#246;gren's syndrome not only has a profoundly dry tongue, but there is also evidence of angular cheilitis at the corners of the mouth. Angular cheilitis is usually caused by candidiasis.</div><div class=\"graphic_reference\">Courtesy of Robert Fox, MD, PhD.</div><div id=\"graphicVersion\">Graphic 51074 Version 2.0</div></div></div>"},"51077":{"type":"graphic_figure","displayName":"Urinary concentrating mechanism","title":"Effect of arginine vasopressin on water permeability in the collecting duct","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Effect of arginine vasopressin on water permeability in the collecting duct</div><div class=\"cntnt\"><img style=\"width:596px; height:440px;\" src=\"images/NEPH/51077_Urinaryconcentmechanism.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Binding of arginine vasopressin (AVP) to the vasopressin V2 receptor in principal cells of the collecting ducts begins a succession of intracellular processes culminating in increased water permeability. These steps include the activation of adenylyl cyclase via the stimulation of G-alpha-s heterometric proteins, increased levels of cAMP, activation of protein kinase A, and the fusion of vesicles consisting of water channel proteins (AQP2) with the luminal membrane.</div><div class=\"graphic_reference\">Reproduced with permission from: Bichet DG. Nephrogenic and central diabetes insipidus. In: Schrier's Diseases of the Kidney, 9th ed, Coffman TM, Falk RJ, Molitoris BA, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 51077 Version 10.0</div></div></div>"},"51078":{"type":"graphic_diagnosticimage","displayName":"Retroperitoneal hematoma","title":"Retroperitoneal psoas hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retroperitoneal psoas hematoma</div><div class=\"cntnt\"><img style=\"width:380px; height:479px;\" src=\"images/NEURO/51078_Retroperitoneal_hematoma_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal magnetic resonance imaging short inversion time inversion recovery (MRI STIR) image of a left retroperitoneal psoas hematoma.</div><div class=\"graphic_reference\">Planner AC, Donaghy M, Moore NR. Causes of lumbrosacral plexopathy. Clin Radiol 2006; 61:987. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 51078 Version 4.0</div></div></div>"},"51079":{"type":"graphic_table","displayName":"Drugs that cause visual hallucinations","title":"Drugs and medications associated with visual hallucinations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs and medications associated with visual hallucinations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nonpsychotropic</td> <td class=\"subtitle1\">Psychotropic</td> <td class=\"subtitle1\">Drugs of abuse</td> <td class=\"subtitle1\">Over-the-counter</td> </tr> <tr> <td> <p>Digoxin</p> <p>Glucocorticoids</p> <p>Amantadine</p> <p>Cimetidine</p> <p>Ranitidine</p> <p>Sildenafil</p> <p>Beta blockers</p> <p>Clarithromycin</p> <p>Cyclosporine</p> <p>Clomiphene</p> <p>Angiotensin-converting enzyme inhibitors</p> <p>Linezolid</p> <p>Moxifloxacin</p> <p>&nbsp;</p> </td> <td> <p>Benzodiazepines</p> <p>L-dopa</p> <p>Dopaminergic (eg, bromocriptine, pergolide)</p> <p>Tricyclic antidepressants</p> <p>Benztropine</p> Narcotics</td> <td> <p>Alcohol</p> <p>d-lysergic acid diethylamide (LSD)</p> <p>Mescaline</p> <p><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Phencyclidine (</span>PCP)</p> <p>Cocaine</p> <p>Narcotics</p> <p>3,4 methylenedioxymethamphetamine (ecstasy)</p> <p>Amphetamine</p> <p>Psilocybin, psilocin (mushrooms)</p> <p>Cannabis</p> </td> <td> <p>Phenylpropanolamine</p> <p>Ephedrine</p> <p>Synthetic cannabinoids</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Liu GL, Volpe NJ, Galetta SL. Neuro-ophthalmology: Diagnosis and Management. WB Saunders Company, Philadelphia 2001. Copyright © 2001 Elsevier.<br /><br />Higdon E, Twilla JD, Sands C. Moxifloxacin-Induced Visual Hallucinations: A Case Report and Review of the Literature. J Pharm Pract 2017; 30:375. <br /><br />Palanippan P, Rajaraman V. Visual hallucinations: a treatment-emergent adverse effect of linezolid. J Neuropsychiatry Clin Neurosci 2015; 27:65. <br /><br />Padilla Peinado R, Esteban Fernández J, Rodríguez Álvarez S, et al. Visual hallucinations related to use of ertapenem. Neurologia 2015; 30:520. <br /><br />Doane J, Stults B. Visual hallucinations related to angiotensin-converting enzyme inhibitor use: case reports and review. J Clin Hypertens (Greenwich) 2013; 15:230. <br /><br />Goldner JA. Metoprolol-induced visual hallucinations: a case series. J Med Case Rep 2012; 15:6. <br /><br />Parkes LO, Cheng MP, Sheppard DC. Visual Hallucinations Associated with High Posaconazole Concentrations in Serum. Antimicrob Agents Chemother 2015; 7:60. <br /><br />Purvin VA. Visual disturbance secondary to clomiphene citrate. Arch Ophthalmol 1995; 113:482.<br /><br />https://www.drugabuse.gov/publications/drugfacts/synthetic-cannabinoids</div><div id=\"graphicVersion\">Graphic 51079 Version 6.0</div></div></div>"},"51081":{"type":"graphic_picture","displayName":"Candida potassium hydroxide preparation low power","title":"Candida albicans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Candida albicans</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/DERM/51081_Candida_KOH_low_power.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Potassium hydroxide preparation of candida infection.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51081 Version 2.0</div></div></div>"},"51082":{"type":"graphic_picture","displayName":"False black widow","title":"False black widow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">False black widow</div><div class=\"cntnt\"><img style=\"width:432px; height:311px;\" src=\"images/EM/51082_Falseblackwidow.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Julian White, MD.</div><div id=\"graphicVersion\">Graphic 51082 Version 1.0</div></div></div>"},"51083":{"type":"graphic_picture","displayName":"Intrauterine tandem apps","title":"High dose rate (HDR) cervix brachytherapy applicators","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">High dose rate (HDR) cervix brachytherapy applicators</div><div class=\"cntnt\"><img style=\"width:397px; height:558px;\" src=\"images/OBGYN/51083_Intrauterine_tandem_apps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intrauterine tandem with (A) vaginal ovoids, with (B) vaginal cylinders, or with a (C) vaginal ring.</div><div class=\"graphic_reference\">Courtesy of Kristin Bradley, MD and Derek McHaffie, MD.</div><div id=\"graphicVersion\">Graphic 51083 Version 2.0</div></div></div>"},"51084":{"type":"graphic_picture","displayName":"AML FAB M5","title":"Acute monoblastic leukemia (M5)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute monoblastic leukemia (M5)</div><div class=\"cntnt\"><img style=\"width:421px; height:288px;\" src=\"images/HEME/51084_AML_FAB_M5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear from a patient with acute monoblastic leukemia (FAB classification M5). (Wright-Giemsa stain.) The two monoblasts on the left have abundant cytoplasm with numerous azurophilic granules. The nuclear membrane of the promonocyte on the right has delicate folds and creases.</div><div class=\"graphic_reference\">From: Brunning RD, McKenna RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 51084 Version 2.0</div></div></div>"},"51085":{"type":"graphic_picture","displayName":"Acral lentiginous melanoma 2","title":"Acral lentiginous melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acral lentiginous melanoma</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/51085_Acral_lentig_melanoma_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Melanoma of the plantar surface.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51085 Version 3.0</div></div></div>"},"51086":{"type":"graphic_picture","displayName":"Thigh sleeve","title":"Thigh sleeve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thigh sleeve</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/EM/51086_Thigh_sleeve_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Karl Fields, MD; Spencer Copland, MD; and John Tipton, MD.</div><div id=\"graphicVersion\">Graphic 51086 Version 1.0</div></div></div>"},"51087":{"type":"graphic_figure","displayName":"Normal abdominal aorta","title":"Normal abdominal aorta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal abdominal aorta</div><div class=\"cntnt\"><img style=\"width:407px; height:515px;\" src=\"images/SURG/51087_Normal_aorta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The abdominal aorta is a retroperitoneal structure that begins at the hiatus of the diaphragm and extends to its bifurcation into the right and left common iliac arteries at the level of the fourth lumbar vertebra. <BR>The branches of the abdominal aorta include (superior to inferior) the left and right inferior phrenic arteries, the celiac axis, left and right middle suprarenal arteries, superior mesenteric artery, left and right renal arteries, left and right gonadal arteries, inferior mesenteric artery, left and right common iliac artery, and middle sacral artery. The paired lumbar arteries (L1-L4) branch from the aorta at mid vertebral body.</div><div id=\"graphicVersion\">Graphic 51087 Version 3.0</div></div></div>"},"51088":{"type":"graphic_figure","displayName":"Trichinellosis life cycle","title":"Trichinellosis life cycle","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Trichinellosis life cycle</div><div class=\"cntnt\"><img style=\"width:493px; height:476px;\" src=\"images/ID/51088_Trichinellosis_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Depending on the classification used, there are several species of <em>Trichinella</em>: <em>T. spiralis</em>, <em>T. pseudospiralis</em>, <em>T. nativa</em>, <em>T. murelli</em>, <em>T. nelsoni</em>, <em>T. britovi</em>, <em>T. papuae</em>, and <em>T. zimbabwensis</em>, all but the last of which have been implicated in human disease. Adult worms and encysted larvae develop within a single vertebrate host, and an infected animal serves as a definitive host and potential intermediate host. A second host is required to perpetuate the life cycle of <em>Trichinella</em>. The domestic cycle most often involved pigs and anthropophilic rodents, but other domestic animals, such as horses, can be involved. In the sylvatic cycle, the range of infected animals is great, but animals most often associated as sources of human infection are bear, moose, and wild boar.<br> Trichinellosis is caused by the ingestion of undercooked meat containing encysted larvae (except for <em>T. pseudospiralis</em> and <em>T. papuae</em>, which do not encyst) of <em>Trichinella</em> species <strong>(1)</strong>. After exposure to gastric acid and pepsin, the larvae are released from the cysts <strong>(2)</strong> and invade the small bowel mucosa where they develop into adult worms <strong>(3)</strong>. Females are 2.2 mm in length; males 1.2 mm. The life span in the small bowel is about four weeks. After one week, the females release larvae <strong>(4)</strong> that migrate to striated muscles where they encyst <strong>(5)</strong>. Diagnosis is usually made based on clinical symptoms, and is confirmed by serology or identification of encysted or nonencysted larvae in biopsy or autopsy specimens.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Trichinellosis. Available at: <A href=\"http://www.cdc.gov/parasites/trichinellosis/\">http://www.cdc.gov/parasites/trichinellosis/</A>.</div><div id=\"graphicVersion\">Graphic 51088 Version 3.0</div></div></div>"},"51089":{"type":"graphic_picture","displayName":"Trichostrongylosis eggs","title":"Trichostrongylosis eggs","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Trichostrongylosis eggs</div><div class=\"cntnt\"><img style=\"width:547px; height:546px;\" src=\"images/ID/51089_Trichostrongylosis_eggs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Eggs of <em>Trichostrongylus</em> spp in an unstained wet mount of stool.<br> (C, D) Eggs of <em>Trichostrongylus</em> spp in an unstained wet mount of stool. Images courtesy of the Indiana State Department of Health.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Trichostrongylosis. Available at: <A href=\"http://www.cdc.gov/dpdx/trichostrongylosis/index.html\">http://www.cdc.gov/dpdx/trichostrongylosis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 51089 Version 4.0</div></div></div>"},"51090":{"type":"graphic_picture","displayName":"Drug packet - Exterior view","title":"Drug packet: Exterior view","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Drug packet: Exterior view</div><div class=\"cntnt\"><img style=\"width:504px; height:426px;\" src=\"images/EM/51090_Drug_packet_exterior.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the hard wax exterior of a drug packet and provides a sense of the packet's size in comparison to average adult fingers.</div><div class=\"graphic_reference\">Courtesy of Robert Hoffman, MD.</div><div id=\"graphicVersion\">Graphic 51090 Version 2.0</div></div></div>"},"51091":{"type":"graphic_figure","displayName":"Genu recurvatum","title":"Genu recurvatum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Genu recurvatum</div><div class=\"cntnt\"><img style=\"width:359px; height:463px;\" src=\"images/PEDS/51091_Genu_recurvatum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In genu recurvatum, the knee is hyperextended such that the angle between the femur and tibia (usually 180 degrees) is increased, as depicted above.</div><div id=\"graphicVersion\">Graphic 51091 Version 2.0</div></div></div>"},"51092":{"type":"graphic_figure","displayName":"Normal versus anomalous pancreaticobiliary junction","title":"Normal versus anomalous pancreaticobiliary junction","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Normal versus anomalous pancreaticobiliary junction</div><div class=\"cntnt\"><img style=\"width:534px; height:339px;\" src=\"images/PEDS/51092_Normal_BPU.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Moises Guelrud, MD.</div><div id=\"graphicVersion\">Graphic 51092 Version 2.0</div></div></div>"},"51094":{"type":"graphic_table","displayName":"HRCT patterns in ILD","title":"HRCT patterns in interstitial lung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">HRCT patterns in interstitial lung disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Normal</td> </tr> <tr> <td>Hypersensitivity pneumonitis</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Bronchiolitis obliterans</td> </tr> <tr> <td>Asbestosis</td> </tr> <tr> <td class=\"subtitle1_single\">Distribution of disease within the lung</td> </tr> <tr> <td class=\"sublist1_start\">Peripheral lung zone</td> </tr> <tr> <td class=\"sublist1\">Idiopathic pulmonary fibrosis</td> </tr> <tr> <td class=\"sublist1\">Asbestosis</td> </tr> <tr> <td class=\"sublist1\">Connective tissue disease</td> </tr> <tr> <td class=\"sublist1\">Cryptogenic organizing pneumonia</td> </tr> <tr> <td class=\"sublist1\">Eosinophilic pneumonia</td> </tr> <tr> <td class=\"sublist1_start\">Central disease (bronchovascular thickening)</td> </tr> <tr> <td class=\"sublist1\">Sarcoidosis</td> </tr> <tr> <td class=\"sublist1\">Lymphangitic carcinoma</td> </tr> <tr> <td class=\"sublist1_start\">Upper zone predominance</td> </tr> <tr> <td class=\"sublist1\">Granulomatous disease</td> </tr> <tr> <td class=\"sublist2\">Sarcoidosis</td> </tr> <tr> <td class=\"sublist2\">Pulmonary histiocytosis X (eosinophilic granuloma)</td> </tr> <tr> <td class=\"sublist2\">Chronic hypersensitivity pneumonitis</td> </tr> <tr> <td class=\"sublist2\">Chronic infectious diseases (eg, tuberculosis, histoplasmosis)</td> </tr> <tr> <td class=\"sublist1\">Pneumoconiosis</td> </tr> <tr> <td class=\"sublist2\">Silicosis</td> </tr> <tr> <td class=\"sublist2\">Berylliosis</td> </tr> <tr> <td class=\"sublist2\">Coal miners' pneumoconiosis</td> </tr> <tr> <td class=\"sublist1_start\">Lower zone predominance</td> </tr> <tr> <td class=\"sublist1\">Idiopathic pulmonary fibrosis</td> </tr> <tr> <td class=\"sublist1\">Rheumatoid arthritis (associated with usual interstitial pneumonia)</td> </tr> <tr> <td class=\"sublist1\">Asbestosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51094 Version 2.0</div></div></div>"},"51096":{"type":"graphic_diagnosticimage","displayName":"Dilated bowel in scleroderma","title":"Small bowel disease in scleroderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small bowel disease in scleroderma</div><div class=\"cntnt\"><img style=\"width:301px; height:347px;\" src=\"images/RHEUM/51096_Dilated_bowel_in_scleroderm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium follow-through examination in a patient with scleroderma shows dilated loops of small bowel, some of which have a \"wire-spring\" appearance due to closely packed valvulae in a dilated bowel (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 51096 Version 3.0</div></div></div>"},"51097":{"type":"graphic_algorithm","displayName":"Treatment of spinal cord ischemia after thoracic aortic repair","title":"Algorithm for the treatment of spinal cord ischemia after thoracic aortic repair","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Algorithm for the treatment of spinal cord ischemia after thoracic aortic repair</div><div class=\"cntnt\"><img style=\"width:529px; height:770px;\" src=\"images/NEURO/51097_SC_infarct_Rx_protocol.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: McGarvey ML, Cheung AT, Szeto W, et al. Management of Neurologic Complications of Thoracic Aortic Surgery. J Clin Neurophysiol 2007; 24:336. Copyright © 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51097 Version 11.0</div></div></div>"},"51098":{"type":"graphic_table","displayName":"Potential indications for using emergency contraception","title":"Potential indications for using emergency contraception","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential indications for using emergency contraception</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>When no contraceptive was used during sexual intercourse within the previous 120 hours</td> </tr> <tr> <td class=\"sublist1_start\">When there is a contraceptive failure or incorrect use of a contraceptive within the previous 120 hours, including:</td> </tr> <tr> <td class=\"sublist1\">Condom breakage, slippage, or incorrect use</td> </tr> <tr> <td class=\"sublist1\">Three or more 30 to 35 mcg ethinyl estradiol pills have been missed (or two or more 20 to 25 mcg pills)*</td> </tr> <tr> <td class=\"sublist1\">Progestin-only pill (minipill) taken more than three hours late</td> </tr> <tr> <td class=\"sublist1\">More than two weeks late for injection of depot-medroxyprogesterone acetate</td> </tr> <tr> <td class=\"sublist1\">Dislodgment, breakage, tearing, or early removal of a diaphragm or cervical cap</td> </tr> <tr> <td class=\"sublist1\">Dislodgment, delay in placing, or early removal of a contraceptive hormonal skin patch or vaginal ring</td> </tr> <tr> <td class=\"sublist1\">Failed coitus interruptus (eg, ejaculation in vagina or on external genitalia)</td> </tr> <tr> <td class=\"sublist1\">Failure of a spermicide tablet or film to melt before sexual intercourse</td> </tr> <tr> <td class=\"sublist1\">Miscalculation of the periodic abstinence method or failure to abstain on fertile day of cycle</td> </tr> <tr> <td class=\"sublist1\">Expulsion of intrauterine contraception</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* We suggest the simpler recommendation that emergency contraception be used after two missed pills, regardless of dose.</div><div class=\"graphic_reference\">Data from: World Health Organization fact sheet No. 244 on Emergency Contraception. 2005.</div><div id=\"graphicVersion\">Graphic 51098 Version 7.0</div></div></div>"},"51099":{"type":"graphic_picture","displayName":"Plasma cell vulvitis2","title":"Plasma cell vulvitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plasma cell vulvitis</div><div class=\"cntnt\"><img style=\"width:318px; height:468px;\" src=\"images/OBGYN/51099_Plasma_cell_vulvitis2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 51099 Version 2.0</div></div></div>"},"51102":{"type":"graphic_figure","displayName":"Sagittal knee anatomy","title":"Anatomy of the knee","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the knee</div><div class=\"cntnt\"><img style=\"width:424px; height:391px;\" src=\"images/PEDS/51102_Sagittal_knee_anatomy_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal view of the knee anatomy demonstrating the relationship between the bones, tendons, and bursae.</div><div id=\"graphicVersion\">Graphic 51102 Version 3.0</div></div></div>"},"51103":{"type":"graphic_form","displayName":"Abnormal involuntary movement scale","title":"Abnormal involuntary movement scale","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Abnormal involuntary movement scale</div><div class=\"cntnt\"><img style=\"width:532px; height:764px;\" src=\"images/PSYCH/51103_Abnrmal_mvmt_scale_ed3.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51103 Version 4.0</div></div></div>"},"51105":{"type":"graphic_figure","displayName":"Obesity and NIDDM","title":"Increasing body weight increases risk of diabetes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Increasing body weight increases risk of diabetes</div><div class=\"cntnt\"><img style=\"width:317px; height:274px;\" src=\"images/ENDO/51105_Obesity_and_NIDDM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rates of impaired glucose tolerance and diagnosed and undiagnosed type 2 diabetes in the United States adult population according to increase in percent desirable weight from age 25 years to age at maximum adult weight (about 50 years).</div><div class=\"graphic_reference\">Data from Harris, MI, Diabetes Care 1989; 12:464.</div><div id=\"graphicVersion\">Graphic 51105 Version 1.0</div></div></div>"},"51107":{"type":"graphic_picture","displayName":"Ischemic ulceration Endosc","title":"Ischemic airway ulceration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ischemic airway ulceration</div><div class=\"cntnt\"><img style=\"width:448px; height:223px;\" src=\"images/PULM/51107_Ischemic_ulceration_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchoscopic images demonstrating ischemic ulceration of the vocal cords (left) and trachea (right) following endotracheal intubation.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 51107 Version 1.0</div></div></div>"},"51108":{"type":"graphic_table","displayName":"Textile workers antigens in HP","title":"Hypersensitivity pneumonitides in textile workers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypersensitivity pneumonitides in textile workers</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Environmental source</td>\n<td class=\"subtitle1\">Major causative antigen</td>\n</tr>\n<tr>\n<td>Byssinosis (\"brown lung\") (unclear if a true cause of HP; asthma is common)</td>\n<td>Cotton mill dust (carding and spinning areas of cotton, flax, and soft-hemp)</td>\n</tr>\n<tr>\n<td>\"Velvet\" worker's lung </td>\n<td>Unknown (? nylon velvet fiber, tannic acid, potato starch)</td>\n</tr>\n<tr>\n<td>Upholstery fabric (nylon filament, cotton/polyester, and latex adhesive)</td>\n<td>Aflatoxin-producing fungus, Fusarium sp</td>\n</tr>\n<tr>\n<td>Lycoperdonosis (lycoperdon puffballs)</td>\n<td>Puffball spores</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 51108 Version 1.0</div></div></div>"},"51110":{"type":"graphic_picture","displayName":"gottrons sign a","title":"Gottron's sign in a patient with amyopathic dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Gottron's sign in a patient with amyopathic dermatomyositis</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/RHEUM/51110_gottrons_sign_a.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Copyright © 2017 American College of Rheumatology. Used with permission.</div><div id=\"graphicVersion\">Graphic 51110 Version 13.0</div></div></div>"},"51111":{"type":"graphic_algorithm","displayName":"Penetrating neck injury through platysma algorithm","title":"Algorithm for penetrating neck injury through the platysma ","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Algorithm for penetrating neck injury through the platysma </div><div class=\"cntnt\"><img style=\"width:493px; height:407px;\" src=\"images/EM/51111_PNI_platysma_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CXR: chest x-ray; MDCT-A: multidetector computed tomography with angiography; OR: operating room.<br> * Preferred imaging studies vary by institution and local expertise.</div><div id=\"graphicVersion\">Graphic 51111 Version 3.0</div></div></div>"},"51112":{"type":"graphic_figure","displayName":"Pudendal nerve terminal motor latency test","title":"Pudendal nerve terminal motor latency tests","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Pudendal nerve terminal motor latency tests</div><div class=\"cntnt\"><img style=\"width:540px; height:757px;\" src=\"images/OBGYN/51112_Pud_nerv_term_mot_lat_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) In this patient, both right and left pudendal nerves fire less than 2 milliseconds after stimulation. This is considered normal.<br> (B) In this patient, the right and left pudendal nerves fire at 2 milliseconds. Since 2 milliseconds is the cut-off between normal and abnormal, this result would be labelled as indeterminate. Longer delays in firing would be labelled as abnormal.</div><div id=\"graphicVersion\">Graphic 51112 Version 2.0</div></div></div>"},"51113":{"type":"graphic_waveform","displayName":"EEG Subclinical rhythmic EEG discharge of adults SREDA","title":"Subclinical rhythmic EEG discharge of adults (SREDA)","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Subclinical rhythmic EEG discharge of adults (SREDA)</div><div class=\"cntnt\"><img style=\"width:492px; height:335px;\" src=\"images/NEURO/51113_SREDA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subclinical rhythmic EEG discharge of adults (SREDA) in a 52 year old woman with headaches, preceded by a widespread, moderate-to-high amplitude, biphasic waveform. This is a rare but normal variant.</div><div class=\"graphic_reference\">Reproduced with permission from: BF, Westmoreland, Klass, DW. A distinctive rhythmic EEG discharge of adults. Electroencephalogr Clin Neurophysiol 1981; 51:186. Copyright ©1981 Elsevier.</div><div id=\"graphicVersion\">Graphic 51113 Version 2.0</div></div></div>"},"51114":{"type":"graphic_diagnosticimage","displayName":"Fetal intralobar sequestration","title":"Prenatal ultrasound and magnetic resonance images of fetal intralobar sequestration at 29 weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound and magnetic resonance images of fetal intralobar sequestration at 29 weeks of gestation</div><div class=\"cntnt\"><img style=\"width:455px; height:478px;\" src=\"images/OBGYN/51114_Intralobar_sequestration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial ultrasound demonstrates a&nbsp;high signal&nbsp;mass in the right lower lobe. (D) Doppler examination shows a dominant vessel originating from the thoracic aorta and coursing to the mass. (B) and (C) T2w magnetic resonance images demonstrate a large echogenic mass in the right lower lobe with mild mediastinal shift to the left; (B) axial and (C) coronal views.&nbsp;The Congenital Pulmonary Airway Malformation Volume Ratio (CVR) is 0.8, indicating a low risk for hydrops.</div><div class=\"graphic_reference\">Courtesy of Dorothy I Bulas, MD.</div><div id=\"graphicVersion\">Graphic 51114 Version 7.0</div></div></div>"},"51115":{"type":"graphic_table","displayName":"Involved sites in untreated HL","title":"Frequency of involved sites in pathologically staged untreated patients with Hodgkin lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of involved sites in pathologically staged untreated patients with Hodgkin lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Site</td> <td class=\"subtitle1\">Percent involved</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Nodal sites, spleen, and liver</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Cervical nodes</td> </tr> <tr> <td class=\"sublist2\">Left side</td> <td class=\"sublist_other\">60 to 70</td> </tr> <tr> <td class=\"sublist2\">Right side</td> <td class=\"sublist_other\">50 to 60</td> </tr> <tr> <td class=\"indent1\">Mediastinal nodes</td> <td>50 to 60</td> </tr> <tr> <td class=\"indent1\">Paraaortic nodes</td> <td>30 to 40</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Axillary nodes</td> </tr> <tr> <td class=\"sublist2\">Left side</td> <td class=\"sublist_other\">30 to 35</td> </tr> <tr> <td class=\"sublist2\">Right side</td> <td class=\"sublist_other\">25 to 35</td> </tr> <tr> <td class=\"indent1\">Spleen</td> <td>30 to 35</td> </tr> <tr> <td class=\"indent1\">Hilar nodes</td> <td>15 to 35</td> </tr> <tr> <td class=\"indent1\">Iliac nodes</td> <td>15 to 20</td> </tr> <tr> <td class=\"indent1\">Inguinal nodes</td> <td>8 to 15</td> </tr> <tr> <td class=\"indent1\">Liver</td> <td>2 to 6</td> </tr> <tr> <td class=\"indent1\">Mesenteric nodes</td> <td>1 to 4</td> </tr> <tr> <td class=\"indent1\">Waldeyer's ring</td> <td>1 to 2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Extranodal sites</td> </tr> <tr> <td class=\"sublist2_start\">Total extranodal</td> <td class=\"sublist_other_start\">10 to 15</td> </tr> <tr> <td class=\"sublist2\">Bone marrow</td> <td class=\"sublist_other\">1 to 4</td> </tr> <tr> <td class=\"sublist2\">Other (eg, lungs, bone)</td> <td class=\"sublist_other\">10 to 12</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Gupta RK, Gospodarowicz MK, Lister TA. Clinical evaluation and staging of Hodgkin's disease. In: Hodgkin's disease, Mauch PM, Armitage JO, Diehl V, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 1999.</div><div id=\"graphicVersion\">Graphic 51115 Version 2.0</div></div></div>"},"51116":{"type":"graphic_figure","displayName":"Hemorrhoid external PI","title":"External hemorrhoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">External hemorrhoid</div><div class=\"cntnt\"><img style=\"width:404px; height:448px;\" src=\"images/PI/51116_Hemorrhoid_external_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows what an external hemorrhoid looks like.</div><div id=\"graphicVersion\">Graphic 51116 Version 1.0</div></div></div>"},"51117":{"type":"graphic_table","displayName":"Pediatric causes metabolic acidosis","title":"Pediatric causes of metabolic acidosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric causes of metabolic acidosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Elevated anion gap</td> </tr> <tr> <td class=\"indent1\"><strong>Lactic acidosis</strong></td> </tr> <tr> <td class=\"indent2\">Hypoperfusion</td> </tr> <tr> <td class=\"indent3\">Cardiac failure</td> </tr> <tr> <td class=\"indent3\">Hypovolemia</td> </tr> <tr> <td class=\"indent3\">Septic shock</td> </tr> <tr> <td class=\"indent2\">Mitochondrial disorders</td> </tr> <tr> <td class=\"indent3\">Mitochondrial, encephalomyopathy, lactic acidosis and strokelike episodes (MELAS)</td> </tr> <tr> <td class=\"indent3\">Myoclonus epilepsy and ragged-red fibers (MERRF)</td> </tr> <tr> <td class=\"indent3\">Kearns-Sayre syndrome</td> </tr> <tr> <td class=\"indent3\">Acquired (antiretroviral therapy in HIV patients)</td> </tr> <tr> <td class=\"indent2\">Inborn errors of carbohydrate metabolism</td> </tr> <tr> <td class=\"indent3\">Fructose 1,6 diphosphatase deficiency</td> </tr> <tr> <td class=\"indent3\">Glycogen storage disease 1 (glucose 6 phosphate deficiency)</td> </tr> <tr> <td class=\"indent3\">Pyruvate dehydrogenase or carboxylase deficiency</td> </tr> <tr> <td class=\"indent1\"><strong>Ketoacidosis</strong></td> </tr> <tr> <td class=\"indent2\">Diabetic ketoacidosis</td> </tr> <tr> <td class=\"indent1\"><strong>Inborn errors of metabolism</strong></td> </tr> <tr> <td class=\"indent2\">Organic acidemia</td> </tr> <tr> <td class=\"indent3\">Maple syrup urine disease (branched-chain amino acids)</td> </tr> <tr> <td class=\"indent3\">Propionic acidemia</td> </tr> <tr> <td class=\"indent3\">Methylmalonic acidemia</td> </tr> <tr> <td class=\"indent3\">Ketothiolase deficiency</td> </tr> <tr> <td class=\"indent3\">Multiple carboxylase deficiency (impaired biotin utilization)</td> </tr> <tr> <td class=\"indent2\">Fatty acid oxidation defects</td> </tr> <tr> <td class=\"indent1\"><strong>Ingestions</strong></td> </tr> <tr> <td class=\"indent2\">Cyanide poisoning</td> </tr> <tr> <td class=\"indent2\">Ethanol intoxication</td> </tr> <tr> <td class=\"indent2\">Ethylene glycol</td> </tr> <tr> <td class=\"indent2\">Iron poisoning</td> </tr> <tr> <td class=\"indent2\">Metformin poisoning</td> </tr> <tr> <td class=\"indent2\">Methanol</td> </tr> <tr> <td class=\"indent2\">Nonsteroidal antiinflammatory drug poisoning</td> </tr> <tr> <td class=\"indent2\">Salicylates</td> </tr> <tr> <td class=\"indent1\"><strong>Renal failure</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Massive rhabdomyolysis</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Tumor lysis syndrome</strong></td> </tr> <tr> <td class=\"subtitle1_single\">Normal anion gap (hyperchloremic metabolic acidosis)</td> </tr> <tr> <td class=\"indent1\"><strong>Loss of bicarbonate (HCO<sub>3</sub>)</strong></td> </tr> <tr> <td class=\"indent2\">Gastrointestinal loss</td> </tr> <tr> <td class=\"indent3\">Diarrhea</td> </tr> <tr> <td class=\"indent3\">Chronic laxative abuse</td> </tr> <tr> <td class=\"indent3\">Enteric fistulae</td> </tr> <tr> <td class=\"indent3\">Ureterosigmoidostomy</td> </tr> <tr> <td class=\"indent2\">Renal loss</td> </tr> <tr> <td class=\"indent3\">Bicarbonate loss</td> </tr> <tr> <td class=\"indent4\">Proximal (Type 2) renal tubular acidosis</td> </tr> <tr> <td class=\"indent4\">Drugs inhibiting proximal tubular carbonic anhydrase</td> </tr> <tr> <td class=\"indent5\">Acetazolamide</td> </tr> <tr> <td class=\"indent5\">Methazolamide</td> </tr> <tr> <td class=\"indent5\">Dichlorphenamide</td> </tr> <tr> <td class=\"indent5\">Topiramate</td> </tr> <tr> <td class=\"indent4\">Drugs causing proximal tubular injury</td> </tr> <tr> <td class=\"indent5\">Aminoglycosides</td> </tr> <tr> <td class=\"indent5\">Cisplatin</td> </tr> <tr> <td class=\"indent5\">Ifosfamide</td> </tr> <tr> <td class=\"indent5\">Tenofovir</td> </tr> <tr> <td class=\"indent5\">Cidofovir</td> </tr> <tr> <td class=\"indent5\">Heavy metals such as lead, cadmium, and mercury</td> </tr> <tr> <td class=\"indent1\"><strong>Diminished acid (H+) secretion</strong></td> </tr> <tr> <td class=\"indent2\">Distal (Type 1) renal tubular acidosis</td> </tr> <tr> <td class=\"indent2\">Early renal failure</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51117 Version 6.0</div></div></div>"},"51119":{"type":"graphic_picture","displayName":"Nesidioblastosis light","title":"Nesidioblastosis: Findings on histopathology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nesidioblastosis: Findings on histopathology</div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/ENDO/51119_Nesidioblastosis_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Positive insulin immunostaining of a hypertrophied islet (upper right) and two beta cells budding from an acinar duct (arrows).</div><div class=\"graphic_reference\">Courtesy of F John Service, MD.</div><div id=\"graphicVersion\">Graphic 51119 Version 3.0</div></div></div>"},"51120":{"type":"graphic_diagnosticimage","displayName":"Pseudomembranous colitis US","title":"Pseudomembranous colitis on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudomembranous colitis on ultrasound</div><div class=\"cntnt\"><img style=\"width:364px; height:280px;\" src=\"images/GAST/51120_Pseudomembranous_colitis_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transabdominal ultrasound of the colon in a patient with pseudomembranous colitis. A characteristic feature is the asymmetric hypoechoic bowel wall thickening (BW) with loss of wall layer structure and \"cobblestone-like\" or pseudopolypous picture of the mucosa and the absence of a visible lumen. Depending upon the degree of inflammation, a hyperechogenic reaction of the mesentery may be seen. Ultrasonography of lymphomatous infiltration of the intestinal wall may display a similar image.</div><div class=\"graphic_reference\">Courtesy of Christoph F Dietrich, MD.</div><div id=\"graphicVersion\">Graphic 51120 Version 4.0</div></div></div>"},"51122":{"type":"graphic_table","displayName":"Heterologous proteins causing serum sickness","title":"Heterologous proteins causing serum sickness","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Heterologous proteins causing serum sickness</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Microbial anti-toxins</td> </tr> <tr> <td class=\"indent1\">Equine anti-diphtheria</td> </tr> <tr> <td class=\"indent1\">Equine or ovine anti-rabies</td> </tr> <tr> <td class=\"indent1\">Equine anti-botulinum toxin</td> </tr> <tr> <td class=\"subtitle1_single\">Venom anti-toxins</td> </tr> <tr> <td class=\"indent1\">Equine, rabbit, ovine anti-snake venom (<em>Crotalidae</em> [pit vipers, rattlesnakes] anti-venin, <em>Micrurus</em> [coral snake] anti-venin)</td> </tr> <tr> <td class=\"indent1\">Equine anti-spider venom (<em>Lactrodectus</em>) anti-venin</td> </tr> <tr> <td class=\"subtitle1_single\">Immune and cell metabolism modulators</td> </tr> <tr> <td class=\"indent1\">Equine or rabbit anti-thymocyte globulin</td> </tr> <tr> <td class=\"indent1\">Murine anti-CD3 (OKT3)</td> </tr> <tr> <td class=\"indent1\">Rituximab (murine/human chimeric anti-CD20)</td> </tr> <tr> <td class=\"indent1\">Infliximab (murine/human chimeric anti-TNF-alpha)</td> </tr> <tr> <td class=\"indent1\">Adalimumab (recombinant human anti-TNF-alpha)&nbsp;(?)</td> </tr> <tr> <td class=\"indent1\">Alemtuzumab (humanized anti-CD52) (?)</td> </tr> <tr> <td class=\"indent1\">Omalizumab (humanized anti-IgE) (?)</td> </tr> <tr> <td class=\"indent1\">Natalizumab (humanized anti-alpha-4 integrin)&nbsp;(?)</td> </tr> <tr> <td class=\"indent1\">Dalotuzumab (anti-insulin growth factor 1)&nbsp;(?)</td> </tr> <tr> <td class=\"indent1\">Obinutuzumab (anti-CD20)&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Immunizations</td> </tr> <tr> <td class=\"indent1\">Rabies antigens (human diploid cell rabies vaccine)</td> </tr> <tr> <td class=\"indent1\">Pneumococcal vaccine (?)</td> </tr> <tr> <td class=\"indent1\">Hemophilus B vaccine (?)</td> </tr> <tr> <td class=\"subtitle1_single\">Tissue culture protein</td> </tr> <tr> <td class=\"indent1\">Bovine serum albumin (tissue culture media) (?)</td> </tr> <tr> <td class=\"subtitle1_single\">Therapeutic fibrinolytic proteins</td> </tr> <tr> <td class=\"indent1\">Streptokinase</td> </tr> <tr> <td class=\"subtitle1_single\">Insect protein</td> </tr> <tr> <td class=\"indent1\">Mosquito salivary proteins (?)</td> </tr> <tr> <td class=\"indent1\">Insect stings</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">(?): case reports; causality is unclear.</div><div class=\"graphic_footnotes\"><FONT color=black>TNF</FONT><FONT color=black>: tumor necrosis factor; IgE immunoglobulin E.</FONT></div><div id=\"graphicVersion\">Graphic 51122 Version 13.0</div></div></div>"},"51123":{"type":"graphic_diagnosticimage","displayName":"Two causes for dry tap MRI","title":"Magnetic resonance image of two causes for dry tap of knee: Lipoma arborescens and a gelatinous mass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance image of two causes for dry tap of knee: Lipoma arborescens and a gelatinous mass</div><div class=\"cntnt\"><img style=\"width:304px; height:360px;\" src=\"images/RHEUM/51123_Two_causes_for_dry_tap_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MR image showing two causes for potential failed arthrocentesis: Chronic synovial hypertrophy with fatty villous hypertrophy (lipoma arborescens, LA), and a nonenhancing gelatinous mass (G). Only placement of the needle into the enhancing fluid area (F, white arrow) would successfully yield fluid.</div><div class=\"graphic_footnotes\">M: medial; L: lateral.</div><div class=\"graphic_reference\">Reproduced with permission from Roberts WN, Hayes CW, Breitbach SA, et al. Am J Med 1996; 100:461.</div><div id=\"graphicVersion\">Graphic 51123 Version 2.0</div></div></div>"},"51124":{"type":"graphic_figure","displayName":"Ambulatory ePAD during progression of diastolic heart failure","title":"Ambulatory ePAD during progression of diastolic heart failure","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Ambulatory ePAD during progression of diastolic heart failure</div><div class=\"cntnt\"><img style=\"width:539px; height:398px;\" src=\"images/CARD/51124_MedianePADdurDHFedt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Changes in LV diastolic pressure as reflected by ambulatory 24-hour median pulmonary artery diastolic pressures (ePAD) in a patient with diastolic heart failure (HF). Time zero represents the day of hospitalization for acute decompensated HF and Day -60 marks 60 days prior to the onset of this event. As shown, left ventricular diastolic pressure is elevated even with compensated HFpEF and then rises as diastolic HF worsens. Following treatment, the diastolic pressure falls to a level close to that in the preceding compensated phase.</div><div class=\"graphic_reference\">Based on data from: Zile MR, Bennett TD, St John Sutton M, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 2008; 118:1433. Courtesy of Dr. Michael Zile.</div><div id=\"graphicVersion\">Graphic 51124 Version 5.0</div></div></div>"},"51125":{"type":"graphic_picture","displayName":"Scabies hand","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/51125_Scabies_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, excoriated papules are present on the hand of this patient with scabies.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51125 Version 6.0</div></div></div>"},"51127":{"type":"graphic_figure","displayName":"Pelvimetry 2","title":"Pelvic inlet","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Pelvic inlet</div><div class=\"cntnt\"><img style=\"width:535px; height:445px;\" src=\"images/OBGYN/51127_Pelvimetry_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three anteroposterior diameters of the pelvic inlet are illustrated: the true conjugate, the obstetrically important obstetric conjugate, and the clinically measurable diagonal conjugate. The anteroposterior diameter of the mid-pelvis is also shown.</div><div class=\"graphic_footnotes\">P: sacral promontory; Sym: symphysis pubis.</div><div class=\"graphic_reference\">Reproduced with permission from: Pritchard JA, MacDonald PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright ©1980 McGraw Hill. p. 278.</div><div id=\"graphicVersion\">Graphic 51127 Version 3.0</div></div></div>"},"51129":{"type":"graphic_diagnosticimage","displayName":"Clear cell carc MRI B","title":"Magnetic resonance images (MRI) of clear cell carcinoma of the kidney","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance images (MRI) of clear cell carcinoma of the kidney</div><div class=\"cntnt\"><img style=\"width:432px; height:311px;\" src=\"images/ONC/51129_Clear_cell_carc_MRI_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal three-dimensional T1-weighted fat-saturated gradient echo image after administration of gadolinium obtained during the excretory phase confirms the presence of enhancement (compared to pre-contrast, not shown) within the mass. After nephrectomy, a low grade (Furhman nuclear grade 2) clear-cell renal cell carcinoma was confirmed.</div><div id=\"graphicVersion\">Graphic 51129 Version 3.0</div></div></div>"},"51130":{"type":"graphic_table","displayName":"Late effects RT CT","title":"Examples of late effects chemotherapy and radiotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of late effects chemotherapy and radiotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Organ system</td> <td class=\"subtitle1\">Late effect of chemotherapy (agents)</td> <td class=\"subtitle1\">Late effect of radiotherapy</td> </tr> <tr> <td>Bone and soft tissues</td> <td> <p>Avascular necrosis</p> <p>(corticosteroids)</p> </td> <td> <p>Short stature</p> <p>Atrophy</p> <p>Fibrosis</p> <p>Osteonecrosis</p> Second cancers</td> </tr> <tr class=\"divider_top\"> <td>Cardiovascular</td> <td> <p>Cardiomyopathy</p> <p>(anthracyclines, trastuzumab)</p> </td> <td> <p>Pericardial effusion</p> <p>Pericarditis</p> <p>Coronary artery and peripheral vascular disease</p> </td> </tr> <tr class=\"divider_top\"> <td>Pulmonary</td> <td> <p>Pulmonary fibrosis</p> <p>Interstitial pneumonitis</p> <p>(bleomycin)</p> </td> <td> <p>Pulmonary fibrosis</p> <p>Decreased lung volumes</p> </td> </tr> <tr class=\"divider_top\"> <td>Central nervous system</td> <td> <p>Leukoencephalopathy</p> <p>(methotrexate)</p> </td> <td> <p>Neurocognitive impairment</p> <p>Radiation necrosis</p> <p>Second malignancies</p> </td> </tr> <tr class=\"divider_top\"> <td>Peripheral nervous system</td> <td> <p>Peripheral neuropathy</p> <p>Hearing loss</p> <p>(cisplatin, taxanes, vinca alkaloids)</p> </td> <td> <p>Brachial plexopathy</p> <p>Lumbosacral plexopathy</p> </td> </tr> <tr class=\"divider_top\"> <td>Hematological</td> <td> <p>Myelodyplastic syndromes and secondary leukemias</p> <p>(alkylating agents)</p> </td> <td>Myelodysplasia</td> </tr> <tr class=\"divider_top\"> <td>Renal</td> <td> <p>Decreased creatinine clearance</p> <p>(cisplatin, methotrexate)</p> </td> <td> <p>Decreased creatinine clearance</p> <p>Hypertension</p> </td> </tr> <tr class=\"divider_top\"> <td>Genitourinary</td> <td> <p>Bladder fibrosis</p> <p>Hemorrhagic cystitis</p> <p>Bladder cancer</p> <p>(cyclophosphamide)</p> </td> <td> <p>Bladder fibrosis</p> <p>Contractures</p> </td> </tr> <tr class=\"divider_top\"> <td>Gastrointestinal</td> <td> <p>Abnormal liver function tests</p> <p>Hepatic fibrosis</p> <p>Cirrhosis</p> <p>(methotrexate)</p> </td> <td> <p>Malabsorption</p> <p>Stricture</p> <p>Radiation proctitis</p> <p>Second cancers</p> </td> </tr> <tr class=\"divider_top\"> <td>Pituitary</td> <td>&ndash;</td> <td> <p>Growth hormone deficiency</p> <p>Pituitary deficiency</p> <p>Metabolic syndrome</p> <p>Obesity</p> <p>Diabetes</p> </td> </tr> <tr class=\"divider_top\"> <td>Thyroid</td> <td> <p>Hypothyroidism</p> <p>(sunitinib)</p> </td> <td> <p>Hyperthyroidism&nbsp;</p> <p>Hypothyroidism</p> <p>Thyroid nodules</p> Thyroid cancer</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Gonadal</td> <td class=\"subtitle2_left\" colspan=\"2\">Men</td> </tr> <tr> <td> <p>Sterility</p> <p>(alkylating agents)</p> </td> <td> <p>Sterility</p> <p>Leydig cell dysfunction</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Women</td> </tr> <tr> <td> <p>Sterility</p> <p>Premature menopause</p> <p>(alkylating agents)</p> </td> <td> <p>Ovarian failure</p> <p>Early menopause</p> </td> </tr> <tr class=\"divider_top\"> <td>Opthalmologic</td> <td> <p>Cataracts</p> <p>(steroids)</p> </td> <td> <p>Cataracts</p> <p>Retinopathy</p> </td> </tr> <tr class=\"divider_top\"> <td>&nbsp;Skin</td> <td>-&nbsp;</td> <td> <p>Second cancers</p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51130 Version 4.0</div></div></div>"},"51133":{"type":"graphic_table","displayName":"ASGE guidelines Abx prophylxs","title":"Antibiotic prophylaxis for endoscopic procedures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotic prophylaxis for endoscopic procedures</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Patient condition</td> <td class=\"subtitle1\">Procedure contemplated</td> <td class=\"subtitle1\">Antibiotic prophylaxis</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">High risk:</td> </tr> <tr> <td class=\"sublist1\" rowspan=\"2\"> <p>Prosthetic heart valve or prosthetic material used for valve repair</p> <p>History of endocarditis</p> <p>Unrepaired cyanotic congenital heart disease (including palliative shunts and conduits)</p> <p>Repaired congential heart disease with residual defects at the site of or adjacent to a prosthetic device</p> <p>Completely repaired congenital heart defects with prosthetic material or device during the first six months after the repair</p> <p>Cardiac valvulopathy in a transplanted heart</p> </td> <td class=\"sublist_other\"> <p>Stricture dilation</p> <p>Variceal sclerotherapy</p> <p>ERCP/obstructed biliary tree</p> </td> <td class=\"sublist_other\">Not recommended</td> </tr> <tr> <td class=\"sublist_other\">Other endoscopic procedures, including EGD and colonoscopy (with or without biopsy/polypectomy), variceal ligation</td> <td class=\"sublist_other\">Not recommended</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\" colspan=\"3\">Moderate risk:</td> </tr> <tr> <td class=\"sublist1\" rowspan=\"2\"> <p>Most other congenital abnormalities</p> <p>Acquired valvular dysfunction (eg, rheumatic heart disease)</p> <p>Hypertrophic cardiomyopathy</p> <p>Mitral valve prolapse with regurgitation or thickened leaflets</p> </td> <td class=\"sublist_other\"> <p>Esophageal stricture dilation</p> <p>Variceal sclerotherapy</p> </td> <td class=\"sublist_other\">Not recommended</td> </tr> <tr> <td class=\"sublist_other\">Other endoscopic procedures, including EGD and colonoscopy (with or without biopsy/polypectomy), variceal ligation</td> <td class=\"sublist_other\">Not recommended</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\" colspan=\"3\">Low risk:</td> </tr> <tr> <td class=\"sublist1\">Other cardiac conditions (CABG, repaired septal defect or patent ductus, mitral valve prolapse without valvular regurgitation, isolated secundum atrial septal defect, physiologic/functional/innocent heart murmurs, rheumatic fever without valvular dysfunction, pacemakers, implantable defibrillators)</td> <td class=\"sublist_other\">All endoscopic procedures</td> <td class=\"sublist_other\">Not recommended</td> </tr> <tr class=\"divider_top\"> <td>Obstructed bile duct without cholangitis</td> <td>ERCP with complete drainage</td> <td>Not recommended</td> </tr> <tr class=\"divider_top\"> <td>Obstructed bile duct with cholangitis</td> <td>ERCP with anticipated incomplete drainage</td> <td>Recommended (continue antibiotics after procedure)</td> </tr> <tr class=\"divider_top\"> <td>Pancreatic cystic lesion</td> <td>ERCP, EUS-FNA</td> <td>Recommended</td> </tr> <tr class=\"divider_top\"> <td>Cirrhosis acute gastrointestinal bleed (required for patients with or without endoscopic procedures)</td> <td>All endoscopic procedures</td> <td>Recommended</td> </tr> <tr class=\"divider_top\"> <td>Ascites, immunocompromised patient</td> <td> <p>Stricture dilation</p> <p>Variceal sclerotherapy</p> <p>Other endoscopic procedures, including EGD and colonoscopy (with or without biopsy/polypectomy), variceal ligation</p> </td> <td>No recommendation</td> </tr> <tr class=\"divider_top\"> <td>All patients</td> <td>Percutaneous endoscopic feeding tube placement</td> <td>Recommended (parenteral cephalosporin or equivalent)</td> </tr> <tr class=\"divider_top\"> <td>Vascular graft</td> <td>&nbsp;</td> <td> <p>AHA: Recommended antibiotic usage within 6 months of procedure</p> <p>ASGE: Antibiotics not recommended</p> </td> </tr> <tr class=\"divider_top\"> <td>Prosthetic joints</td> <td>All endoscopic procedures</td> <td>Not recommended</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This summary table is based upon recommendations from the American Society of Gastrointestinal Endoscopy (Banerjee, S, Shen, B, Baron, T, et al. Gastrointest Endosc 2008; 67:791) and the American Heart Association (Wilson, W, Taubert, KA, Gewitz, M, et al. Circulation 2007; 116:1736 and Nishimura, RA, Carabello, BA, Faxon, DP, et al. Circulation 2008; 118:887). NOTE: See other table (&quot;Antibiotic regimens: Prophylaxis for endoscopic procedures&quot;) for specific regimens.</div><div class=\"graphic_footnotes\">CABG: coronary artery bypass graft; ERCP: endoscopic retrograde cholangiopancreatography; EGD: esophagogastroduodenoscopy; EUS-FNA: endoscopic ultrasound with fine needle aspiration; AHA: American Heart Association; ASGE: American Society for Gastrointestinal Endoscopy.</div><div class=\"graphic_reference\">Modified with permission from: Hirota WK, Petersen K, Baron TH, et al. Guidelines for Antibiotic Prophylaxis for GI Endoscopy. Gastrointest Endosc 2003; 58:475. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 51133 Version 4.0</div></div></div>"},"51135":{"type":"graphic_diagnosticimage","displayName":"Tracheal bronchus CT","title":"Tracheal bronchus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheal bronchus</div><div class=\"cntnt\"><img style=\"width:320px; height:484px;\" src=\"images/PULM/51135_Tracheal_bronchus_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography demonstrates an accessory bronchus originating from the right aspect of the distal trachea (bronchus suis).</div><div id=\"graphicVersion\">Graphic 51135 Version 2.0</div></div></div>"},"51137":{"type":"graphic_figure","displayName":"Diagram of pathologic changes with CAV","title":"Diagram of pathologic changes with CAV","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Diagram of pathologic changes with CAV</div><div class=\"cntnt\"><img style=\"width:480px; height:379px;\" src=\"images/CARD/51137_Diagram_changes_CAV_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Differences between typical nontransplant coronary atherosclerosis and typical transplant vasculopathy.</div><div class=\"graphic_reference\">Courtesy of Dr. Finn Gustafsson.</div><div id=\"graphicVersion\">Graphic 51137 Version 2.0</div></div></div>"},"51138":{"type":"graphic_picture","displayName":"Pseudofolliculitis barbae - chin and neck","title":"Pseudofolliculitis barbae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudofolliculitis barbae</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/51138_Pseudofol_barbae_chin_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented papules and small pustules are present on the mandible and neck.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51138 Version 4.0</div></div></div>"},"51139":{"type":"graphic_picture","displayName":"Flat warts linear","title":"Flat warts","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Flat warts</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/51139_Flat_warts_linear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple flat-topped papules are present on the forehead. Note the linear arrangement of lesions on the left. These linear lesions are likely a result of autoinoculation during scratching.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51139 Version 6.0</div></div></div>"},"51140":{"type":"graphic_table","displayName":"Lab eval men osteo","title":"Laboratory evaluation for men osteoporosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory evaluation for men osteoporosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Initial laboratory tests</td> </tr> <tr> <td>Complete chemistry profile (including alkaline phosphatase)</td> </tr> <tr> <td>Complete blood count</td> </tr> <tr> <td>Calcium, phosphorus</td> </tr> <tr> <td>25-hydroxyvitamin D</td> </tr> <tr> <td>Testosterone</td> </tr> <tr> <td>Urinary calcium excretion</td> </tr> <tr> <td class=\"subtitle1_single\">Additional laboratory tests if indicated</td> </tr> <tr> <td>24-hour urine for free cortisol</td> </tr> <tr> <td>FSH, LH</td> </tr> <tr> <td>Estradiol</td> </tr> <tr> <td>Prolactin</td> </tr> <tr> <td>Magnesium</td> </tr> <tr> <td>1,25-dihydroxyvitamin D</td> </tr> <tr> <td>Intact PTH</td> </tr> <tr> <td>TSH</td> </tr> <tr> <td>Celiac screen</td> </tr> <tr> <td>Serum protein electrophoresis/urine protein electrophoresis</td> </tr> <tr> <td>Erythrocyte sedimentation rate</td> </tr> <tr> <td>Rheumatoid factor</td> </tr> <tr> <td>Ferritin</td> </tr> <tr> <td>Iron and total iron binding capacity</td> </tr> <tr> <td>Serum tryptase and histamine levels</td> </tr> <tr> <td>Homocysteine</td> </tr> <tr> <td>Skin biopsy for connective tissue disorders</td> </tr> <tr> <td>COL1A genetic testing for osteogenesis imperfecta</td> </tr> <tr> <td>Serum and urine markers of bone turnover</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FSH: follicle-stimulating hormone; LH: luteinizing hormone; PTH: parathyroid hormone; TSH: thyroid-stimulating hormone.</div><div id=\"graphicVersion\">Graphic 51140 Version 6.0</div></div></div>"},"51141":{"type":"graphic_picture","displayName":"Photo birth 1","title":"Delivery sequence from crowning through birth of the newborn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Delivery sequence from crowning through birth of the newborn</div><div class=\"cntnt\"><img style=\"width:432px; height:295px;\" src=\"images/OBGYN/51141_Photo_birth_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early crowning of the fetal head. Notice the bulging of the perineum.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright &#169;2009.</div><div id=\"graphicVersion\">Graphic 51141 Version 1.0</div></div></div>"},"51142":{"type":"graphic_picture","displayName":"Type 4 breast lobule","title":"Type 4 breast lobule","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Type 4 breast lobule</div><div class=\"cntnt\"><img style=\"width:468px; height:354px;\" src=\"images/SURG/51142_Breast_lobule_type4_light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a type 4 breast lobule type 4 obtained at beginning of lactation as viewed by light microscopy.<br />Microscopic sections fixed and stained with hematoxylin and eosin (H&amp;E). Photographs at 2.5x, and 40x respectively.</div><div class=\"graphic_reference\">Reproduced with permission from: Russo J, Hu Y-F, Silva IDCG, and Russo IH. Cancer risk related to mammary gland structure and development. Microscopy Research and Technique 2001; 52:204. Copyright &copy; 2001 American Cancer Society.</div><div id=\"graphicVersion\">Graphic 51142 Version 3.0</div></div></div>"},"51143":{"type":"graphic_table","displayName":"Chemotherapy induced amenorrhea by age and specific regimen","title":"Incidence of prolonged chemotherapy-induced amenorrhea according to age and type of adjuvant chemotherapy regimen","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of prolonged chemotherapy-induced amenorrhea according to age and type of adjuvant chemotherapy regimen</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Regimen</td> <td class=\"subtitle1\" colspan=\"2\">Incidence chemotherapy-induced amenorrhea according to age at treatment initiation (percent)</td> </tr> <tr> <td class=\"subtitle2\">&#60;40 years</td> <td class=\"subtitle2\">&#8805;40 years</td> </tr> <tr> <td>CMF</td> <td>30 to 80</td> <td>60 to 96</td> </tr> <tr> <td>AC</td> <td>13 to 30</td> <td>57 to 63</td> </tr> <tr> <td>FEC/FAC</td> <td>10 to 25</td> <td>80 to 90</td> </tr> <tr> <td>AC followed by a single agent taxane</td> <td>15 to 42</td> <td>66 to 77</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AC: doxorubicin plus cyclophosphamide; CMF: cyclophosphamide, methotrexate plus fluorouracil; FAC: fluorouracil, doxorubicin plus cyclophosphamide; FEC: fluorouracil, epirubicin plus cyclophosphamide.</div><div class=\"graphic_reference\">Data from: Stearns V, Schneider B, Henry NL, et al. Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nat Rev Cancer 2006; 6:886.</div><div id=\"graphicVersion\">Graphic 51143 Version 6.0</div></div></div>"},"51144":{"type":"graphic_figure","displayName":"Nerves prone to stretch or compression in lithotomy","title":"Nerves prone to stretch or compression in lithotomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nerves prone to stretch or compression in lithotomy</div><div class=\"cntnt\"><img style=\"width:446px; height:659px;\" src=\"images/SURG/51144_Bony_relat_low_extr_ner_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sciatic and femoral nerve stretching occurs with hip flexion and external rotation. The fibular (peroneal) nerve is superficial in the proximal leg and this site is prone to compression. The posterior tibial nerve is stretched with ankle dorsiflexion and is at risk when the foot is in stirrups.</div><div id=\"graphicVersion\">Graphic 51144 Version 5.0</div></div></div>"},"51145":{"type":"graphic_figure","displayName":"Apoptotic cells immune response","title":"A possible mechanism explaining how defective clearance of apoptotic cells predisposes to systemic autoimmunity","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">A possible mechanism explaining how defective clearance of apoptotic cells predisposes to systemic autoimmunity</div><div class=\"cntnt\"><img style=\"width:547px; height:351px;\" src=\"images/RHEUM/51145_Apoptotic_cells_immune_resp.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Keith Elkon, MD.</div><div id=\"graphicVersion\">Graphic 51145 Version 1.0</div></div></div>"},"51147":{"type":"graphic_table","displayName":"ADA recognition measures","title":"American Diabetes Association provider recognition measures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Diabetes Association provider recognition measures</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Measure</td> <td class=\"subtitle1\">Frequency</td> </tr> <tr> <td>A1C test (calculate proportion of patients with A1C value of less than 8 and 10 percent)</td> <td>At least once a year</td> </tr> <tr> <td>Retinal examination</td> <td>At least once a year</td> </tr> <tr> <td>Foot care evaluation</td> <td>At least once a year</td> </tr> <tr> <td>Blood pressure measurement (calculate proportion of patients with diastolic pressures of less than 90 mmHg)</td> <td>At least twice a year</td> </tr> <tr> <td>Measurement of urinary protein/microalbumineria</td> <td>Once a year</td> </tr> <tr> <td>Lipid profile evaluation</td> <td>Once a year</td> </tr> <tr> <td>Tobacco smoking status and counseling referral (document in chart)</td> <td>&nbsp;</td> </tr> <tr> <td>Assessment of patient monitoring of blood glucose (obtained from patient survey)</td> <td>&nbsp;</td> </tr> <tr> <td>Patient satisfaction questions (obtained from patient survey)</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">A1C: glycated hemoglobin.</div><div id=\"graphicVersion\">Graphic 51147 Version 2.0</div></div></div>"},"51148":{"type":"graphic_picture","displayName":"Follicular thyroid cancer magnification","title":"Follicular thyroid cancer: Magnification of surgical specimen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Follicular thyroid cancer: Magnification of surgical specimen</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/ENDO/51148_magnification_follic_thyroi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnification of surgical specimen demonstrating capsular invasion of a follicular neoplasm. Diagnosis of follicular thyroid cancer is based on the identification of capsular and/or vascular invasion of the tumor, not simply cytologic features.</div><div class=\"graphic_reference\">Courtesy of Stephanie L Lee, MD, PhD.</div><div id=\"graphicVersion\">Graphic 51148 Version 4.0</div></div></div>"},"51149":{"type":"graphic_picture","displayName":"Hepatic adenoma Light","title":"Hepatic adenoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatic adenoma</div><div class=\"cntnt\"><img style=\"width:395px; height:259px;\" src=\"images/GAST/51149_Hepatic_adenoma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin and eosin slide of an hepatic adenoma. Adenoma cells resemble normal hepatocytes but have small regular nuclei and some fat vacuoles and are arranged in thickened trabeculae. There is a characteristic absence of portal tracts.</div><div class=\"graphic_reference\">Courtesy of Sanjiv Chopra, MD.</div><div id=\"graphicVersion\">Graphic 51149 Version 1.0</div></div></div>"},"51152":{"type":"graphic_figure","displayName":"Lead exposure questionnaire","title":"Adult lead exposure questionnaire","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Adult lead exposure questionnaire</div><div class=\"cntnt\"><img style=\"width:462px; height:530px;\" src=\"images/NEPH/51152_Lead_exposure_questionnaire.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Virginia M Weaver, MD, MPH and Bernard G Jaar, MD, MPH, FASN.</div><div id=\"graphicVersion\">Graphic 51152 Version 2.0</div></div></div>"},"51153":{"type":"graphic_table","displayName":"Osmoregulation v volume reg","title":"Differences between osmoregulation and volume regulation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differences between osmoregulation and volume regulation</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">&nbsp;</td>\r\n                    <td class=\"subtitle1\">Osmoregulation</td>\r\n                    <td class=\"subtitle1\">Volume regulation</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>What is being sensed</td>\r\n                    <td>Plasma osmolality</td>\r\n                    <td>Effective circulating volume</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"3\">Sensors</td>\r\n                    <td rowspan=\"3\">Hypothalamic osmoreceptors</td>\r\n                    <td>Carotic sinus</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Afferent glomerular arteriole</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Atria</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"5\">Effectors</td>\r\n                    <td rowspan=\"5\">Antidiuretic hormone</td>\r\n                    <td>Sympathetic nervous system</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Renin-angiotensin-aldosterone</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Natriuretic peptides</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Pressure natriuresis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Antidiuretic hormone</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"2\">What is affected</td>\r\n                    <td>Water excretion (via ADH)</td>\r\n                    <td rowspan=\"2\">Sodium excretion</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Water intake (via thirst)</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 51153 Version 2.0</div></div></div>"},"51155":{"type":"graphic_table","displayName":"LV dose adjustment","title":"Recommendations for dose adjustment of leucovorin (d,l-racemic mixture) for prolonged methotrexate excretion*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for dose adjustment of leucovorin (d,l-racemic mixture) for prolonged methotrexate excretion*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical situation</td> <td class=\"subtitle1\">Laboratory findings</td> <td class=\"subtitle1\">Leucovorin dosage and duration</td> </tr> <tr class=\"divider_bottom\"> <td>Normal methotrexate elimination</td> <td>Serum methotrexate level approximately 10 micromolar at 24 hours after administration, 1 micromolar at 48 hours, and less than 0.2 micromolar at 72 hours.</td> <td>15 mg orally, IM, or IV every 6 hours for 60 hours (10 doses starting at 24 hours after start of methotrexate infusion).</td> </tr> <tr class=\"divider_bottom\"> <td>Delayed late methotrexate elimination</td> <td>Serum methotrexate level remaining above 0.2 micromolar at 72 hours, and more than 0.05 micromolar at 96 hours after administration.</td> <td>Continue 15 mg orally, IM, or IV every 6 hours, until methotrexate level is less than 0.05 micromolar.</td> </tr> <tr> <td>Delayed early methotrexate elimination and/or evidence of acute renal injury</td> <td>Serum methotrexate level of 50 micromolar or more at 24 hours, or 5 micromolar or more at 48 hours after administration, OR; a 100% or greater increase in serum creatinine level at 24 hours after methotrexate administration (eg, an increase from 0.5 mg/dL to a level of 1 mg/dL or more).</td> <td>150 mg IV every 3 hours, until methotrexate level is less than 1 micromolar; then 15 mg IV every 3 hours until methotrexate level is less than 0.05 micromolar.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* This table is for general use only, local hospital practice and specific protocol predefined leucovorin dose adjustments should supercede use of this table for clinical practice.<br />&para; Consider adjunctive means of lowering methotrexate (MTX) levels (see section on \"Adjuctive rescue techniques\").</div><div class=\"graphic_reference\">Leucovorin calcium injection, powder, for solution. United States Prescribing Information. Revised 9, 2014. US National Library of Medicine. (Available online at <a href=\"http://www.dailymed.nlm.nih.gov/\" spellcheck=\"true\" target=\"_blank\">www.dailymed.nlm.nih.gov</a>).</div><div id=\"graphicVersion\">Graphic 51155 Version 4.0</div></div></div>"},"51156":{"type":"graphic_algorithm","displayName":"Hirschsprung diagnosis","title":"Assessment for Hirschsprung disease in infants and young children","html":"<div class=\"graphic\"><div style=\"width: 794px\" class=\"figure\"><div class=\"ttl\">Assessment for Hirschsprung disease in infants and young children</div><div class=\"cntnt\"><img style=\"width:774px; height:519px;\" src=\"images/PEDS/51156_Hirschsprung_diagnosis_edt3.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* The \"squirt sign\" is a forceful expulsion of gas and stool as the finger is withdrawn from the anus after the digital rectal examination, particularly in infants.<br />¶ For more details on the evaluation and management of Hirschsprung-associated entercolitis (HAEC), refer to UpToDate content on emergency complications of Hirschsprung disease.<br />Δ In our practice, we generally perform a barium enema rather than suction biopsy as the initial diagnostic procedure; if a clear transition zone is seen, the study is virtually pathognomonic of Hirschsprung disease and helps the surgeon plan the level of resection preoperatively. We always confirm the diagnosis by biopsy even when the barium enema shows typical features of Hirschsprung disease. Even if a transition zone is not seen, Hirschsprung disease cannot be entirely excluded. The barium enema may have false-negative results if performed within 24 hours of a digital rectal examination.<br /><FONT class=lozenge>◊</FONT> Some providers proceed to an anorectal manometry and/or rectal suction biopsy without a barium enema. If ganglia are seen in an appropriately performed suction biopsy, Hirschsprung disease is excluded. Lack of ganglia on the suction biopsy is suspicious for Hirschsprung disease, but the diagnosis may have to be confirmed by a full-thickness rectal biopsy if the pathologist considers the suction biopsy to be an inadequate sample. Similarly, normal results of anorectal manometry can exclude Hirschsprung disease, but abnormal results should be confirmed by biopsy. Anorectal manometry is less accurate in infants under one month of age.</div><div id=\"graphicVersion\">Graphic 51156 Version 6.0</div></div></div>"},"51157":{"type":"graphic_figure","displayName":"Thoracic aortic aneurysm expansion by location","title":"Thoracic aortic aneurysm expansion by location","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Thoracic aortic aneurysm expansion by location</div><div class=\"cntnt\"><img style=\"width:470px; height:330px;\" src=\"images/CARD/51157_Thoracic_aneurysm_expansion.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear expansion rate is shown according to segment level; aneurysms located in the mid portion of the thoracic aorta (segments D and E) have the greatest rate of expansion, while those in the ascending aorta (segments A to C) had the slowest rate of growth.</div><div class=\"graphic_reference\">Data from Bonser, RS, Pagano, D, Lewis, ME, et al. Heart 2000; 84:277.</div><div id=\"graphicVersion\">Graphic 51157 Version 2.0</div></div></div>"},"51160":{"type":"graphic_picture","displayName":"Pappenheimer bodies","title":"Siderocyte containing Pappenheimer bodies in sideroblastic anemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Siderocyte containing Pappenheimer bodies in sideroblastic anemia</div><div class=\"cntnt\"><img style=\"width:416px; height:286px;\" src=\"images/HEME/51160_Pappenheimer_bodies_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral smear from a patient with clonal sideroblastic anemia, showing a population of hypochromic and microcytic red cells. One hypochromic red cell (arrow) has three iron-containing inclusions, called Pappenheimer bodies.</div><div class=\"graphic_reference\">Courtesy of Sylvia Bottomley, MD.</div><div id=\"graphicVersion\">Graphic 51160 Version 4.0</div></div></div>"},"51161":{"type":"graphic_picture","displayName":"Interdigital scabies","title":"Interdigital lesions of scabies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Interdigital lesions of scabies</div><div class=\"cntnt\"><img style=\"width:256px; height:400px;\" src=\"images/PC/51161_Interdigital_scabies.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The essential lesion is a small, erythematous, nondescript papule.</div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 51161 Version 2.0</div></div></div>"},"51162":{"type":"graphic_figure","displayName":"Pulmonary artery tracing","title":"Pulmonary artery pressure tracing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary artery pressure tracing</div><div class=\"cntnt\"><img style=\"width:404px; height:300px;\" src=\"images/PULM/51162_Pulmonary_artery_tracing.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schematic diagram shows the demonstrates key features of the pulmonary artery pressure tracing. A simultaneous ECG is shown to demonstrate the timing of the different components. The peak systolic pressure falls within the electrocardiographic T wave.</div><div class=\"graphic_reference\">Redrawn from Gore, JM, Alpert, JS, Benotti, JR, et al, Handbook of hemodynamic monitoring, 1st edition, Boston, Little Brown &amp; Co, 1985.</div><div id=\"graphicVersion\">Graphic 51162 Version 1.0</div></div></div>"},"51164":{"type":"graphic_picture","displayName":"Shawl sign","title":"The shawl sign in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The shawl sign in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:432px; height:264px;\" src=\"images/RHEUM/51164_shawl_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of John H. Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 51164 Version 2.0</div></div></div>"},"51165":{"type":"graphic_picture","displayName":"Acral lentiginous melanoma in situ","title":"Acral lentiginous melanoma in situ","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Acral lentiginous melanoma in situ</div><div class=\"cntnt\"><img style=\"width:756px; height:697px;\" src=\"images/DERM/51165_Acrl_lntgns_melanoma_situ.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acral lentiginous melanoma in situ on the left index finger of a 74-year-old man, presenting as a linear pigmented streak (melanonychia striata) with Hutchinson sign (pigmentation of the proximal and lateral nail folds).</div><div id=\"graphicVersion\">Graphic 51165 Version 2.0</div></div></div>"},"51166":{"type":"graphic_picture","displayName":"Neonatal lupus erythematosus","title":"Neonatal lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Neonatal lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/51166_Neonatal_lupus_erythematos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular erythematous thin plaques are present on the head.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51166 Version 3.0</div></div></div>"},"51167":{"type":"graphic_diagnosticimage","displayName":"Cavernous transformation PV CT","title":"Cavernous transformation of portal vein thrombosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cavernous transformation of portal vein thrombosis</div><div class=\"cntnt\"><img style=\"width:387px; height:288px;\" src=\"images/GAST/51167_CavernoustransformationPV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced CT scan of the upper abdomen in a 45-year-old male alcoholic demonstrates multiple periportal collateral vessels (small arrows) which have developed secondary to chronic portal vein thrombosis. The portal vein thrombosed due to chronic pancreatitis; a small pancreatic pseudocyst is seen in the body of the pancreas (large arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 51167 Version 4.0</div></div></div>"},"51169":{"type":"graphic_picture","displayName":"Tertiary syphilis","title":"Tertiary syphilis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tertiary syphilis</div><div class=\"cntnt\"><img style=\"width:395px; height:252px;\" src=\"images/ID/51169_Tertiary_syphilis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Noduloulcerative lesions in a ring-like distribution on the posterior thigh, known as lues maligna, in a patient with tertiary syphilis.</div><div class=\"graphic_reference\">Courtesy of David H Martin and Tomasz F Mroczkowski. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 51169 Version 5.0</div></div></div>"},"51170":{"type":"graphic_table","displayName":"Clinical features of myoclonus","title":"Clinical features of specific types of myoclonus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of specific types of myoclonus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Distribution</td> <td class=\"subtitle1\">Temporal profile</td> <td class=\"subtitle1\">Activation</td> <td class=\"subtitle1\">Clinical neurophysiology</td> <td class=\"subtitle1\">Anatomic-physiologic classification</td> <td class=\"subtitle1\">Clinical-etiologic classification</td> <td class=\"subtitle1\">Specific etiology</td> </tr> <tr> <td>Hypnic jerks (massive myoclonus of sleep)</td> <td>Generalized</td> <td>Usually single</td> <td>Occur only during sleep or sleep transitions</td> <td>Not studied</td> <td>Presumed subcortical-nonsegmental</td> <td>Physiologic</td> <td>Normal phenomenon</td> </tr> <tr class=\"divider_top\"> <td>Partial myoclonic jerks (of sleep)</td> <td>Multifocal, distal muscles</td> <td>Usually single</td> <td>Occur only during sleep or sleep transitions</td> <td>Not studied</td> <td>Presumed subcortical-nonsegmental</td> <td>Physiologic</td> <td>Normal phenomenon</td> </tr> <tr class=\"divider_top\"> <td>Myoclonus-dystonia</td> <td>Neck, trunk, proximal arms</td> <td>Irregular</td> <td>Rest, action, and posture</td> <td>EMG with 50 to 100 ms discharges; EEG and SEP normal</td> <td>Subcortical-nonsegmental</td> <td>Essential</td> <td>Genetically heterogeneous; DYT11, DYT15 mutations</td> </tr> <tr class=\"divider_top\"> <td>Juvenile myoclonic epilepsy</td> <td>Usually generalized</td> <td>Irregular</td> <td>Occurs from rest</td> <td>EEG with 4 to 6-hertz polyspike and wave discharge</td> <td>Cortical-subcortical</td> <td>Epileptic</td> <td>Genetically heterogeneous; EFHC1 and GABRA1 mutations</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Palatal tremor</td> <td rowspan=\"2\">Palate, larynx, face; usually bilateral</td> <td rowspan=\"2\">Rhythmic</td> <td rowspan=\"2\">Persistent, continues during sleep</td> <td rowspan=\"2\">EMG with &#62;100 ms rhythmic discharges</td> <td rowspan=\"2\">Segmental</td> <td>Symptomatic (secondary) palatal tremor</td> <td>Brainstem pathology in the region of the Guillain-Mollaret triangle</td> </tr> <tr> <td>Essential palatal tremor</td> <td>Idiopathic</td> </tr> <tr class=\"divider_top\"> <td>Posthypoxic myoclonus</td> <td>Multifocal and/or generalized</td> <td>Irregular, less often rhythmic</td> <td>Action and reflex</td> <td>EMG discharges &#60;50 ms; cortical EEG correlate grossly time-locked with EEG back-averaging</td> <td>Cortical</td> <td>Symptomatic (secondary)</td> <td>Hypoxic brain injury</td> </tr> <tr class=\"divider_top\"> <td>Progressive myoclonus epilepsy (PME) and progressive myoclonus ataxia (PMA)</td> <td>Multifocal and/or generalized</td> <td>Irregular</td> <td>Action and reflex</td> <td>EMG discharges &#60;50 ms; cortical EEG correlate grossly time-locked with EEG back-averaging</td> <td>Cortical</td> <td>Symptomatic (secondary)</td> <td>Unverricht-Lundborg disease, Lafora body disease, neuronal ceroid lipofuscinosis, myoclonic epilepsy with ragged red fibers (MERRF), sialidosis</td> </tr> <tr class=\"divider_top\"> <td>Toxic-metabolic myoclonus</td> <td>Multifocal, sometimes generalized</td> <td>Irregular</td> <td>Rest and action</td> <td>Variable; positive or negative myoclonus; EMG discharges or silence lasting 50 to 200 ms; cortical correlate possible</td> <td>Cortical most common</td> <td>Symptomatic (secondary)</td> <td>Drugs, toxins, organ failure</td> </tr> <tr class=\"divider_top\"> <td>Neurodegenerative disease</td> <td>Multifocal and worse distally; sometimes generalized</td> <td>Irregular</td> <td>Action most common, then rest and reflex</td> <td>EMG discharges &#60;50 ms; cortical EEG correlate grossly time-locked with EEG back-averaging</td> <td>Cortical</td> <td>Symptomatic</td> <td>Alzheimer disease, dementia with Lewy bodies, Parkinson disease, Huntington disease</td> </tr> <tr class=\"divider_top\"> <td>Creutzfeldt-Jakob disease</td> <td>Focal, multifocal, or generalized</td> <td>Single, irregular, or rhythmic</td> <td>Rest, action, and/or reflex in response to somatosensory stimuli, particularly loud noise (startle)</td> <td>EEG with periodic synchronous biphasic or triphasic sharp wave complexes; EMG discharge &#60;50 ms</td> <td>Cortical</td> <td>Symptomatic (secondary)</td> <td>Prion disease</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51170 Version 5.0</div></div></div>"},"51171":{"type":"graphic_figure","displayName":"Paracervical block OBS","title":"Paracervical block","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paracervical block</div><div class=\"cntnt\"><img style=\"width:419px; height:366px;\" src=\"images/OBGYN/51171_Paracervical_block_OBS.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51171 Version 2.0</div></div></div>"},"51172":{"type":"graphic_table","displayName":"Reg nodal stations colorectal CA","title":"The regional lymph nodal stations for each segment of the colon and rectum","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The regional lymph nodal stations&nbsp;for each segment of the colon and rectum</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Segment</td> <td class=\"subtitle1\">Regional lymph nodes</td> </tr> <tr> <td>Cecum</td> <td>Pericolic, anterior cecal, posterior cecal, ileocolic, right colic</td> </tr> <tr> <td>Ascending colon</td> <td>Pericolic, ileocolic, right colic, middle colic</td> </tr> <tr> <td>Hepatic flexure</td> <td>Pericolic, middle colic, right colic</td> </tr> <tr> <td>Transverse colon</td> <td>Pericolic, middle colic</td> </tr> <tr> <td>Splenic flexure</td> <td>Pericolic, middle colic, left colic, inferior mesenteric</td> </tr> <tr> <td>Descending colon</td> <td>Pericolic, left colic, inferior mesenteric, sigmoid</td> </tr> <tr> <td>Sigmoid colon</td> <td>Pericolic, inferior mesenteric, superior rectal (hemorrhoidal), sigmoidal, sigmoid mesenteric</td> </tr> <tr> <td>Rectosigmoid</td> <td>Pericolic, perirectal, left colic, sigmoid mesenteric, sigmoidal, inferior mesenteric, superior rectal (hemorrhoidal), middle rectal (hemorrhoidal)</td> </tr> <tr> <td>Rectum</td> <td>Perirectal, sigmoid mesenteric, inferior mesenteric, lateral sacral presacral, internal iliac, sacral promontory, internal iliac, superior rectal (hemorrhoidal), middle rectal (hemorrhoidal), inferior rectal (hemorrhoidal)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 51172 Version 14.0</div></div></div>"},"51173":{"type":"graphic_picture","displayName":"Dermoscopy melanoma 4","title":"Melanoma with white shiny lines","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Melanoma with white shiny lines</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/51173_Dermoscopy_melanoma_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Melanoma with crystalline structures (white shiny lines) (dashed square).</div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 51173 Version 2.0</div></div></div>"},"51174":{"type":"graphic_picture","displayName":"Scapular strength Y PI","title":"Scapular strengthening exercise - \"Y\"","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scapular strengthening exercise - \"Y\"</div><div class=\"cntnt\"><img style=\"width:344px; height:646px;\" src=\"images/PI/51174_Scapular_strength_Y_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) For these exercises, you should lie face down on an elevated surface, like a bed, exercise bench, or large exercise ball. The head should be held in line with the body, hanging over the edge of the bed or bench.<br />(B) Let the arms rest below the body.<br />(C) Extend the arms next to the head to form a \"Y\"; make sure your thumbs are facing up. Hold the position for a second or two, then let the arms return to the floor. Repeat 10 to 15 times. Movements should be steady, smooth, and pain-free.</div><div id=\"graphicVersion\">Graphic 51174 Version 4.0</div></div></div>"},"51175":{"type":"graphic_table","displayName":"Key messages in anaphylaxis education","title":"Key messages in anaphylaxis education*: Anaphylaxis = Killer allergy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key messages in anaphylaxis education*: Anaphylaxis = Killer allergy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Who is at risk?</td> </tr> <tr> <td class=\"indent1\">Anyone, especially those allergic to foods, such as peanut, tree nuts, shellfish, fish, milk, or egg or to insect stings or bites, medications, or natural rubber latex.</td> </tr> <tr> <td class=\"subtitle2_left\">When can it happen?</td> </tr> <tr> <td class=\"indent1\">Within minutes, anytime the allergic person comes in contact with the substance (allergen) causing&nbsp;his/her anaphylaxis.</td> </tr> <tr> <td class=\"subtitle2_left\">How is it recognized?</td> </tr> <tr> <td class=\"indent1\">Several symptoms occur at the same time, such as sudden onset of itching, hives, flushing, hoarse voice, difficulty breathing, vomiting, diarrhea, dizziness, confusion, or shock.</td> </tr> <tr> <td class=\"subtitle2_left\">Where can it happen?</td> </tr> <tr> <td class=\"indent1\">Anywhere, such as home, restaurant, school, childcare or sports facility, summer camp, car, bus, or airplane.</td> </tr> <tr> <td class=\"subtitle2_left\">What should an observer or bystander do?</td> </tr> <tr> <td class=\"indent1\">Inject epinephrine, call 911 or local emergency medical service number, and notify the individual's family (in that order)! Act quickly. Anaphylaxis can be mild or it can be fatal.</td> </tr> <tr> <td class=\"subtitle2_left\">Why is follow-up needed?</td> </tr> <tr> <td class=\"indent1\">Anaphylaxis can recur. The trigger needs to be confirmed, and long-term preventative strategies need to be implemented.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For individuals at risk and their caregivers and for the general public.</div><div class=\"graphic_reference\">Reproduced with permission from: Simons FER. Anaphylaxis, killer allergy: Long-term management in the community. J Allergy Clin Immunol 2006; 117:367. Copyright © 2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 51175 Version 11.0</div></div></div>"},"51176":{"type":"graphic_figure","displayName":"Abdomen anatomy adult","title":"Adult abdominal anatomy","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Adult abdominal anatomy</div><div class=\"cntnt\"><img style=\"width:517px; height:576px;\" src=\"images/GAST/51176_Abdomen_anatomy_adult.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51176 Version 2.0</div></div></div>"},"51178":{"type":"graphic_waveform","displayName":"Electrocardiographic changes adenosine","title":"ECG changes in paroxysmal SVT after administration of adenosine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ECG changes in paroxysmal SVT after administration of adenosine</div><div class=\"cntnt\"><img style=\"width:436px; height:363px;\" src=\"images/PEDS/51178_ECG_changes_adenosine.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three sets of simultaneous electrocardiographic rhythms in a two-month-old baby with signs and symptoms of mild heart failure and in whom ice-cold wet cloth failed to convert the paroxysmal SVT (PSVT) of 293 bpm (cycle length of 205 msec). Adenosine successfully converted the PSVT to sinus rhythm with an intravenous bolus dose of 150 microgram/kg (panel C) after failure at lower doses. The prediction of an orthodromic reciprocating tachycardia mechanism by noting P waves in the ST-T segments during tachycardia is supported by the finding of Wolff-Parkinson-White syndrome during sinus rhythm after conversion (panel C).</div><div class=\"graphic_footnotes\">SVT: supraventricular tachycardia; HR: heart rate; bpm: beats per minute.</div><div class=\"graphic_reference\">Reproduced with permission from: Kugler JD, Danford DA. Management of infants, children, and adolescents with paroxysmal supraventricular tachycardia. J Pediatr 1996; 129:324. Copyright &copy; 1996 Elsevier.</div><div id=\"graphicVersion\">Graphic 51178 Version 4.0</div></div></div>"},"51180":{"type":"graphic_table","displayName":"Screening SUDs","title":"Screening for alcohol and drug use: The CAGE-AID questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Screening for alcohol and drug use: The CAGE-AID questionnaire</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Item\n   </td>\n   <td  class=\"subtitle1\">\n   Text\n   </td>\n   </tr>\n   <tr>\n   <td>1.</td>\n   <td>Have you ever felt you ought to cut down on your drinking or drug use?</td>\n   </tr>\n   <tr>\n   <td>2.</td>\n   <td>Have people annoyed you by criticizing your drinking or drug use?</td>\n   </tr>\n   <tr>\n   <td>3.</td>\n   <td>Have you ever felt bad or guilty about your drinking or drug use?</td>\n   </tr>\n   <tr>\n   <td>4.</td>\n   <td>Have your ever had a drink or used drugs first thing in the morning to steady your nerves or get rid of a hangover?</td>\n   </tr>\n </table></div><div class=\"graphic_lgnd\">NOTE: The CAGE-AID is a modification of the CAGE questionnaire, adapted to include drugs in addition to alcohol use. Use of the CAGE-AID should be preceded by the following instruction: &quot;When thinking about drug use, include illegal drug use and the use of prescription drugs other than as prescribed.&quot;</div><div class=\"graphic_reference\">Reproduced from: Brown, RL, Leonard, T, Saunders, LA, Papasouliotis, O. The prevalence and detection of substance use disorder among inpatients ages 18 to 49: An opportunity for prevention. Preventive Medicine 1998; 27:101. Illustration used with permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 51180 Version 1.0</div></div></div>"},"51182":{"type":"graphic_figure","displayName":"Radial head and neck fracture","title":"Radial head and neck fracture","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Radial head and neck fracture</div><div class=\"cntnt\"><img style=\"width:461px; height:312px;\" src=\"images/EM/51182_Radialheadandneckfrac.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radial neck angulation.</div><div class=\"graphic_reference\">Reproduced with permission from: Pring ME, Wenger DR, Rang M. Elbow: Proximal radius and ulna. In: Rang's Children's Fractures, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 51182 Version 9.0</div></div></div>"},"51183":{"type":"graphic_table","displayName":"Treatment of leprosy in adults","title":"Multidrug regimens for treatment of leprosy in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Multidrug regimens for treatment of leprosy in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">National Hansen's Disease Program (NHDP)*</td> <td class=\"subtitle1\" colspan=\"2\">World Health Organization (WHO)<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2\">Regimen</td> <td class=\"subtitle2\">Dose</td> <td class=\"subtitle2\">Duration<sup>&#916;</sup></td> <td class=\"subtitle2\">Dose</td> <td class=\"subtitle2\">Duration</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Tuberculoid (\"paucibacillary\"): TT and BT<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Dapsone</td> <td>100 mg daily</td> <td class=\"divider_bottom\" rowspan=\"2\">12 months</td> <td>100 mg daily</td> <td class=\"divider_bottom\" rowspan=\"2\">6 months</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Rifampin</td> <td>600 mg daily</td> <td>600 mg once a month</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Lepromatous (\"multibacillary\"): LL, BL, BB<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Dapsone</td> <td>100 mg daily</td> <td rowspan=\"3\">24 months</td> <td>100 mg daily</td> <td rowspan=\"3\">12 months</td> </tr> <tr> <td class=\"indent1\">Rifampin</td> <td>600 mg daily</td> <td>600 mg once a month</td> </tr> <tr> <td class=\"indent1\">Clofazimine<sup>&#167;</sup></td> <td>50 mg daily</td> <td>300 mg once a month, and 50 mg daily</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TT: tuberculoid; BT: borderline tuberculoid; LL: lepromatous; BL: borderline lepromatous; BB: mid-borderline. <br />* Additional information available at the NHDP website: <A href=\"http://www.hrsa.gov/hansensdisease/diagnosis/recommendedtreatment.html\" target=_blank>http://www.hrsa.gov/hansensdisease/diagnosis/recommendedtreatment.html</A>.<br />¶ Additional information available at the WHO website: <A href=\"http://www.searo.who.int/en/Section10/Section20/Section2000.htm\" target=_blank>http://www.searo.who.int/en/Section10/Section20/Section2000.htm</A>.<br />Δ The durations of treatment outlined by NHDP are sufficient even though large numbers of dead bacilli may remain in tissues for several years before they are eliminated by physiologic processes. There is no evidence that prolonged treatment hastens the elimination of these dead organisms.<br /><FONT class=lozenge>◊</FONT> TT, BT, BB, BL, and LL refer to the Ridley-Jopling classification (refer to the&nbsp;text).<br />§ In the United States, the NHDP holds the Investigational New Drug (IND) application for clofazimine treatment of leprosy. For further information or to request investigator status to use clofazimine, contact the NHDP: 1-800-642-2477. Clofazimine should be taken either with or immediately after food or milk to facilitate absorption. If clofazimine is not tolerated, daily minocycline may be substituted.</div><div id=\"graphicVersion\">Graphic 51183 Version 6.0</div></div></div>"},"51184":{"type":"graphic_movie","displayName":"Pericardial effusion without tamponade subcostal view","title":"Pericardial effusion","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pericardial effusion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/51184_subpref1conv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:320px; height:240px;\" src=\"images/CARD/51184_subpref1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subcostal four-chamber view from a two-dimensional echocardiogram shows a moderate-sized pericardial effusion (PE) in a patient with normal hemodynamics at cardiac catheterization. The effusion surrounds the right atrium (RA), right ventricle (RV) and left ventricle (LV).</div><div class=\"graphic_reference\">Courtesy of Ralph Shabetai, MD.</div><div id=\"graphicVersion\">Graphic 51184 Version 2.0</div></div></div>"},"51185":{"type":"graphic_table","displayName":"Fetal leukocyte count by GA","title":"Total leukocyte count, 10<sup>9</sup>/L","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Total leukocyte count, 10<sup>9</sup>/L</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">GA</td>\n<td class=\"subtitle1\">5th percentile</td>\n<td class=\"subtitle1\">Mean</td>\n<td class=\"subtitle1\">95th percentile</td>\n</tr>\n<tr>\n<td>20</td>\n<td>1.73</td>\n<td>2.82</td>\n<td>4.16</td>\n</tr>\n<tr>\n<td>22</td>\n<td>2.07</td>\n<td>3.23</td>\n<td>4.67</td>\n</tr>\n<tr>\n<td>24</td>\n<td>2.33</td>\n<td>3.56</td>\n<td>5.07</td>\n</tr>\n<tr>\n<td>26</td>\n<td>2.56</td>\n<td>3.84</td>\n<td>5.42</td>\n</tr>\n<tr>\n<td>28</td>\n<td>2.81</td>\n<td>4.16</td>\n<td>5.81</td>\n</tr>\n<tr>\n<td>30</td>\n<td>3.15</td>\n<td>4.58</td>\n<td>6.34</td>\n</tr>\n<tr>\n<td>32</td>\n<td>3.65</td>\n<td>5.21</td>\n<td>7.12</td>\n</tr>\n<tr>\n<td>34</td>\n<td>4.45</td>\n<td>6.19</td>\n<td>8.34</td>\n</tr>\n<tr>\n<td>36</td>\n<td>5.71</td>\n<td>7.75</td>\n<td>10.26</td>\n</tr>\n<tr>\n<td>38</td>\n<td>7.73</td>\n<td>10.26</td>\n<td>13.39</td>\n</tr>\n<tr>\n<td>40</td>\n<td>10.98</td>\n<td>14.45</td>\n<td>18.77</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 51185 Version 1.0</div></div></div>"},"51186":{"type":"graphic_table","displayName":"Blood pressure children","title":"Normal blood pressure in children: 50th to 90th percentiles","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal blood pressure in children: 50th to 90th percentiles</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Systolic pressure, mm Hg</td> <td class=\"subtitle1\">Diastolic pressure, mm Hg</td> </tr> <tr> <td>Birth, 12 hours, &#60;1000 g</td> <td>39-59</td> <td>16-36</td> </tr> <tr> <td>Birth, 12 hours, 3 kg </td> <td>50-70</td> <td>25-45</td> </tr> <tr> <td>Neonate, 96 hours</td> <td>60-90</td> <td>20-60</td> </tr> <tr> <td>Infant, 6 months</td> <td>87-105</td> <td>53-66</td> </tr> <tr> <td>Toddler, 2 years</td> <td>95-105</td> <td>53-66</td> </tr> <tr> <td>School age, 7 years</td> <td>97-112</td> <td>57-71</td> </tr> <tr> <td>Adolescent, 15 years</td> <td>112-128</td> <td>66-88</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The median (50th percentile) systolic blood pressure for children older than 1 year may be approximated by the following formula: 90 mm Hg + (2 x age in years). The lower limit (5th percentile) of systolic blood pressure can be estimated with this formula: 70mm Hg + (2 x age in years).<br> A low systolic blood pressure should prompt an immediate evaluation for additional signs of inadequate perfusion, such as diminished mental status, prolonged capillary refill, and tachycardia.</div><div class=\"graphic_reference\">Data from: Vershold, H. Aortic blood pressure during the first 12 hours of life in infants with birth weight 610-4220 grms. Pediatrics 1981; 67:107 and Report of the second Task Force on Blood Pressure Control in Children--1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. Pediatrics 1987; 79:1.</div><div id=\"graphicVersion\">Graphic 51186 Version 3.0</div></div></div>"},"51187":{"type":"graphic_diagnosticimage","displayName":"Humeral fracture infant","title":"Left distal humerus fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left distal humerus fracture</div><div class=\"cntnt\"><img style=\"width:360px; height:369px;\" src=\"images/PEDS/51187_Humeral_fracture_infant.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Rajvee Shah, MD.</div><div id=\"graphicVersion\">Graphic 51187 Version 2.0</div></div></div>"},"51188":{"type":"graphic_table","displayName":"Severity of illness score pediatric DLD","title":"Severity-of-illness score for children with chronic interstitial lung disease (diffuse lung disease)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Severity-of-illness score for children with chronic&nbsp;interstitial lung disease (diffuse lung disease)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td>1.</td>\n\n\n      <td>Asymptomatic</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>2.</td>\n\n\n      <td>Symptomatic, normal room air oxygen saturation under all conditions</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>3.</td>\n\n\n      <td>Symptomatic, normal resting room air saturation, but abnormal saturation (&#60;90 percent) with sleep or exercise</td>\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n      <td>4.</td>\n\n\n      <td>Symptomatic, abnormal resting room air saturation (&#60;90 percent)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>5.</td>\n\n\n      <td>Symptomatic with pulmonary hypertension</td>\n\n\n    </tr>\n\n\n  \n  </tbody>\n</table>\n\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=55839&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Severity_of_illness_score_P.htm</title></head></div><div class=\"graphic_lgnd\">Diffuse lung disease (DLD) is traditionally known as interstitial lung disease (ILD). Because many of these disorders are associated with extensive alteration of alveolar and airway architecture, in addition to changes in the interstitial compartment, we prefer the term DLD rather than ILD. </div><div class=\"graphic_reference\">Reproduced with permission from: Fan LL, Kozinetz CA. Factors influencing survival in children with chronic interstitial lung disease. Am J Respir Crit Care Med 1997; 156:939. Official Journal of the American Thoracic Society. Copyright ©1997 American Lung Association.</div><div id=\"graphicVersion\">Graphic 51188 Version 4.0</div></div></div>"},"51189":{"type":"graphic_algorithm","displayName":"Thyroid screening for preterm infants","title":"Suggested protocol for thyroid screening in preterm infants (birth weight <1500 g or gestational age <32 weeks)","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Suggested protocol for thyroid screening in preterm infants (birth weight &lt;1500 g or gestational age &lt;32 weeks)</div><div class=\"cntnt\"><img style=\"width:537px; height:649px;\" src=\"images/PEDS/51189_thyroidscreenpreterm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Protocol may vary depending on infant's gestational age and on whether the screening program uses T4 versus TSH as a primary screening test.</div><div class=\"graphic_footnotes\">DOL: day of life; T4: thyroxine; TSH: thyrotropin stimulating hormone.<br />* A low T4 and non-elevated (normal or low) TSH on the initial screen is a common finding in preterm babies when screened by the primary T4-reflex TSH method. Infants with this result on the initial screen do not require serologic testing, but should be screened again at 2 to 4 weeks of age. Most infants will have normal results on the second screen. Those with persistent low T4 require further evaluation with serologic testing to evaluate for the possibility of central hypothyroidism.</div><div id=\"graphicVersion\">Graphic 51189 Version 6.0</div></div></div>"},"51190":{"type":"graphic_figure","displayName":"Flow CLL","title":"Flow cytometry of chronic lymphocytic leukemia","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Flow cytometry of chronic lymphocytic leukemia</div><div class=\"cntnt\"><img style=\"width:458px; height:452px;\" src=\"images/HEME/51190_FlowCLL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunophenotypic analysis of chronic lymphocytic leukemia (CLL) is usually performed using flow cytometry. Typically, the cells express CD23 and dim CD20. This figure displays flow cytometry results for CD5 and CD20 expression. The CLL cells are shown in red and demonstrate&nbsp;dim expression of CD20.</div><div class=\"graphic_reference\">Reproduced with permission from: Armitage JO, Mauch PM, Harris NL, et al. Non-Hodgkin Lymphomas, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins.&nbsp;<A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>. &nbsp;</div><div id=\"graphicVersion\">Graphic 51190 Version 12.0</div></div></div>"},"51191":{"type":"graphic_diagnosticimage","displayName":"Neurodegenerative CNS LCH","title":"Neurodegenerative central nervous system in Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neurodegenerative central nervous system in Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:360px; height:391px;\" src=\"images/HEME/51191_Neurodegenerative_CNS_LCH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T-2 FLAIR image brain in an LCH patient with neurodegenerative LCH. Hyperintense signal in the pons and cerebellum.</div><div class=\"graphic_footnotes\">LCH: Langerhans cell histiocytosis; FLAIR: fluid-attenuated inversion recovery. </div><div class=\"graphic_reference\">Courtesy of Kenneth L McClain, MD, PhD.</div><div id=\"graphicVersion\">Graphic 51191 Version 3.0</div></div></div>"},"51192":{"type":"graphic_diagnosticimage","displayName":"Ruptured spleen with arterial blush","title":"Ruptured spleen with arterial blush on contrast-enhanced computed tomography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ruptured spleen with arterial blush on contrast-enhanced computed tomography</div><div class=\"cntnt\"><img style=\"width:431px; height:329px;\" src=\"images/EM/51192_Ruptured_spleen_blush_ed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This adolescent received a direct blow to his left upper quadrant while playing soccer. Note the extravasation of intravenous contrast from the spleen (arrow) and the large amount of free fluid in the abdomen (arrowheads). He recovered without operation after one transfusion.</div><div class=\"graphic_reference\">Courtesy of David Wesson, MD.</div><div id=\"graphicVersion\">Graphic 51192 Version 4.0</div></div></div>"},"51193":{"type":"graphic_waveform","displayName":"ECG sick sinus syndrome","title":"Single lead electrocardiogram (ECG) showing sick sinus syndrome and atrial fibrillation","html":"<div class=\"graphic normal\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Single lead electrocardiogram (ECG) showing sick sinus syndrome and atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:547px; height:113px;\" src=\"images/CARD/51193_Sick_sinus_syndrome_ED.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rhythm strip showing sick sinus syndrome. The initial part (left) of the tracing reveals coarse atrial fibrillation with irregular ventricular response in the absence of drugs that slow AV nodal conduction. The atrial fibrillation terminates and is followed by a sinus beat with a prolonged sinus node recovery time of nearly four seconds.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 51193 Version 7.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"51194":{"type":"graphic_diagnosticimage","displayName":"Trabeculations HCM","title":"Apical trabeculations in hypertrophic cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apical trabeculations in hypertrophic cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:374px; height:234px;\" src=\"images/CARD/51194_Trabeculations_HCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical four-chamber echocardiographic view (panel A) from a patient with a hypertrophic cardiomyopathy shows heavy left ventricular (LV) apical trabeculations, suggestive of apical thrombus (arrows). However, on an ungated computed tomography scan with contrast (panel B) no filling defects suggestive of thrombus were seen.</div><div class=\"graphic_footnotes\">LA: left atrium; RA: right atrium; RV: right ventricle.</div><div id=\"graphicVersion\">Graphic 51194 Version 4.0</div></div></div>"},"51195":{"type":"graphic_figure","displayName":"Distal tibia intraosseous site","title":"Distal tibial intraosseous access site","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal tibial intraosseous access site</div><div class=\"cntnt\"><img style=\"width:344px; height:536px;\" src=\"images/EM/51195_DistaltibiaIOsite.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Entry site at the distal tibia.</div><div class=\"graphic_reference\">Reproduced with permission from: Hodge Dee III. Intraosseous infusion. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 51195 Version 11.0</div></div></div>"},"51197":{"type":"graphic_figure","displayName":"Mass closure of abdominal incisions","title":"Mass closure of abdominal incisions","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Mass closure of abdominal incisions</div><div class=\"cntnt\"><img style=\"width:462px; height:567px;\" src=\"images/SURG/51197_Mass_closure_of_incisions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Smead-Jones closure. Far-far-near-near. Suture passes laterally through rectus sheath and peritoneum and adjacent fat. The suture crosses midline to pick up medial edge of fascia on opposite side of incision. (B) Alternative closure. Far-near-near-far. The far bite is 1 to 1.5 cm away from the edge. The near bite is 5 mm from the edge. (C) Running mass closure. Two sutures are used, beginning from each pole of the incision. Sutures are 1 cm away from edge and 1 cm apart. The sutures are tied at the midpoint of the incision.</div><div class=\"graphic_reference\">Courtesy of Therese Trenhaile, MD.</div><div id=\"graphicVersion\">Graphic 51197 Version 2.0</div></div></div>"},"51198":{"type":"graphic_picture","displayName":"Abnormal larynx examples","title":"Abnormal larynx examples","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abnormal larynx examples</div><div class=\"cntnt\"><img style=\"width:225px; height:220px;\" src=\"images/PC/51198_Abnormal_larynx_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Photograph shows grade 1+ vocal fold edema.<br />(B) Grade 2+ vocal fold edema virtually always represents pseudosulcus vocalis.<br />(C) Pseudosulcus vocalis is seen on the right and some sessile changes on the left. The sessile changes are characteristic of grade 3+ vocal fold edema.<br />(D) Polypoid degeneration is graded as 4+ vocal fold edema. All four of these views also show partial or complete ventricular obliteration and various degrees of posterior commissure hypertrophy.</div><div class=\"graphic_reference\">Reproduced with permission from: Belafsky, P, Postma, G, Amin, M, Koufman, J. Symptoms and findings of laryngopharyngeal reflux. Ear Nose Throat J 2002; 81(9 Suppl 2):10. Copyright © 2002 Ear, Nose, and Throat Journal.</div><div id=\"graphicVersion\">Graphic 51198 Version 4.0</div></div></div>"},"51199":{"type":"graphic_picture","displayName":"Idiopathic granulomatous mastitis","title":"Idiopathic granulomatous mastitis (IGM)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Idiopathic granulomatous mastitis (IGM)</div><div class=\"cntnt\"><img style=\"width:307px; height:586px;\" src=\"images/PC/51199_IGM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) IGM at presentation with skin ulceration.<br />(B) IGM following spontaneous resolution&nbsp;nine months later.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 51199 Version 6.0</div></div></div>"},"51200":{"type":"graphic_table","displayName":"Drug and toxin related pulse changes","title":"Drug- and toxin-induced changes in blood pressure and pulse","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug- and toxin-induced changes in blood pressure and pulse</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Hypertension with tachycardia</td> </tr> <tr> <td class=\"sublist1_start\">Sympathomimetics</td> </tr> <tr> <td class=\"sublist1\">Amphetamines</td> </tr> <tr> <td class=\"sublist1\">Cocaine</td> </tr> <tr> <td class=\"sublist1\">Ephedrine</td> </tr> <tr> <td class=\"sublist1\">Pseudoephedrine</td> </tr> <tr> <td class=\"sublist1\">Theophylline</td> </tr> <tr> <td class=\"sublist1\">Caffeine</td> </tr> <tr> <td class=\"sublist1\">Methylphenidate</td> </tr> <tr> <td class=\"sublist1\">Cathinones</td> </tr> <tr> <td class=\"sublist1_start\">Anticholinergics</td> </tr> <tr> <td class=\"sublist1\">Antihistamines</td> </tr> <tr> <td class=\"sublist1\">TCAs (early)</td> </tr> <tr> <td class=\"sublist1\">Phenothiazines (some)</td> </tr> <tr> <td class=\"sublist1\">Antiparkinson agents</td> </tr> <tr> <td class=\"sublist1\">Muscle relaxants</td> </tr> <tr> <td class=\"sublist1\">Clozapine</td> </tr> <tr> <td class=\"sublist1_start\">Central hallucinogens</td> </tr> <tr> <td class=\"sublist1\">Designer amphetamines</td> </tr> <tr> <td class=\"sublist1\">Lysergic acid diethylamide (LSD)</td> </tr> <tr> <td class=\"sublist1\">Phencyclidine (PCP)</td> </tr> <tr> <td class=\"sublist1\">Synthetic cannabinoids</td> </tr> <tr> <td class=\"sublist1_start\">Envenomations</td> </tr> <tr> <td class=\"sublist1\">Black widow spider bite</td> </tr> <tr> <td class=\"sublist1\">Scorpion stings</td> </tr> <tr> <td>Drug withdrawal states</td> </tr> <tr> <td>MAOIs (foods with tyramine)</td> </tr> <tr> <td>Nicotine</td> </tr> <tr> <td class=\"sublist1_start\">Cholinergic agents (sometimes)</td> </tr> <tr> <td class=\"sublist1\">Organophosphates</td> </tr> <tr> <td class=\"sublist1\">Carbamates</td> </tr> <tr> <td>Thyroid hormone</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Hypertension with bradycardia</td> </tr> <tr> <td class=\"sublist1_start\">Alpha-adrenergic agonists</td> </tr> <tr> <td class=\"sublist1\">Phenylpropanolamine</td> </tr> <tr> <td class=\"sublist1\">Phenylephrine</td> </tr> <tr> <td class=\"sublist1\">Phentermine</td> </tr> <tr> <td>Ergot alkaloids</td> </tr> <tr> <td>Sumatriptan</td> </tr> <tr> <td>Clonidine (early)</td> </tr> <tr> <td>Guanfacine</td> </tr> <tr> <td class=\"sublist1_start\">Imidazolines</td> </tr> <tr> <td class=\"sublist1\">Tetrahydrozoline</td> </tr> <tr> <td class=\"sublist1\">Oxymetazoline</td> </tr> <tr> <td class=\"sublist1_start\">Cholinergic agents</td> </tr> <tr> <td class=\"sublist1\">Organophosphates</td> </tr> <tr> <td class=\"sublist1\">Carbamates</td> </tr> <tr> <td class=\"sublist1_start\">Steroid hormones</td> </tr> <tr> <td class=\"sublist1\">Glucocorticoids</td> </tr> <tr> <td class=\"sublist1\">Mineralocorticoids</td> </tr> <tr> <td class=\"sublist1\">Estrogen</td> </tr> <tr> <td class=\"sublist1\">Progesterone</td> </tr> <tr> <td class=\"sublist1\">Androgens</td> </tr> <tr> <td>Yohimbine</td> </tr> <tr> <td class=\"sublist1_start\">Heavy metals</td> </tr> <tr> <td class=\"sublist1\">Lead</td> </tr> <tr> <td>Disulfiram reaction (early)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Hypotension with tachycardia</td> </tr> <tr> <td class=\"sublist1_start\">Beta-adrenergic agonists</td> </tr> <tr> <td class=\"sublist1\">Theophylline</td> </tr> <tr> <td class=\"sublist1\">Albuterol</td> </tr> <tr> <td class=\"sublist1\">Isoproterenol</td> </tr> <tr> <td class=\"sublist1\">Terbutaline</td> </tr> <tr> <td class=\"sublist1\">Caffeine</td> </tr> <tr> <td>Disulfiram reaction (late) </td> </tr> <tr> <td class=\"sublist1_start\">Toxic alcohols</td> </tr> <tr> <td class=\"sublist1\">Isopropyl alcohol</td> </tr> <tr> <td class=\"sublist1_start\">Carbon monoxide</td> </tr> <tr> <td class=\"sublist1_start\">Alpha-adrenergic antagonists</td> </tr> <tr> <td class=\"sublist1\">Phenothiazines</td> </tr> <tr> <td class=\"sublist1\">TCAs</td> </tr> <tr> <td class=\"sublist1\">Hydralazine</td> </tr> <tr> <td class=\"sublist1_start\">Heavy metals (acute)</td> </tr> <tr> <td class=\"sublist1\">Iron</td> </tr> <tr> <td class=\"sublist1\">Arsenic</td> </tr> <tr> <td>Colchicine</td> </tr> <tr> <td>Nitrates</td> </tr> <tr> <td>Sodium nitroprusside</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Hypotension with bradycardia</td> </tr> <tr> <td>Beta-blockers</td> </tr> <tr> <td>Calcium-channel blockers</td> </tr> <tr> <td class=\"sublist1_start\">Cardiac glycosides</td> </tr> <tr> <td class=\"sublist1\">Digoxin</td> </tr> <tr> <td class=\"sublist1\">Digitalis purpurea</td> </tr> <tr> <td class=\"sublist1\">Oleander</td> </tr> <tr> <td class=\"sublist1\">Red squill</td> </tr> <tr> <td class=\"sublist1\">Bufotenin</td> </tr> <tr> <td>Clonidine</td> </tr> <tr> <td>Alpha-methyldopa</td> </tr> <tr> <td>Cyanide</td> </tr> <tr> <td>Carbon monoxide (late)</td> </tr> <tr> <td>Opioids</td> </tr> <tr> <td class=\"sublist1_start\">Sedative-hypnotics</td> </tr> <tr> <td class=\"sublist1\">Barbiturates</td> </tr> <tr> <td class=\"sublist1\">Benzodiazepines</td> </tr> <tr> <td class=\"sublist1_start\">Cholinergics</td> </tr> <tr> <td class=\"sublist1\">Organophosphates</td> </tr> <tr> <td class=\"sublist1\">Carbamates</td> </tr> <tr> <td>Antiarrhythmics</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51200 Version 8.0</div></div></div>"},"51201":{"type":"graphic_table","displayName":"Initiation protocol NPPV","title":"Protocol for initiation of noninvasive positive pressure ventilation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Protocol for initiation of noninvasive positive pressure ventilation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Appropriately monitored location, oximetry, respiratory impedance, vital signs as clinically indicated</td> </tr> <tr> <td>2. Patient in bed or chair at &#62;30-degree angle</td> </tr> <tr> <td>3. Select and fit interface</td> </tr> <tr> <td>4. Select ventilator</td> </tr> <tr> <td>5. Apply headgear; avoid excessive strap tension (one or two fingers under strap)</td> </tr> <tr> <td>6. Connect interface to ventilator tubing and turn on ventilator</td> </tr> <tr> <td>7. Start with low pressure in spontaneously triggered mode with backup rate; pressure limited: 8 to 12 cmH<sub>2</sub>O inspiratory pressure; 3 to 5 cmH<sub>2</sub>O expiratory pressure</td> </tr> <tr> <td>8. Gradually increase inspiratory pressure (10 to 20 cmH<sub><span style=\"font-size: 13px;\">2</span></sub>O) as tolerated to achieve alleviation of dyspnea, decreased respiratory rate, increased tidal volume (if being monitored), and good patient<span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif';\">&ndash;</span>ventilator synchrony</td> </tr> <tr> <td>9. Provide O<sub>2</sub> supplementation as needed to keep O<sub>2</sub> saturation &#62;90 percent</td> </tr> <tr> <td>10. Check for air leaks, readjust straps as needed</td> </tr> <tr> <td>11. Add humidifier as indicated</td> </tr> <tr> <td>12. Consider mild sedation (eg, intravenously administered lorazepam 0.5 mg) in agitated patients</td> </tr> <tr> <td>13. Encouragement, reassurance, and frequent checks and adjustments as needed</td> </tr> <tr> <td>14. Monitor occasional blood gases (within 1 to 2 hours) and then as needed</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from International Concensus Conferences in Intensive Care Medicine: Noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 2001; 163:288. Copyright © 2001 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 51201 Version 3.0</div></div></div>"},"51203":{"type":"graphic_table","displayName":"Rules for good sleep PI","title":"Basic rules for a good night's sleep","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Basic rules for a good night's sleep</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Sleep only as much as you need to feel rested and then get out of bed</td> </tr> <tr> <td>Keep a regular sleep schedule</td> </tr> <tr> <td>Avoid forcing sleep</td> </tr> <tr> <td>Exercise regularly for at least 20 minutes, preferably 4 to 5 hours before bedtime</td> </tr> <tr> <td>Avoid caffeinated beverages after lunch</td> </tr> <tr> <td>Avoid alcohol near bedtime: no \"night cap\"</td> </tr> <tr> <td>Avoid smoking, especially in the evening</td> </tr> <tr> <td>Do not go to bed hungry</td> </tr> <tr> <td>Adjust bedroom environment</td> </tr> <tr> <td>Avoid prolonged use of light-emitting screens before bedtime&nbsp;</td> </tr> <tr> <td>Deal with your worries before bedtime</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51203 Version 3.0</div></div></div>"},"51204":{"type":"graphic_figure","displayName":"Causes of cervical radiculopathy","title":"Causes of cervical radiculopathy","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Causes of cervical radiculopathy</div><div class=\"cntnt\"><img style=\"width:523px; height:429px;\" src=\"images/NEURO/51204_Causes_cervical_radiculopat.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51204 Version 3.0</div></div></div>"},"51205":{"type":"graphic_table","displayName":"Staging ovarian tubal peritoneal cancer","title":"Staging ovarian, fallopian tubal, and peritoneal cancer (TNM and International Federation of Gynecology and Obstetrics [FIGO])","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Staging ovarian, fallopian tubal, and peritoneal cancer (TNM and International Federation of Gynecology and Obstetrics [FIGO])</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr> <td class=\"subtitle2\">TNM categories</td> <td class=\"subtitle2\">FIGO stages</td> <td class=\"subtitle2\" colspan=\"2\">Definition</td> </tr> <tr> <td>TX</td> <td>&nbsp;</td> <td colspan=\"2\">Primary tumor cannot be assessed</td> </tr> <tr> <td>T0</td> <td>&nbsp;</td> <td colspan=\"2\">No evidence of primary tumor</td> </tr> <tr> <td class=\"sublist1_start\">T1</td> <td class=\"sublist_other_start\">I</td> <td class=\"sublist_other_start\" colspan=\"2\">Tumor confined to ovaries or fallopian tubes</td> </tr> <tr> <td class=\"sublist1\">T1a</td> <td class=\"sublist_other\">IA</td> <td class=\"sublist_other\" colspan=\"2\">Tumor limited to one ovary (capsule intact) or fallopian tube; no tumor on ovarian or fallopian tube surface; no malignant cells in ascites or peritoneal washings</td> </tr> <tr> <td class=\"sublist1\">T1b</td> <td class=\"sublist_other\">IB</td> <td class=\"sublist_other\" colspan=\"2\">Tumor limited to both ovaries (capsules intact) or fallopian tubes; no tumor on ovarian or fallopian tube surface; no malignant cells in ascites or peritoneal washings</td> </tr> <tr> <td class=\"sublist1\" rowspan=\"4\">T1c</td> <td class=\"sublist_other\">IC</td> <td class=\"sublist_other\" colspan=\"2\">Tumor limited to one or both ovaries or fallopian tubes, with any of the following:</td> </tr> <tr> <td class=\"sublist_other\">IC1</td> <td class=\"sublist1\" colspan=\"2\">Surgical spill</td> </tr> <tr> <td class=\"sublist_other\">IC2</td> <td class=\"sublist1\" colspan=\"2\">Capsule ruptured before surgery or tumor on ovarian or fallopian tube surface</td> </tr> <tr> <td class=\"sublist_other\">IC3</td> <td class=\"sublist1\" colspan=\"2\">Malignant cells in the ascites or peritoneal washings</td> </tr> <tr> <td class=\"sublist1_start\">T2</td> <td class=\"sublist_other_start\">II</td> <td class=\"sublist_other_start\" colspan=\"2\">Tumor involves one or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or peritoneal cancer*</td> </tr> <tr> <td class=\"sublist1\">T2a</td> <td class=\"sublist_other\">IIA</td> <td class=\"sublist_other\" colspan=\"2\">Extension and/or implants on uterus and/or tube(s) and/or ovaries</td> </tr> <tr> <td class=\"sublist1\">T2b</td> <td class=\"sublist_other\">IIB</td> <td class=\"sublist_other\" colspan=\"2\">Extension to other pelvic intraperitoneal tissues</td> </tr> <tr> <td class=\"sublist1_start\">T3</td> <td class=\"sublist_other_start\">III</td> <td class=\"sublist_other_start\" colspan=\"2\">Tumor involves one or both ovaries or fallopian tubes, or peritoneal cancer, with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes</td> </tr> <tr> <td class=\"sublist1\" rowspan=\"5\">T3a</td> <td class=\"sublist_other\">IIIA</td> <td class=\"sublist_other\" colspan=\"2\">Positive retroperitoneal lymph nodes and/or microscopic metastasis beyond pelvis</td> </tr> <tr> <td class=\"sublist_other\">IIIA1</td> <td class=\"sublist_other\" colspan=\"2\">Positive retroperitoneal lymph nodes only (cytologically or histologically proven)</td> </tr> <tr> <td class=\"sublist_other\">IIIA1 (i)</td> <td class=\"sublist_other\" colspan=\"2\">Metastasis up to 10 mm in greatest dimension</td> </tr> <tr> <td class=\"sublist_other\">IIIA1 (ii)</td> <td class=\"sublist_other\" colspan=\"2\">Metastasis more than 10 mm in greatest dimension</td> </tr> <tr> <td class=\"sublist_other\">IIIA2</td> <td class=\"sublist_other\" colspan=\"2\">Microscopic extrapelvic (above the pelvic brim) peritoneal involvement, with or without positive retroperitoneal lymph nodes</td> </tr> <tr> <td class=\"sublist1\">T3b</td> <td class=\"sublist_other\">IIIB</td> <td class=\"sublist_other\" colspan=\"2\">Macroscopic peritoneal metastasis beyond pelvis up to 2 cm in greatest dimension, with or without positive retroperitoneal lymph nodes</td> </tr> <tr> <td class=\"sublist1\">T3c</td> <td class=\"sublist_other\">IIIC</td> <td class=\"sublist_other\" colspan=\"2\">Macroscopic peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ), with or without positive retroperitoneal lymph nodes </td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr> <td class=\"subtitle2\">TNM categories</td> <td class=\"subtitle2\">FIGO stages</td> <td class=\"subtitle2\" colspan=\"2\">Definition</td> </tr> <tr> <td>NX</td> <td>&nbsp;</td> <td colspan=\"2\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td>N0</td> <td>&nbsp;</td> <td colspan=\"2\">No regional lymph node metastasis</td> </tr> <tr> <td>N1</td> <td>III</td> <td colspan=\"2\">Regional lymph node metastasis</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr> <td class=\"subtitle2\">TNM categories</td> <td class=\"subtitle2\">FIGO stages</td> <td class=\"subtitle2\" colspan=\"2\">Definition</td> </tr> <tr> <td>M0</td> <td>&nbsp;</td> <td colspan=\"2\">No distant metastasis</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">M1</td> <td>IV</td> <td colspan=\"2\">Distant metastasis (excludes peritoneal metastasis)</td> </tr> <tr> <td>IVA</td> <td colspan=\"2\">Pleural effusion with positive cytology</td> </tr> <tr class=\"divider_bottom\"> <td>IVB</td> <td colspan=\"2\">Parenchymal metastases and metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity)<sup>&#182;</sup></td> </tr> <tr> <td colspan=\"4\"><strong>pTNM pathologic classification.</strong> The pT, pN, and pM categories correspond to the T, N, and M categories.</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Anatomic stage/prognostic groups</td> </tr> <tr> <td>Stage I</td> <td>T1</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IA</td> <td>T1a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IB</td> <td>T1b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IC</td> <td>T1c</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage II</td> <td>T2</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IIA</td> <td>T2a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IIB</td> <td>T2b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IIC</td> <td>T2c</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage III</td> <td>T3</td> <td>N0&nbsp;or N1</td> <td>M0</td> </tr> <tr> <td>Stage IIIA</td> <td>T3a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>&nbsp;</td> <td>&#8804;T3a</td> <td>N1</td> <td>&nbsp;</td> </tr> <tr> <td>Stage IIIB</td> <td>T3b</td> <td>N0 or N1</td> <td>M0</td> </tr> <tr> <td>Stage IIIC</td> <td>T3c</td> <td>N0 or N1</td> <td>M0</td> </tr> <tr> <td>Stage IV</td> <td>Any T</td> <td>Any N</td> <td>M1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: cTNM is the clinical classification, pTNM is the pathologic classification.</div><div class=\"graphic_footnotes\">* Dense adhesions with histologically proven tumor cells justify upgrading to stage II.<br />&para; Transmural bowel infiltration or umbilical deposit are stage IVB.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>The American Joint Committee on Cancer, AJCC Cancer Staging Manual, Seventh Edition, New York: Springer, 2010.</LI>&#xD;&#xA;<LI>Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014; 124:1.</LI></OL></div><div id=\"graphicVersion\">Graphic 51205 Version 19.0</div></div></div>"},"51206":{"type":"graphic_figure","displayName":"Cumulative incidence back pain","title":"Back pain: Cumulative incidence age in adolescents and adults","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Back pain: Cumulative incidence age in adolescents and adults</div><div class=\"cntnt\"><img style=\"width:481px; height:373px;\" src=\"images/PEDS/51206_Cumulative_incidence_back_p.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lifetime cumulative incidence of low-back pain for males and females, aged 12 to 41 years.</div><div class=\"graphic_reference\">Data from Leboeuf-Yde DC, Kyvik KO. At what age does low back pain become a common problem? A study of 29,424 individuals aged 12-41 years. Spine 1998; 23:228.</div><div id=\"graphicVersion\">Graphic 51206 Version 2.0</div></div></div>"},"51207":{"type":"graphic_diagnosticimage","displayName":"MPS I forearm","title":"Radiograph of the arm in a patient with mucopolysaccharidosis type I (MPS I)","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Radiograph of the arm in a patient with mucopolysaccharidosis type I (MPS I)</div><div class=\"cntnt\"><img style=\"width:468px; height:217px;\" src=\"images/PEDS/51207_MPS_I_forearm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical features of bone disease include tilting of the radius and ulna distal epiphyses (arrow 1) and abnormal tubulation of the long bones, leading to the arching shape of the radius (arrow 2).</div><div class=\"graphic_reference\">Courtesy of Emil Kakkis, MD, PhD.</div><div id=\"graphicVersion\">Graphic 51207 Version 3.0</div></div></div>"},"51210":{"type":"graphic_picture","displayName":"Pediculosis pubis nits","title":"Pediculosis - nits and louse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pediculosis - nits and louse</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/51210_Pediculosis_pubis_nits.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light microscopy reveals two nits attached to a hair shaft (left). A louse is present on the right.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51210 Version 4.0</div></div></div>"},"51211":{"type":"graphic_table","displayName":"Radiographic views for identifying fractures by location","title":"Radiographic views for identifying fractures by location","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Radiographic views for identifying fractures by location</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Anatomic region</td> <td class=\"subtitle1\">Plain radiograph fracture views</td> </tr> <tr> <td>Wrist</td> <td> <p>All patients: AP, lateral</p> <p>Oblique: Fracture suspected but AP/lateral negative*</p> Scaphoid: Scaphoid fracture suspected</td> </tr> <tr> <td>Elbow</td> <td>AP, lateral, oblique</td> </tr> <tr> <td>Shoulder</td> <td>AP, scapular Y</td> </tr> <tr> <td>Knee</td> <td> <p>AP, lateral, oblique<sup>&#182;</sup> (internal or externally rotated)</p> Sunrise (axial, tangential): patellar injury</td> </tr> <tr> <td>Foot</td> <td> <p>AP, lateral</p> Oblique: If fracture seen</td> </tr> <tr> <td>Tibia, femur, humerus, and forearm</td> <td>AP, lateral</td> </tr> <tr> <td>Ankle</td> <td>AP, lateral, and mortise<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AP: anterior posterior.<br />* Allows view of the scaphoid-trapezoid-trapezium articulation.<br />¶ Provides a different projection of the femoral condyles and tibial tuberosities as well as a cleaner view of the medial and lateral margins of the patella.<br />Δ The mortise view requires 10 to 20 degrees of internal rotation and allows the tibia and fibula to be viewed without superimposition on one another.</div><div id=\"graphicVersion\">Graphic 51211 Version 5.0</div></div></div>"},"51212":{"type":"graphic_figure","displayName":"Continuous GnRH LH and FSH","title":"Importance of the pattern of GnRH secretion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Importance of the pattern of GnRH secretion</div><div class=\"cntnt\"><img style=\"width:449px; height:260px;\" src=\"images/ENDO/51212_Continuous_GnRH_LH_and_FSH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serum LH and FSH concentrations in an ovariectomized monkey. Pulsatile administration (given for six minutes every hour) of GnRH maintains serum FSH and LH concentrations. In comparison, a continuous infusion of GnRH (middle panel) leads to rapid and reversible suppression of both LH and FSH release.</div><div class=\"graphic_footnotes\">FSH: follicle-stimulating hormone; GnRH: gonadotropin-releasing hormone; LH: luteinizing hormone.</div><div class=\"graphic_reference\">Data from: Belchetz PE, Plant TM, Nakai Y, et al. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone.&nbsp;Science 1978; 202:631.</div><div id=\"graphicVersion\">Graphic 51212 Version 3.0</div></div></div>"},"51213":{"type":"graphic_figure","displayName":"Nissen fundoplication","title":"Nissen fundoplication","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Nissen fundoplication</div><div class=\"cntnt\"><img style=\"width:465px; height:411px;\" src=\"images/GAST/51213_Nissenfundoplication.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Nissen fundoplication provides a 360° \"wrap\" or collar around the esophagus. Mobilization of the fundus is generally accomplished by dividing the short gastric vessels to the spleen.</div><div id=\"graphicVersion\">Graphic 51213 Version 4.0</div></div></div>"},"51214":{"type":"graphic_diagnosticimage","displayName":"Typhlitis pneumatosis KUB","title":"Typhlitis (neutropenic enterocolitis) on plain radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Typhlitis (neutropenic enterocolitis) on plain radiograph</div><div class=\"cntnt\"><img style=\"width:304px; height:336px;\" src=\"images/GAST/51214_Typhlitis_pneumatosis_KUB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Supine film of the abdomen showing pneumatosis intestinalis of the right ascending colon (arrows) with slightly distended small bowel loops from typhlitis.</div><div class=\"graphic_reference\">Reproduced with permission from Katz JA, et al. Typhlitis: An 18-year experience and postmortem review. Cancer 1990; 65:1041. Copyright © 1990 John Wiley &amp; Sons, Inc.</div><div id=\"graphicVersion\">Graphic 51214 Version 4.0</div></div></div>"},"51215":{"type":"graphic_picture","displayName":"Ureteral course","title":"Ureteral course: laparoscopic view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ureteral course: laparoscopic view</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/OBGYN/51215_Ureteral_course.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superior view of the ureter during laparoscopy. Dots represent the course of the ureter.</div><div class=\"graphic_reference\">Courtesy of Thomas Lyons, MD.</div><div id=\"graphicVersion\">Graphic 51215 Version 1.0</div></div></div>"},"51217":{"type":"graphic_figure","displayName":"Normal airway sleeping PI","title":"Normal airway during sleep","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Normal airway during sleep</div><div class=\"cntnt\"><img style=\"width:527px; height:353px;\" src=\"images/PI/51217_Norm_airway_sleep_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows how the tongue, uvula, and soft palate (which make up the upper airway) should normally look in a person who is sleeping.</div><div id=\"graphicVersion\">Graphic 51217 Version 5.0</div></div></div>"},"51218":{"type":"graphic_picture","displayName":"Linear morphea","title":"Linear morphea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Linear morphea</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/51218_Linear_morphea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A shiny, sclerotic, hyperpigmented plaque is present in a linear distribution on the arm.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51218 Version 3.0</div></div></div>"},"51219":{"type":"graphic_picture","displayName":"Scurvy - perifollicular hemorrhage","title":"Scurvy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scurvy</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/51219_Scurvy_perifoll_hemorrhage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perifollicular purpuric macules are present in this patient with scurvy.</div><div id=\"graphicVersion\">Graphic 51219 Version 1.0</div></div></div>"},"51220":{"type":"graphic_picture","displayName":"Contact dermatitis feet","title":"Allergic contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Allergic contact dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/51220_ShoecontactdermatitisPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, scaly plaques on the dorsum of the feet of a patient with shoe allergic contact dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51220 Version 5.0</div></div></div>"},"51221":{"type":"graphic_figure","displayName":"Mesorectum - Male pelvis lateral view","title":"Mesorectum - Male pelvis lateral view","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Mesorectum - Male pelvis lateral view</div><div class=\"cntnt\"><img style=\"width:453px; height:558px;\" src=\"images/SURG/51221_Mesorectum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the lateral view of the male pelvis,&nbsp;illustrating the relationship of the mesorectum to the posterior rectum and presacral space. The mesorectum is&nbsp;not a true mesentery but rather is perirectal areolar tissue that is thicker posteriorly and contains terminal branches of the inferior mesenteric artery.</div><div id=\"graphicVersion\">Graphic 51221 Version 2.0</div></div></div>"},"51222":{"type":"graphic_figure","displayName":"Calcium blockers and MI risk","title":"Association of short-acting calcium channel blockers with increased MI risk","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Association of short-acting calcium channel blockers with increased MI risk</div><div class=\"cntnt\"><img style=\"width:540px; height:249px;\" src=\"images/NEPH/51222_Calcium_blockers_MI_ris_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The relative risk of myocardial infarction (MI) according to the type of antihypertensive therapy in 623 cases and 2032 controls. The relative risk was increased in patients taking any form of calcium channel blocker (CCB), an effect that was greatest with concurrent therapy with a thiazide diuretic (Tz). There was no increase in risk with a beta blocker (β-blk) or an angiotensin converting enzyme inhibitor (ACEI). The right panel shows that the deleterious effect of calcium channel blocker therapy was seen only with moderate and high doses.</div><div class=\"graphic_reference\">Data from: Psaty BM, Heckbert SR, Koepsell TD, et al. JAMA 1995; 274:620.</div><div id=\"graphicVersion\">Graphic 51222 Version 5.0</div></div></div>"},"51224":{"type":"graphic_figure","displayName":"Direct inguinal hernia","title":"Direct inguinal hernia","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Direct inguinal hernia</div><div class=\"cntnt\"><img style=\"width:520px; height:268px;\" src=\"images/PEDS/51224_Direct_inguinal_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Direct inguinal hernias are medial and inferior to the deep epigastric vessels. As seen in this transverse section of the anterior abdominal wall, the hernia passes directly through the external inguinal ring and does not traverse the inguinal canal.</div><div class=\"graphic_reference\">Adapted from O'Rahilly. Abdominal walls. In: Basic Human Anatomy, W.B. Saunders Company, Philadelphia 1983. p.230.</div><div id=\"graphicVersion\">Graphic 51224 Version 1.0</div></div></div>"},"51225":{"type":"graphic_table","displayName":"Nonallergic adverse food reactions","title":"Nonallergic adverse food reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonallergic adverse food reactions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Gastrointestinal disorders</td> </tr> <tr> <td class=\"indent1\">Celiac disease</td> </tr> <tr> <td class=\"indent1\">Nonceliac gluten sensitivity</td> </tr> <tr> <td class=\"indent1\">Gastroesophageal reflux</td> </tr> <tr> <td class=\"indent1\">Carbohydrate malabsorption</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Lactase deficiency </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Sucrose-isomaltase deficiency </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Irritable bowel syndrome</td> </tr> <tr> <td class=\"indent1\">Intolerance of short-chain fermentable carbohydrates (FODMAPs)</td> </tr> <tr> <td class=\"indent1\">Yeast overgrowth syndrome</td> </tr> <tr> <td class=\"indent1\">Pancreatic insufficiency (cystic fibrosis)</td> </tr> <tr> <td class=\"indent1\">Peptic ulcer disease</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gallbladder disease</td> </tr> <tr> <td class=\"subtitle1_single\">Toxic reactions</td> </tr> <tr> <td class=\"indent1\">Seafood</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Scombroid poisoning (fresh tuna and mackerel) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Ciguatera poisoning (grouper, snapper) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Saxitoxin (shellfish) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Other food poisoning</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Fungal toxins</td> </tr> <tr> <td class=\"subtitle1_single\">Intolerances</td> </tr> <tr> <td class=\"indent1\">Pharmacologic agents</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Caffeine </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Theobromine (tea, chocolate) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Histamine and histamine-like compounds (berries, wine, fish, sauerkraut) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Tryptamine (tomato, plum) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Tyramine (aged cheeses, pickled fish) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Serotonin (banana, tomato) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Phenylethylamine (chocolate) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Glycosidal alkaloid solanine (potatoes) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Alcohol </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Flavorings and preservatives</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Sodium metabisulfite </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Monosodium glutamate </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic reactions</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Auriculotemporal syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Psychologic reactions</td> </tr> <tr> <td class=\"indent1\">Food phobias</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Food aversions</td> </tr> <tr> <td class=\"subtitle1_single\">Accidental contaminations</td> </tr> <tr> <td class=\"indent1\">Pesticides</td> </tr> <tr> <td class=\"indent1\">Antibiotics (if allergy present)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Sampson HA. Differential diagnosis in adverse reactions to foods. J Allergy Clin Immunol 1986; 78:212.</div><div id=\"graphicVersion\">Graphic 51225 Version 9.0</div></div></div>"},"51226":{"type":"graphic_table","displayName":"Positions of function selected joints","title":"Positions of function for selected joints","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Positions of function for selected joints</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Splint</td> <td class=\"subtitle1\">Position</td> </tr> <tr> <td>Volar</td> <td>Neutral forearm (thumb up), wrist at 20 degrees flexion</td> </tr> <tr> <td>Ulnar/radial gutter</td> <td>Neutral forearm, wrist at 20 degrees extension, MCP at 50 degrees flexion, PIP in slight flexion (10 degrees), DIP in extension</td> </tr> <tr> <td>Thumb spica</td> <td>Forearm neutral, wrist at 25 degrees extension, allowing thumb-index finger opposition and alignment of the thumb and forearm</td> </tr> <tr> <td>Sugar tong/posterior arm</td> <td>Elbow at 90 degrees flexion, neutral flexion, neutral wrist</td> </tr> <tr> <td>Knee</td> <td>Knee fully extended if possible, up to 15 degrees of flexion</td> </tr> <tr> <td>Posterior ankle/ankle stirrup</td> <td>Ankle at 90 degrees</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=55083&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">MCP: metacarpophalangeal; PIP: proximal interphalangeal; DIP: distal interphalangeal.</div><div class=\"graphic_reference\">Adapted from: Chudnofsky C. Splinting techniques. In: Clinical Procedures in Emergency Medicine, Roberts J, Hedges J (Eds), WB Saunders, Philadelphia, 1998. p.852.</div><div id=\"graphicVersion\">Graphic 51226 Version 5.0</div></div></div>"},"51227":{"type":"graphic_figure","displayName":"Intermittent transdermal NTG","title":"Efficacy of intermittent transdermal nitroglycerin","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Efficacy of intermittent transdermal nitroglycerin</div><div class=\"cntnt\"><img style=\"width:502px; height:265px;\" src=\"images/CARD/51227_Intermittent_transdermal_NT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Within day changes on day 1 and day 30 in treadmill walking time to moderate angina in 291 patients with stable angina treated with placebo or increasing doses of transdermal nitroglycerin for 12 hours per day. Transdermal NTG was associated with a dose-dependent increase in exercise tolerance that attenuated over the course of 12 hours but was maintained over the long term.</div><div class=\"graphic_reference\">Data from Parker JO, Amies MH, Hawkinson RW, et al. Circulation 1995; 91:1368.</div><div id=\"graphicVersion\">Graphic 51227 Version 2.0</div></div></div>"},"51228":{"type":"graphic_figure","displayName":"Postinfarction angina with EKG changes predicts reinfarction","title":"Postinfarction angina with ST segment changes predicts reinfarction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postinfarction angina with ST segment changes predicts reinfarction</div><div class=\"cntnt\"><img style=\"width:450px; height:366px;\" src=\"images/CARD/51228_Postinfarctischemiareinf.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 40,848 patients with an acute myocardial infarction entered into GUSTO-I, 20 percent had recurrent ischemia after thrombolytic therapy. The 30-day reinfarction rate was significantly higher in patients with recurrent ischemia associated with ST segment changes compared to those without recurrent ischemia or those with recurrent ischemia without ST segment changes (p &lt;0.0001).</div><div class=\"graphic_reference\">Redrawn from Betriu A, Califf RM, Bosch X, et al, for the GUSTO-I Investigators. J Am Coll Cardiol 1998; 31:94.</div><div id=\"graphicVersion\">Graphic 51228 Version 4.0</div></div></div>"},"51229":{"type":"graphic_movie","displayName":"Overhead arm raise exercise video","title":"Strength exercise video: Overhead arm raise","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Strength exercise video: Overhead arm raise</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PC/51229_Overheadarmraisevideo.mp4\" style=\"width:480px;height:336px\"></div><img style=\"width:374px; height:306px;\" src=\"images/PC/51229_OverhdarmraiseexrimgPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This exercise will strengthen your shoulders and arms. It should make swimming and other activities such as lifting and carrying grandchildren easier.<br> <ol> <li>You can do this exercise while standing or sitting in a sturdy, armless chair. </li> <li>Keep your feet flat on the floor, shoulder-width apart. </li> <li>Hold weights* at your sides at shoulder height with palms facing forward. Breathe in slowly. </li> <li>Slowly breathe out as you raise both arms up over your head keeping your elbows slightly bent. </li> <li>Hold the position for one second. </li> <li>Breathe in as you slowly lower your arms. </li> <li>Repeat 10 to 15 times. </li> <li>Rest; then repeat 10 to 15 more times. </li> </ol> As you progress, use a heavier weight and alternate arms until you can lift the weight confortably with both arms.</div><div class=\"graphic_footnotes\">* Handheld weights or household items (soup cans, bottles of water).</div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 51229 Version 2.0</div></div></div>"},"51230":{"type":"graphic_picture","displayName":"Periorificial dermatitis - perinasal","title":"Periorificial dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Periorificial dermatitis</div><div class=\"cntnt\"><img style=\"width:448px; height:504px;\" src=\"images/DERM/51230_Periorificial_derm_paranas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules and mild scale are present on the perinasal skin.</div><div class=\"graphic_reference\">Reprinted by permission of Edizioni Minerva Medica from G Ital Dermatol Venereol 2010; 145:433. Copyright &#169; 2010. All rights reserved.</div><div id=\"graphicVersion\">Graphic 51230 Version 2.0</div></div></div>"},"51231":{"type":"graphic_picture","displayName":"Nephroscope","title":"Nephroscope","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nephroscope</div><div class=\"cntnt\"><img style=\"width:382px; height:253px;\" src=\"images/OBGYN/51231_Nephroscope.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51231 Version 1.0</div></div></div>"},"51232":{"type":"graphic_table","displayName":"Three common porphyrias","title":"The three most common porphyrias and their contrasting presentations, exacerbating factors, and approaches to diagnosis and treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The three most common porphyrias and their contrasting presentations, exacerbating factors, and approaches to diagnosis and treatment</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Presenting symptoms</td> <td class=\"subtitle1\">Exacerbating factors</td> <td class=\"subtitle1\">Most important screening tests</td> <td class=\"subtitle1\">Treatment</td> </tr> <tr> <td>Porphyria cutanea tarda (PCT)</td> <td>Chronic, blistering skin lesions*</td> <td>Iron; alcohol; smoking; estrogens; hepatitis C; HIV; halogenated hydrocarbons</td> <td>Plasma or urine porphyrins<sup>&#182;</sup></td> <td>Phlebotomy; low-dose hydroxychloroquine or chloroquine</td> </tr> <tr> <td>Acute intermittent porphyria (AIP)</td> <td>Neurovisceral<sup>&#916;</sup></td> <td>Drugs (mostly cytochrome P450-inducers); progesterone; dietary restrictions<sup>&#916;</sup></td> <td>Urinary porphobilinogen (PBG)<sup>&#916;</sup></td> <td>Hemin; glucose<sup>&#916;</sup></td> </tr> <tr> <td>Erythropoietic protoporphyria (EPP)</td> <td>Acute, nonblistering skin photosensitivity</td> <td>&nbsp;</td> <td>Erythrocyte protoporphyrin (total or free)</td> <td>&#946;-carotene</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Porphyria cutanea tarda (PCT) and acute intermittent porphyria (AIP) share features with some less common porphyrias (refer to footnotes).</div><div class=\"graphic_footnotes\">* Also may occur in variegate porphyria (VP) and less commonly in hereditary coproporphyria (HCP); much more severe in congenital erythropoietic protoporphyria (EPP) and hepatoerythropoietic porphyria (HEP).<br />&para; Also useful for diagnosis of variegate porphyria (VP), congenital erythropoietic porphyria (VP), and hepatoerythropoietic porphyria (HEP).<br />&Delta; Features shared with hereditary coproporphyria (HCP), variegate porphyria (VP), and ALA dehydratase porphyria (ADP).</div><div class=\"graphic_reference\">Provided by Karl Anderson, MD, FACP.</div><div id=\"graphicVersion\">Graphic 51232 Version 4.0</div></div></div>"},"51235":{"type":"graphic_table","displayName":"Probability of MI in chest pain","title":"Clinical features that increase the probability of myocardial infarction in patients presenting with new chest pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features that increase the probability of myocardial infarction in patients presenting with new chest pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Clinical feature</td> <td class=\"subtitle1\">Likelihood ratio (95 percent CI)</td> </tr> <tr> <td>Pain in chest or left arm</td> <td>2.7*</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Chest pain radiation</td> </tr> <tr> <td class=\"sublist1\">Right shoulder</td> <td class=\"sublist_other\">2.9 (1.4-6)</td> </tr> <tr> <td class=\"sublist1\">Left arm</td> <td class=\"sublist_other\">2.3 (1.7-3.1)</td> </tr> <tr> <td class=\"sublist1\">Both left and right arm</td> <td class=\"sublist_other\">7.1 (3.6-14.2)</td> </tr> <tr> <td>Chest pain most important symptom</td> <td>2*</td> </tr> <tr> <td>History of myocardial infarction</td> <td>1.5-3<sup>&#182;</sup></td> </tr> <tr> <td>Nausea or vomiting</td> <td>1.9 (1.7-2.3)</td> </tr> <tr> <td>Diaphoresis</td> <td>2 (1.9-2.2)</td> </tr> <tr> <td>Third heart sound on auscultation</td> <td>3.2 (1.6-6.5)</td> </tr> <tr> <td>Hypotension (systolic BP &#8804;80 mmHg)</td> <td>3.1 (1.8-5.2)</td> </tr> <tr> <td>Pulmonary crackles on auscultation</td> <td>2.1 (1.4-3.1)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Data not available to calculate confidence interval (CI).<br />¶ In heterogeneous studies the likelihood ratios are reported as ranges.</div><div class=\"graphic_reference\">Adapted from Panju, AA, Hemmelgarn, BR, Guyatt, GH, Simel, DL, JAMA 1998; 280:1256.</div><div id=\"graphicVersion\">Graphic 51235 Version 2.0</div></div></div>"},"51236":{"type":"graphic_waveform","displayName":"12-lead ECG midseptal WPW ","title":"12-lead electrocardiogram (ECG) of a midseptal accessory AV pathway","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) of a midseptal accessory AV pathway</div><div class=\"cntnt\"><img style=\"width:498px; height:278px;\" src=\"images/CARD/51236_Midseptal_WPW_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram from a patient with Wolff-Parkinson-White syndrome. The ECG criteria for a midseptal pathway are intermediate between those for posteroseptal and anteroseptal connections within the triangle of Koch. These pathways have been difficult to predict from the surface ECG and have usually been grouped as septal pathways. The ECG shows positive delta waves in the lateral leads I, aVL, and V6, with early transition and a tall R wave in lead V2. The delta wave is positive in leads II and aVF and negative in lead III, and the QRS axis is &lt;0°, localizing the pathway in the midseptum.</div><div id=\"graphicVersion\">Graphic 51236 Version 3.0</div></div></div>"},"51237":{"type":"graphic_diagnosticimage","displayName":"Discoid malacia CT","title":"Discoid trachea due to tracheomalacia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Discoid trachea due to tracheomalacia</div><div class=\"cntnt\"><img style=\"width:286px; height:194px;\" src=\"images/PULM/51237_Discoid_malacia_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic scan shows a narrow sagittal diameter and wide coronal diameter of the trachea. These findings are the opposite of those associated with a saber sheath trachea. This is an example of&nbsp;the \"frown sign\".</div><div id=\"graphicVersion\">Graphic 51237 Version 3.0</div></div></div>"},"51238":{"type":"graphic_table","displayName":"ACR neuropsychiatric SLE","title":"Neuropsychiatric manifestations of systemic lupus erythematosus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neuropsychiatric manifestations of systemic lupus erythematosus</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Central</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Aseptic meningitis</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Cerebrovascular disease</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Demyelinating syndrome</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Headache</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Movement disorder</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Seizure disorder</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Myelopathy</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Acute confusional state</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Anxiety disorder</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Cognitive dysfunction</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Mood disorder</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Psychosis</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Peripheral</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Guillain-Barre syndrome</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Autonomic neuropathy</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Mononeuropathy</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Myasthenia gravis</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Cranial neuropathy</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Plexopathy</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Polyneuropathy</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42:599.</div><div id=\"graphicVersion\">Graphic 51238 Version 2.0</div></div></div>"},"51241":{"type":"graphic_table","displayName":"Dosing of parenteral beta-lactams for adult patients","title":"Dosing of selected parenteral beta-lactam antibiotics for adult patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing of selected parenteral beta-lactam antibiotics for adult patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">CrCl (mL/minute)</td> <td class=\"subtitle1\">Adult dose</td> <td class=\"subtitle1\">Frequency</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Beta-lactamase inhibitor combinations</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"5\">Ampicillin-sulbactam (mild to moderate infections)</td> <td>&#8805;30</td> <td>1.5 g</td> <td>Every 6 hours</td> </tr> <tr> <td>15 to 29</td> <td>1.5 g</td> <td>Every 12 hours</td> </tr> <tr> <td>5 to 14</td> <td>1.5 g</td> <td>Every 24 hours</td> </tr> <tr> <td>iHD*</td> <td>1.5 g</td> <td>Every 12 to 24 hours</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>&#182;</sup><sup>[1]</sup></td> <td>1.5 g</td> <td>Every 6 to 12 hours</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"5\">Ampicillin-sulbactam (moderate to severe infections)</td> <td>&#8805;30</td> <td>3 g</td> <td>Every 6 hours</td> </tr> <tr> <td>15 to 29</td> <td>3 g</td> <td>Every 12 hours</td> </tr> <tr> <td>5 to 14</td> <td>3 g</td> <td>Every 24 hours</td> </tr> <tr> <td>iHD*</td> <td>3 g</td> <td>Every 12 to 24 hours</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>&#182;</sup><sup>[1]</sup></td> <td>3 g</td> <td>Every 6 to 12 hours</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"5\">Piperacillin-tazobactam (mild to moderate infections)</td> <td>&#62;40</td> <td>3.375 g</td> <td>Every 6 hours</td> </tr> <tr> <td>20 to 40</td> <td>2.25 g</td> <td>Every 6 hours</td> </tr> <tr> <td>&#60;20</td> <td>2.25 g</td> <td>Every 8 hours</td> </tr> <tr> <td>iHD*</td> <td>2.25 g</td> <td>Every 12 hours</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>&#182;</sup><sup>[1]</sup></td> <td>2.25 g</td> <td>Every 6 to 8 hours</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"5\">Piperacillin-tazobactam (severe infections, including <em>Pseudomonas aeruginosa</em>)</td> <td>&#62;40</td> <td>4.5 g</td> <td>Every 6 hours</td> </tr> <tr> <td>20 to 40</td> <td>3.375 g</td> <td>Every 6 hours</td> </tr> <tr> <td>&#60;20</td> <td>2.25 g</td> <td>Every 6 hours</td> </tr> <tr> <td>iHD*</td> <td>2.25 g</td> <td>Every 8 hours</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>&#182;</sup><sup>[1]</sup></td> <td>3.375 g</td> <td>Every 6 to 8 hours</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"6\">Ceftolozane-tazobactam (complicated UTI and intra-abdominal infections)</td> <td>&#62;50</td> <td>1.5 g</td> <td>Every 8 hours</td> </tr> <tr> <td>30 to 50</td> <td>750 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>15 to 29</td> <td>375 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>&#60;15</td> <td>Has not been studied</td> <td>&nbsp;</td> </tr> <tr> <td>iHD*</td> <td>750 mg once, followed by 150 mg</td> <td>Every 8 hours</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>[2]</sup> (based on preliminary data)</td> <td>750 mg</td> <td>Every 8 hours</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"6\">Ceftolozane-tazobactam (severe infections)<sup>[3,4]</sup></td> <td>&#62;50</td> <td>3 g</td> <td>Every 8 hours</td> </tr> <tr> <td>30 to 50</td> <td>1.5 g</td> <td>Every 8 hours</td> </tr> <tr> <td>15 to 29</td> <td>750 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>&#60;15</td> <td>Has not been studied</td> <td>&nbsp;</td> </tr> <tr> <td>iHD*</td> <td>750 mg once, followed by 375 mg</td> <td>Every 8 hours</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>[2]</sup> (based on preliminary data)</td> <td>1.5 g</td> <td>Every 8 hours</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"7\">Ceftazidime-avibactam</td> <td>&#62;50</td> <td>2.5 g</td> <td>Every 8 hours</td> </tr> <tr> <td>31 to 50</td> <td>1.25 g</td> <td>Every 8 hours</td> </tr> <tr> <td>16 to 30</td> <td>0.94 g</td> <td>Every 12 hours</td> </tr> <tr> <td>6 to 15</td> <td>0.94 g</td> <td>Every 24 hours</td> </tr> <tr> <td>&#8804;5</td> <td>0.94 g</td> <td>Every 48 hours</td> </tr> <tr> <td>iHD*</td> <td>0.94 g</td> <td> <p>CrCl 6 to 15 mL/minute: Every 24 hours</p> <p>CrCl &#8804;5 mL/minute: Every 48 hours</p> Administer after iHD on dialysis days</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>[5]</sup> (based on preliminary data)</td> <td>1.25 g</td> <td>Every 8 hours</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"5\"> <p>Meropenem-vaborbactam</p> NOTE: Use MDRD equation formula to estimate renal function (eGFR).</td> <td>&#8805;50</td> <td>4 g</td> <td>Every 8 hours (infused over 3 hours)</td> </tr> <tr> <td>30 to 49</td> <td>2 g</td> <td>Every 8 hours (infused over 3 hours)</td> </tr> <tr> <td>15 to 29</td> <td>2 g</td> <td>Every 12 hours (infused over 3 hours)</td> </tr> <tr> <td>&#60;15</td> <td>1 g</td> <td>Every 12 hours (infused over 3 hours)</td> </tr> <tr class=\"divider_bottom\"> <td>iHD*</td> <td>1 g</td> <td>Every 12 hours (infused over 3 hours) administered after an iHD session</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Carbapenems</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"6\">Imipenem-cilastatin (moderate infection)<sup>[6]</sup></td> <td>&#62;70 to 89</td> <td>500 mg</td> <td>Every 6 hours</td> </tr> <tr> <td>41 to 70</td> <td>500 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>21 to 40</td> <td>250 mg</td> <td>Every 6 hours</td> </tr> <tr> <td>&#60;21</td> <td>250 mg</td> <td>Every 12 hours</td> </tr> <tr> <td>iHD*</td> <td>250 mg</td> <td>Every 12 hours; administer after iHD on dialysis days</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>&#182;</sup><sup>[1]</sup></td> <td>250 to 500 mg</td> <td>Every 6 to 8 hours</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"6\">Imipenem-cilastatin (severe infection)<sup>[6]</sup></td> <td>&#62;70 to 89</td> <td>1 g</td> <td>Every 6<sup>&#916;</sup> to 8 hours</td> </tr> <tr> <td>41 to 70</td> <td>500 mg</td> <td>Every 6 hours</td> </tr> <tr> <td>21 to 40</td> <td>500 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>&#60;21</td> <td>500 mg</td> <td>Every 12 hours</td> </tr> <tr> <td>iHD*</td> <td>500 mg</td> <td>Every 12 hours; administer after iHD on dialysis days</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>&#182;</sup><sup>[1]</sup></td> <td>500 mg</td> <td>Every 6 to 8 hours</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"6\">Meropenem (moderate to severe infection)<sup>&#9674;</sup></td> <td>&#62;50</td> <td>1 g</td> <td>Every 8 hours</td> </tr> <tr> <td>26 to 50</td> <td>1 g</td> <td>Every 12 hours</td> </tr> <tr> <td>10 to 25</td> <td>500 mg</td> <td>Every 12 hours</td> </tr> <tr> <td>&#60;10</td> <td>500 mg</td> <td>Every 24 hours</td> </tr> <tr> <td>iHD*</td> <td>500 mg</td> <td>Every 24 hours; administer after iHD on dialysis days</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>&#182;</sup><sup>[1]</sup></td> <td>500 mg or 1 g</td> <td>Every 8 to 12 hours</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"6\">Meropenem (meningitis, cystic fibrosis pulmonary exacerbation)</td> <td>&#62;50</td> <td>2 g</td> <td>Every 8 hours</td> </tr> <tr> <td>26 to 50</td> <td>2 g</td> <td>Every 12 hours</td> </tr> <tr> <td>10 to 25</td> <td>1 g</td> <td>Every 12 hours</td> </tr> <tr> <td>&#60;10</td> <td>1 g</td> <td>Every 24 hours</td> </tr> <tr> <td>iHD*</td> <td>1 g</td> <td>Every 24 hours; administer after iHD on dialysis days</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>&#182;</sup><sup>[1]</sup></td> <td>500 mg or 1 g</td> <td>Every 8 to 12 hours</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"4\">Ertapenem</td> <td>&#62;30</td> <td>1 g</td> <td>Every 24 hours</td> </tr> <tr> <td>&#8804;30</td> <td>500 mg</td> <td>Every 24 hours</td> </tr> <tr> <td>iHD*</td> <td>500 mg</td> <td>Every 24 hours; administer after iHD on dialysis days</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>&#182;</sup><sup>[7]</sup> (based on preliminary data)</td> <td>1 g</td> <td>Every 24 hours</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"6\">Doripenem</td> <td>&#62;50</td> <td>500 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>30 to 50</td> <td>250 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>11 to 29</td> <td>250 mg</td> <td>Every 12 hours</td> </tr> <tr> <td>&#60;10</td> <td>Has not been studied</td> <td>&nbsp;</td> </tr> <tr> <td>iHD*</td> <td>250 to 500 mg</td> <td>Every 24 hours</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>&#182;</sup></td> <td>250 mg to 1 g</td> <td>Every 8 to 12 hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Monobactam</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"5\">Aztreonam (moderate infection)</td> <td>&#62;30</td> <td>1 g</td> <td>Every 8 hours</td> </tr> <tr> <td>10 to 30</td> <td>500 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>&#60;10</td> <td>250 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>iHD*</td> <td>1 g once, followed by 250 mg</td> <td>Every 8 to 12 hours</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>&#182;</sup><sup>[1]</sup></td> <td>2 g once, followed by 1 or 2 g</td> <td>1 g every 8 hours or 1 to 2 g every 12 hours</td> </tr> <tr> <td class=\"indent1\" rowspan=\"5\">Aztreonam (severe infection)</td> <td>&#62;30</td> <td>2 g</td> <td>Every 8 hours</td> </tr> <tr> <td>10 to 30</td> <td>1 g</td> <td>Every 8 hours</td> </tr> <tr> <td>&#60;10</td> <td>500 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>iHD*</td> <td>2 g once, followed by 500 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>CRRT<sup>&#182;</sup><sup>[1]</sup></td> <td>2 g once, followed by 1 or 2 g</td> <td>1 g every 8 hours or 1 to 2 g every 12 hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table lists doses of selected beta-lactam antibiotics, with suggested dosing adjustments for renal impairment. The first dose listed for each agent represents the suggested dose for normal renal function. Renal function is evaluated based on estimated CrCl using the Cockcroft-Gault equation. A calculator for estimating CrCl based on the Cockcroft-Gault equation is available in UpToDate.<br /><STRONG>NOTE:</STRONG> Doses listed for the combination beta-lactam/beta-lactamase inhibitors are expressed as the total of grams for both components.</div><div class=\"graphic_footnotes\">CrCl: creatinine clearance; CRRT: continuous renal replacement therapy; eGFR: estimated glomerular filtration rate; iHD: intermittent hemodialysis; MDRD: Modification of Diet in Renal Disease.<br />* Based on three times weekly dialysis sessions of 3 to 4 hours each; on dialysis days administer dose after dialysis. A loading dose may be warranted for some antibiotics depending on clinical scenario; refer to Lexicomp monograph for detail.<br />¶ General dose and interval range for different types of CRRT based on dialysate/ultrafiltration rate of 1 to 2 L/hour are listed. Specific dosing depends on CRRT method, flow rate, and filter type. For specific recommendations; refer to Lexicomp monograph included in UpToDate.<br />Δ An imipenem dose of 1 g given every 6 hours has been associated with an increased risk of seizures.<SUP>[8]</SUP><br /><FONT class=lozenge>◊</FONT> A lower dose is recommended for some skin/skin structure and urinary tract infections. Refer to Lexicomp monograph.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29:562.</LI>&#xD;&#xA;<LI>Bremmer DN, Nicolau DP, Burcham P, et al. Ceftolozane/tazobactam pharmacokinetics in a critically ill adult receiving continuous renal replacement therapy. Pharmacotherapy 2016; 36:e30.</LI>&#xD;&#xA;<LI>Munita JM, Aitken SL, Miller WR, et al. Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa. Clin Infect Dis 2017 [Epub ahead of print].</LI>&#xD;&#xA;<LI>Caston JJ, De la Torre A, Ruiz Camps I, et al. Salvage therapy with ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 2017; 61:e02136.</LI>&#xD;&#xA;<LI>Wenzler E, Bunnel KL, Belasdale SC, et al. Pharmacokinetics and dialytic clearance of ceftazidime-avibactam in a critically ill patient on continuous venovenous hemofiltration. Antimicrobial Agents Chemother 2017 [Epub ahead of print].</LI>&#xD;&#xA;<LI>Pham PA, Bartlett JG. Imipenem/cilastatin. In: Johns Hopkins Antibiotics Guide (<A href=\"https://www.hopkinsguides.com/hopkins\" target=_blank>https://www.hopkinsguides.com/hopkins</A>), Unbound Medicine, 2017.</LI>&#xD;&#xA;<LI>Eyler RF, Vilay AM, Nader AM, et al. Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration. Antimicrob Agents Chemother 2014; 58:1320.</LI>&#xD;&#xA;<LI>Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007; 67:1027.</LI></OL>Courtesy of Stephen B Calderwood, MD and Alyssa R Letourneau, MD, with additional data from Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 51241 Version 7.0</div></div></div>"},"51244":{"type":"graphic_diagnosticimage","displayName":"Computed tomography scan of bilateral acute pyelonephritis","title":"Computed tomography scan of bilateral acute pyelonephritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography scan of bilateral acute pyelonephritis</div><div class=\"cntnt\"><img style=\"width:360px; height:242px;\" src=\"images/NEPH/51244_Bilateral_acute_pyelo_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced CT scan in bilateral acute pyelonephritis showing triangular hypodense streaks spreading from the pelvis to the renal cortex (arrows).</div><div class=\"graphic_reference\">Courtesy of Alain Meyrier, MD.</div><div id=\"graphicVersion\">Graphic 51244 Version 3.0</div></div></div>"},"51245":{"type":"graphic_diagnosticimage","displayName":"Empyema after liver biopsy PA","title":"Empyema after liver biopsy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Empyema after liver biopsy</div><div class=\"cntnt\"><img style=\"width:324px; height:313px;\" src=\"images/PULM/51245_Empyema_after_liver_biops1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Homogeneous opacification of the right hemithorax with visible pulmonary vessels, the so-called filter effect, typical of a pleural process.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 51245 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"51246":{"type":"graphic_table","displayName":"Causes of neonatal hypertension","title":"Causes of neonatal hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of neonatal hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Renovascular</td> </tr> <tr> <td class=\"indent1\">Thromboembolism</td> </tr> <tr> <td class=\"indent1\">Renal artery stenosis</td> </tr> <tr> <td class=\"indent1\">Mid-aortic coarctation</td> </tr> <tr> <td class=\"indent1\">Renal venous thrombosis</td> </tr> <tr> <td class=\"indent1\">Renal artery compression</td> </tr> <tr> <td class=\"indent1\">Idiopathic arterial calcification</td> </tr> <tr> <td class=\"indent1\">Congenital rubella syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Renal parenchymal disease</td> </tr> <tr> <td class=\"subtitle2_single\">Congenital</td> </tr> <tr> <td class=\"indent1\">Polycystic kidney disease</td> </tr> <tr> <td class=\"indent1\">Multicystic-dysplastic kidney disease</td> </tr> <tr> <td class=\"indent1\">Tuberous sclerosis</td> </tr> <tr> <td class=\"indent1\">Ureteropelvic junction obstruction</td> </tr> <tr> <td class=\"indent1\">Unilateral renal hypoplasia</td> </tr> <tr> <td class=\"indent1\">Congenital nephrotic syndrome</td> </tr> <tr> <td class=\"indent1\">Renal tubular dysgensis</td> </tr> <tr> <td class=\"subtitle2_single\">Acquired</td> </tr> <tr> <td class=\"indent1\">Acute tubular necrosis</td> </tr> <tr> <td class=\"indent1\">Cortical necrosis</td> </tr> <tr> <td class=\"indent1\">Interstitial nephritis</td> </tr> <tr> <td class=\"indent1\">Hemolytic uremic syndrome</td> </tr> <tr> <td class=\"indent1\">Obstruction (stones, tumors)</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary</td> </tr> <tr> <td class=\"indent1\">Bronchopulmonary dysplasia</td> </tr> <tr> <td class=\"indent1\">Pneumothorax</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiac</td> </tr> <tr> <td class=\"indent1\">Thoracic aortic coarctation</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine</td> </tr> <tr> <td class=\"indent1\">Congenital adrenal hyperplasia</td> </tr> <tr> <td class=\"indent1\">Hyperaldosteronism</td> </tr> <tr> <td class=\"indent1\">Hyperthyroidism</td> </tr> <tr> <td class=\"indent1\">Pseudohypoaldosteronism type II</td> </tr> <tr> <td class=\"subtitle1_single\">Medications/intoxications</td> </tr> <tr> <td class=\"subtitle2_single\">Infant</td> </tr> <tr> <td class=\"indent1\">Dexamethasone</td> </tr> <tr> <td class=\"indent1\">Adrenergic agents</td> </tr> <tr> <td class=\"indent1\">Vitamin D intoxication</td> </tr> <tr> <td class=\"indent1\">Theophylline</td> </tr> <tr> <td class=\"indent1\">Caffeine</td> </tr> <tr> <td class=\"indent1\">Pancuronium</td> </tr> <tr> <td class=\"indent1\">Phenylephrine</td> </tr> <tr> <td class=\"subtitle2_single\">Maternal</td> </tr> <tr> <td class=\"indent1\">Cocaine</td> </tr> <tr> <td class=\"indent1\">Heroin</td> </tr> <tr> <td class=\"subtitle1_single\">Neoplasia</td> </tr> <tr> <td class=\"indent1\">Wilms tumor</td> </tr> <tr> <td class=\"indent1\">Mesoblastic nephroma</td> </tr> <tr> <td class=\"indent1\">Neuroblastoma</td> </tr> <tr> <td class=\"indent1\">Pheochromocytoma</td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic</td> </tr> <tr> <td class=\"indent1\">Pain</td> </tr> <tr> <td class=\"indent1\">Intracranial hypertension</td> </tr> <tr> <td class=\"indent1\">Seizures</td> </tr> <tr> <td class=\"indent1\">Familial dysautonomia</td> </tr> <tr> <td class=\"indent1\">Subdural hematoma</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Total parenteral nutrition</td> </tr> <tr> <td class=\"indent1\">Closure of abdominal wall defect</td> </tr> <tr> <td class=\"indent1\">Adrenal hemorrhage</td> </tr> <tr> <td class=\"indent1\">Hypercalcemia</td> </tr> <tr> <td class=\"indent1\">Traction</td> </tr> <tr> <td class=\"indent1\">Extracorporeal membrane oxygenation</td> </tr> <tr> <td class=\"indent1\">Birth asphyxia</td> </tr> <tr> <td class=\"indent1\">Nephrocalcinosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Dionne JM, Abitbol CL, Flynn JT. Hypertension in infancy: diagnosis, management, and outcome. Pediatr Nephrol 2011 with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2011.</div><div id=\"graphicVersion\">Graphic 51246 Version 4.0</div></div></div>"},"51248":{"type":"graphic_picture","displayName":"Linear IgA bullous dermatosis on extremity","title":"Linear IgA bullous dermatosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Linear IgA bullous dermatosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/51248_Line_IgA_bull_derm_extrem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple inflammatory vesicles and crusts are present on the extremity.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51248 Version 3.0</div></div></div>"},"51249":{"type":"graphic_table","displayName":"Initial reaction severity versus risk after VIT","title":"Re-sting risk after stopping venom immunotherapy in relation to severity of pretreatment reaction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Re-sting risk after stopping venom immunotherapy in relation to severity of pretreatment reaction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Author</td> <td class=\"subtitle1\" colspan=\"2\">Mild PTR (I to II)*</td> <td class=\"subtitle1\" colspan=\"2\">Severe PTR (III to IV)*</td> </tr> <tr> <td class=\"subtitle2\">Number of patients</td> <td class=\"subtitle2\">Number with SAR (percentage)</td> <td class=\"subtitle2\">Number of patients</td> <td class=\"subtitle2\">Number with SAR (percentage)</td> </tr> <tr> <td>Golden<sup>[1]</sup></td> <td>10</td> <td>1 (10)</td> <td>18</td> <td>5 (28)</td> </tr> <tr> <td>Keating<sup>[2]</sup></td> <td>30</td> <td>0</td> <td>15</td> <td>2 (13)</td> </tr> <tr> <td>Reisman<sup>[3]</sup></td> <td>66</td> <td>3 (4.5)</td> <td>47</td> <td>7 (15)</td> </tr> <tr class=\"divider_bottom\"> <td>Lerch<sup>[4]</sup></td> <td>17</td> <td>1 (6)</td> <td>183</td> <td>24 (13)</td> </tr> <tr> <td><strong>Total<sup>&#182;</sup></strong></td> <td><strong>123</strong></td> <td><strong>4 (4)</strong></td> <td><strong>263</strong></td> <td><strong>38 (14.5)</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PTR: pretreatment reaction; SAR: systemic allergic reaction.<br />* Grade of severity according to Mueller<SUP>[5]</SUP>.<br />¶ x<SUP>2</SUP> = 11.32; p&lt;0.001.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Golden DB, Johnson K, Addison BI, et al. Clinical and immunologic observations in patients who stop venom immunotherapy. J Allergy Clin Immunol 1986; 77:435.</LI>&#xD;&#xA;<LI>Keating MU, Kagey-Sobotka A, Hamilton RG, Yunginger JW. Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol 1991; 88:339.</LI>&#xD;&#xA;<LI>Reisman RE. Duration of venom immunotherapy: Relationship to the severity of symptoms of initial insect sting anaphylaxis. J Allergy Clin Immunol 1993; 92:831.</LI>&#xD;&#xA;<LI>Lerch E, Müller UR. Long-term protection after stopping venom immunotherapy: Results of re-stings in 200 patients. J Allergy Clin Immunol 1998; 101:606.</LI>&#xD;&#xA;<LI>Mueller HL. Diagnosis and treatment of insect sensitivity. J Asthma Res 1966; 3:331.</LI></OL></div><div id=\"graphicVersion\">Graphic 51249 Version 6.0</div></div></div>"},"51250":{"type":"graphic_table","displayName":"Echo views cardiac structures","title":"Commonly used views to evaluate specific cardiac structures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly used views to evaluate specific cardiac structures</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Structure</td>\n\n      <td class=\"subtitle1\">Views</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Left atrium</td>\n\n      <td>PLA, PSA (base), apical 4-chamber, apical 2-chamber, apical 5-chamber</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Left ventricle</td>\n\n      <td>PLA, PSA (mid/apical), apical 4-chamber, apical 2-chamber, apical 5-chamber, apical long axis,\nsubcostal 4-chamber</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Right atrium</td>\n\n      <td>Parasternal RV inflow, PSA (base), apical 4-chamber, apical 5-chamber, subcostal 4-chamber, subcostal short\naxis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Right ventricle</td>\n\n      <td>PLA, PSA (mid/apical), apical 4-chamber, apical 5-chamber, subcostal 4-chamber, subcostal short axis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ascending aorta</td>\n\n      <td>PLA, PSA (base), apical long axis, apical 5-chamber, right parasternal</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Transverse\naorta</td>\n\n      <td>Suprasternal</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Descending\naorta</td>\n\n      <td>PLA, PSA, subcostal, suprasternal</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Interatrial septum</td>\n\n      <td>PSA (base), apical 4-chamber, subcostal 4-chamber</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Coronary\nsinus</td>\n\n      <td>PLA, RV inflow</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pericardial\neffusion</td>\n\n      <td>PLA, PSA, apical 4-chamber, subcostal 4-chamber</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">PLA: parasternal long axis; PSA: parasternal short axis.</div><div id=\"graphicVersion\">Graphic 51250 Version 1.0</div></div></div>"},"51251":{"type":"graphic_table","displayName":"Varicocele grading","title":"Varicocele grading","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Varicocele grading</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Size</td> <td class=\"subtitle1\">Clinical description</td> </tr> <tr> <td>1</td> <td>Small</td> <td>Palpable only with Valsalva maneuver</td> </tr> <tr> <td>2</td> <td>Moderate</td> <td>Nonvisible on inspection but palpable upon standing</td> </tr> <tr> <td>3</td> <td>Large</td> <td>Visible on gross inspection</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51251 Version 3.0</div></div></div>"},"51253":{"type":"graphic_figure","displayName":"HDL metabolism","title":"Reverse cholesterol transport","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Reverse cholesterol transport</div><div class=\"cntnt\"><img style=\"width:583px; height:299px;\" src=\"images/PC/51253_HDL_metabolism_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ApoA-I is produced by the liver and acquires free cholesterol and phospholipid from liver and peripheral cells (including macrophages) via the ATP-binding cassette transporter A1 (ABCA1) to form nascent (discoidal) HDL particles. Nonlipidated apoA-I is cleared by the kidney. Free cholesterol efflux from macrophages to HDL particles is also promoted by the ABCG1 transporter and scavenger receptor class B type 1 (SR-BI). The free cholesterol in discoidal HDL particles is converted to cholesteryl ester by lecithin-cholesterol acyltransferase (LCAT) activity leading to the formation of mature, spherical HDL particles. Phospholipid transfer protein (PLTP) mediates transfer of phospholipids from VLDL into HDL, thereby providing phospholipids for the LCAT reaction. Mature HDL particles can be remodeled to smaller particles with the release of apoA-I by the actions of hepatic lipase and endothelial lipase, which hydrolyze HDL triglycerides and phospholipids, respectively. In humans, but not rodents, HDL cholesterol ester can be transferred to the VLDL/LDL pool by cholesteryl ester transfer protein (CETP) and taken up by endocytosis into hepatocytes via interaction with the LDL receptor (LDLR). HDL cholesterol ester and free cholesterol are also transferred directly to hepatocytes via SR-BI-mediated selective uptake. Cholesterol taken up by the liver can be recycled back into the ABCA1 pathway, secreted into bile as either free cholesterol or bile acids, or assembled into lipoprotein particles that are secreted back into the circulation (not shown).</div><div class=\"graphic_footnotes\">CE: cholesterol ester; FC: free cholesterol; TG: triacylglycerol.</div><div class=\"graphic_reference\">Reproduced with permission from: Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 2010; 21:229. Copyright © 2010 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51253 Version 10.0</div></div></div>"},"51255":{"type":"graphic_diagnosticimage","displayName":"Lung cancer liver metastases CT ","title":"Liver metastases from lung cancer","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Liver metastases from lung cancer</div><div class=\"cntnt\"><img style=\"width:562px; height:255px;\" src=\"images/PULM/51255_Bronchogenic_carcinoma_CT_V.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) CT scan of the lower chest shows a large, opacified right lung mass (lung cancer) with mucoid bronchograms appearing as low attenuation branching structures.<br />(B) Upper abdominal CT scan from the same patient shows several large low attenuation metastases in the liver, which define a metastatic disease.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 51255 Version 4.0</div></div></div>"},"51256":{"type":"graphic_table","displayName":"CSF concentrations penicillins","title":"Peak CSF concentrations of penicillins in bacterial meningitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Peak CSF concentrations of penicillins in bacterial meningitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td>Penicillin G </td>\n\n      <td>1.0-2.5&#181;g/mL</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Nafcillin </td>\n\n      <td>9.5&nbsp;&#181;g/mL</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ampicillin </td>\n\n      <td>9.9&nbsp;&#181;g/mL</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ticarcillin </td>\n\n      <td>26-33&nbsp;&#181;g/mL</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Piperacillin </td>\n\n      <td>13-35&nbsp;&#181;g/mL</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">The doses used varied from study to study, making comparisons between drugs unreliable.</div><div id=\"graphicVersion\">Graphic 51256 Version 1.0</div></div></div>"},"51257":{"type":"graphic_diagnosticimage","displayName":"Doppler echo cardiac tamponade","title":"Doppler echocardiogram in cardiac tamponade","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Doppler echocardiogram in cardiac tamponade</div><div class=\"cntnt\"><img style=\"width:329px; height:495px;\" src=\"images/CARD/51257_Dopplerechocardiactampon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In cardiac tamponade, the Doppler echocardiogram shows respiratory variation of left-sided Doppler flow signals. Drift in electrocardiogram (ECG) baseline identifies respiration. Panel A is recorded from the left ventricular outflow tract; the arrows denote the peak forward velocity of each beat, demonstrating that respiration causes a change in velocity that exceeds 25 percent. Panel B is obtained from the mitral inflow; the large and small arrows are the E and A waves, respectively. The E and A waves change in amplitude with respect to each other within each beat (ie, E&gt;A or A&gt;E) and to their analogues in neighboring beats. The pattern of mitral inflow and E/A ratio are similar to those seen with the major types of diastolic dysfunction.</div><div id=\"graphicVersion\">Graphic 51257 Version 4.0</div></div></div>"},"51261":{"type":"graphic_picture","displayName":"Radiohumeral range of motion","title":"Range of motion of the radiohumeral joint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Range of motion of the radiohumeral joint</div><div class=\"cntnt\"><img style=\"width:403px; height:353px;\" src=\"images/EM/51261_Radiohumeral_range_of_motio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Passive supination and pronation are compared side to side while palpating the radial head. Loss of full supination or pronation suggests a previous fracture or dislocation of the elbow, or osteonecrosis.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 51261 Version 2.0</div></div></div>"},"51266":{"type":"graphic_diagnosticimage","displayName":"Submucosal fibroid","title":"Fibroid in 53-year-old woman who presented with postmenopausal bleeding","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Fibroid in 53-year-old woman who presented with postmenopausal bleeding</div><div class=\"cntnt\"><img style=\"width:508px; height:223px;\" src=\"images/OBGYN/51266_Submucosal_fibroid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Sagittal transvaginal sonogram shows hypoechoic endometrial thickening (arrowheads).<br />(B) Sagittal sonohysterogram shows submucosal fibroid with thin overlying endometrium (cursors).</div><div class=\"graphic_reference\">Reproduced with permission from: Joizzo JR, Chen MY, Riccio GJ. Endometrial polyps: Sonohysterographic evaluation. AJR Am J Roentgenol 2001; 176:617. Copyright &copy; 2001 American Journal of Roentgenology.</div><div id=\"graphicVersion\">Graphic 51266 Version 3.0</div></div></div>"},"51272":{"type":"graphic_table","displayName":"Surgical wound classification","title":"Surgical wound classification","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Surgical wound classification</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Class I/Clean </td>\n\n    </tr>\n\n    <tr>\n\n      <td>An uninfected operative wound in which no inflammation\nis encountered and the respiratory, alimentary, genital, or uninfected\nurinary tract is not entered. In addition, clean wounds are primarily\nclosed and, if necessary, drained with closed drainage. Operative\nincisional wounds that follow nonpenetrating (blunt) trauma should be\nincluded in this category if they meet the criteria.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Class\nII/Clean-Contaminated</td>\n\n    </tr>\n\n    <tr>\n\n      <td> An operative wound in which the respiratory,\nalimentary, genital, or urinary tracts are entered under controlled\nconditions and without unusual contamination. Specifically, operations\ninvolving the biliary tract, appendix, vagina, and oropharynx are\nincluded in this category, provided no evidence of infection or major\nbreak in technique is encountered.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Class\nIII/Contaminated </td>\n\n    </tr>\n\n    <tr>\n\n      <td>Open, fresh, accidental wounds. In addition, operations\nwith major breaks in sterile technique (eg, open cardiac massage) or\ngross spillage from the gastrointestinal tract, and incisions in which\nacute, nonpurulent inflammation is encountered are included in this\ncategory.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Class\nIV/Dirty-Infected </td>\n\n    </tr>\n\n    <tr>\n\n      <td>Old traumatic wounds with retained devitalized tissue\nand those that involve existing clinical infection or perforated\nviscera. This definition suggests that the organisms causing\npostoperative infection were present in the operative field before the\noperation.</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">8.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=33308&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Surgical_wound_classificati.htm</title></head></div><div class=\"graphic_reference\">Garner JS. CDC guideline for prevention of surgical wound infections, 1985. Supercedes guideline for prevention of surgical wound infections published in 1982. (Originally published in 1995). Revised. Infect Control 1986; 7:193.<BR>Simmons BP. Guideline for prevention of surgical wound infections. Infect Control 1982; 3:185.</div><div id=\"graphicVersion\">Graphic 51272 Version 3.0</div></div></div>"},"51274":{"type":"graphic_figure","displayName":"Linear interpolation","title":"Linear interpolation in CT scanning","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Linear interpolation in CT scanning</div><div class=\"cntnt\"><img style=\"width:226px; height:324px;\" src=\"images/PULM/51274_Linear_interpolation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of linear interpolation. Data at point 3 are inferred mathematically from the nearest scanned points 1 and 2.</div><div id=\"graphicVersion\">Graphic 51274 Version 3.0</div></div></div>"},"51277":{"type":"graphic_table","displayName":"Sources of electromagnetic interference with cardiac devices","title":"Documented sources of electromagnetic interference (EMI) in patients with implanted cardiac devices","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Documented sources of electromagnetic interference (EMI) in patients with implanted cardiac devices</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Source</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Electromagnetic fields</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"4\">Daily life*</td> <td>Faulty home appliances</td> </tr> <tr> <td>Metal detectors</td> </tr> <tr> <td>Anti-theft equipment</td> </tr> <tr class=\"divider_bottom\"> <td>Slot machines</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"5\">Work and industrial environment</td> <td>High voltage power lines<sup>&#182;</sup></td> </tr> <tr> <td>Welding equipment<sup>&#916;</sup></td> </tr> <tr> <td>Electronic motors while \"on\"</td> </tr> <tr> <td>Induction furnaces</td> </tr> <tr class=\"divider_bottom\"> <td>Degaussing coils</td> </tr> <tr> <td class=\"indent1\" rowspan=\"9\">Medical/hospital environment</td> <td>Magnetic resonance imaging</td> </tr> <tr> <td>Defibrillation or cardioversion</td> </tr> <tr> <td> <p>Device-device interaction</p> (eg, pacemaker and neural stimulator)</td> </tr> <tr> <td>Radiofrequency ablation</td> </tr> <tr> <td>Electrocautery</td> </tr> <tr> <td>Transcutaneous nerve stimulation</td> </tr> <tr> <td>Therapeutic diathermy</td> </tr> <tr> <td>Lithotripsy</td> </tr> <tr> <td>Radiation therapy<sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* There are many potential sources of single-beat inhibition. However, single-beat inhibition is not clinically significant and does not merit specific mention.<br />¶ If working at or near the level of the power line. There is no convincing evidence that being under the power lines at ground level will cause interference.<br />Δ Although all welding equipment is capable of causing interference, it most commonly occurs with equipment that operates at ≥150 amps.<br /><FONT class=lozenge>◊</FONT> Radiation therapy may cause electromagnetic interference but may also result in direct damage to the pulse generator resulting in sudden no output or \"runaway.\"</div><div class=\"graphic_reference\">Reproduced with permission from: Pinski SL, Trohman RG. Interference in implanted cardiac devices, Part I. Pacing Clin Electrophysiol 2002; 25:1367. Copyright &copy; 2002 Blackwell Publishing.</div><div id=\"graphicVersion\">Graphic 51277 Version 7.0</div></div></div>"},"51281":{"type":"graphic_diagnosticimage","displayName":"Cryptogenic organizing pneumonia CXR I","title":"Cryptogenic organizing pneumonitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cryptogenic organizing pneumonitis</div><div class=\"cntnt\"><img style=\"width:343px; height:293px;\" src=\"images/PULM/51281_BOOP_PA_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sixty-two year old man with a one month history of dyspnea with exertion, fatigue, and weight loss due to cryptogenic organizing pneumonitis. Posteroanterior roentgenogram reveals bilateral patchy alveolar opacities. There was complete resolution following&nbsp;glucocorticoid therapy. Unfortunately, the disease recurred several times following withdrawal of&nbsp;glucocorticoid therapy.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 51281 Version 4.0</div></div></div>"},"51282":{"type":"graphic_table","displayName":"Effects of sedative drugs","title":"Effects of sedative drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effects of sedative drugs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug </td> <td class=\"subtitle1\">Anxiolysis </td> <td class=\"subtitle1\">Hypnosis </td> <td class=\"subtitle1\">Amnesia </td> <td class=\"subtitle1\">Analgesia </td> </tr> <tr> <td>Benzodiazepines</td> <td>+</td> <td>+</td> <td>+</td> <td>&ndash;</td> </tr> <tr> <td>Dexmedetomidine</td> <td>+</td> <td>&ndash;</td> <td>&ndash;</td> <td>+</td> </tr> <tr> <td>Haloperidol</td> <td>+</td> <td>+*</td> <td>+*</td> <td>&ndash;</td> </tr> <tr> <td>Opioid analgesics</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>+</td> </tr> <tr> <td>Propofol</td> <td>+<sup>&#182;</sup></td> <td>+</td> <td>+*</td> <td>&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Minimal effect.<br />&para; Only at low doses.</div><div id=\"graphicVersion\">Graphic 51282 Version 2.0</div></div></div>"},"51286":{"type":"graphic_diagnosticimage","displayName":"Retromembranous bleed 2","title":"Retromembranous bleed 2","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retromembranous bleed 2</div><div class=\"cntnt\"><img style=\"width:360px; height:233px;\" src=\"images/OBGYN/51286_Retromemembran_bleed_2_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrows point to a retromembranous bleed.</div><div class=\"graphic_reference\">Courtesy of Charles Lockwood, MD.</div><div id=\"graphicVersion\">Graphic 51286 Version 3.0</div></div></div>"},"51287":{"type":"graphic_table","displayName":"Disadv main Rx prost CA","title":"The disadvantages of the main treatment options for early prostate cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The disadvantages of the main treatment options for early prostate cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">External beam radiation therapy</td> </tr> <tr> <td class=\"indent1\">Significant risk of erectile dysfunction</td> </tr> <tr> <td class=\"indent1\">Lack of lymph node removed; Late rectal symptoms more common than with brachytherapy or radical prostatectomy</td> </tr> <tr> <td class=\"indent1\">Knowledge of possible metastasis to lymph nodes is not available</td> </tr> <tr> <td class=\"indent1\">Up to half of patients have some temporary bladder or bowel symptoms during treatment</td> </tr> <tr> <td class=\"subtitle1_single\">Brachytherapy</td> </tr> <tr> <td class=\"indent1\">Significant risk of erectile dysfunction</td> </tr> <tr> <td class=\"indent1\">Lack of lymph node removed; Knowledge of possible metastasis to lymph nodes is not available</td> </tr> <tr> <td class=\"indent1\">Up to half of patients have some temporary bladder or bowel symptoms with treatment</td> </tr> <tr> <td class=\"subtitle1_single\">Radical prostatectomy</td> </tr> <tr> <td class=\"indent1\">Significant risk of erectile dysfunction</td> </tr> <tr> <td class=\"indent1\">Risk of operative morbidity</td> </tr> <tr> <td class=\"indent1\">Low risk of long-term incontinence</td> </tr> <tr> <td class=\"subtitle1_single\">Active surveillance</td> </tr> <tr> <td class=\"indent1\">Tumor may progress beyond the possibility for cure</td> </tr> <tr> <td class=\"indent1\">Later treatment may result in more side effects</td> </tr> <tr> <td class=\"indent1\">Living with untreated cancer may cause anxiety</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from: Vogelzang NJ, Scardino PT, Shipley WU, et al. Comprehensive textbook of genitourinary oncology, 3rd Edition, Lippincott Williams &amp; Wilkins 2005.</div><div id=\"graphicVersion\">Graphic 51287 Version 18.0</div></div></div>"},"51288":{"type":"graphic_figure","displayName":"Interventricular septum","title":"Anatomic components of the interventricular septum","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Anatomic components of the interventricular septum</div><div class=\"cntnt\"><img style=\"width:490px; height:298px;\" src=\"images/PEDS/51288_Interventricular_septum_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A schematic presentation of the three main anatomic components of the interventricular septum as seen from the morphologic left ventricle (A) and the morphologic right ventricle (B). Component 1: septum of the atrioventricular canal; Component 2: septum of the muscular septum; and Component 3: parietal band or distal conal septum.</div><div class=\"graphic_reference\">Drawings by Emily McIntosh.</div><div id=\"graphicVersion\">Graphic 51288 Version 3.0</div></div></div>"},"51289":{"type":"graphic_algorithm","displayName":"Subacute or chronic weakness in children","title":"Subacute or chronic weakness in children","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subacute or chronic weakness in children</div><div class=\"cntnt\"><img style=\"width:385px; height:501px;\" src=\"images/EM/51289_Chronicweaknessalgorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CNS: central nervous system.<br> * For example, metachromatic leukodystrophy, Alexander disease, Krabbe disease.</div><div class=\"graphic_reference\">Adapted with permission from: Tsarouhas N, Decker JM. Weakness. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 51289 Version 13.0</div></div></div>"},"51291":{"type":"graphic_figure","displayName":"Actin myosin interaction","title":"Actin-myosin interaction in myocardial contractility","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Actin-myosin interaction in myocardial contractility</div><div class=\"cntnt\"><img style=\"width:543px; height:347px;\" src=\"images/CARD/51291_Actinmyosininteraction.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A model of the sliding filament theory of muscular contraction. Panel A shows myosin in the relaxed state having just been bound by ATP. Panel B shows the first step by which myosin is energized via hydrolysis of an ATP high energy phosphate bond, resulting in the formation of ADP and inorganic phosphate (Pi). The myosin head then binds actin at the myosin binding site, forming the actin-myosin crossbridge as shown in Panel C. Panel D shows release of ADP and inorganic phosphate, plus flexion of the myosin molecule at its hinge point, causing the filaments to slide past each other. The cross-bridge remains until myosin is again bound by ATP, which allows dissociation of the myosin and actin and relaxation of the myosin molecule. The actin-myosin complex returns to the state in Panel A except that the filaments have now moved relative to each other.</div><div class=\"graphic_reference\">Courtesy of Timothy W Smith, MD, PhD.</div><div id=\"graphicVersion\">Graphic 51291 Version 3.0</div></div></div>"},"51292":{"type":"graphic_figure","displayName":"Pharmacokinetics of epoetin alfa and darbepoetin alfa","title":"Graph showing pharmacokinetics of epoetin alfa and darbepoetin alfa","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Graph showing pharmacokinetics of epoetin alfa and darbepoetin alfa</div><div class=\"cntnt\"><img style=\"width:492px; height:424px;\" src=\"images/HEME/51292_Kinetics_of_Epo_darbepoieti.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graph shows the pharmacokinetics of intravenously administered darbepoetin alfa (11 subjects) and epoetin alfa (10 subjects) in patients with end-stage renal failure on continuous ambulatory peritoneal dialysis. Error bars represent mean ± SD.</div><div class=\"graphic_reference\">Data from: Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10:2392.</div><div id=\"graphicVersion\">Graphic 51292 Version 5.0</div></div></div>"},"51294":{"type":"graphic_diagnosticimage","displayName":"Med bronchogen cyst CT I","title":"Mediastinal subcarinal bronchogenic cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mediastinal subcarinal bronchogenic cyst</div><div class=\"cntnt\"><img style=\"width:360px; height:250px;\" src=\"images/PULM/51294_Med_bronchogen_cyst_CT_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan proves the cystic nature of the subcarinal mass that bulges to the right into azygoesophageal recess.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 51294 Version 3.0</div></div></div>"},"51295":{"type":"graphic_table","displayName":"Chest radiograph findings in vascular rings","title":"Chest radiograph findings in vascular rings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chest radiograph findings in vascular rings</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Lateral</td> </tr> <tr> <td>Anterior tracheal bowing (92%)</td> </tr> <tr> <td>Retrotracheal opacity (79%)</td> </tr> <tr> <td>Tracheal narrowing (77%)</td> </tr> <tr> <td>All the above (62%)</td> </tr> <tr> <td class=\"subtitle1_single\">Frontal</td> </tr> <tr> <td>Right aortic arch (85%)</td> </tr> <tr> <td>Distal tracheal indentation (73%)</td> </tr> <tr> <td>Right descending aorta (66%)</td> </tr> <tr> <td>All the above (49%)</td> </tr> <tr> <td>Normal (10%)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Pickhardt PJ, Siegel MJ, Gutierrez FR. Vascular rings in symptomatic children: frequency of chest radiographic findings. Radiology 1997; 203:423.</div><div id=\"graphicVersion\">Graphic 51295 Version 3.0</div></div></div>"},"51296":{"type":"graphic_picture","displayName":"Klippel-Trenaunay syndrome - leg","title":"Klippel-Trenaunay syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Klippel-Trenaunay syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/51296_Klippel_Trenaunay_synd_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A capillary malformation and limb hypertrophy are present on the right leg of this child with Klippel-Trenaunay syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51296 Version 3.0</div></div></div>"},"51297":{"type":"graphic_figure","displayName":"Anatomy of hand fractures - Scaphoid","title":"Anatomy of hand fractures - Scaphoid","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Anatomy of hand fractures - Scaphoid</div><div class=\"cntnt\"><img style=\"width:475px; height:488px;\" src=\"images/SURG/51297_Anat_hand_fx_scaphoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A precise anatomical description of the exact location of the fracture aids in localizing the fracture. The anatomical sites of scaphoid fracture are the tubercle, waist, proximal pole, and distal pole.</div><div id=\"graphicVersion\">Graphic 51297 Version 2.0</div></div></div>"},"51298":{"type":"graphic_figure","displayName":"Anatomy common femoral artery ","title":"Anatomy common femoral artery","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Anatomy common femoral artery</div><div class=\"cntnt\"><img style=\"width:499px; height:610px;\" src=\"images/SURG/51298_Anatomy_Fem_central_line.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51298 Version 4.0</div></div></div>"},"51299":{"type":"graphic_table","displayName":"Rare causes ascites","title":"Rare causes of ascites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rare causes of ascites</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Infectious\n   </td>\n   </tr>\n   <tr>\n   <td>Amebiasis</td>\n   </tr>\n   <tr>\n   <td>Ascariasis</td>\n   </tr>\n   <tr>\n   <td>Brucellosis</td>\n   </tr>\n   <tr>\n   <td>Chlamydia peritonitis</td>\n   </tr>\n   <tr>\n   <td>Complications related to HIV infection</td>\n   </tr>\n   <tr>\n   <td>Pelvic inflammatory disease</td>\n   </tr>\n   <tr>\n   <td>Pseudomembranous colitis</td>\n   </tr>\n   <tr>\n   <td>Salmonellosis</td>\n   </tr>\n   <tr>\n   <td>Whipple's disease</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Hematologic\n   </td>\n   </tr>\n   <tr>\n   <td>Amyloidosis</td>\n   </tr>\n   <tr>\n   <td>Castleman's syndrome</td>\n   </tr>\n   <tr>\n   <td>Extramedullary hematopoiesis</td>\n   </tr>\n   <tr>\n   <td>Hemophagocytic syndrome</td>\n   </tr>\n   <tr>\n   <td>Histiocytosis X</td>\n   </tr>\n   <tr>\n   <td>Leukemia</td>\n   </tr>\n   <tr>\n   <td>Lymphoma</td>\n   </tr>\n   <tr>\n   <td>Mastocytosis</td>\n   </tr>\n   <tr>\n   <td>Multiple myeloma</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Miscellaneous\n   </td>\n   </tr>\n   <tr>\n   <td>Abdominal pregnancy</td>\n   </tr>\n   <tr>\n   <td>Crohn's disease</td>\n   </tr>\n   <tr>\n   <td>Endometriosis</td>\n   </tr>\n   <tr>\n   <td>Gaucher's disease</td>\n   </tr>\n   <tr>\n   <td>Lymphangioleiomyomatosis</td>\n   </tr>\n   <tr>\n   <td>Myxedema</td>\n   </tr>\n   <tr>\n   <td>Nephrotic syndrome (in children, adults with nephrotic syndrome and ascites usually have another cause such as cirrhosis)</td>\n   </tr>\n   <tr>\n   <td>Operative lymphatic tear or ureteral injury</td>\n   </tr>\n   <tr>\n   <td>Ovarian hyperstimulation syndrome</td>\n   </tr>\n   <tr>\n   <td>POEMS syndrome</td>\n   </tr>\n   <tr>\n   <td>Systemic lupus erythematosus</td>\n   </tr>\n   <tr>\n   <td>Ventriculoperitoneal shunt</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 51299 Version 1.0</div></div></div>"},"51300":{"type":"graphic_table","displayName":"Host factors Salmonella","title":"Host factors that predispose to severe Salmonella infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Host factors that predispose to severe Salmonella infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Impaired cell-mediated immunity</td> </tr> <tr> <td>AIDS</td> </tr> <tr> <td>Use of corticosteroids or other immunomodulatory agents</td> </tr> <tr> <td>Malignancy</td> </tr> <tr> <td class=\"subtitle1_single\">Impaired phagocytic function</td> </tr> <tr> <td>Hemoglobinopathies</td> </tr> <tr> <td>Chronic granulomatous disease</td> </tr> <tr> <td>Malaria</td> </tr> <tr> <td>Histoplasmosis</td> </tr> <tr> <td>Schistosomiasis</td> </tr> <tr> <td class=\"subtitle1_single\">Extremes of age</td> </tr> <tr> <td>Neonates</td> </tr> <tr> <td>Elderly</td> </tr> <tr> <td class=\"subtitle1_single\">Decreased gastric acidity</td> </tr> <tr> <td>Antacids or suppression of acid secretion</td> </tr> <tr> <td>Achlorhydria</td> </tr> <tr> <td class=\"subtitle1_single\">Altered intestinal function</td> </tr> <tr> <td>Inflammatory bowel disease</td> </tr> <tr> <td>Prior antibiotic therapy</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51300 Version 3.0</div></div></div>"},"51302":{"type":"graphic_table","displayName":"Risk of placental abnormality by number of cesareans","title":"Risk of placenta previa and accreta according to number of previous cesarean deliveries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk of placenta previa and accreta according to number of previous cesarean deliveries</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Number of cesareans</td> <td class=\"subtitle1\">Previa<br /> (percent)</td> <td class=\"subtitle1\">Accreta<br /> (percent)</td> <td class=\"subtitle1\">Accreta in patients with previa<br /> (percent)</td> </tr> <tr> <td>Two</td> <td class=\"centered\">1.33</td> <td class=\"centered\">0.31</td> <td class=\"centered\">11</td> </tr> <tr> <td>Three</td> <td class=\"centered\">1.14</td> <td class=\"centered\">0.57</td> <td class=\"centered\">40</td> </tr> <tr> <td>Four</td> <td class=\"centered\">2.27</td> <td class=\"centered\">2.13</td> <td class=\"centered\">61</td> </tr> <tr> <td>Five</td> <td class=\"centered\">2.33</td> <td class=\"centered\">2.33</td> <td class=\"centered\">67</td> </tr> <tr> <td>Six or more</td> <td class=\"centered\">3.37</td> <td class=\"centered\">6.74</td> <td class=\"centered\">67</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The baseline risk of placenta previa in the general obstetrical population is 1 in 200 deliveries. Placenta accreta occurs in fewer than 1 in 500 deliveries.</div><div class=\"graphic_reference\">Adapted from: Silver RM, Landon MB, Rouse DJ, et al. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol 2006; 107:1226.</div><div id=\"graphicVersion\">Graphic 51302 Version 5.0</div></div></div>"},"51303":{"type":"graphic_figure","displayName":"Pain scale children PI","title":"Wong-Baker FACES pain rating scale","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Wong-Baker FACES pain rating scale</div><div class=\"cntnt\"><img style=\"width:479px; height:163px;\" src=\"images/PI/51303_Pain_scale_children_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Explain to the child that each face is for a person who feels happy because he has no pain (hurt) or sad because he has some or a lot of pain. Face 0 is very happy because he doesn't hurt at all. Face 1 hurts just a little bit. Face 2 hurts a little more. Face 3 hurts even more. Face 4 hurts a whole lot. Face 5 hurts as much as you can imagine, although you don't have to be crying to feel this bad. Ask the child to choose the face that best describes how he is feeling. Rating scale is recommended for persons age three years and older. Point to each face using the words to describe the pain intensity. Ask the child to choose the face that best describes own pain and record the appropriate number.</div><div class=\"graphic_reference\">Reproduced with permission from: Wong DL, Hockenberry-Eaton M, Wilson D, et al. Wong's Essentials of Pediatric Nursing, 6th ed. Mosby, St. Louis, 2001. p.301. Copyright © 2001 Elsevier.</div><div id=\"graphicVersion\">Graphic 51303 Version 3.0</div></div></div>"},"51304":{"type":"graphic_diagnosticimage","displayName":"Lumbosacral spinal lipoma","title":"Lumbosacral spinal lipoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lumbosacral spinal lipoma</div><div class=\"cntnt\"><img style=\"width:504px; height:409px;\" src=\"images/PEDS/51304_Lumbosacral_spinal_lipoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal magnetic resonance imaging (MRI) study showing a lumbosacral spinal lipoma (asterisk) on fluid attenuated inversion recovery (FLAIR) (A) and T2 (B) sequences. The latter view shows that the lipoma extends into the subcutaneous fat (arrowhead), and hence is palpable on physical exam in this patient.</div><div class=\"graphic_reference\">Courtesy of Chaouki El-Khoury, BS, MD.</div><div id=\"graphicVersion\">Graphic 51304 Version 4.0</div></div></div>"},"51305":{"type":"graphic_picture","displayName":"Padding short arm cast","title":"Padding for a short arm cast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Padding for a short arm cast</div><div class=\"cntnt\"><img style=\"width:355px; height:468px;\" src=\"images/EM/51305_Padding_short_arm_cast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Padding is applied over the stockinette in a distal to proximal direction. Each layer should overlap the preceding layer by approximately 50 percent. Additional padding should be placed over bony prominences.</div><div class=\"graphic_reference\">Courtesy of Stephen Titus, MD.</div><div id=\"graphicVersion\">Graphic 51305 Version 1.0</div></div></div>"},"51306":{"type":"graphic_waveform","displayName":"Advanced case 10 with answer","title":"Chronic obstructive pulmonary disease","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Chronic obstructive pulmonary disease</div><div class=\"cntnt\"><img style=\"width:519px; height:352px;\" src=\"images/CARD/51306_Advanced_case_10_with_answe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram showing characteristic signs of severe COPD including sinus tachycardia (107 beats/min), peaked P waves in leads II, III, aVF, and V1 (P pulmonale), right axis deviation, and delayed precordial transition zone in which the net QRS area does not become positive until lead V5. Nonspecific ST-T abnormalities are also present. Although not seen here, patients with COPD often have low voltage in the limb leads.The prominent S wave in V3 raises consideration of left ventricular hypertrophy (eg, to to concomitant systemic hypertension).</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 51306 Version 5.0</div></div></div>"},"51307":{"type":"graphic_table","displayName":"Staging uterine carcinoma","title":"Staging uterine carcinoma* (TNM and International Federation of Gynecology and Obstetrics [FIGO])","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Staging uterine carcinoma* (TNM and International Federation of Gynecology and Obstetrics [FIGO])</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"4\">Primary tumor (T) (surgical-pathologic findings)</td> </tr> <tr> <td class=\"subtitle2\">TNM categories</td> <td class=\"subtitle2\">FIGO stages</td> <td class=\"subtitle2\" colspan=\"2\">Definition</td> </tr> <tr> <td>TX</td> <td>&nbsp;</td> <td colspan=\"2\">Primary tumor cannot be assessed</td> </tr> <tr> <td>T0</td> <td>&nbsp;</td> <td colspan=\"2\">No evidence of primary tumor</td> </tr> <tr> <td>Tis<sup>&#182;</sup></td> <td>&nbsp;</td> <td colspan=\"2\">Carcinoma in situ (preinvasive carcinoma)</td> </tr> <tr> <td class=\"sublist1_start\">T1</td> <td class=\"sublist_other_start\">I</td> <td class=\"sublist_other_start\" colspan=\"2\">Tumor confined to corpus uteri</td> </tr> <tr> <td class=\"sublist1\">T1a</td> <td class=\"sublist_other\">IA</td> <td class=\"sublist_other\" colspan=\"2\">Tumor limited to endometrium or invades less than one-half of the myometrium</td> </tr> <tr> <td class=\"sublist1\">T1b</td> <td class=\"sublist_other\">IB</td> <td class=\"sublist_other\" colspan=\"2\">Tumor invades one-half or more of the myometrium</td> </tr> <tr> <td>T2</td> <td>II</td> <td colspan=\"2\">Tumor invades stromal connective tissue of the cervix but does not extend beyond uterus<sup>&#916;</sup></td> </tr> <tr> <td>T3a</td> <td>IIIA</td> <td colspan=\"2\">Tumor involves serosa and/or adnexa (direct extension or metastasis)</td> </tr> <tr> <td>T3b</td> <td>IIIB</td> <td colspan=\"2\">Vaginal involvement (direct extension or metastasis) or parametrial involvement</td> </tr> <tr> <td>T4</td> <td>IVA</td> <td colspan=\"2\">Tumor invades bladder mucosa and/or bowel mucosa (bullous edema is not sufficient to classify a tumor as T4)</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr> <td class=\"subtitle2\">TNM categories</td> <td class=\"subtitle2\">FIGO stages</td> <td class=\"subtitle2\" colspan=\"2\">Definition</td> </tr> <tr> <td>NX</td> <td>&nbsp;</td> <td colspan=\"2\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td>N0</td> <td>&nbsp;</td> <td colspan=\"2\">No regional lymph node metastasis</td> </tr> <tr> <td>N1</td> <td>IIIC1</td> <td colspan=\"2\">Regional lymph node metastasis to pelvic lymph nodes</td> </tr> <tr> <td>N2</td> <td>IIIC2</td> <td colspan=\"2\">Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr> <td class=\"subtitle2\">TNM categories</td> <td class=\"subtitle2\">FIGO stages</td> <td class=\"subtitle2\" colspan=\"2\">Definition</td> </tr> <tr> <td>M0</td> <td>&nbsp;</td> <td colspan=\"2\">No distant metastasis</td> </tr> <tr> <td>M1</td> <td>IVB</td> <td colspan=\"2\">Distant metastasis (includes metastasis to inguinal lymph nodes intraperitoneal disease, or lung, liver, or bone. It excludes metastasis to para-aortic lymph nodes, vagina, pelvic serosa, or adnexa.)</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Anatomic stage/prognostic groups</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"4\">Carcinomas*</td> </tr> <tr> <td>Stage 0<sup>&#182;</sup></td> <td>Tis</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage I</td> <td>T1</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IA</td> <td>T1a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IB</td> <td>T1b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage II</td> <td>T2</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage III</td> <td>T3</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IIIA</td> <td>T3a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IIIB</td> <td>T3b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IIIC1</td> <td>T1-T3</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>Stage IIIC2</td> <td>T1-T3</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>Stage IVA</td> <td>T4</td> <td>Any N</td> <td>M0</td> </tr> <tr> <td>Stage IVB</td> <td>Any T</td> <td>Any N</td> <td>M1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: cTNM is the clinical classification, pTNM is the pathologic classification.</div><div class=\"graphic_footnotes\">* Carcinosarcomas should be staged as carcinoma.<br />¶ FIGO no longer includes Stage 0 (Tis).<br />Δ Endocervical glandular involvement only should be considered as Stage I and not as Stage II.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 51307 Version 15.0</div></div></div>"},"51308":{"type":"graphic_table","displayName":"LMWH versus oral anticoagulants knee","title":"Clinical trials comparing low molecular weight heparin with oral anticoagulants in knee replacement","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical trials comparing low molecular weight heparin with oral anticoagulants in knee replacement</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Design</td> <td class=\"subtitle1\">Regimens</td> <td class=\"subtitle1\">All DVT, n/n (percent)</td> <td class=\"subtitle1\">Proximal DVT*, n/n (percent)</td> <td class=\"subtitle1\">Occurrence of major bleeding, n/n (percent)</td> </tr> <tr> <td rowspan=\"2\">N Engl J Med 1993; 329:1370</td> <td rowspan=\"2\">Randomized double-blind; Bilateral venogram</td> <td>Tinzaparin 75 Xa units/kg sc once daily vs</td> <td>116/258 (45)*</td> <td>20/258 (8)</td> <td>9/317 (2.8)</td> </tr> <tr> <td>Warfarin sodium (INR 2-3)</td> <td>152/277 (55)</td> <td>34/277 (12)</td> <td>3/324 (0.9)</td> </tr> <tr> <td rowspan=\"2\">Ann Intern Med 1996; 124:619</td> <td rowspan=\"2\">Randomized double-blind; Bilateral venogram</td> <td>Enoxaparin 30 mg sc bid vs</td> <td>76/206 (37)*</td> <td>24/206 (12)</td> <td>7/336 (2)</td> </tr> <tr> <td>Warfarin sodium (INR 2-3)</td> <td>109/211 (52)</td> <td>22/211 (10)</td> <td>6/334 (2)</td> </tr> <tr> <td rowspan=\"2\">Thromb Haemost 1994; 74:1428</td> <td rowspan=\"2\">Randomized single-blind; Bilateral venogram</td> <td>Nadroparin 60 Xa units/kg sc once daily vs</td> <td>16/65 (25)*</td> <td>5/65 (8)</td> <td>2/65 (3)</td> </tr> <tr> <td>Acenocoumarol (INR 2-3)</td> <td>23/61 (38)</td> <td>6/61 (10)</td> <td>1/61 (1)</td> </tr> <tr> <td rowspan=\"2\">Bone Joint Surg Am 2001; 83:900</td> <td rowspan=\"2\">Randomized single-blind; Unilateral venography<sup>&#182;</sup></td> <td>Enoxaparin 30 mg SC once daily vs</td> <td>44/173 (25)</td> <td>3/173 (2)</td> <td>9/173 (5)</td> </tr> <tr> <td>Warfarin sodium (INR 2-3)</td> <td>80/176 (46)*</td> <td>20/176 (11)</td> <td>4/176 (2)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DVT: deep vein thrombosis; INR: international normalized ratio; sc: subcutaneously.<br />* (P&lt;0.05).<br />&para; Contrast venography or ultrasonography of the contra-lateral extremity bid: twice daily.</div><div id=\"graphicVersion\">Graphic 51308 Version 3.0</div></div></div>"},"51309":{"type":"graphic_picture","displayName":"Renal hypoplasia","title":"Renal hypoplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Renal hypoplasia</div><div class=\"cntnt\"><img style=\"width:339px; height:514px;\" src=\"images/PEDS/51309_Renal_hypoplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) High power light microscopy shows large glomeruli with interstitial fibrosis and foci of atrophic tubules in a patient with renal hypoplasia and chronic renal disease. B) High power light microscopy of normal kidney.</div><div class=\"graphic_reference\">Courtesy of Dr. Patrick Niaudet.</div><div id=\"graphicVersion\">Graphic 51309 Version 1.0</div></div></div>"},"51312":{"type":"graphic_table","displayName":"Methacholine preparation","title":"Methacholine challenge dilution schedule","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Methacholine challenge dilution schedule</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td colspan=\"4\">Schedule for making dilutions from a 100 mg vial of methacholine chloride for the 2-minute tidal breathing protocol.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Take</td>\n\t\t\t\t\t<td class=\"subtitle1\">Volume NaCl to add (0.9 percent)</td>\n\t\t\t\t\t<td class=\"subtitle1\">Obtain dilution</td>\n\t\t\t\t\t<td class=\"subtitle1\">Dilution, number</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">100 mg in vial</td>\n\t\t\t\t\t<td>6.25 mL</td>\n\t\t\t\t\t<td>16 mg/mL</td>\n\t\t\t\t\t<td>10</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">3 mL of dilution 10</td>\n\t\t\t\t\t<td>3 mL</td>\n\t\t\t\t\t<td>8 mg/mL</td>\n\t\t\t\t\t<td>9</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">3 mL of dilution 9</td>\n\t\t\t\t\t<td>3 mL</td>\n\t\t\t\t\t<td>4 mg/mL</td>\n\t\t\t\t\t<td>8</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">3 mL of dilution 8</td>\n\t\t\t\t\t<td>3 mL</td>\n\t\t\t\t\t<td>2 mg/mL</td>\n\t\t\t\t\t<td>7</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">3 mL of dilution 7</td>\n\t\t\t\t\t<td>3 mL</td>\n\t\t\t\t\t<td>1 mg/mL</td>\n\t\t\t\t\t<td>6</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">3 mL of dilution 6</td>\n\t\t\t\t\t<td>3 mL</td>\n\t\t\t\t\t<td>0.5 mg/mL</td>\n\t\t\t\t\t<td>5</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">3 mL of dilution 5</td>\n\t\t\t\t\t<td>3 mL</td>\n\t\t\t\t\t<td>0.25 mg/mL</td>\n\t\t\t\t\t<td>4</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">3 mL of dilution 4</td>\n\t\t\t\t\t<td>3 mL</td>\n\t\t\t\t\t<td>0.12 5 mg/mL</td>\n\t\t\t\t\t<td>3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">3 mL of dilution 3</td>\n\t\t\t\t\t<td>3 mL</td>\n\t\t\t\t\t<td>0.0625 mg/mL</td>\n\t\t\t\t\t<td>2</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">3 mL of dilution 2</td>\n\t\t\t\t\t<td>3 mL</td>\n\t\t\t\t\t<td>0.031 mg/mL</td>\n\t\t\t\t\t<td>1</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td colspan=\"4\">Start with the most dilute solution (#1) and administer progressively more concentrated dilutions via nebulizer in 2 minute increments; each dose is followed by reassessment of spirometry. Progress to the next more concentrated dose only when there is no significant decrease in forced expiratory volume in 1 second (FEV1) and the patient is asymptomatic.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td colspan=\"4\">Actual starting dose may vary depending on patient conditions. Some laboratories may choose to skip some doses to shorten total duration of testing. This is only done when the patient is not showing any symptoms or decrement in lung function.</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Crapo, RO, Casaburi, R, Coates, AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000; 161:309.</div><div id=\"graphicVersion\">Graphic 51312 Version 1.0</div></div></div>"},"51313":{"type":"graphic_table","displayName":"Causes of dizziness in children and adolescents","title":"Causes of dizziness in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of dizziness in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">True vertigo*</td> <td class=\"subtitle1\">Pseudovertigo</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Life threatening</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>CNS infection<sup>&#182;</sup></p> <p>Head trauma</p> <p>Middle ear trauma</p> <p>Poisoning or adverse medication effect</p> <p>Stroke</p> Brain tumor</td> <td> <p>Arrhythmia</p> <p>Heat illness</p> <p>Hypoglycemia</p> Poisoning or adverse medication effect</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Common</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Benign paroxysmal vertigo of childhood</p> <p>Labyrinthitis (vestibular neuritis)</p> <p>Migraine</p> <p>Motion sickness</p> Otitis media</td> <td> <p>Anemia</p> <p>Anxiety</p> <p>Depression</p> <p>Hyperventilation</p> <p>Orthostatic hypotension</p> <p>Pregnancy</p> Presyncope</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other</td> </tr> <tr> <td class=\"indent1\"> <p>Benign paroxysmal positional vertigo</p> <p>Cholesteatoma</p> <p>Congenital defects<sup>&#916;</sup></p> <p>Mastoiditis</p> <p>Meniere disease</p> <p>Multiple sclerosis</p> <p>Perilymph fistula</p> <p>Ramsay Hunt syndrome</p> Seizure</td> <td>Pseudovertigo</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system.<br />* True vertigo refers to dizziness with a sense of spinning.<br />&para; Meningitis, encephalitis, or intracranial abscess.<br />&Delta; Eg, Mondini dysplasia, Usher syndrome, Joubert syndrome, Schiebe deformity, enlarged vestibular aqueduct syndrome.</div><div id=\"graphicVersion\">Graphic 51313 Version 10.0</div></div></div>"},"51314":{"type":"graphic_picture","displayName":"Central line catheter insertion","title":"Central venous catheter being advanced over guidewire","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Central venous catheter being advanced over guidewire</div><div class=\"cntnt\"><img style=\"width:432px; height:302px;\" src=\"images/EM/51314_Central_L_catheter_insert.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As the catheter is advanced, the guidewire emerges from the distal port. Control should be maintained of both the catheter and the guidewire throughout this process.</div><div class=\"graphic_reference\">UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.</div><div id=\"graphicVersion\">Graphic 51314 Version 3.0</div></div></div>"},"51316":{"type":"graphic_figure","displayName":"Assessment of LV volume with 3D echo","title":"Accuracy of real time three-dimensional echocardiography (RT3DE) measurements of left ventricular (LV) volume","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Accuracy of real time three-dimensional echocardiography (RT3DE) measurements of left ventricular (LV) volume</div><div class=\"cntnt\"><img style=\"width:444px; height:311px;\" src=\"images/CARD/51316_assess_lv_vol_and_func_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of LV volume time curves obtained in one patient from RT3DE and MR images. Results of linear regression (bottom, left) and Bland-Altman (bottom, right) analyses of the point-by-point measurements of LV volume obtained in 16 patients.</div><div class=\"graphic_reference\">Corsi C, Lang RM, Veronesi F, et al. Volumetric quantification of global and regional left ventricular function from real-time three-dimensional echocardiographic images. Circulation 2005; 112:1161.</div><div id=\"graphicVersion\">Graphic 51316 Version 4.0</div></div></div>"},"51319":{"type":"graphic_figure","displayName":"Transient neutropenia during HD","title":"Graph showing transient neutropenia in one patient during hemodialysis","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Graph showing transient neutropenia in one patient during hemodialysis</div><div class=\"cntnt\"><img style=\"width:471px; height:250px;\" src=\"images/NEPH/51319_Neutropenia_during_hemodial.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sequential changes in the total neutrophil and band count in a patient after the onset of hemodialysis with a cuprophan membrane. There is a dramatic and rapid fall in the total neutrophil count (solid line) that reaches a nadir at 15 minutes and then gradually returns toward baseline. The initial phase of the recovery is due in part to a marked increase in the number of immature band forms (dashed line).</div><div class=\"graphic_reference\">Data from Kaplow LS, Goffinet JA. Profound neutropenia during the early phase of hemodialysis.&nbsp;JAMA 1968; 203:1135.</div><div id=\"graphicVersion\">Graphic 51319 Version 3.0</div></div></div>"},"51320":{"type":"graphic_table","displayName":"Evaluation of myoclonus","title":"Evaluation of myoclonus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of myoclonus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\"> <p>Part one:</p> History, physical examination, and clinical syndrome classification</td> </tr> <tr> <td class=\"sublist1_start\">Full history</td> </tr> <tr> <td class=\"sublist1\">Mode of myoclonus onset</td> </tr> <tr> <td class=\"sublist1\">Presence of other neurological problems including seizures</td> </tr> <tr> <td class=\"sublist1\">Drug or toxin exposure</td> </tr> <tr> <td class=\"sublist1\">Other medical problems</td> </tr> <tr> <td class=\"sublist1\">Family history</td> </tr> <tr> <td class=\"sublist1_start\">Physical examination</td> </tr> <tr> <td class=\"sublist1\">Distribution (may be focal, segmental, multifocal, hemi, generalized)</td> </tr> <tr> <td class=\"sublist1\">Temporal profile (includes rhythmic or irregular)</td> </tr> <tr> <td class=\"sublist2\">Continuous</td> </tr> <tr> <td class=\"sublist2\">Intermittent (sporadic or trains)</td> </tr> <tr> <td class=\"sublist1\">Activation profile</td> </tr> <tr> <td class=\"sublist2\">Rest (spontaneous myoclonus)</td> </tr> <tr> <td class=\"sublist2\">Voluntary movement (action myoclonus)</td> </tr> <tr> <td class=\"sublist2\">Reflex stimuli (any combination of touch, light, sound, or muscle stretch)</td> </tr> <tr> <td class=\"sublist1_start\">Determine major clinical syndrome category:</td> </tr> <tr> <td class=\"sublist1\">Physiologic (normal subjects)</td> </tr> <tr> <td class=\"sublist1\">Essential (primary symptom, nonprogressive history)</td> </tr> <tr> <td class=\"sublist1\">Epileptic (associated with a chronic seizure disorder or syndrome)</td> </tr> <tr> <td class=\"sublist1\">Symptomatic (secondary, but not defined by occurrence of seizures)</td> </tr> <tr> <td class=\"subtitle1_single\"> <p>Part two:</p> Ancillary testing</td> </tr> <tr> <td>Electrolytes</td> </tr> <tr> <td>Glucose</td> </tr> <tr> <td>Renal function tests</td> </tr> <tr> <td>Hepatic function tests</td> </tr> <tr> <td>Thyroid antibodies and function</td> </tr> <tr> <td>Drug and toxin screen (if history suggests)</td> </tr> <tr> <td>Paraneoplastic antibodies</td> </tr> <tr> <td>Brain imaging</td> </tr> <tr> <td>Spine imaging (if focal or segmental)</td> </tr> <tr> <td>Cerebrospinal fluid analysis (eg, for infectious and inflammatory disorders, prion disease)</td> </tr> <tr> <td class=\"subtitle1_single\"> <p>Part three:</p> Clinical neurophysiology testing to determine physiologic classification (see text)</td> </tr> <tr> <td>Electroencephalography (EEG)</td> </tr> <tr> <td>Surface electromyography (EMG)</td> </tr> <tr> <td>Simultaneous electroencephalography-electromyography polygraphy (EEG-EMG polygraphy)</td> </tr> <tr> <td>Somatosensory evoked potentials (SEPs)</td> </tr> <tr> <td>Jerk-locked back-averaging of EEG transients and/or SEPs to EMG discharges</td> </tr> <tr> <td>Long latency EMG responses to peripheral nerve stimulation (eg, C reflex)</td> </tr> <tr> <td class=\"subtitle1_single\"> <p>Part four:</p> Testing for uncommon and rare diagnoses</td> </tr> <tr> <td class=\"sublist1_start\">If not otherwise ruled out, the following should be considered:</td> </tr> <tr> <td class=\"sublist1\">Body imaging for occult cancer, even in the absence of paraneoplastic antibodies</td> </tr> <tr> <td class=\"sublist1\">Evaluation for malabsorption disorders such as Celiac sprue and Whipple disease</td> </tr> <tr> <td class=\"sublist1\">Enzyme assays for neuraminidase deficiency (sialidosis) and biotinidase deficiency (multiple carboxylase deficiency)</td> </tr> <tr> <td class=\"sublist1\">Evaluation for Wilson disease</td> </tr> <tr> <td class=\"sublist1\">Evaluation for ataxia-telangiectasia</td> </tr> <tr> <td class=\"sublist1\">Genetic testing (and tissue biopsy if indicated) for inherited disorders, such as Unverricht-Lundborg disease (EPM1 gene), Lafora body disease (EPM2A and EPM2B genes), neuronal ceroid lipofuscinosis, and Huntington disease</td> </tr> <tr> <td class=\"sublist1\">Evaluation for mitochondrial disorders, including serum lactate, muscle biopsy, and genetic testing </td> </tr> <tr> <td class=\"sublist1\">Next generation DNA&nbsp;sequencing for all genes associated with myoclonus</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from: Caviness JN, Brown P. Myoclonus: current concepts and recent advances. Lancet Neurol 2004; 3:598.</div><div id=\"graphicVersion\">Graphic 51320 Version 7.0</div></div></div>"},"51321":{"type":"graphic_figure","displayName":"Technique of above-knee amputation","title":"Technique of above-knee amputation","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Technique of above-knee amputation</div><div class=\"cntnt\"><img style=\"width:502px; height:659px;\" src=\"images/SURG/51321_Above-knee-amputation- edit2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51321 Version 2.0</div></div></div>"},"51322":{"type":"graphic_movie","displayName":"Membranous VSD with aneurysm color","title":"Membranous VSD with aneurysm color","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Membranous VSD with aneurysm color</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/51322_MembrVSDaneurysmmovie.mp4\" style=\"width:496px;height:384px\"></div><img style=\"width:546px; height:397px;\" src=\"images/CARD/51322_MembrVSDaneurysmposter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Membranous VSD with apposed \"aneurysm\" tissue is demonstrated in still frames obtained from long axis imaging planes. Movie clip from study of the same patient shows the defect in an apical four chamber view. The color flow jet of residual flow across the VSD is seen exiting into the right ventricle beneath the apposed septal leaflet of the tricuspid valve. The adherent tissue limits flow into the right ventricle, occluding a portion of the defect.</div><div class=\"graphic_footnotes\">LV: left ventricle; LA: left atrium; RV: right ventricle; AO: aorta; MV: mitral valve; arrows; VSD.</div><div id=\"graphicVersion\">Graphic 51322 Version 5.0</div></div></div>"},"51324":{"type":"graphic_table","displayName":"Relative risk of fracture","title":"Relative risk of fracture for each age-adjusted standard deviation decrease in BMD","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relative risk of fracture for each age-adjusted standard deviation decrease in BMD</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Skeletal site of BMD measurement</td>\n\n      <td class=\"subtitle1\">Hip fracture</td>\n\n      <td class=\"subtitle1\">Vertebral fracture</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Distal radius</td>\n\n      <td>1.8</td>\n\n      <td>1.7</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Proximal radius</td>\n\n      <td>2.1</td>\n\n      <td>2.2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Calcaneus</td>\n\n      <td>2.0</td>\n\n      <td>2.4</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Spine</td>\n\n      <td>1.6</td>\n\n      <td>2.3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Femoral neck</td>\n\n      <td>2.6</td>\n\n      <td>1.8</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">4.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=15881&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Relative_Risk_of_fracture.htm</title></head></div><div class=\"graphic_footnotes\">BMD: bone mineral density.</div><div class=\"graphic_reference\">Data from: Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312:1254.</div><div id=\"graphicVersion\">Graphic 51324 Version 3.0</div></div></div>"},"51325":{"type":"graphic_figure","displayName":"Pomeroy tubal ligation B","title":"Pomeroy tubal ligation B","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pomeroy tubal ligation B</div><div class=\"cntnt\"><img style=\"width:298px; height:450px;\" src=\"images/OBGYN/51325_PomeroytuballigationB.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 51325 Version 1.0</div></div></div>"},"51329":{"type":"graphic_figure","displayName":"Pelvic floor muscles 2","title":"Muscles of the female pelvic floor","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Muscles of the female pelvic floor</div><div class=\"cntnt\"><img style=\"width:564px; height:464px;\" src=\"images/OBGYN/51329_Pelvic_floor_muscles_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pelvic diaphragm - view into the pelvic floor illustrating the muscles of the pelvic diaphragm and their attachments to the bony pelvis.</div><div class=\"graphic_reference\">Reproduced with permission from: LifeART. Copyright &#169; 2010 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 51329 Version 1.0</div></div></div>"},"51330":{"type":"graphic_table","displayName":"Abnormal findings on a videofluoroscopic swallow study (VFSS)","title":"Abnormal findings on a videofluoroscopic swallow study (VFSS)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Abnormal findings on a videofluoroscopic swallow study (VFSS)*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Phase</td> <td class=\"subtitle1\">Radiographic finding</td> </tr> <tr> <td rowspan=\"2\"><strong>Oral preparatory</strong></td> <td>Lack of bolus formation</td> </tr> <tr> <td>Adherence to hard palate</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Oral</strong></td> <td>Delayed oral transit time</td> </tr> <tr> <td>Reduced tongue elevation</td> </tr> <tr> <td>Tongue incoordination</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"7\"><strong>Pharyngeal</strong></td> <td>Velopharyngeal incoordination/reflux</td> </tr> <tr> <td>Delayed pharyngeal transit time</td> </tr> <tr> <td>Pooling in pharyngeal recesses</td> </tr> <tr> <td>Residue in pharyngeal recesses</td> </tr> <tr> <td>Laryngeal penetration</td> </tr> <tr> <td>Cricopharyngeal dysfunction</td> </tr> <tr> <td>Aspiration</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Esophageal</strong></td> <td>Reduced esophageal peristalsis</td> </tr> <tr> <td>Gastroesophageal reflux</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=81996&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">* A videofluoroscopic swallow study (VFSS) is also known as a modified barium swallow (MBS).</div><div id=\"graphicVersion\">Graphic 51330 Version 4.0</div></div></div>"},"51331":{"type":"graphic_movie","displayName":"Suprasternal color of Doppler TOF","title":"Suprasternal notch short axis view with color flow mapping in tetralogy of Fallot (TOF)","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Suprasternal notch short axis view with color flow mapping in tetralogy of Fallot (TOF)</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/51331_SupracolorDoppTOF.mp4\" style=\"width:432px;height:400px\"></div><img style=\"width:452px; height:373px;\" src=\"images/PEDS/51331_SupracolorDopplerTOF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This still frame from the accompanying echocardiographic video clip of the suprasternal notch short axis view in a patient with tetralogy of Fallot (TOF) highlights the flow in the right (RPA) and left pulmonary arteries (LPA). These vessels are without evidence of proximal stenosis.</div><div class=\"graphic_footnotes\">Ao: ascending aorta.</div><div id=\"graphicVersion\">Graphic 51331 Version 1.0</div></div></div>"},"51333":{"type":"graphic_figure","displayName":"Urothelial carcinoma","title":"Urothelial carcinoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Urothelial carcinoma</div><div class=\"cntnt\"><img style=\"width:504px; height:287px;\" src=\"images/ONC/51333_Urothelial_carcinoma.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 51333 Version 1.0</div></div></div>"},"51335":{"type":"graphic_figure","displayName":"Folate and alcohol intake and CHD risk in women","title":"Women with the highest intake of folate and alcohol have the lowest risk for coronary heart disease","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Women with the highest intake of folate and alcohol have the lowest risk for coronary heart disease</div><div class=\"cntnt\"><img style=\"width:549px; height:303px;\" src=\"images/CARD/51335_Folate_alcohol_CHD_women.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The relative risk of coronary heart disease (nonfatal myocardial infarction and fatal coronary heart disease) by quintiles of folate intake across levels of alcohol consumption among 80,082 women in the Nurses' Health Study. Women in the lowest quintile of folate who did not drink alcohol were the reference category (relative risk 1.0). The benefits from increasing amounts of folate intake are seen primarily in women who consume alcohol and the benefit increases as alcohol consumption increases.</div><div class=\"graphic_reference\">Data from: Rimm EB, Willeh WC, Hu FB, et al. JAMA 1998; 279:359.</div><div id=\"graphicVersion\">Graphic 51335 Version 3.0</div></div></div>"},"51337":{"type":"graphic_picture","displayName":"Eczema herpeticum arm","title":"Eczema herpeticum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eczema herpeticum</div><div class=\"cntnt\"><img style=\"width:425px; height:265px;\" src=\"images/PC/51337_Eczema_herpeticum_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Punched-out ulcers are due to herpes simplex virus infection present on the arm of this patient with underlying atopic dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig S, Baskin MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright ©2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51337 Version 2.0</div></div></div>"},"51338":{"type":"graphic_diagnosticimage","displayName":"FNH MRI T1 weighted","title":"Focal nodular hyperplasia of the liver seen on MRI","html":"<div class=\"graphic\"><div style=\"width: 577px\" class=\"figure\"><div class=\"ttl\">Focal nodular hyperplasia of the liver seen on MRI</div><div class=\"cntnt\"><img style=\"width:557px; height:423px;\" src=\"images/GAST/51338_FNH_MRI_T1_weighted.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T1-weighted magnetic resonance imaging (MRI) pre-gadolinium shows a hypointense lesion in the left lobe of the liver (top left). Immediately after gadolinium infusion, the arterial phase reveals a hyperintense mass with a hypodense central scar, characteristic of focal nodular hyperplasia (top right). After two minutes, the mass appears nearly isodense with the normal liver, and the central scar is difficult to distinguish (bottom left). After three minutes, the central scar is hyperdense&nbsp;due to delayed accumulation of gadolinium (bottom right).</div><div class=\"graphic_reference\">Courtesy of Douglas R LaBrecque, MD.</div><div id=\"graphicVersion\">Graphic 51338 Version 5.0</div></div></div>"},"51340":{"type":"graphic_table","displayName":"Sources for epidural abscess","title":"Sources of infection for spinal epidural abscess","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sources of infection for spinal epidural abscess</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Source</td>\n<td class=\"subtitle1\">Number of patients, percent</td>\n</tr>\n<tr>\n<td>No source identified</td>\n<td>30</td>\n</tr>\n<tr>\n<td>Skin and soft tissue </td>\n<td>22</td>\n</tr>\n<tr>\n<td>Spinal surgery or procedures </td>\n<td>12</td>\n</tr>\n<tr>\n<td>Injection drug use </td>\n<td>10</td>\n</tr>\n<tr>\n<td>Other sources, including epidural catheters </td>\n<td>8</td>\n</tr>\n<tr>\n<td>Bone or joint </td>\n<td>7</td>\n</tr>\n<tr>\n<td>Urinary tract </td>\n<td>3</td>\n</tr>\n<tr>\n<td>Upper respiratory tract </td>\n<td>3</td>\n</tr>\n<tr>\n<td>Sepsis </td>\n<td>2</td>\n</tr>\n<tr>\n<td>Abdomen </td>\n<td>2</td>\n</tr>\n<tr>\n<td>Intravascular catheter associated </td>\n<td>&#60;1</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">8.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=33107&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Sources_for_epidural_absces.htm</title></head></div><div class=\"graphic_reference\">Data from Danner R, Hartman BJ. Rev Infect Dis 1975; 9:265; Nussbaum ES, Rigamonti D, Standiford H, et al. Surg Neurol 1992; 38:225; Gellin BG, Weingarten K, Gamache FW Jr, et al. Epidural Abscess. In: Infections of the Central Nervous System, 2nd ed, Scheld WM, Whitley RJ, Durack DT (Eds), Lippincott-Raven Publishers, Philadelphia 1997. p.507; Rigamonti D, Liem L, Wolf AL, et al. Mt Sinai J Med 1994; 61:357; Kapeller P, Fazekas F, Krametter D, et al. Eur Neurol 1997; 38:94.</div><div id=\"graphicVersion\">Graphic 51340 Version 2.0</div></div></div>"},"51342":{"type":"graphic_picture","displayName":"Fundus appearance in central retinal artery occulsion","title":"Fundus appearance in central retinal artery occlusion","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Fundus appearance in central retinal artery occlusion</div><div class=\"cntnt\"><img style=\"width:504px; height:519px;\" src=\"images/NEURO/51342_Fundus_after_CRAO.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fundus appearance of a complete central retinal artery occlusion.</div><div id=\"graphicVersion\">Graphic 51342 Version 3.0</div></div></div>"},"51345":{"type":"graphic_table","displayName":"APL induction regimens","title":"Chemotherapy induction regimens for acute promyelocytic leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chemotherapy induction regimens for acute promyelocytic leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drugs</td> <td class=\"subtitle1\">Dosing</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td rowspan=\"2\">ATRA <strong>plus</strong> idarubicin<sup>[1]</sup></td> <td><strong>ATRA:</strong> 45 mg/m<sup>2</sup> per day in two divided doses until complete response.</td> <td rowspan=\"2\">This is the AIDA protocol that yields a 94 percent remission rate. After three intensive consolidation courses plus maintenance therapy, the event-free survival at 12 years was 69 percent.</td> </tr> <tr> <td><strong>Idarubicin:</strong> 12 mg/m<sup>2</sup> intravenous push days 2, 4, 6, and 8.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">ATRA <strong>plus</strong> daunorubicin <strong>plus</strong> cytarabine<sup>[2]</sup></td> <td><strong>ATRA:</strong> 45 mg/m<sup>2</sup> per day in two divided doses until complete response.</td> <td rowspan=\"3\">This North American Intergroup regimen had a high complete remission rate of 90 percent. When followed by arsenic trioxide for consolidation, the event-free survival was 80 percent and overall survival 86 percent at three years. Disease-free survival was 90 percent.</td> </tr> <tr> <td><strong>Daunorubicin:</strong> 50 mg/m<sup>2</sup> intravenous push on each of days 3 through 6 (four doses).</td> </tr> <tr> <td><strong>Cytarabine:</strong> 200 mg/m<sup>2</sup> daily as a continuous infusion for days 3 through 9 (seven days).</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">ATRA <strong>plus</strong> arsenic trioxide<sup>[3]</sup></td> <td><strong>ATRA:</strong> 45 mg/m<sup>2</sup> per day in two divided doses until complete response.</td> <td rowspan=\"2\">Initial studies demonstrate good results with short follow-up. Yields a &#62;85 percent remission rate. May be an excellent option for patients with low or intermediate risk disease, especially those who are not able to tolerate anthracycline-based therapy. Hydroxyurea, daunorubicin, or gemtuzumab ozogamicin have been added if the WBC count rises dramatically.</td> </tr> <tr> <td><strong>Arsenic trioxide:</strong> 0.15 mg/kg per day until complete response.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">ATRA <strong>plus</strong> arsenic trioxide <strong>plus</strong> gemtuzumab ozogamicin<sup>[4]</sup></td> <td><strong>ATRA:</strong> 45 mg/m<sup>2</sup> per day in two divided doses until complete response.</td> <td rowspan=\"3\">Initial study demonstrated a response rate of 92 percent. At a median follow-up of 24 months, the estimated three-year survival rate was 85 percent. Disease-related complications resulted in an early death rate of 8 percent.</td> </tr> <tr> <td><strong>Arsenic trioxide:</strong> 0.15 mg/kg per day beginning on day 1 with the ATRA and continuing until complete response.</td> </tr> <tr> <td><strong>Gemtuzumab ozogamicin:</strong> 9 mg/m<sup>2</sup> on day 1 for high risk patients (defined as white count &#8805;10x10<sup>9</sup>/L).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ATRA: all-trans retinoic acid (tretinoin).</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood 2011; 117:4716. </li>&#xD;&#xA;    <li>Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010; 116:3751. </li>&#xD;&#xA;    <li>Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013; 369:111.</li>&#xD;&#xA;    <li>Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with All-Trans-Retinoic Acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009; 27:504. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 51345 Version 6.0</div></div></div>"},"51346":{"type":"graphic_table","displayName":"Acute acetaminophen poisoning in adults - Rapid overview","title":"Acute acetaminophen poisoning in adults: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute acetaminophen poisoning in adults: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical presentation</td> </tr> <tr> <td>Nausea and vomiting are common early symptoms</td> </tr> <tr> <td>Patients that subsequently develop hepatic injury and death may be asymptomatic for HOURS after an acute ingestion</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td>In all patients with suspected acetaminophen (APAP) toxicity, obtain the following: serum acetaminophen concentration, baseline liver function tests (AST, ALT, total bilirubin), PT and INR, and basic chemistry panel (electrolytes, BUN, creatinine)</td> </tr> <tr> <td>In all patients with a suspected intentional overdose, obtain serum salicylate concentration, fingerstick glucose, ECG, and qualitative pregnancy test in women of childbearing age</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td>Secure airway, breathing, and circulation as necessary</td> </tr> <tr> <td>Give <strong>activated charcoal (AC)</strong> 50 g to all adult patients presenting within 4 hours of ingestion, unless contraindicated; AC may be useful for coingestants beyond 4 hours</td> </tr> <tr> <td class=\"sublist1_start\">Treat with <strong>N-acetylcysteine (NAC)</strong> if:</td> </tr> <tr> <td class=\"sublist1\">Serum APAP concentration drawn at 4 hours or more after a single acute ingestion is above the \"treatment\" line of the treatment nomogram for APAP poisoning</td> </tr> <tr> <td class=\"sublist1\">Serum APAP concentration is unavailable or will not return within 8 hours of time of ingestion and APAP ingestion is suspected</td> </tr> <tr> <td class=\"sublist1\">Time of ingestion is unknown and serum APAP level is greater than 10 mcg/mL (66 &#181;mol/L)</td> </tr> <tr> <td class=\"sublist1\">There is evidence of ANY hepatotoxicity with a history of APAP ingestion</td> </tr> <tr> <td class=\"sublist1\">Patient reports or clinician suspects repeated excessive APAP ingestions, patient has risk factors for APAP-induced hepatotoxicity, and the serum APAP concentration is greater than 10 mcg/mL (66 &#181;mol/L)</td> </tr> <tr> <td class=\"sublist1_start\">Oral dosing of NAC:</td> </tr> <tr> <td class=\"sublist1\">Oral dosing is acceptable for non-pregnant patients with a functional GI tract and no evidence of hepatotoxicity</td> </tr> <tr> <td class=\"sublist1\">Dose 140 mg/kg loading dose, followed by 17 doses of 70 mg/kg every 4 hours</td> </tr> <tr> <td class=\"sublist1\">If vomiting occurs within 1 hour of NAC dosing, a full NAC dose should be repeated as rapidly as possible</td> </tr> <tr> <td class=\"sublist1\">Therapy may be terminated by 24 to 36 hours after ingestion if the acetaminophen level is below 10 micrograms/mL, and the patient does not develop evidence of hepatotoxicity and remains clinically well</td> </tr> <tr> <td class=\"sublist1_start\">Intravenous (IV) dosing of NAC:</td> </tr> <tr> <td class=\"sublist1\">In patients with no biochemical evidence of hepatic failure (ie, those with INR &#60;2), use 21 hour IV protocol: 150 mg/kg loading dose over 60 minutes, followed by 50 mg/kg infused over 4 hours, with the final 100 mg/kg infused over the remaining 16 hours</td> </tr> <tr> <td class=\"sublist1\">In patients with biochemical evidence of hepatic failure (ie, those with INR &#62;2), administer the 21 hour IV protocol (150 mg/kg loading dose over 60 minutes, followed by 50 mg/kg infused over 4 hours, followed by 100 mg/kg infused over the next 16 hours) followed by a continuous IV NAC infusion at 6.25 mg/kg per hour until INR is &#60;2</td> </tr> <tr> <td class=\"sublist1\">IV dosing is acceptable in all cases of acetaminophen toxicity, but should be used INSTEAD of oral dosing in patients unable to tolerate oral NAC (eg, intractable vomiting), patients with a medical condition precluding administration of oral NAC (eg, corrosive ingestion, GI bleed), patients with significant hepatotoxicity (INR &#62;2), and pregnant patients</td> </tr> <tr> <td class=\"sublist1_start\">Antiemetic therapy:</td> </tr> <tr> <td class=\"sublist1\">May give 5-HT3 receptor antagonist (eg, ondansetron) or metoclopromide</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51346 Version 10.0</div></div></div>"},"51347":{"type":"graphic_table","displayName":"Limitations of provocative testing for GH deficiency","title":"Limitations of provocative testing for growth hormone deficiency in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Limitations of provocative testing for growth hormone deficiency in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Pharmacological testing is not physiologic</td> </tr> <tr> <td>Normality is arbitrarily defined, if defined at all</td> </tr> <tr> <td>Reproducibility in both normal and abnormal children is poor, even when the same test is performed</td> </tr> <tr> <td>Age and sex steroid hormone status affect the response</td> </tr> <tr> <td>Nutritional adequacy and body composition, particularly, adiposity, can affect response</td> </tr> <tr> <td>There is no standard serum growth hormone assay, and there are large&nbsp;interassay variations among the assays&nbsp;in use</td> </tr> <tr> <td>All the tests are costly</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51347 Version 2.0</div></div></div>"},"51348":{"type":"graphic_picture","displayName":"Peptic eso stricture Endosc","title":"Peptic esophageal stricture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peptic esophageal stricture</div><div class=\"cntnt\"><img style=\"width:288px; height:288px;\" src=\"images/GAST/51348_Peptic_eso_stricture_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy shows a peptic esophageal stricture with adjacent areas of inflammation and ulceration due to reflux-induced injury.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 51348 Version 1.0</div></div></div>"},"51350":{"type":"graphic_figure","displayName":"Use of nasal reservoir cannula","title":"Use of nasal reservoir cannula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Use of nasal reservoir cannula</div><div class=\"cntnt\"><img style=\"width:396px; height:343px;\" src=\"images/PULM/51350_Use_of_Oxymizer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Top panel: During exhalation, the membrane in the Oxymizer reservoir cannula&nbsp;is thrust forward, creating a 20 mL chamber. Bottom panel: When the patient is ready to inhale, he/she receives the stored oxygen in addition to the supply oxygen. This allows the patient to become adequately oxygenated at lower supply flows.</div><div id=\"graphicVersion\">Graphic 51350 Version 2.0</div></div></div>"},"51351":{"type":"graphic_diagnosticimage","displayName":"Adult shoulder scapular Y","title":"Scapular Y-view of the shoulder","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Scapular Y-view of the shoulder</div><div class=\"cntnt\"><img style=\"width:467px; height:514px;\" src=\"images/EM/51351_Adult_shoulder_scapular_Y.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This radiograph utilizes a scapular Y-view of the shoulder to assess the location of the humeral head. Anterior or posterior dislocation are excluded by a normal position of the humeral head (HH) relative to the coracoid (C) and the acromion process (A). The inferior portion of the &quot;Y&quot; is formed by the body of the scapula (S).</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 51351 Version 2.0</div></div></div>"},"51352":{"type":"graphic_figure","displayName":"Map of the MHC","title":"Map of the major histocompatibility complex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Map of the major histocompatibility complex</div><div class=\"cntnt\"><img style=\"width:438px; height:469px;\" src=\"images/RHEUM/51352_Map_of_the_MHC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left portion represents the entire MHC region on chromosome 6, with the Class I, II, and III regions designated. The right portion is an enlargement of the Class II region and includes pseudogenes, other genes involved in immune function, and genes of unrelated or unknown function, as well as the &quot;classical&quot; Class II genes. The expressed &quot;classical&quot; Class II dimers are noted on the far right in bold letters (DR, DQ, and DP), and the genes encoding them are connected with dotted lines. Two different DR dimers are expressed, each sharing the same DR alpha chain (DRA), but using different DR beta chains (DRB1 and DRB3).</div><div id=\"graphicVersion\">Graphic 51352 Version 1.0</div></div></div>"},"51353":{"type":"graphic_table","displayName":"Selected high-risk drugs","title":"Selected high-risk drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected high-risk drugs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Potential harm</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td>Insulin</td> <td>Hypoglycemia</td> <td>May often be appropriate; however, aggressive glycemic control may often yield greater harms than benefits in older adults.<sup>[1-3]</sup></td> </tr> <tr> <td>Sulfonylureas</td> <td>Hypoglycemia</td> <td>Older hospitalized patients at significant risk for hypogylcemia; avoid or use with great caution.<sup>[4]</sup></td> </tr> <tr> <td>Warfarin</td> <td>Gastrointestinal, intracranial bleeding</td> <td>Although a high-risk drug, benefits of warfarin therapy often outweigh harms; maintenance of prothrombin time/international normalized ratio&nbsp;(INR)&nbsp;in therapeutic range tightly linked to risk/benefit ratio.<sup>[5]</sup></td> </tr> <tr> <td>Digoxin</td> <td>Impairment of cognition, heart block</td> <td>May have a third-line role in management of systolic heart failure; suboptimal choice for rate control in atrial fibrillation.</td> </tr> <tr> <td>Benzodiazepines</td> <td>Falls</td> <td>Associated with as much as a&nbsp;60% increase in fall risk.<sup>[6]</sup></td> </tr> <tr> <td>Diphenhydramine, other first-generation antihistamines</td> <td>Impaired cognition, urinary retention in men</td> <td>Poor choice as sleep aid due to anticholinergic effects, next-day sedation, impact on performance including driving; close medication reconciliation important because patients may also obtain over-the-counter drugs.</td> </tr> <tr> <td>Opioid analgesics</td> <td>Constipation, sedation, confusion, cardiorespiratory depression, seizures</td> <td>Codeine, meperidine, pentazocine, butorphanol, and nalbuphine are poor choices for analgesia. Fentanyl, morphine, or oxycodone are often appropriate with careful dose adjustment.</td> </tr> <tr> <td>Antipsychotics</td> <td>Death, pneumonia</td> <td>Elevated risk of death when used to treat behavioral complications of dementia, although, in selected cases, benefits may exceed risks if consistent with patient goals of care.<sup>[7]</sup></td> </tr> <tr> <td>Chemotherapeutic agents</td> <td>Myelosuppression (neutropenia, anemia), hepatotoxicity, cardiotoxicity</td> <td>Comprehensive assessment is required for determining goals of treatment, particularly in light of comorbidities. When indicated, chemotherapy dose and schedule should be carefully individualized for organ function and anticipated toxicities of treatment. In general, greater treatment-related toxicity is accepted when the expected outcome of treatment is cure.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Selected antimicrobials</td> </tr> <tr> <td class=\"indent1\">Fluoroquinolones</td> <td>Tendon inflammation and rupture, hypoglycemia, cardiac arrhythmias, <em>Clostridium difficile</em>-associated diarrhea, exacerbation of myasthenia gravis</td> <td>Elevated risk of tendon rupture in combination with glucocorticoids.</td> </tr> <tr> <td class=\"indent1\">Nitrofurantoin</td> <td>In chronic use (rarely): Pulmonary fibrosis, neuropathy, hepatotoxicity</td> <td>Avoid in older adults with&nbsp;creatinine clearance&nbsp;&#60;30 mL/minute; does not reach therapeutic concentrations in urine and increased risk of toxicity.</td> </tr> <tr> <td class=\"indent1\">Trimethoprim-sulfamethoxazole (co-trimoxazole)</td> <td>Hyperkalemia, hypoglycemia (with sulfonylurea), severe dermatologic reaction (rare)</td> <td>Drug interactions include warfarin (&#8593; INR), agents that increase serum potassium, and sulfonylureas (&#8593; hypoglycemic effect).</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Brown AF, Mangione CM, Saliba D, Sarkisian CA; California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003; 51:S265. </LI>&#xD;&#xA;<LI>Greenfield S, Billimek J, Pellegrini F, et al. Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes. Ann Intern Med 2009; 151:854. </LI>&#xD;&#xA;<LI>Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545. </LI>&#xD;&#xA;<LI>Deusenberry CM, Coley KC, Korytkowski MT, et al; Hypoglycemia in hospitalized patients treated with sulfonylureas. Pharmacotherapy 2012; doi: 10.1002/j. 1875-9114.2011.01088.x (ePublished ahead of print May 8, 2012).</LI>&#xD;&#xA;<LI>Mant J, Hobbs FD, Fletcher K, et al; BAFTA Investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA). Lancet. 2007; 370 (9586):493-503. </LI>&#xD;&#xA;<LI>Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 2009; 169:1952. </LI>&#xD;&#xA;<LI>Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. JAMA 2005; 294:1934. </LI>&#xD;&#xA;<LI>American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63:2227.</LI></OL>Revisions and additional information included with data from: Steinman MA, Hanlon JT. Managing medications in clinically complex elders: \"There's got to be a happy medium.\" JAMA 2010; 304:1592.</div><div id=\"graphicVersion\">Graphic 51353 Version 11.0</div></div></div>"},"51354":{"type":"graphic_figure","displayName":"Control of liver bleeding using the Pringle maneuver","title":"Control of liver bleeding using the Pringle maneuver","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Control of liver bleeding using the Pringle maneuver</div><div class=\"cntnt\"><img style=\"width:436px; height:414px;\" src=\"images/SURG/51354_Pringle-maneuver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Control of bleeding from the injured liver can be accomplished by occluding arterial and portal venous flow into the liver with manual compression or using a vascular clamp.</div><div id=\"graphicVersion\">Graphic 51354 Version 3.0</div></div></div>"},"51355":{"type":"graphic_picture","displayName":"Bilateral cryptorchidism 2","title":"Bilateral undescended testicles","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral undescended testicles</div><div class=\"cntnt\"><img style=\"width:259px; height:395px;\" src=\"images/PEDS/51355_Bilateral_cryptorchid_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Clark DA. Atlas of Neonatology - A companion to Disease of the Newborn, 1st ed. WB Saunders Co., Philadelphia 2000. Copyright © 2000 Elsevier.</div><div id=\"graphicVersion\">Graphic 51355 Version 7.0</div></div></div>"},"51356":{"type":"graphic_table","displayName":"Differential diagnosis of BRUE","title":"Differential diagnosis of a brief resolved unexplained event (BRUE) in an infant","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of a brief resolved unexplained event (BRUE) in an infant</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cause</td> <td class=\"subtitle1\">Comments</td> <td class=\"subtitle1\">Evaluation for low-risk infants*</td> <td class=\"subtitle1\">Further evaluation in selected infants</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Normal (misinterpreted as abnormal behavior)</td> </tr> <tr> <td class=\"indent1\">Transient choke, gag or cough during feeding, or during an episode of regurgitation</td> <td>Suggests laryngospasm. Does not necessarily mean abnormal degree of GER, or that treatment of GER will prevent similar events in the future.</td> <td>History is sufficient in low-risk infants*</td> <td>Swallowing evaluation if recurrent events. Possible evaluation for pathologic GER, but results are rarely conclusive.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Periodic breathing or respiratory pauses</td> <td>Pauses of 5 to 15 seconds are normal, with longer pauses after a sigh</td> <td>History, PE with spot pulse oximetry</td> <td>Observation, possible polysomnography</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Infectious disease</td> </tr> <tr> <td class=\"indent1\">Respiratory infections (pertussis, RSV, bronchiolitis)</td> <td>Somewhat common cause of apneic episodes in infants who are premature or &#60;2 months</td> <td>History, PE. Optional testing for pertussis, RSV in infants with symptoms.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sepsis, meningitis, encephalitis</td> <td>Usually have other symptoms and/or multiple BRUE. Isolated UTI causes &#60;3% of BRUE.</td> <td>History, PE</td> <td>Evaluation as indicated by clinical symptoms; may include cultures of urine, blood and cerebrospinal fluid, and chest radiography</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Cardiopulmonary</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Central or obstructive apnea, or arrhythmias</td> <td>Uncommon cause of apnea in infants who are not premature and who are &#62;60 days old</td> <td>PE with spot pulse oximetry. ECG optional.</td> <td>Observation, possible polysomnography</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Neurologic disease</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Epilepsy or CNS disease</td> <td>Epilepsy ultimately diagnosed in about 10 percent of infants with BRUE, but testing has low sensitivity</td> <td>Routine testing not warranted</td> <td>Observation, neuroimaging, EEG, and/or polysomnography with expanded EEG montage</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Child abuse</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Intentional suffocation, non-accidental head injury, intentional poisoning or factitious illness</td> <td>Reported in 0.5 to 11 percent of infants with BRUE</td> <td>Focused history for social risk factors; PE for any signs of abuse</td> <td>Neuroimaging, skeletal series, toxicology screen, dilated eye examination for retinal hemorrhage</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Metabolic disease</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Inborn error of metabolism</td> <td> <p>Rare; diverse manifestations including apnea, vomiting, lethargy, and altered sensorium, often in recurrent or cyclic patterns.</p> Metabolic acidosis or hypoglycemia warrants a detailed evaluation.</td> <td>History, PE, family history for metabolic disease or unexplained death</td> <td> <p>Laboratory testing including glucose, electrolytes, BUN, creatinine, lactic acid and ammonia.</p> Further testing for metabolic disorders may include liver enzymes, urine organic acids, plasma amino acids, and acylcarnitines (refer to UpToDate topic reviews on inborn errors of metabolism).</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Other</td> </tr> <tr> <td class=\"indent1\">Acute GI obstruction (intussusception, volvulus)</td> <td>Suggested by vomiting, abdominal distention, bloody stools, and/or lethargy</td> <td>History, PE</td> <td>Abdominal ultrasound and/or plain radiographs</td> </tr> <tr> <td class=\"indent1\">Toxic ingestion (eg, medications such as hypoglycemic agents or sedatives) or ethanol; carbon monoxide poisoning</td> <td>Often associated with altered sensorium, respiratory depression, or vomiting</td> <td>History, PE</td> <td>Toxicology screen and/or specific testing</td> </tr> <tr> <td class=\"indent1\">Disorder of central respiratory control (eg, CCHS)</td> <td>Very rare; typically present with cyanosis at rest or during sleep, with no respiratory distress</td> <td>History, PE</td> <td>Pulse oximetry during sleep; blood gas (refer to UpToDate topic on CCHS)</td> </tr> <tr> <td class=\"indent1\">Upper airway obstruction</td> <td>Eg, due to vocal cord dysfunction, laryngotracheomalacia, or vascular ring</td> <td>History, PE</td> <td>Evaluation as indicated by respiratory symptoms (refer to UpToDate topics on stridor and congenital abnormalities of the intrathoracic airways)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GER: gastroesophageal reflux; PE: physical examination; RSV: respiratory syncytial virus; UTI: urinary tract infection; BRUE: brief resolved unexplained event; ECG: electrocardiogram; CNS: central nervous system; CCHS: congenital central hypoventilation syndrome.<br />* Low-risk infants are those who are &gt;60 days old and not premature; have experienced only one BRUE (no prior BRUE, and no clusters) which lasted &lt;1 minute; no cardiopulmonary resuscitation by a trained provider was performed; and no concerning features on history or physical examination.</div><div id=\"graphicVersion\">Graphic 51356 Version 8.0</div></div></div>"},"51358":{"type":"graphic_figure","displayName":"Spondylolysis 2","title":"Spondylolysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spondylolysis</div><div class=\"cntnt\"><img style=\"width:396px; height:302px;\" src=\"images/PC/51358_Spondylolysis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spondylolysis refers to a defect in the pars interarticularis (a bone connecting one facet joint to another).</div><div class=\"graphic_reference\">Reproduced with permission from: LifeArt. Copyright &#169; 2010 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 51358 Version 1.0</div></div></div>"},"51361":{"type":"graphic_figure","displayName":"Distal acid secretion","title":"Acid-secreting type A intercalated cells","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Acid-secreting type A intercalated cells</div><div class=\"cntnt\"><img style=\"width:489px; height:305px;\" src=\"images/NEPH/51361_Distalacidsecretion.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transport mechanisms involved in hydrogen secretion and HCO<sub>3</sub><sup>&ndash;</sup> and K<sup>+</sup> reabsorption in type A intercalated cells, which are present from the late distal convoluted tubule to the initial portion of the inner medullary collecting duct. Water within the cell dissociates into H<sup>+</sup> and OH<sup>&ndash;</sup> ions. The former are secreted into the lumen by H-ATPase pumps in the luminal membrane, where they combine with urinary buffers to generate titratable acid (eg, convert HPO<sub>4</sub><sup>&ndash;2</sup> to H<sub>2</sub>PO<sub>4</sub><sup>&ndash;</sup>) and convert NH<sub>3</sub> to NH<sub>4</sub><sup>+</sup>. The OH<sup>&ndash;</sup> ions in the cell combine with CO<sub>2</sub> to form HCO<sub>3</sub><sup>&ndash;</sup> in a reaction catalyzed by carbonic anhydrase (CA). Driven by their electrochemical concentration gradients, cellular bicarbonate enters the peritubular capillaries in exchange for extracellular chloride via Cl-HCO<sub>3</sub> exchangers on the basolateral membrane. H-K-ATPase pumps, which secrete H<sup>+</sup> and reabsorb K<sup>+</sup>, are also present in the luminal membrane of the type A intercalated cells. The number and activity of these pumps are increased by K<sup>+</sup> depletion, suggesting that they may be important for K<sup>+</sup> conservation.</div><div id=\"graphicVersion\">Graphic 51361 Version 9.0</div></div></div>"},"51366":{"type":"graphic_waveform","displayName":"M-mode LA aorta","title":"M-mode echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiogram</div><div class=\"cntnt\"><img style=\"width:248px; height:306px;\" src=\"images/CARD/51366_M_mode_LA_aorta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">M-mode echocardiogram obtained from the parasternal long axis view at the level of the aortic valve (AoV) and left atrium (LA). The AoV leaflets are seen to open and close within the aortic root (Ao).</div><div id=\"graphicVersion\">Graphic 51366 Version 4.0</div></div></div>"},"51367":{"type":"graphic_figure","displayName":"Current ERT and bone density","title":"Postmenopausal women who take estrogen continuously have higher bone density","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Postmenopausal women who take estrogen continuously have higher bone density</div><div class=\"cntnt\"><img style=\"width:467px; height:553px;\" src=\"images/ENDO/51367_Current_ERT_and_bone_densit.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation between bone mineral density in the hip and lumbar spine according to status of estrogen replacement therapy. Bone density is highest in current continuous users and current late users. The values are adjusted for other risk factors such as smoking, exercise, thiazide diuretics, glucocorticoid therapy, and alcohol intake.</div><div class=\"graphic_reference\">Data from: Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study.&nbsp;JAMA 1997; 277:543.</div><div id=\"graphicVersion\">Graphic 51367 Version 2.0</div></div></div>"},"51368":{"type":"graphic_figure","displayName":"Tryptophan and serotonin metabolism","title":"Tryptophan and serotonin metabolism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tryptophan and serotonin metabolism</div><div class=\"cntnt\"><img style=\"width:355px; height:414px;\" src=\"images/ENDO/51368_Tryptophan_serotonin_metabo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pathways of tryptophan and serotonin metabolism in the carcinoid tumor cell. Patients with the carcinoid syndrome often have increased levels of 5-hydroxyindoleacetic acid (5-HIAA) excretion in the urine and serotonin in the blood; urinary serotonin excretion is either normal or slightly increased.</div><div id=\"graphicVersion\">Graphic 51368 Version 4.0</div></div></div>"},"51371":{"type":"graphic_table","displayName":"Classification of cryoglobulins","title":"Contrasting features of types of cryoglobulinemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contrasting features of types of cryoglobulinemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Type I</td> <td class=\"subtitle1\">Type II</td> <td class=\"subtitle1\">Type III</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Associated diseases</strong></td> <td>LPD &#62;&#62;&#62;</td> <td>HCV &#62;&#62;</td> <td>HCV &#62;&#62;</td> </tr> <tr> <td>MGUS &#62;</td> <td>&#62; CTD</td> <td>CTD &#62;&#62;</td> </tr> <tr> <td>Idiopathic</td> <td>&#62; Idiopathic</td> <td>Idiopathic</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>&#62; LPD &#62; other infections</td> <td>&#62; Other infections</td> </tr> <tr> <td colspan=\"4\"><strong>Symptoms and signs</strong></td> </tr> <tr> <td class=\"indent1\">Purpura</td> <td>+</td> <td>+++</td> <td>+++</td> </tr> <tr> <td class=\"indent1\">Gangrene/acrocyanosis</td> <td>+++</td> <td>+ to ++</td> <td>&#177;</td> </tr> <tr> <td class=\"indent1\">Athralgias &#62;&#62; arthritis</td> <td>+</td> <td>++</td> <td>+++</td> </tr> <tr> <td class=\"indent1\">Renal</td> <td>+</td> <td>++</td> <td>+</td> </tr> <tr> <td class=\"indent1\">Neurologic</td> <td>+</td> <td>++</td> <td>++</td> </tr> <tr> <td class=\"indent1\">Liver</td> <td>&#177;</td> <td>++</td> <td>+++</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Type I: monoclonal immunoglobulin (Ig); Type II: mixed monoclonal Ig and polyclonal Ig; Type III: mixed polyclonal Ig.<br />Idiopathic: cases of symptomatic cryoglobulinemia that are not associated with a clear-cut CTD, LPD, or infection (also called 'essential' mixed cryoglobulinemia).<br />+ and &gt; indicate relative increasing frequency of occurrence.<br />Prior to the discovery of HCV in 1989, the HCV-associated cases were considered idiopathic or \"essential.\"</div><div class=\"graphic_footnotes\">LPD: lymphoproliferative or plasmaproliferative disorder; MGUS: monoclonal gammopathy of undetermined significance; CTD: connective tissue disorder; HCV: hepatitis C virus.</div><div class=\"graphic_reference\">Reproduced with permission from: Dispenzieri A, Gorevic PD. Cryoglobulinemia. Hematology - Oncology Clinics of North America 1999; 42:2507. Copyright &copy; 1999 W.B. Saunders Company.</div><div id=\"graphicVersion\">Graphic 51371 Version 4.0</div></div></div>"},"51376":{"type":"graphic_diagnosticimage","displayName":"Pelvic AP compression fracture type","title":"Pelvic AP compression fracture: Type III","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Pelvic AP compression fracture: Type III</div><div class=\"cntnt\"><img style=\"width:514px; height:392px;\" src=\"images/EM/51376_Pelvicantpostfx3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three images of a Type III AP compression fracture: (A) schematic; (B) AP radiograph; (C) CT scan.</div><div class=\"graphic_footnotes\">AP: anterior posterior; CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Sagi C. Lower extremity: Pelvic ring fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 51376 Version 12.0</div></div></div>"},"51379":{"type":"graphic_diagnosticimage","displayName":"Brain MRI ages 1 and 3 months infantile Alexander disease","title":"Brain MRI of a patient with biopsy-confirmed infantile Alexander disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain MRI of a patient with biopsy-confirmed infantile Alexander disease</div><div class=\"cntnt\"><img style=\"width:396px; height:524px;\" src=\"images/NEURO/51379_MRI_infa_1mo_3mo_Alex_Dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A and B: At the age of 1.5 months, the frontal white matter has a slightly higher signal intensity on T2-weighted images and slightly lower signal intensity on unenhanced T1-weighted images than does the remainder of the cerebral white matter, which has normal signal intensity for unmyelinated white matter. There is a periventricular rim of low signal intensity on T2-weighted images (arrows, A) and high signal intensity on T1-weighted images (arrows, B), with some extensions into the frontal white matter (arrowheads, A and B). The caudate nucleus and putamen have high signal intensity on T2-weighted images and are mildly swollen.<br />C and D: At the age of 3 months, a major increase in ventricular size is seen with extreme thinning of the posterior cerebral mantle. The frontal white matter has a more abnormal signal intensity than the occipital white matter, appears markedly swollen, and shows early cystic degeneration (arrows, D). There is a thin periventricular rim of low signal intensity on T2-weighted images (arrows, C). The basal ganglia are now markedly atrophic. After contrast administration, enhancement occurs in the ventricular lining, caudate nucleus, putamen, frontal white matter, and parts of the frontal cortex (D).</div><div class=\"graphic_footnotes\"><SPAN id=footnote data-bind=\"template: 'footnoteTemplate'\"><SPAN jQuery1458763715845=\"3646\">MRI: magnetic resonance imaging.</SPAN></SPAN></div><div class=\"graphic_reference\">Reproduced with permission from: van der Knaap MS, Naidu S, Breiter SN, et al. Alexander disease: diagnosis with MR imaging. AJNR Am J Neuroradiol 2001; 22:541. Copyright &copy;2001 American Society of Neuroradiology.</div><div id=\"graphicVersion\">Graphic 51379 Version 4.0</div></div></div>"},"51380":{"type":"graphic_figure","displayName":"Tissue damage in monopolar electrosurgery","title":"Tissue damage in monopolar electrosurgery","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Tissue damage in monopolar electrosurgery</div><div class=\"cntnt\"><img style=\"width:536px; height:415px;\" src=\"images/OBGYN/51380_Currents_thermal_spread.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Range of currents and tissue damage in monopolar electrosurgery</div><div id=\"graphicVersion\">Graphic 51380 Version 3.0</div></div></div>"},"51382":{"type":"graphic_table","displayName":"Patient selection guidelines for APBI","title":"Patient selection for accelerated partial breast irradiation (APBI) from the ABS, ASBS, and ASTRO","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient selection for accelerated partial breast irradiation (APBI) from the ABS, ASBS, and ASTRO</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Criteria</td> <td class=\"subtitle1\">ABS<sup>[1]</sup></td> <td class=\"subtitle1\">ASBS<sup>[2]</sup></td> <td class=\"subtitle1\">ASTRO<sup>[3]</sup></td> </tr> <tr> <td rowspan=\"2\">Age, years</td> <td rowspan=\"2\">&#8805;50</td> <td>&#8805;45 (for invasive disease)</td> <td rowspan=\"2\">&#8805;60</td> </tr> <tr> <td>&#8805;50 (for in situ disease)</td> </tr> <tr> <td>Histology</td> <td>All invasive subtypes and ductal carcinoma in situ</td> <td>Invasive or in situ ductal carcinoma</td> <td>Invasive ductal or other favorable subtypes*</td> </tr> <tr> <td>Tumor size</td> <td>&#8804;3 cm</td> <td>&#8804;3 cm</td> <td>&#8804;2 cm</td> </tr> <tr> <td>Resection margins</td> <td>Negative</td> <td>Negative microscopic surgical margins</td> <td>Negative by at least 2 mm</td> </tr> <tr> <td>Axillary node status</td> <td>Negative (by ALND or SLN)</td> <td>Negative (by ALND or SLN)</td> <td>Negative (by ALND or SLN)</td> </tr> <tr> <td>Lymphovascular space invasion</td> <td>Not present</td> <td>Not addressed</td> <td>Not addressed</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ABS: American Brachytherapy Society; ASBS: American Society of Breast Surgeons; ASTRO: American Society for Radiation Oncology; ALND: axillary lymph node dissection; SLN: sentinal lymph node biopsy.<br />* Favorable subtypes include mucinous, tubular, and colloid.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Shaw C, et al. Brachytherapy 2013; 12:267.</li>&#xD;&#xA;    <li><a href=\"https://www.breastsurgeons.org/new_layout/about/statements/PDF_Statements/APBI.pdf\" target=\"_blank\">https://www.breastsurgeons.org/new_layout/about/statements/PDF_Statements/APBI.pdf</a>.</li>&#xD;&#xA;    <li>Smith BD, et al. Int J Radiat Oncol Biol Phys 2009; 74:987. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 51382 Version 5.0</div></div></div>"},"51383":{"type":"graphic_diagnosticimage","displayName":"Duodenal carcinoid EUS","title":"Carcinoid tumor in the duodenum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carcinoid tumor in the duodenum</div><div class=\"cntnt\"><img style=\"width:315px; height:322px;\" src=\"images/GAST/51383_Duodenal_carcinoid_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endosonographic view of a duodenal carcinoid tumor (arrow). Carcinoids are hypo- or isoechoic with regular margins. They arise from the mucosa/lamina propria (second layer of the GI tract) and can invade the submucosal layer.</div><div class=\"graphic_reference\">Courtesy of Mary Lee Krinsky, DO and Kenneth Binmoeller, MD.</div><div id=\"graphicVersion\">Graphic 51383 Version 3.0</div></div></div>"},"51384":{"type":"graphic_figure","displayName":"Intest transplant children","title":"Indication for intestinal transplantation in children","html":"<div class=\"graphic\"><div style=\"width: 627px\" class=\"figure\"><div class=\"ttl\">Indication for intestinal transplantation in children</div><div class=\"cntnt\"><img style=\"width:607px; height:383px;\" src=\"images/GAST/51384_Intest_transplant_children.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Data from: the Intestinal Transplant Registry, Final Summary 2003. Reproduced with permission from David Grant, MD. http://www.intestinaltransplant.org.</div><div id=\"graphicVersion\">Graphic 51384 Version 1.0</div></div></div>"},"51385":{"type":"graphic_table","displayName":"Medications for malabsorption","title":"Medications used in malabsorption and maldigestion (adult)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications used in malabsorption and maldigestion (adult)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication/dosage</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Antidiarrheal agents</td> </tr> <tr> <td class=\"sublist1\">Loperamide 2 to 4 mg as needed, not to exceed 12 mg/day</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Diphenoxylate with atropine (Lomotil) 1 to 2 tabs after loose stool, not to exceed 8 per day</td> <td class=\"sublist_other\">1 tab = 2.5 mg diphenoxylate component</td> </tr> <tr> <td class=\"sublist1\">Deodorized opium tincture 10 percent (10 mg per mL) 0.3 to 0.6 mL three times daily</td> <td class=\"sublist_other\">NOTE: Highly concentrated. Contains 25 times more morphine than paregoric. Abrupt discontinuation may cause withdrawal symptoms.</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Bile acid binding resins</td> </tr> <tr> <td class=\"sublist1\">Cholestyramine 4 g three times daily</td> <td class=\"sublist_other\">Administer &#8805;1 hour before or &#62;4 hours after other drugs to prevent decreased absorption of other drug(s)</td> </tr> <tr> <td class=\"sublist1\">Colestipol granules 5 to 10 g three times daily</td> <td class=\"sublist_other\">Administer &#8805;1 hour before or &#62;4 hours after other drugs to prevent decreased absorption of other drug(s)</td> </tr> <tr> <td class=\"sublist1_start\">Pancreatic enzymes*</td> <td class=\"sublist_other_start\">General: Approximately 30,000 units (90,000 USP) (lipase component) with each meal</td> </tr> <tr> <td class=\"sublist1\">Pancrelipase delayed-release capsules (Creon minimicrospheres)</td> <td class=\"sublist_other\">Enteric-coated micro pellets may be sprinkled on soft acidic foods</td> </tr> <tr> <td class=\"sublist1\">Pancrelipase tablets and powder (Viokase, others) 1 g (equivalent to 20,000 units lipase component) with meals</td> <td class=\"sublist_other\">Effect improved if given with acid-suppressing drugs</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Vitamins and minerals<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist1\">Vitamin A 40,000 to 50,000 units twice daily during acute repletion</td> <td class=\"sublist_other\">Maintenance: 8000 to 20,000 units/day (dosage &#8805;15,000 units can be teratogenic)</td> </tr> <tr> <td class=\"sublist1\">Vitamin D3 (cholecalciferol) 30,000 to 50,000 units/day</td> <td class=\"sublist_other\">Monitor serum calcium</td> </tr> <tr> <td class=\"sublist1\">Vitamin K 2.5 to 12.5 mg daily</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Folic acid 5 mg/day during repletion</td> <td class=\"sublist_other\">Maintenance: 1 mg/day</td> </tr> <tr> <td class=\"sublist1\">Vitamin B12 (cyanocobalamin) 1 mg subcutaneously (should be repeated x three over first week of repletion)</td> <td class=\"sublist_other\">Maintenance: 100 micrograms every 1 to 2 months</td> </tr> <tr> <td>Calcium carbonate 500 mg (elemental calcium) twice daily</td> <td>Monitor serum calcium</td> </tr> <tr> <td>Magnesium gluconate 1 to 4 g (54 to 216 mg elemental magnesium) four times daily</td> <td>Often produces diarrhea</td> </tr> <tr> <td>Ferrous sulfate<sup>&#916;</sup> 325 mg (65 mg elemental iron) three times daily</td> <td>Dose reduce if gastrointestinal symptoms occur</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">All dosages are oral, if not otherwise stated.</div><div class=\"graphic_footnotes\">IU: international units; USP: United States pharmacopeia.<br />* Dose titration may be needed.<br />¶ Maintenance doses for fat-soluble vitamins are highly dependent upon the degree of ongoing malabsorption. Blood levels should be checked every one to two years.<br />Δ Available as a solution. Equivalent dosage mixed in 8 ounces orange juice will greatly enhance absorptive efficiency due to vitamin C content of juice.</div><div class=\"graphic_reference\">Modified from: Heimburger DC, Weinsier RL. Gastrointestinal and liver diseases, In: Handbook of Clinical Nutrition, 3rd ed, Heimburger DC, Weinsier RL (Eds), Mosby, St Louis 1997. p.424.</div><div id=\"graphicVersion\">Graphic 51385 Version 5.0</div></div></div>"},"51387":{"type":"graphic_figure","displayName":"FVC carmustine lung fibrosis","title":"Lung function in carmustine pulmonary toxicity","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Lung function in carmustine pulmonary toxicity</div><div class=\"cntnt\"><img style=\"width:527px; height:407px;\" src=\"images/PULM/51387_FVC_carmustine_lung_fibrosi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serial forced vital capacity (FVC) measurements of eight patients with late onset carmustine (BCNU) lung fibrosis confirmed by chest radiography and/or biopsies Most patients had a gradual decline in FVC during five to nine years of follow-up. The two patients with the best preserved lung function were treated in their teenage years; all except one of the other patients were treated at age 10 or less.</div><div id=\"graphicVersion\">Graphic 51387 Version 1.0</div></div></div>"},"51388":{"type":"graphic_picture","displayName":"Annular elastolytic giant cell granuloma - arm","title":"Annular elastolytic giant cell granuloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Annular elastolytic giant cell granuloma</div><div class=\"cntnt\"><img style=\"width:325px; height:432px;\" src=\"images/DERM/51388_Annu_elast_giant_gran_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular erythematous patches and plaques are present on sun-exposed skin. A biopsy revealed findings consistent with annular elastolytic giant cell granuloma.</div><div class=\"graphic_reference\">Copyright © Benjamin Ehst, MD, PhD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 51388 Version 5.0</div></div></div>"},"51390":{"type":"graphic_picture","displayName":"Grade I nipple inversion","title":"Grade I nipple inversion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Grade I nipple inversion</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/SURG/51390_Nipple_inversion_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In Grade I nipple inversion, the nipple is easily pulled out with gentle retraction or squeezing of the areolar skin. Nipple projection is well maintained for several minutes but then the nipple reverts to an inverted state.</div><div id=\"graphicVersion\">Graphic 51390 Version 1.0</div></div></div>"},"51391":{"type":"graphic_figure","displayName":"Midface anatomy","title":"Midfacial anatomy","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">Midfacial anatomy</div><div class=\"cntnt\"><img style=\"width:579px; height:448px;\" src=\"images/EM/51391_Midfaceanatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Ochs MW. Bony Oral-Maxillofacial Injuries. In: The Trauma Manual: Trauma and Acute Care Surgery, 3rd edition, Peitzman AB, Rhodes M, Schwab CW, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 51391 Version 11.0</div></div></div>"},"51393":{"type":"graphic_diagnosticimage","displayName":"MRI T2 PMD","title":"T2-weighted brain MRI of Pelizaeus-Merzbacher disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">T2-weighted brain MRI of Pelizaeus-Merzbacher disease</div><div class=\"cntnt\"><img style=\"width:442px; height:506px;\" src=\"images/NEURO/51393_MRI_T2_PMD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figures A and B demonstrate diffuse supratentorial high signal intensity throughout the deep and subcortical white matter. Figure C demonstrates infratentorial high signal in the cerebellar white matter, and some sparing of white matter in the brainstem.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Delilah M. Burrowes, MD, Children's Memorial Hospital, Chicago, IL.</div><div id=\"graphicVersion\">Graphic 51393 Version 3.0</div></div></div>"},"51395":{"type":"graphic_diagnosticimage","displayName":"Polymyositis whole body MRI","title":"56-year-old man with suspected polymyositis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">56-year-old man with suspected polymyositis</div><div class=\"cntnt\"><img style=\"width:192px; height:361px;\" src=\"images/RHEUM/51395_Polymyositis_whole_body_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Whole-body turbo short tau inversion recovery&nbsp;MRI (TR/TE, 4000/30; inversion time, 160 msec) of posterior aspect of upper torso shows extensive inflammation in deltoid, trapezius, triceps, and latissimus dorsi muscles bilaterally (straight arrows) and further muscle edema and inflammation in vastus medialis and lateralis muscles of left thigh (curved arrow). Note susceptibility artifact at site of right hip prosthesis, limiting assessment of muscles adjacent to this site.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">O'Connell MJ, Powell T, Brennan D, et al. Whole-body MR imaging in the dianosis of polymyositis. Am J Roentgenol 2002; 179:967. Reprinted with permission from the American Journal of Roentgenology. Copyright &copy; 2002 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 51395 Version 11.0</div></div></div>"},"51396":{"type":"graphic_figure","displayName":"Mechanisms for development B cell NHL","title":"Schematic overview of potential mechanisms for the development of B cell non-Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Schematic overview of potential mechanisms for the development of B cell non-Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:521px; height:677px;\" src=\"images/HEME/51396_Mechanisms-for-development-B-cell-NHL.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Ag: antigen; CLL/SLL: chronic lymphocytic leukemia/small lymphocytic lymphoma; GCB DLBCL: germinal center B cell diffuse large B cell lymphoma; FL: follicular lymphoma; MZL: marginal zone lymphoma; ABC DLBCL: activated B cell diffuse large B cell lymphoma; MM: multiple myeloma.</div><div id=\"graphicVersion\">Graphic 51396 Version 5.0</div></div></div>"},"51397":{"type":"graphic_picture","displayName":"Skin snip in onchocerciasis","title":"Skin snip in onchocerciasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin snip in onchocerciasis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ID/51397_Skin_snip_onchocerciasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Taking a skin snip using a corneoscleral punch.</div><div class=\"graphic_reference\">Reproduced with permission from: Murdoch ME. The skin and the immune response in onchocerciasis. Tropical Doctor 1992; 22(Suppl 1):44. Copyright &#169; 1992 The Royal Society of Medicine Press.</div><div id=\"graphicVersion\">Graphic 51397 Version 1.0</div></div></div>"},"51399":{"type":"graphic_figure","displayName":"Morgan lens close up","title":"Morgan® lens","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Morgan® lens</div><div class=\"cntnt\"><img style=\"width:324px; height:170px;\" src=\"images/EM/51399_Morgan_lens_close_up.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Morgan® lens provides a simple and effective means for irrigating eyes exposed to toxic chemicals.</div><div class=\"graphic_reference\">Reproduced with permission from: MorTan, Inc. Copyright © 2009.</div><div id=\"graphicVersion\">Graphic 51399 Version 4.0</div></div></div>"},"51401":{"type":"graphic_figure","displayName":"Focal photocoag for Tx ME","title":"Focal photocoagulation for the treatment of macular edema: Appearance on fundus photograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Focal photocoagulation for the treatment of macular edema: Appearance on fundus photograph</div><div class=\"cntnt\"><img style=\"width:396px; height:330px;\" src=\"images/ENDO/51401_Focal_photocoag_for_Tx_ME.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color fundus photograph displaying the laser photocoagulation burns used in grid treatment of diabetic macular edema; note: photograph modified to accentuate the burns, which typically are much less visible on color photographs.</div><div id=\"graphicVersion\">Graphic 51401 Version 2.0</div></div></div>"},"51402":{"type":"graphic_figure","displayName":"Testosterone critical illness","title":"Correlation of serum testosterone with severity of critical illness","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Correlation of serum testosterone with severity of critical illness</div><div class=\"cntnt\"><img style=\"width:351px; height:233px;\" src=\"images/ENDO/51402_Testosterone_critical_illne.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The serum testosterone concentration on admission (left panel) and the nadir level in the hospital (right panel) in men with critical illness according to disease severity as measured by the APACHE score. Men with increasingly severe illnesses have lower serum testosterone concentrations. To convert serum testosterone values to ng/dL, divide by 0.0347.</div><div class=\"graphic_footnotes\">APACHE: Acute Physiology and Chronic Health Evaluation.</div><div class=\"graphic_reference\">Redrawn from Spratt DI, Cox P, Orav J, et al. Reproductive axis suppression in acute illness is related to disease severity.&nbsp;J Clin Endocrinol Metab 1993; 76:1548.</div><div id=\"graphicVersion\">Graphic 51402 Version 2.0</div></div></div>"},"51406":{"type":"graphic_table","displayName":"Causes acquired methemoglobinemia","title":"Medications and chemicals that may cause acquired methemoglobinemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications and chemicals that may cause acquired methemoglobinemia</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Medications</td> </tr> <tr> <td class=\"indent1\">Amino salicylic acid (also called p-aminosalicylic acid or 4-aminosalicylic acid)</td> </tr> <tr> <td class=\"indent1\">Clofazimine</td> </tr> <tr> <td class=\"indent1\">Chloroquine</td> </tr> <tr> <td class=\"indent1\">Dapsone</td> </tr> <tr> <td class=\"indent1\">Local anesthetics, topical sprays and creams including benzocaine (in teething rings and ointments), lidocaine, and prilocaine</td> </tr> <tr> <td class=\"indent1\">Menadione</td> </tr> <tr> <td class=\"indent1\">Metoclopramide</td> </tr> <tr> <td class=\"indent1\">Methylene blue*</td> </tr> <tr> <td class=\"indent1\">Nitroglycerin</td> </tr> <tr> <td class=\"indent1\">Phenacetin</td> </tr> <tr> <td class=\"indent1\">Phenazopyridine</td> </tr> <tr> <td class=\"indent1\">Primaquine</td> </tr> <tr> <td class=\"indent1\">Rasburicase</td> </tr> <tr> <td class=\"indent1\">Quinones</td> </tr> <tr> <td class=\"indent1\">Sulfonamides</td> </tr> <tr> <td class=\"subtitle1_single\">&nbsp;Chemicals and environmental substances</td> </tr> <tr> <td class=\"indent1\">Acetanilide (used in varnishes, rubber, and dyes)</td> </tr> <tr> <td class=\"indent1\">Anilines and aniline dyes (eg, diaper and laundry marking inks, leather dyes, red wax crayons)</td> </tr> <tr> <td class=\"indent1\"><span style=\"color: black;\">Antifreeze</span></td> </tr> <tr> <td class=\"indent1\">Benzene derivatives (used as solvents)</td> </tr> <tr> <td class=\"indent1\">Chlorates and chromates (used in chemical and industrial synthesis)</td> </tr> <tr> <td class=\"indent1\">Hydrogen peroxide (used as a disinfectant and cleaner)</td> </tr> <tr> <td class=\"indent1\">Naphthalene (used in mothballs)</td> </tr> <tr> <td class=\"indent1\">Naphthoquinone (used in chemical synthesis)</td> </tr> <tr> <td class=\"indent1\">Nitrates and nitrites (eg, amyl nitrite, farryl nitrite, sodium nitrite, nitrate- and nitrite-containing foods, nitric oxide, well water)</td> </tr> <tr> <td class=\"indent1\">Nitrobenzene (used as a solvent)</td> </tr> <tr> <td class=\"indent1\">Paraquat (used in herbicides)</td> </tr> <tr> <td class=\"indent1\">Resorcinol (used in resin melting and wood extraction)</td> </tr> <tr> <td class=\"subtitle1_single\">&nbsp;Inherited disorders (extremely rare)</td> </tr> <tr> <td class=\"indent1\">Cytochrome b5-reductase deficiency</td> </tr> <tr> <td class=\"indent1\">Hemoglobin M disease</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> </tr> <tr> </tr> <tr> </tr> <tr> </tr> <tr> </tr> <tr> </tr> <tr> </tr> <tr> </tr> <tr> </tr> <tr> </tr> <tr> </tr> <tr> </tr> <tr> </tr> <tr> </tr> <tr> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on methemoglobinemia for additional details regarding these medications and chemicals, as well as citations with supporting evidence for their role in causing methemoglobinemia and information on congenital methemoglobinemia syndromes.</div><div class=\"graphic_footnotes\">G6PD: glucose-6-phosphate dehydrogenase.<br />* While methylene blue is a recognized treatment for methemoglobinemia, it also has oxidant potential and may worsen the clinical status of individuals with&nbsp;G6PD deficiency because it induces acute hemolysis that can further decrease oxygen delivery to the tissues. In high doses, methylene blue can paradoxically increase methemoglobinemia.</div><div id=\"graphicVersion\">Graphic 51406 Version 7.0</div></div></div>"},"51410":{"type":"graphic_figure","displayName":"Cerebral arterial circulation","title":"Anatomy of the cerebral arterial circulation","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Anatomy of the cerebral arterial circulation</div><div class=\"cntnt\"><img style=\"width:574px; height:660px;\" src=\"images/NEURO/51410_Cerebralcirculationedt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frontal view of the carotid arteries, vertebral arteries, and intracranial vessels and their communication with each other via the circle of Willis.</div><div class=\"graphic_reference\">Reproduced with permission from: Uflacker R. Atlas Of Vascular Anatomy: An Angiographic Approach, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51410 Version 6.0</div></div></div>"},"51411":{"type":"graphic_table","displayName":"Nonplat combinations NSCLC","title":"Nonplatinum-based combination regimens for advanced NSCLC","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonplatinum-based combination regimens for advanced NSCLC</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Regimen</td>\n\t\t\t\t\t<td class=\"subtitle1\">Dose and schedule</td>\n\t\t\t\t\t<td class=\"subtitle1\">Frequency</td>\n\t\t\t\t\t<td class=\"subtitle1\">Reference</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Gemcitabine/Docetaxel</td>\n\t\t\t\t\t<td><p>Gemcitabine 1000 mg/m2 days 1, 8</p>\n\t\t\t\t\t\t<p>Docetaxel 85 mg/m2 day 8</p></td>\n\t\t\t\t\t<td>Every 3 weeks</td>\n\t\t\t\t\t<td>Ann Oncol 2005; 16:602</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Gemcitabine/Paclitaxel</td>\n\t\t\t\t\t<td><p>Gemcitabine 1000 mg/m2 days 1, 8</p>\n\t\t\t\t\t\t<p>Paclitaxel 200 mg/m2 day 1</p></td>\n\t\t\t\t\t<td>Every 3 weeks</td>\n\t\t\t\t\t<td>J Clin Oncol 2002; 20:3578</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Paclitaxel/Vinorelbine</td>\n\t\t\t\t\t<td><p>Paclitaxel 135 mg/m2 day 1</p>\n\t\t\t\t\t\t<p>Vinorelbine 25 mg/m2 day 1</p></td>\n\t\t\t\t\t<td>Every 2 weeks</td>\n\t\t\t\t\t<td>Ann Oncol 2004; 15:1048</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Gemcitabine/Vinorelbine</td>\n\t\t\t\t\t<td><p>Gemcitabine 1000 mg/m2 days 1, 8</p>\n\t\t\t\t\t\t<p>Vinorelbine 25 mg/m2 days 1, 8</p></td>\n\t\t\t\t\t<td>Every 3 weeks</td>\n\t\t\t\t\t<td>J Clin Oncol 2004; 22:2348</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_lgnd\">These are representative doses and schedules, which have varied in different trials.</div><div class=\"graphic_footnotes\">NSCLC: Non-small cell lung cancer.</div><div id=\"graphicVersion\">Graphic 51411 Version 1.0</div></div></div>"},"51412":{"type":"graphic_table","displayName":"RINV guidelines","title":"Radiotherapy-induced nausea and vomiting: MASCC/ESMO 2010 and ASCO 2011 guidelines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Radiotherapy-induced nausea and vomiting: MASCC/ESMO 2010 and ASCO 2011 guidelines</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Risk level\n   </td>\n   <td  class=\"subtitle1\">\n   Risk factors\n   </td>\n   <td  class=\"subtitle1\">\n   Antiemetic guidelines\n   </td>\n   </tr>\n   <tr>\n   <td>High</td>\n   <td>TBI</td>\n   <td>Prophylaxis with 5-HT3-RA + DEX</td>\n   </tr>\n   <tr>\n   <td>Moderate</td>\n   <td>Upper abdomen, HBI, UBI</td>\n   <td>Prophylaxis with 5-HT3-RA + optional DEX</td>\n   </tr>\n   <tr>\n   <td>Low</td>\n   <td>Cranium (all), craniospinal, H &amp; N, lower thorax region, pelvis</td>\n   <td>Prophylaxis or rescue with 5-HT3-RA</td>\n   </tr>\n   <tr>\n   <td>Minimal</td>\n   <td>Extremities, breast</td>\n   <td>Rescue with dopamine receptor antagonist or 5-HT3-RA</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=47868&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>RINV_guidelines.htm</title></head></div><div class=\"graphic_footnotes\">ASCO: American Society of Clinical Oncology; MASCC: Multinational Association for Supportive Care in Cancer; ESMO: European Society of Medical Oncology; TBI: total body irradiation; HBI: half body irradiation; UBI: upper body irradiation; 5-HT3-RA: 5-HT3-receptor-antagonist; DEX: dexamethasone.<BR>* In concomitant radiochemotherapy the antiemetic prophylaxis is according to the chemotherapy-related antiemetic guidelines of the corresponding risk category, unless the risk of emesis is higher with radiotherapy than chemotherapy.</div><div id=\"graphicVersion\">Graphic 51412 Version 2.0</div></div></div>"},"51413":{"type":"graphic_figure","displayName":"EEG recording leads","title":"EEG recording leads in ECT","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">EEG recording leads in ECT</div><div class=\"cntnt\"><img style=\"width:526px; height:355px;\" src=\"images/PSYCH/51413_EEG_recording_leads.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electroencephalogram (EEG) electrode placement.</div><div class=\"graphic_reference\">Reprinted with permission from: Handbook of ECT (Copyright 1997). American Psychiatric Publishing, Inc.</div><div id=\"graphicVersion\">Graphic 51413 Version 7.0</div></div></div>"},"51415":{"type":"graphic_picture","displayName":"Placental malaria infection","title":"Placental malaria infection","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Placental malaria infection</div><div class=\"cntnt\"><img style=\"width:480px; height:360px;\" src=\"images/OBGYN/51415_Placental_malaria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin and eosin stained placental parenchyma with malarial sequestration. The intervillous space demonstrates numerous infected red blood cells and hemozoin pigment in red blood cells and histiocytes. The infant was liveborn at 38 weeks of gestation. The blue arrows point to examples of red blood cells containing pigment and the black arrow points to an example of a pigment-containing histiocyte.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 51415 Version 2.0</div></div></div>"},"51417":{"type":"graphic_table","displayName":"Causes of delayed gastric emptying","title":"Causes of delayed gastric emptying","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of delayed gastric emptying</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_left\">Anatomic</td>\n<td>Pyloric stenosis, duodenal stenosis, duodenal web</td>\n</tr>\n<tr>\n<td class=\"subtitle1_left\">Metabolic</td>\n<td>Hypokalaemia, acidosis, hypothyroidism, diabetic gastroparesis</td>\n</tr>\n<tr>\n<td class=\"subtitle1_left\">Drugs</td>\n<td>Opioids, anticholinergics, neuromuscular blockade</td>\n</tr>\n<tr>\n<td class=\"subtitle1_left\">Neuronal dysfunction</td>\n<td>CNS disease, vagotomy, intestinal pseudoobstruction</td>\n</tr>\n<tr>\n<td class=\"subtitle1_left\">Muscle disease</td>\n<td>Visceral myopathy, SLE, myotonic dystrophy</td>\n</tr>\n<tr>\n<td class=\"subtitle1_left\">Infection</td>\n<td>Viral, bacterial toxins, post-viral gastroparesis</td>\n</tr>\n<tr>\n<td class=\"subtitle1_left\">Idiopathic</td>\n<td>Slow-wave arrhythmias</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">CNS: central nervous system; SLE: systemic lupus erythematosus.</div><div class=\"graphic_reference\">Adapted from: Milla PJ. Motor disorders including pyloric stenosis. In: Pediatric Gastrointestinal Disease, 3rd ed, Walker WA, Durie PR, Hamilton JR, Walker-Smith JA (Eds) B.C. Decker, Hamilton, Ontario 2000. p.415.</div><div id=\"graphicVersion\">Graphic 51417 Version 2.0</div></div></div>"},"51418":{"type":"graphic_table","displayName":"Congen dyseryth anemias","title":"Congenital dyserythropoietic anemias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Congenital dyserythropoietic anemias</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Type</td>\r\n            <td class=\"subtitle1\">Bone Marrow</td>\r\n            <td class=\"subtitle1\">Anemia</td>\r\n            <td class=\"subtitle1\">Acidified serum test</td>\r\n            <td class=\"subtitle1\">Inheritance</td>\r\n            <td class=\"subtitle1\">Gene localization</td>\r\n            <td class=\"subtitle1\">MCV</td>\r\n            <td class=\"subtitle1\">i antigen</td>\r\n        </tr>\r\n        <tr>\r\n            <td>I</td>\r\n            <td>Megaloblastoid erythroid hyperplasia; Nuclear chromatin bridges between erythroblasts</td>\r\n            <td>Mild- moderate</td>\r\n            <td>Negative</td>\r\n            <td>AR</td>\r\n            <td>15q15.1-15.3</td>\r\n            <td>Increased</td>\r\n            <td>Normal</td>\r\n        </tr>\r\n        <tr>\r\n            <td>II (HEMPAS*)</td>\r\n            <td>Erythroblastic multinuclearity</td>\r\n            <td>Mild- severe</td>\r\n            <td>Positive</td>\r\n            <td>AR</td>\r\n            <td>20q11.1</td>\r\n            <td>Normal or increased</td>\r\n            <td>Increased</td>\r\n        </tr>\r\n        <tr>\r\n            <td>III</td>\r\n            <td>Erythroblastic multinuclearity (up to 12 nuclei) with gigantoblasts</td>\r\n            <td>Mild- moderate</td>\r\n            <td>Negative</td>\r\n            <td>AD, sporadic cases</td>\r\n            <td>15q22</td>\r\n            <td>Increased</td>\r\n            <td>Normal</td>\r\n        </tr>\r\n        <tr>\r\n            <td>IV</td>\r\n            <td>Erythroblastic multinuclearity</td>\r\n            <td>&nbsp;</td>\r\n            <td>Negative</td>\r\n            <td>AD</td>\r\n            <td>&nbsp;</td>\r\n            <td>Normal or increased</td>\r\n            <td>Normal</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_footnotes\">AR: autosomal recessive; AD: autosomal dominant.<BR>* HEMPAS: Hereditary Erythroblastic Multinuclearity with Positive Acidified Serum test.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<OL>&#xD;&#xA;<LI>Alter BP, Young NS. The bone marrow failure syndromes. In: Nathan and Oski's Hematology of Infancy and Childhood, Nathan DG, Orkin SH (Eds), W.B. Saunders Company, 1998, p.237 </LI>&#xD;&#xA;<LI>Wickramasinghe SN. Congenital dyserythropoietic anaemias: clinical features, haematological morphology and new biochemical data. Blood Rev 1998; 12:178 </LI>&#xD;&#xA;<LI>Gasparini P, Miraglia del Giudice E, Delaunay, J, et al. Localization of the congenital dyserythropoietic anemia II locus to chromosome 20q11.2 by genomewide search. Am J Hum Genet 1997; 61:1112&nbsp; </LI>&#xD;&#xA;<LI>Benjamin JT, Rosse WF, Daldorf FG, McMillan CW. Congenital dyserythropoietic anemia - type IV. J Pediatr 1975; 87:210.</LI></OL></div><div id=\"graphicVersion\">Graphic 51418 Version 2.0</div></div></div>"},"51419":{"type":"graphic_picture","displayName":"Choanal atresia repair","title":"Transpalatal choanal atresia repair","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transpalatal choanal atresia repair</div><div class=\"cntnt\"><img style=\"width:289px; height:341px;\" src=\"images/PEDS/51419_Choanal_atresia_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note reflected palatal flap and endotracheal tube stent in nasopharynx.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 51419 Version 1.0</div></div></div>"},"51420":{"type":"graphic_diagnosticimage","displayName":"EP study idiopathic LV tachycardia","title":"Electrophysiology study (EPS) tracing of idiopathic left ventricular tachycardia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrophysiology study (EPS) tracing of idiopathic left ventricular tachycardia</div><div class=\"cntnt\"><img style=\"width:399px; height:275px;\" src=\"images/CARD/51420_Idiopathic_LV_tachycardia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Idiopathic LV tachycardia originates from the inferior portion of the ventricular septum. Surface leads (I, II, III, V1, and V6), and intracardiac recordings from the high right atrium (HRA), His bundle region (HBE), right ventricular apex (RVA), right ventricular outflow tract (RVOT), and several recordings from the left ventricle at the site of successful ablation (LV fixed, LV var, LV bipol, LV uni) are shown. The presence of a sharp potential in the LV recordings (arrow) is consistent with local activation of the Purkinje system. This potential precedes the onset of the QRS during ventricular tachycardia (VT) by 40 msec.</div><div class=\"graphic_reference\">Reprinted with permission of Futura Publishing Company.</div><div id=\"graphicVersion\">Graphic 51420 Version 4.0</div></div></div>"},"51421":{"type":"graphic_table","displayName":"Differential diagnosis of memory loss","title":"Differential diagnosis of memory loss","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of memory loss</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">Usual cause</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td class=\"sublist1_start\">Gradual onset of short-term memory loss and functional impairment in more than one domain:</td> <td class=\"sublist_other_start\" rowspan=\"3\">Dementia</td> <td class=\"sublist_other_start\" rowspan=\"3\">Alzheimer disease, Parkinson dementia, Lewy body dementia, frontotemporal dementia, alcohol-related dementia, Creutzfeld-Jacob disease</td> </tr> <tr> <td class=\"sublist1\">I. Executive function (finances, shopping, cooking, laundry, transportation)</td> </tr> <tr> <td class=\"sublist1\">II. Basic activities of daily living (feeding, dressing, bathing, toileting, transfers)</td> </tr> <tr> <td>Stepwise, sudden deterioration in cognition; episodes of confusion, aphasia, slurred speech, focal weakness</td> <td>Cerebrovascular disease</td> <td>Vascular dementia, multi-infarct dementia, Binswanger dementia (subcortical dementia)</td> </tr> <tr> <td>Acute cognitive impairment with clouded sensorium; difficulty with attention; may have hypersomnolence</td> <td>Delirium</td> <td>Hypo- or hyperglycemia, hypo- or hypernatremia, hypoxemia, anemia, intermittent cerebral ischemia, thyrotoxicosis, myxedema, alcohol withdrawal, sepsis, drugs (especially cholinergics, benzodiazepines, etc)</td> </tr> <tr> <td>Complains of memory loss, decreased concentration, impaired judgment, feels worse in morning and hopeless</td> <td>Depression</td> <td>Minor depression, dysthymic disorder, major depression, pathologic grief reaction</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51421 Version 4.0</div></div></div>"},"51423":{"type":"graphic_table","displayName":"Types of inferior vena cava filters","title":"Types of inferior vena cava filters","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of inferior vena cava filters</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Maximum IVC diameter (mm)</td> <td class=\"subtitle1\">Manufacturer</td> <td class=\"subtitle1\">Required sheath size (O.D.)*</td> <td class=\"subtitle1\">Insertion sites</td> <td class=\"subtitle1\">Material</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Permanent (nonretrievable)</td> </tr> <tr> <td class=\"indent1\">Titanium Greenfield</td> <td>28</td> <td>Boston Scientific</td> <td>12 Fr</td> <td>Jugular, femoral</td> <td>Titanium</td> </tr> <tr> <td class=\"indent1\">Over the Wire Greenfield</td> <td>28</td> <td>Boston Scientific</td> <td>12 Fr</td> <td>Jugular, femoral</td> <td>316 stainless steel</td> </tr> <tr> <td class=\"indent1\">Gianturco-Roehm Bird's nest</td> <td>40</td> <td>Cook</td> <td>12 Fr&nbsp;</td> <td>Jugular, femoral</td> <td>304 stainless steel</td> </tr> <tr> <td class=\"indent1\">Simon Nitinol Filter (SNF)</td> <td>28</td> <td>Bard</td> <td>9 Fr</td> <td>Jugular, femoral, subclavian, antecubital</td> <td>Nitinol (Ni-Ti)</td> </tr> <tr> <td class=\"indent1\">TrapEase</td> <td>30</td> <td>Cordis (J&#38;J)</td> <td>6 Fr</td> <td>Jugular, femoral, antecubital</td> <td>Elgiloy&#182;</td> </tr> <tr> <td class=\"indent1\">Vena Tech LGM</td> <td>28</td> <td>B. Braun Medical</td> <td>12 Fr</td> <td>Jugular/femoral single system</td> <td>Phynox&#182;</td> </tr> <tr> <td class=\"indent1\">Vena Tech LP</td> <td>28</td> <td>B. Braun Medical</td> <td>9 Fr</td> <td>Jugular, femoral</td> <td>Phynox&#182;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Optional (permanent or retrievable)</td> </tr> <tr> <td class=\"indent1\">Denali</td> <td>28</td> <td>Bard&nbsp;</td> <td>8.4 Fr&nbsp;&#916;</td> <td>Jugular, femoral&nbsp;</td> <td>Nitinol (Ni-Ti)</td> </tr> <tr> <td class=\"indent1\">OptEase&nbsp;</td> <td>30</td> <td>Cordis (J&#38;J)&nbsp;</td> <td>6 Fr</td> <td>Jugular, femoral, antecubital</td> <td>Elgiloy&#182;</td> </tr> <tr> <td class=\"indent1\">Gunther tulip</td> <td>30</td> <td>Cook</td> <td>8.5 Fr&nbsp;</td> <td>Jugular, femoral</td> <td>Conichrome&#182;</td> </tr> <tr> <td class=\"indent1\">Cook Celect</td> <td>30</td> <td>Cook</td> <td>7 Fr (IJ), 8.5 Fr (F)</td> <td>Jugular, femoral, UniSet</td> <td>Conichrome*</td> </tr> <tr> <td class=\"indent1\">Option</td> <td>30</td> <td>Argon Medical</td> <td>6.5 Fr</td> <td>Jugular, femoral</td> <td>Nitinol (Ni-Ti)</td> </tr> <tr> <td class=\"indent1\">ALN filter</td> <td>32</td> <td>ALN International&nbsp;</td> <td>7 Fr</td> <td>Jugular, femoral, basilic</td> <td>316 stainless steel</td> </tr> <tr> <td class=\"indent1\">Crux filter</td> <td>28</td> <td>Volcano</td> <td>9 Fr</td> <td>Jugular, femoral</td> <td>Nitinol (Ni-Ti)</td> </tr> <tr> <td class=\"indent1\">Vena Tech&nbsp;Convertible</td> <td>28</td> <td>B. Braun Medical</td> <td>9 Fr </td> <td>Jugular, femoral&nbsp;</td> <td>Cobalt chromium</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Each of the filters depicted is approved for use in the United States as a permanent filter, but some are approved as optional (ie, permanent or retrievable). </div><div class=\"graphic_footnotes\">IVC: inferior vena cava; Fr: French; IJ: internal jugular; F: femoral.<br />* Outer diameter (O.D.) specified where the information is available.<br />¶&nbsp;Trademark names for the cobalt-chromium-nickel-molybdenum-iron alloy specified by ASTM F1058 and ISO 5832-7.<br />Δ Inner diameter.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>http://www.astm.org. </LI>&#xD;&#xA;<LI>http://www.iso.org. </LI></OL></div><div id=\"graphicVersion\">Graphic 51423 Version 7.0</div></div></div>"},"51424":{"type":"graphic_diagnosticimage","displayName":"Provocable obstruction HCM","title":"Provocable outflow tract obstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Provocable outflow tract obstruction</div><div class=\"cntnt\"><img style=\"width:373px; height:209px;\" src=\"images/CARD/51424_Provocable_obstruction_HCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The two-chamber echocardiographic views of the mitral valve (MV) and left ventricular outflow tract (LVOT) demonstrate the site and appearance of systolic anterior motion of the mitral valve. In panel A, the patient is at rest and the LVOT is open. In panel B, the patient has been given amyl nitrite and the recording was made at its full effect; the coapted mitral valve/chordae tip has moved into the LVOT and now abuts the septum (arrow). In panel C, the effect has passed and the valve has returned toward its resting position.</div><div id=\"graphicVersion\">Graphic 51424 Version 4.0</div></div></div>"},"51429":{"type":"graphic_picture","displayName":"Failed mandibular fusion","title":"Failed midline mandibular fusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Failed midline mandibular fusion</div><div class=\"cntnt\"><img style=\"width:366px; height:280px;\" src=\"images/PEDS/51429_Failed_mandibular_fusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arrows mark the unfused ends of the mandible.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 51429 Version 1.0</div></div></div>"},"51431":{"type":"graphic_table","displayName":"Differential diagnosis of pediatric limp by age and duration","title":"Causes of limp in children by age and duration of symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of limp in children by age and duration of symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">All ages</td> <td class=\"subtitle1\"> <p>Preschool</p> <p>(1 to 5 yrs)</p> </td> <td class=\"subtitle1\"> <p>School-age</p> <p>(5 to 12 yrs)</p> </td> <td class=\"subtitle1\"> <p>Adolescent</p> <p>(13 to 19 yrs)</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Acute</td> </tr> <tr> <td class=\"indent1\"> <p>Contusion</p> <p>Foot foreign body</p> <p>Fracture</p> <p>Lyme arthritis*</p> <p>Osteomyelitis</p> <p>Poor shoe fit</p> <p>Reactive arthritis</p> <p>Septic arthritis</p> <p>Transient synovitis</p> </td> <td> <p>Child abuse</p> <p>Hand-foot-mouth disease (enterovirus infection)</p> <p>Hemarthrosis (hemophilia)</p> <p>Henoch Sh&#246;nlein purpura</p> <p>Immunization (IM shot)</p> <p>Salter I fracture</p> <p>Septic hip</p> <p>Toddler's fracture</p> </td> <td> <p>Salter I fracture</p> <p>Myositis</p> </td> <td> <p>Sprain or strain</p> <p>Tendonitis</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Chronic</td> </tr> <tr> <td class=\"indent1\"> <p>Rheumatic disease</p> <p>(Preschool: systemic JIA;</p> <p>School-age: JIA, dermatomyositis, acute rheumatic fever;</p> <p>Adolescent: IBD, SLE)</p> </td> <td> <p>Blount disease</p> <p>Cerebral palsy</p> <p>Developmental dysplasia of the hip</p> <p>Discitis</p> <p>K&#246;hler disease</p> <p>Leg length discrepancy</p> <p>Vertical talus</p> </td> <td> <p>Avascular necrosis of the hip (Legg-Calve-Perthe disease)</p> <p>Baker cyst</p> <p>K&#246;hler disease</p> <p>Leukemia</p> <p>Spinal dysraphism (tethered cord)</p> <p>Tarsal coalition</p> </td> <td> <p>Chondromalacia of the patella</p> <p>CRPS</p> <p>Gonoccoccal arthritis</p> <p>Herniated lumbar vertebral disc</p> <p>Hypermobility syndrome</p> <p>Osteochondritis dissecans</p> <p>Overuse syndromes, Osgood-Schlatter disease</p> <p>Scoliosis</p> <p>Slipped capital femoral epiphysis</p> <p>Spinal dysraphism (tethered cord)</p> <p>Spondylolisthesis</p> <p>Tumor</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CRPS: complex regional pain syndrome; IBD: inflammatory bowel disease; IM: intramuscular; JIA: juvenile idiopathic arthritis; SLE: systemic lupus erythematosus.<br> * In areas endemic for Lyme disease.</div><div id=\"graphicVersion\">Graphic 51431 Version 3.0</div></div></div>"},"51432":{"type":"graphic_picture","displayName":"Endoscopic image of eosinophilic esophagitis","title":"Endoscopic image of eosinophilic esophagitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic image of eosinophilic esophagitis</div><div class=\"cntnt\"><img style=\"width:320px; height:315px;\" src=\"images/GAST/51432_Eosinophilic_esophagitis_En.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This upper endoscopy in a 36-year-old man with dysphagia showed multiple rings&nbsp;in the proximal to mid esophagus, giving it the appearance of a trachea. Small whitish papules are also visible representing eosinophilic abscesses on histology. The patient's symptoms responded to&nbsp;swallowed (ie, topical)&nbsp;fluticasone.</div><div class=\"graphic_reference\">Courtesy of Eric D Libby, MD.</div><div id=\"graphicVersion\">Graphic 51432 Version 4.0</div></div></div>"},"51434":{"type":"graphic_picture","displayName":"High grade CIN","title":"High grade cervical intraepithelial lesion ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">High grade cervical intraepithelial lesion </div><div class=\"cntnt\"><img style=\"width:334px; height:307px;\" src=\"images/OBGYN/51434_High_grade_cervical_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coarse punctation is seen on the anterior lip of the cervix.</div><div class=\"graphic_reference\">Reproduced with permission from: Brotzman GL, Apgar BS. Abnormal transformation zone. In: Colposcopy Principles and Practice, Apgar BS, Brotzman GL, Spitzer M (Eds), W.B. Saunders Company, Philadelphia 2002. p.186. Copyright © 2002 Elsevier.</div><div id=\"graphicVersion\">Graphic 51434 Version 3.0</div></div></div>"},"51435":{"type":"graphic_picture","displayName":"Giant proerythroblast in PRCA","title":"Giant proerythroblast in pure red cell aplasia due to parvovirus infection","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Giant proerythroblast in pure red cell aplasia due to parvovirus infection</div><div class=\"cntnt\"><img style=\"width:447px; height:288px;\" src=\"images/HEME/51435_Giant_proerythroblast_in_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow from a patient with pure red cell aplasia due to parvovirus B19 infection, showing a characteristic giant proerythroblast. Compare the size of this cell with that of the surrounding cells of the neutrophilic series and the mature red blood cells.</div><div class=\"graphic_reference\">Courtesy of Stanley L Schrier, MD.</div><div id=\"graphicVersion\">Graphic 51435 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal bone marrow biopsy at low power</div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/HEME/68384_Normal_bone_marrow_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a normal bone marrow biopsy. The overall cellularity is between 30 and 70 percent, with the remainder of the space being occupied by fat and stroma.</div><div class=\"graphic_reference\">Courtesy of Stanley L Schrier, MD.</div><div id=\"graphicVersion\">Graphic 68384 Version 2.0</div></div></div>"},"51436":{"type":"graphic_diagnosticimage","displayName":"Cavitating bronchogenic ca CT","title":"Cavitating bronchogenic carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cavitating bronchogenic carcinoma</div><div class=\"cntnt\"><img style=\"width:321px; height:270px;\" src=\"images/PULM/51436_Cavitating_bronchogenic_ca.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The irregular internal wall contour and the wall thickness of the cavitating lesion are suggestive of malignancy.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 51436 Version 2.0</div></div></div>"},"51437":{"type":"graphic_table","displayName":"Initiation of pressure-cycled NPPV in NM disease","title":"Protocol for initiation of noninvasive positive pressure ventilation using pressure-cycled ventilator","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Protocol for initiation of noninvasive positive pressure ventilation using pressure-cycled ventilator</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>1. Choose appropriately monitored location.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>2. Direct patient to sit in bed or chair at &#62;30 angle. Ensure patient comfort.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>3. Obtain baseline vital signs, arterial blood gas, and oximetry, as clinically indicated.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>4. Select and fit interface (nasal or oronasal mask).</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>5. Apply headgear; avoid excessive strap tension (one or two fingers under strap).</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>6. Select ventilator.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>7. Connect interface to ventilator tubing and turn on ventilator.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>8. For pressure-cycled ventilator, start with low pressure in spontaneously triggered mode; pressure limited: inspiratory pressure (IPAP) 8 to 10 cm H2O; expiratory pressure (EPAP) 4 to 5 cm H2O. A back up rate of 2 breaths per minute below the patient's spontaneous nocturnal rate.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>9. Gradually increase inspiratory pressure by 2.5 cm H2O increments, as tolerated, to achieve alleviation of dyspnea, decreased respiratory rate, increased tidal volume (if being monitored), and good patient-ventilator synchrony.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>10. Check for air leaks, readjust straps as needed. Add chin strap, if oral air leak noted.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>11. Add heated humidification, as indicated.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>12. Provide encouragement, reassurance, and frequent checks and adjustments as needed.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>13. Monitor vital signs and oximetry during trial; obtain occasional blood gases (within 1 to 2 hours) and then as needed.</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 51437 Version 2.0</div></div></div>"},"51438":{"type":"graphic_picture","displayName":"Skin biopsy subacute SLE I","title":"Subacute cutaneous lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subacute cutaneous lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:360px; height:238px;\" src=\"images/RHEUM/51438_Skin_biopsy_subacute_SLE_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph demonstrating a&nbsp;vasculopathic interface dermatitis without conspicuous follicular plugging. The infiltrate is largely confined to the superficial half of the dermis.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 51438 Version 2.0</div></div></div>"},"51439":{"type":"graphic_algorithm","displayName":"Guideline for cervical spine clearance in the reliable child","title":"Guideline for cervical spine clearance in the reliable pediatric patient","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Guideline for cervical spine clearance in the reliable pediatric patient</div><div class=\"cntnt\"><img style=\"width:552px; height:866px;\" src=\"images/EM/51439_Guideline_c-spine_exm_child.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">c-spine: cervical spine; AP: antero-posterior; D/C: discontinue; MRI: magnetic resonance imaging; CT: computed tomography.<br />* Awake and alert with Glasgow Coma Scale (GCS) = 15.<br />¶ Meets NEXUS criteria (no midline cervical spine tenderness, no focal neurologic deficit, normal alertness, no intoxication, and no painful, distracting injury) AND moves head in flexion/extension AND rotate 45 degrees to both sides with no pain.<br />Δ Change to long term cervical spine collar as soon as appropriate.</div><div class=\"graphic_reference\">Reproduced with permission from: Chung S, Mikrogianakis A, Wales PW, et al. Trauma Association of Canada Pediatric Subcommittee National Pediatric Cervical Spine Evaluation Pathway: Consensus Guidelines. J Trauma 2011; 70:873. Copyright © 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51439 Version 9.0</div></div></div>"},"51440":{"type":"graphic_figure","displayName":"Soft tissue filler injection techniques","title":"Soft tissue filler injection techniques","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Soft tissue filler injection techniques</div><div class=\"cntnt\"><img style=\"width:527px; height:651px;\" src=\"images/DERM/51440_Soft-tissue-filler-injection-techniques.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51440 Version 4.0</div></div></div>"},"51441":{"type":"graphic_figure","displayName":"Construction of a loop colostomy - abdominal wall","title":"Construction of a loop colostomy - abdominal wall","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Construction of a loop colostomy - abdominal wall</div><div class=\"cntnt\"><img style=\"width:451px; height:461px;\" src=\"images/SURG/51441_Loop-colostomy-abd-wall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These figures depict the loop of colon being brought onto the abdominal wall. A plastic rod or red rubber catheter prevents retraction of the bowel into the abdominal cavity.<BR>Figure A shows a small opening made in the mesentery with a finger, just large enough to pass the rod or catheter.<BR>Figure B shows the rod in place.<BR>Figure C shows a tube catheter attached to each end of the rod.</div><div id=\"graphicVersion\">Graphic 51441 Version 2.0</div></div></div>"},"51446":{"type":"graphic_waveform","displayName":"Third degree or complete AV block with wide QRS escape","title":"Third degree (complete) atrioventricular block with wide QRS escape rhythm","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Third degree (complete) atrioventricular block with wide QRS escape rhythm</div><div class=\"cntnt\"><img style=\"width:434px; height:68px;\" src=\"images/CARD/51446_Complete_HB_ventricular_esc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The P waves are completely dissociated from the QRS complexes and the PR intervals are variable. The atrial or PP rate (75 beats per minute) is faster than the ventricular or RR rate (30 beats per minute), establishing complete atrioventricular blockade as the etiology. The QRS complexes are wide indicating that the escape rhythm is ventricular.</div><div id=\"graphicVersion\">Graphic 51446 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"51447":{"type":"graphic_picture","displayName":"Normal membranes","title":"Normal membranes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal membranes</div><div class=\"cntnt\"><img style=\"width:400px; height:568px;\" src=\"images/OBGYN/51447_Normal_membranes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal chorioamniotic membrane.<br />(B) Light micrograph illustrating leukocytes extending through the full thickness of choriamniotic membrane.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 51447 Version 3.0</div></div></div>"},"51448":{"type":"graphic_table","displayName":"Dietary fiber in foods","title":"Amount of dietary fiber in common foods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Amount of dietary fiber in common foods</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">&#8805;4 g/serving</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>All bran (1/3 cup)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Blackberries (3/4 cup)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Bran Buds</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Bran Chex</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Corn Bran</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Fiber One</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>100 percent Bran</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Raspberries (1 cup)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Wheat bran (unprocessed or miller's, 1 tbsp)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Wheatena, cooked</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">2 or 3 g/serving</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Beans, baked (canned, 1/4 cup)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Boysenberries (1/3 cup)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Bran flakes, 40 percent</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Raisin bran</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Ry-Krisp (3 triple crackers)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Bran muffin (1 average)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Oat bran (cooked)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Peas, dried (cooked, 1/3 cup)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Popcorn, popped (3 cups)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Pumpkin (3 cups)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Whole-wheat bread, roll, or bun (1 piece)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">1 g/serving</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_single\">Fruits</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Apricot</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Apple</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Grapefruit</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Melon</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Orange</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Peach</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Pear</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Pineapple</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_single\">Vegetables products</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Asparagus</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Beans (string)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Broccoli</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Beets</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Carrots</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Cauliflower</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Greens</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_single\">Whole-grain</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Granola</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Oatmeal</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Pasta (from whole-wheat flour)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Total</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Wheat Chex</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div class=\"graphic_footnotes\">One serving equals 1/2 cup unless noted.</div><div class=\"graphic_reference\">Reproduced with permission from: the American Gastroenterological Association. Gastroenterology 2000; 119:1766.</div><div id=\"graphicVersion\">Graphic 51448 Version 2.0</div></div></div>"},"51450":{"type":"graphic_algorithm","displayName":"Two day method algorithm","title":"Two day method algorithm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two day method algorithm</div><div class=\"cntnt\"><img style=\"width:217px; height:283px;\" src=\"images/OBGYN/51450_Two_day_method_algo_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Arevalo M, Jennings V, Nikula M, Sinai I. Efficacy of the new Two Day Method of family planning. Fertil Steril 2004; 82:885. Copyright © 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 51450 Version 4.0</div></div></div>"},"51451":{"type":"graphic_table","displayName":"VIP germ cell tumors","title":"Cisplatin, etoposide, and ifosfamide for relapsed germ cell tumors (VIP)<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cisplatin, etoposide, and ifosfamide for relapsed germ cell tumors (VIP)<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.<br /> <strong>Total cycles:</strong> 4. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Cisplatin</td> <td>20 mg/m<sup>2</sup> IV per day</td> <td>Dilute with 250 mL normal saline (NS) and administer over one hour. Do not administer with aluminum needles or intravenous sets.</td> <td>Days 1 to 5</td> </tr> <tr> <td>Etoposide*</td> <td>75 mg/m<sup>2</sup> IV per day</td> <td>Dilute with 500 mL NS (concentration &#60;0.4 mg/mL) and administer over one hour.</td> <td>Days 1 to 5</td> </tr> <tr> <td>Ifosfamide*</td> <td>1200 mg/m<sup>2</sup> per day IV infusion over a minimum of 30 minutes</td> <td>Dilute with sterile water for injection to a final concentration of 50 mg/mL.</td> <td>Days 1 to 5</td> </tr> <tr> <td>Mesna</td> <td>120 mg/m<sup>2</sup> IV</td> <td>Dilute with NS for injection and administer via slow IV push prior to day 1 infusion of ifosfamide. Total concentration of mesna should not exceed 20 mg/mL.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Mesna<sup>&#182;</sup></td> <td>1200 mg/m<sup>2</sup> per day continuous IV infusion</td> <td>Dilute with NS for injection and administer as continuous infusion over 24 hours.<sup>[2]</sup> Total concentration of mesna should not exceed 20 mg/mL. Can mix with ifosfamide.</td> <td>Days 1 to 5</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Induction of diuresis using intravenous NS minimizes the risk of cisplatin nephrotoxicity. At least 2000 mL of NS should be administered at a rate of 100 to 125 mL per hour throughout the five days of treatment and continued for at least two hours after the last dose of cisplatin. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% frequency of emesis). </li> <li>Aprepitant can be given orally (125 mg on day 1, 80 mg on days 2 and 3) with ondansetron, prochlorperazine, and dexamethasone daily. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation.<sup>[3]</sup> </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors was administered as a routine component of this regimen.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Dose adjustment in the setting of baseline renal impairment (ie, creatinine &#62;3.0 mg/dL or GFR &#60;50 mL/min) requires a balanced discussion of the goals of treatment and the risks of cisplatin. </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Basic metabolic panel (creatinine and electrolytes) prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Liver function tests prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Cisplatin is associated with significant nephrotoxicity. Ifosfamide is associated with cumulative nephrotoxicity, mostly at a total dose above 60 grams/m<sup>2</sup>. Clinical manifestations may include hypophosphatemia, renal potassium wasting, metabolic acidosis with a normal ion gap, and rarely, polyuria due to nephrogenic diabetes insipidus. Assess creatinine and electrolytes, including potassium and phosphate, daily during treatment and prior to each subsequent treatment cycle. </li> <li>Refer to UpToDate topic on \"Ifosfamide nephrotoxicity\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Mesna does not prevent hemorrhagic cystitis in all patients.<sup>[2]</sup> Monitor a morning specimen of urine for hematuria daily, on days 1 through 5. </li> <li>Refer to UpToDate topic on \"Cystitis in patients with cancer\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for neurotoxicity (confusion, coma, rarely seizures, weakness, neuropathy, ataxia, cranial nerve dysfunction) daily, on days 1 through 5. Central nervous system side effects may be especially problematic for those over age 60. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of non-platinum cancer chemotherapy\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor vital signs during etoposide infusion. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Reduce doses of etoposide and ifosfamide each by 25% for subsequent cycles for granulocytopenic fever or thrombocytopenic bleeding with the previous course of therapy.<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Neuropathy usually is seen after cumulative doses of cisplatin beyond 400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment.<sup>[3]</sup> </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Nephrotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>It is recommended that subsequent doses of cisplatin be withheld until the serum creatinine is &#60;3.0 mg/dL. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; GFR: glomerular filtration rate; CBC: complete blood count.<br />* The initial protocol included empiric reduction of etoposide and ifosfamide doses by 25% for patients who have received prior radiation therapy.<SUP>[1]</SUP><br />¶ Due to a longer half-life of ifosfamide and associated metabolites at higher doses, some references recommend continuation of mesna for 12 to 24 hours beyond completion of ifosfamide to reduce the risk of hemorrhagic cystitis.<SUP>[2]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Nichols CR, et al. J Clin Oncol 1998; 16:1287.</LI>&#xD;&#xA;<LI>MESNA injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed December 20, 2011).</LI>&#xD;&#xA;<LI>Cisplatin injection, powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 20, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 51451 Version 14.0</div></div></div>"},"51455":{"type":"graphic_picture","displayName":"Polymorphous light eruption on face","title":"Polymorphous light eruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Polymorphous light eruption</div><div class=\"cntnt\"><img style=\"width:432px; height:305px;\" src=\"images/DERM/51455_PMLE_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 12-year-old girl developed a pruritic eruption that consisted of discrete and coalescing erythematous papules on the face. The lesions were photodistributed and appeared within hours after intense sun exposure in the spring.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 51455 Version 6.0</div></div></div>"},"51456":{"type":"graphic_table","displayName":"Rapid overview of rapid sequence intubation in children","title":"Rapid overview of rapid sequence intubation in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid overview of rapid sequence intubation in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Preparation: Utilize an active checklist to:</td> </tr> <tr> <td class=\"indent1\">Begin preoxygenation as described below.</td> </tr> <tr> <td class=\"indent1\">Identify conditions that will affect choice of medications (eg, increased intracranial pressure, septic shock, bronchospasm, status epilepticus, or, if succinylcholine use is planned, absolute contraindications for its use as listed below).</td> </tr> <tr> <td class=\"indent1\">Identify conditions that will predict difficult intubation or bag-mask ventilation (eg, small chin, inability to fully open the mouth, upper airway trauma, or infection). </td> </tr> <tr> <td class=\"indent1\">Assemble equipment and check for function.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Develop contingency plan for failed intubation (refer to UpToDate topics on devices for difficult endotracheal intubation).</td> </tr> <tr> <td class=\"subtitle1_single\">Preoxygenation</td> </tr> <tr> <td class=\"indent1\">Begin preoxygenation as soon as rapid sequence intubation is potentially needed: <ul class=\"decimal_heading\"> <li>Spontaneously breathing: 100% FiO<sub>2</sub> (7 L/min oxygen flow) by nonrebreather mask for 3 minutes </li> <li>Apneic or inadequate breathing: Bag-mask ventilation with small tidal breaths using 100% FiO<sub>2</sub> </li> <li>During induction and paralysis, apneic oxygenation via nasal cannula at flow rate of 1 L/kg/min (maximum flow 15 L/min) may be provided </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Administer oxygen at the highest concentration available.</td> </tr> <tr> <td class=\"subtitle1_single\">Pretreatment (optional)</td> </tr> <tr> <td class=\"indent1\">Atropine: Although not routinely recommended, many experts suggest atropine as pretreatment for: <ul class=\"decimal_heading\"> <li>Children &#8804;1 year </li> <li>Children in shock </li> <li>Children &#60;5 years receiving succinylcholine </li> <li>Older children receiving a second dose of succinylcholine </li> </ul> Dose: 0.02 mg/kg IV without a minimum dose (maximum single dose 0.5 mg; if no IV access, can be given IM). </td> </tr> <tr> <td class=\"indent1\">Fentanyl: Optional for increased intracranial pressure in patients with normal or elevated blood pressure. Dose: 1 to 3 mcg/kg given over 30 to 60 seconds to avoid respiratory depression and chest wall rigidity. Give 3 minutes before induction agent is administered.</td> </tr> <tr> <td class=\"indent1\">Lidocaine: Optional for increased intracranial pressure (not recommended for pretreatment in children by some airway experts). Dose: 1 to 2 mg/kg IV (maximum dose 200 mg). Give 2 to 3 minutes before intubation.&nbsp;&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Sedation</td> </tr> <tr> <td class=\"indent1\"> <p>Etomidate:</p> <ul> <li>Safe with hemodynamic instability, neuroprotective, transient adrenal cortico-suppression. Do <strong>not</strong> use routinely in patients with septic shock. </li> <li>Dose: 0.3 mg/kg IV. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <p>Ketamine: </p> <ul> <li>Safe with hemodynamic instability if patient is not catecholamine depleted. Use in patients with bronchospasm and septic shock. Use with <strong>caution </strong>in hypertensive patients with increased intracranial pressure.&nbsp; </li> <li>Dose: 1 to 2 mg/kg IV (if no IV access, can be given IM dose: 3 to 7 mg/kg). </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <p>Propofol:</p> <ul> <li>Causes hypotension. May use in hemodynamically stable patients with status epilepticus. </li> <li>Dose 1 to 1.5 mg/kg IV. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <p>Midazolam:</p> <ul> <li>May use in hemodynamically stable patients with status epilepticus. Time to clinical effect is longer, inconsistently induces unconsciousness. May cause hemodynamic instability at doses required for sedation. </li> <li>Dose: 0.2 to 0.3 mg/kg IV (maximum dose 10 mg, onset of effect requires 2 to 3 minutes). </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <p>Fentanyl:</p> <ul> <li>Optional for cardiogenic shock or catecholamine-depleted shock (eg, persistent hypotension despite vasopressor therapy). Limited evidence in children. </li> <li>Dose 1 to 5 mcg/kg titrated to effect. Start at lower end of range in hypotensive patients. Give over 30 to 60 seconds to avoid respiratory depression or chest wall rigidity. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Thiopental: </p> <ul> <li>Neuroprotective. Do <strong>not </strong>use with hemodynamic instability. </li> <li>Dose: 3 to 5 mg/kg IV.* </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Paralytic</td> </tr> <tr> <td class=\"indent1\"> <p>Rocuronium:</p> <ul> <li>Use for children with contraindication for succinylcholine or as primary paralytic if sugammadex is immediately available. </li> <li>Dose: 1 mg/kg IV.<sup>&#182;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Succinycholine:</p> <ul> <li>Do not use with extensive crush injury with rhabdomyolysis, chronic skeletal muscle disease (eg, Becker muscular dystrophy)&nbsp;or denervating neuromuscular disease (eg, cerebral palsy with paralysis); 48 to 72 hours after burn, multiple trauma, or denervating injury; patients with history or malignant hyperthermia; or pre-existing hyperkalemia. </li> <li>Dose: Infants and children &#8804;2 years: 2 mg/kg IV, older children and adolescents: 1 to 1.5 mg/kg IV (if IV access unobtainable, can be given IM, dose: 3 to 5 mg/kg).<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Protection and positioning</td> </tr> <tr> <td class=\"indent1\">Maintain manual cervical spine immobilization during intubation in the trauma patient.</td> </tr> <tr> <td class=\"indent1\">If cervical spine injury is not potentially present, put the patient in the \"sniffing position\" (ie, head forward so that the external auditory canal is anterior to the shoulder and the nose and mouth point to the ceiling).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Utilize external laryngeal manipulation or, in infants, gentle cricoid pressure to optimize the view of the glottis during direct laryngoscopy if the initial view is suboptimal or inadequate despite correct laryngoscope blade positioning.<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Positioning, with placement</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Confirm tracheal tube placement with end-tidal CO<sub>2</sub> detection and auscultation.</td> </tr> <tr> <td class=\"subtitle1_single\">Postintubation management</td> </tr> <tr> <td class=\"indent1\">Obtain a chest radiograph to confirm the depth of tracheal tube insertion.</td> </tr> <tr> <td class=\"indent1\">Provide ongoing sedation (eg, midazolam), analgesia (eg, fentanyl 1 mcg/kg), and, if indicated, paralysis.<sup>&#167;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">If IV access unobtainable, intraosseous administration of drugs listed is an acceptable alternative.</div><div class=\"graphic_footnotes\">IM: intramuscularly; IV: intravenously.<br />* Not available in many countries, including the United States and Canada.<br />¶ Sugammadex in a dose of&nbsp;16 mg/kg can provide immediate reversal of paralysis when given approximately 3 minutes after a single dose of rocuronium. Vecuronium may be used in children with contraindications to succinylcholine and when rocuronium is not available. Suggested dose for rapid sequence intubation: 0.15 to 0.2 mg/kg. Patients may experience prolonged and unpredictable duration of paralysis at this dose.<br />Δ Defasciculating agents (eg, rocuronium or vecuronium at one-tenth of the paralyzing dose) are not routinely recommended for children receiving succinylcholine. <br />◊&nbsp;Bimanual laryngoscopy, also called external laryngeal manipulation (ELM), entails manipulating the thyroid cartilage or hyoid bone with the right hand during laryngoscopy in order to improve the view of the glottis. For a description of how to perform ELM, refer to topics on emergency endotracheal intubation in children and rapid sequence intubation in children.<br />§&nbsp;If decompensation occurs after successful intubation, use the DOPE mnemonic to find the cause: &#xD;&#xA;<UL>&#xD;&#xA;<LI>D: Dislodgement of the tube (right mainstem or esophageal)</LI>&#xD;&#xA;<LI>O: Obstruction of tube</LI>&#xD;&#xA;<LI>P: Pneumothorax</LI>&#xD;&#xA;<LI>E: Equipment failure (ventilator malfunction, oxygen disconnected or not on)</LI></UL></div><div id=\"graphicVersion\">Graphic 51456 Version 34.0</div></div></div>"},"51458":{"type":"graphic_table","displayName":"Types of bronchoscopy","title":"Relative attributes of rigid, flexible and virtual bronchoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relative attributes of rigid, flexible and virtual bronchoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Rigid</td> <td class=\"subtitle1\">Flexible</td> <td class=\"subtitle1\">Virtual</td> </tr> <tr> <td>Invasiveness</td> <td>+++</td> <td>+++</td> <td>-</td> </tr> <tr> <td>Examination of upper lobe airways</td> <td>-</td> <td>+++</td> <td>+++</td> </tr> <tr> <td>Tissue sampling</td> <td>+++</td> <td>+++</td> <td>-</td> </tr> <tr> <td>Level of anesthesia/sedation</td> <td>+++</td> <td>+</td> <td>-</td> </tr> <tr> <td>Airway stent placement</td> <td>+++</td> <td>++</td> <td>-</td> </tr> <tr> <td>Endobronchial tumor debulking</td> <td>+++</td> <td>+</td> <td>-</td> </tr> <tr> <td>Technology availability</td> <td>+</td> <td>+++</td> <td>+</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51458 Version 3.0</div></div></div>"},"51459":{"type":"graphic_picture","displayName":"Disseminated granuloma annulare - papules","title":"Disseminated granuloma annulare","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disseminated granuloma annulare</div><div class=\"cntnt\"><img style=\"width:432px; height:381px;\" src=\"images/DERM/51459_Disseminated_granuloma_papules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 60 year-old patient with disseminated granuloma annulare presented with hundreds of erythematous papules and plaques on the medial arms, medial thighs, and buttocks. None of the lesions showed central clearing.</div><div id=\"graphicVersion\">Graphic 51459 Version 1.0</div></div></div>"},"51460":{"type":"graphic_picture","displayName":"Erythrodermic sarcoidosis - chest","title":"Erythrodermic sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythrodermic sarcoidosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/51460_Erythrodermic_sarcoidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythrodermic sarcoidosis. This patient has large, geometric, erythematous plaques covering most of the body.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc. Original photo provided by NYU (Tisch) Department of Dermatology.</div><div id=\"graphicVersion\">Graphic 51460 Version 4.0</div></div></div>"},"51462":{"type":"graphic_picture","displayName":"Laparoscopic resection of the crura of the diaphragm","title":"Laparoscopic resection of the crura of the diaphragm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic resection of the crura of the diaphragm</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/SURG/51462_Lapar_resec_crura_diap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This intraoperative photograph shows the Penrose drain around the esophagus. It serves to facilitate dissection of the posterior aspect of the paraesophageal hernia sac. The crura of the diaphragm have been completely dissected using the laparoscopic technique. The arrow indicates the Penrose drain.</div><div class=\"graphic_reference\">Courtesy of Michael Rosen, MD.</div><div id=\"graphicVersion\">Graphic 51462 Version 2.0</div></div></div>"},"51463":{"type":"graphic_table","displayName":"Testing in diabetic pregnancy","title":"Frequency of testing during pregnancy in women with pregestatonal diabetes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of testing during pregnancy in women with pregestatonal diabetes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Frequency</td> </tr> <tr> <td>Hemoglobin A1C</td> <td>Every 4 to 6 weeks</td> </tr> <tr> <td>Blood glucose</td> <td>Home measurements 4 to 8 times daily</td> </tr> <tr> <td>Urine ketones</td> <td>During period of illness; when any blood glucose value is &#62;200 mg/dL (11.1 mmol/L)</td> </tr> <tr> <td>Urine protein</td> <td>Diptstick at office visits, quantitate 24 hour excretion each trimester in women with nephropathy</td> </tr> <tr> <td>Serum creatinine</td> <td>Each trimester in women with nephropathy</td> </tr> <tr> <td>Thyroid function tests</td> <td>Baseline&nbsp;TSH measurement</td> </tr> <tr> <td>Eye examination</td> <td>Baseline and then as necessary per retinal specialist</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TSH: Thyroid stimulating hormone; A1C: Glycated hemoglobin</div><div id=\"graphicVersion\">Graphic 51463 Version 4.0</div></div></div>"},"51464":{"type":"graphic_table","displayName":"Outcomes RT series","title":"Outcome of definitive radiation therapy from contemporary series (in percent)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outcome of definitive radiation therapy from contemporary series (in percent)</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Series\n   </td>\n   <td  class=\"subtitle1\">\n   Median RT dose\n   </td>\n   <td  class=\"subtitle1\">\n   Subsites\n   </td>\n   <td  class=\"subtitle1\">\n   Stage\n   </td>\n   <td  class=\"subtitle1\" colspan=\"2\">\n   Locoregional control\n   </td>\n   <td  class=\"subtitle1\" colspan=\"2\">\n   Disease free survival\n   </td>\n   <td  class=\"subtitle1\">\n   Pattern of failure\n   </td>\n   </tr>\n   <tr>\n   <td  rowspan=\"4\">\n   Gupta 2009<sup>[1]</sup> (n=501)\n   </td>\n   <td  rowspan=\"4\">\n   70 Gy/2 Gy daily\n   </td>\n   <td>74 PS</td>\n   <td>I: 1.6</td>\n   <td  rowspan=\"4\">\n   3y\n   </td>\n   <td>I: 100</td>\n   <td  rowspan=\"4\">\n   3y\n   </td>\n   <td>I: 100</td>\n   <td  rowspan=\"4\">\n   &#62;90 LRF\n   </td>\n   </tr>\n   <tr>\n   <td>14 PPW</td>\n   <td>II: 15.3</td>\n   <td>II: 58</td>\n   <td>II: 54.7</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   10 PC\n   </td>\n   <td>III: 45</td>\n   <td>III: 47.8</td>\n   <td>III: 43.8</td>\n   </tr>\n   <tr>\n   <td>IV: 38</td>\n   <td>IV: 34.7</td>\n   <td>IV: 28.8</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"4\">\n   Johansen 2000<sup>[2]</sup> (n=138)\n   </td>\n   <td  rowspan=\"4\">\n   61 Gy/ 2Gy daily\n   </td>\n   <td>86 PS</td>\n   <td>I: 13</td>\n   <td  rowspan=\"4\">\n   5y\n   </td>\n   <td>I: 41</td>\n   <td  rowspan=\"4\">\n   5y\n   </td>\n   <td>I: 49</td>\n   <td>55 LF (any)</td>\n   </tr>\n   <tr>\n   <td>9 PPW</td>\n   <td>II: 10</td>\n   <td>II: 43</td>\n   <td>II: 42</td>\n   <td>39 RF</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   6 PC\n   </td>\n   <td>III: 38</td>\n   <td>III: 25</td>\n   <td>III: 35</td>\n   <td  rowspan=\"2\">\n   14 DM\n   </td>\n   </tr>\n   <tr>\n   <td>IV: 39</td>\n   <td>IV: 5</td>\n   <td>IV: 4</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"4\">\n   Chen 2008<sup>[3]</sup> (n=108)\n   </td>\n   <td  rowspan=\"4\">\n   70.2 Gy/1.8 Gy daily (81 percent received chemo)\n   </td>\n   <td  rowspan=\"4\">\n   95 PS\n   </td>\n   <td>I: 1.8</td>\n   <td  rowspan=\"4\">\n   5y\n   </td>\n   <td>I/II: 66</td>\n   <td  rowspan=\"4\">\n   5y\n   </td>\n   <td>I/II: 64</td>\n   <td>55 LF (any)</td>\n   </tr>\n   <tr>\n   <td>II: 10.2</td>\n   <td>III: 46</td>\n   <td>III: 43</td>\n   <td>39 RF</td>\n   </tr>\n   <tr>\n   <td>III: 39</td>\n   <td  rowspan=\"2\">\n   IV: 20\n   </td>\n   <td  rowspan=\"2\">\n   IV: 17\n   </td>\n   <td  rowspan=\"2\">\n   14 DM\n   </td>\n   </tr>\n   <tr>\n   <td>IV: 56</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"4\">\n   Nakamura 2006<sup>[4]</sup> (n=115)\n   </td>\n   <td  rowspan=\"4\">\n   63 to 66 Gy/1.5-2 Gy daily OR 63.5 to 70 Gy/1.2 to 1.6 Gy twice daily\n   </td>\n   <td>69.6 PS</td>\n   <td>I: 34</td>\n   <td  rowspan=\"4\">\n   5y\n   </td>\n   <td>I: 77</td>\n   <td  rowspan=\"4\">\n   5y\n   </td>\n   <td>I: 95.8</td>\n   <td>59.5 LF</td>\n   </tr>\n   <tr>\n   <td>18.3 PPW</td>\n   <td  rowspan=\"3\">\n   II: 66\n   </td>\n   <td  rowspan=\"3\">\n   II: 60\n   </td>\n   <td  rowspan=\"3\">\n   II: 70.1\n   </td>\n   <td>21.4 RF</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   5.2 PC\n   </td>\n   <td>11.9 L+RF</td>\n   </tr>\n   <tr>\n   <td>7 DM</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"4\">\n   Rabbani 2008<sup>[5]</sup> (n=123)\n   </td>\n   <td  rowspan=\"4\">\n   74.4 Gy (once a day or twice daily) (10 percent received chemo +ND for N2/3)\n   </td>\n   <td  rowspan=\"4\">\n   100 PS\n   </td>\n   <td>I: 5</td>\n   <td  rowspan=\"4\">\n   5y\n   </td>\n   <td>I/II: 86</td>\n   <td  rowspan=\"4\">\n   5y\n   </td>\n   <td>I/II: 85</td>\n   <td  rowspan=\"4\">\n   95 failure observed within 2y\n   </td>\n   </tr>\n   <tr>\n   <td>II: 15</td>\n   <td>III: 83</td>\n   <td>III: 73</td>\n   </tr>\n   <tr>\n   <td>III: 17</td>\n   <td>IVa: 65</td>\n   <td>IVa: 62</td>\n   </tr>\n   <tr>\n   <td>IV: 63</td>\n   <td>IVb: 24</td>\n   <td>IVb: 22</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">ACB: acclerated concomitant boost; DM: distant metastases; Gy: Gray; LF: local failure; LRF:locoregional failure; ND: neck dissection; PS: piriform sinus; PPW: posterior pharyngeal wall; PC: postcricoid space; RF: regional failure; RT: radiation therapy; y: year.</div><div class=\"graphic_reference\">1. Gupta T, Chopra S, Agarwal JP, et al. Squamous cell carcinoma of the hypopharynx: single-institution outcome analysis of a large cohort of patients treated with primary non-surgical approaches. Acta Oncol 2009; 48:541.<br>2. Johansen LV, Grau C, Overgaard J. Hypopharyngeal squamous cell carcinoma: treatment results in 138 consecutively admitted patients. Acta Oncol 2000; 39:529.<br>3. Chen SW, Tsai MH, Yang SN, et al. Hypopharyngeal cancer treatment based on definitive radiotherapy: who is suitable for laryngeal preservation? J Laryngol Otol 2008; 122:506.<br>4. Nakamura K, Shioyama Y, Kawashima M, et al. Multi-institutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2006; 65:1045.<br>5. Rabbani A, Amdur RJ, Mancuso AA, et al. Definitive radiotherapy for T1-T2 squamous cell carcinoma of pyriform sinus. Int J Radiat Oncol Biol Phys 2008; 72:351.</div><div id=\"graphicVersion\">Graphic 51464 Version 1.0</div></div></div>"},"51465":{"type":"graphic_table","displayName":"Causes of acute upper airway obstruction in children","title":"Differential diagnosis of acute upper airway obstruction in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of acute upper airway obstruction in children</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Condition\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Characteristic features\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Radiographic features\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Epiglottitis (supraglottitis)</td>\r\n  \r\n   <td>Fever, toxic appearance; anxiety out of proportion to degree of respiratory distress; \"tripod\" and/or \"sniffing\" posture; drooling</td>\r\n  \r\n   <td>Swollen epiglottis (\"thumb sign\") on lateral neck radiograph</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Laryngotracheitis (croup)</td>\r\n  \r\n   <td>Typically occurs in children 6 to 36 months; \"barking\" cough, stridor; \"steeple sign\" on anteroposterior neck radiograph</td>\r\n  \r\n   <td>\t<p>Tapering of upper airway (\"steeple sign\") on anteroposterior neck radiograph</p>\n\t<p>    \t\tSubglottic narrowing and distended hypopharynx on lateral neck radiograph</p>\n</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bacterial tracheitis</td>\r\n  \r\n   <td>Fever, toxic appearance</td>\r\n  \r\n   <td>Intraluminal membranes and tracheal wall irregularity</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Uvulitis</td>\r\n  \r\n   <td>Swelling and erythema of the uvula</td>\r\n  \r\n   <td>Radiographs usually not necessary</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Foreign body</td>\r\n  \r\n   <td>History of sudden onset of choking (though this history is frequently absent); hoarseness or stridor with laryngeal or upper esophageal foreign body</td>\r\n  \r\n   <td>Visualization of radio-opaque foreign body; upper esophageal foreign body may cause distortion or deviation of extrathoracic trachea</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Retropharyngeal abscess</td>\r\n  \r\n   <td>Typically occurs in children aged two to four years; neck pain, fever, pain with swallowing; drooling; unwillingness to move the neck; trismus; midline or unilateral swelling of posterior pharyngeal wall</td>\r\n  \r\n   <td>Widening of the retropharyngeal space and reversal of the normal cervical spine curvature</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Peritonsillar abscess</td>\r\n  \r\n   <td>Typically occurs in older children and adolescents; drooling; trismus; muffled voice; tonsillar swelling with deviation of the uvula</td>\r\n  \r\n   <td>Radiographs usually not necessary for diagnosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Angioedema</td>\r\n  \r\n   <td>Rapid onset without prodromal viral illness; swelling of lips and tongue; urticarial rash; dysphagia without hoarseness; possible history of previous attack</td>\r\n  \r\n   <td>Radiographs usually not necessary for diagnosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Congenital anomalies (eg, laryngeal web, laryngomalacia)</td>\r\n  \r\n   <td>Generally have a chronic course and lack systemic symptoms (unless airway narrowing is exacerbated by concomitant infection)</td>\r\n  \r\n   <td>Radiographs usually not necessary for diagnosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Respiratory diphtheria</td>\r\n  \r\n   <td>Gradual onset of symptoms: sore throat, malaise, and low-grade fever; presence of diphtheritic membrane</td>\r\n  \r\n   <td>Radiographs usually not necessary for diagnosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Thermal or chemical injury</td>\r\n  \r\n   <td>History of exposure; lack of fever or prodromal illness</td>\r\n  \r\n   <td>Radiographs usually not necessary for diagnosis</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=51384&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>DDx_acute_airway_obs_child.htm</title></head></div><div id=\"graphicVersion\">Graphic 51465 Version 3.0</div></div></div>"},"51466":{"type":"graphic_diagnosticimage","displayName":"Elevated right hemidiaphragm","title":"Eventration of the diaphragm in a neonate","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Eventration of the diaphragm in a neonate</div><div class=\"cntnt\"><img style=\"width:507px; height:210px;\" src=\"images/PEDS/51466_Elevated_right_hemidiaphrag.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anteroposterior and lateral views of the chest demonstrating an elevated right hemidiaphragm in a neonate. On the lateral view, the anterior and posterior diaphragmatic attachments are in the correct positions. With diaphragmatic paralysis, the elevated hemidiaphragm would be uniformly elevated.</div><div class=\"graphic_reference\">Courtesy of the Department of Diagnostic Imaging, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 51466 Version 3.0</div></div></div>"},"51467":{"type":"graphic_figure","displayName":"Musculoskeletal screen 1","title":"The pGALS musculoskeletal screen","html":"<div class=\"graphic\"><div style=\"width: 609px\" class=\"figure\"><div class=\"ttl\">The pGALS musculoskeletal screen</div><div class=\"cntnt\"><img style=\"width:589px; height:780px;\" src=\"images/PEDS/51467_Musculoskeletal_screen_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">pGALS: pediatric Gait Arms Legs Spine.</div><div class=\"graphic_reference\">Reproduced with permission from: Foster HE, Jandial S. pGALS - A Screening Examination of the Musculoskeletal System in School-Aged Children. Reports on the Rheumatic Diseases (Series 5), Hands On 15. Arthritis Research Campaign; 2008 June. Copyright &copy; 2008 Arthritis Research Campaign.</div><div id=\"graphicVersion\">Graphic 51467 Version 3.0</div></div></div>"},"51469":{"type":"graphic_diagnosticimage","displayName":"Extending perinephric abscess","title":"Extensive perinephric abscess on computed tomography scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extensive perinephric abscess on computed tomography scan</div><div class=\"cntnt\"><img style=\"width:369px; height:277px;\" src=\"images/ID/51469_Extending_perinephric_absce.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic scan of a right perinephric phlegmon with extension toward the flank wall.</div><div class=\"graphic_reference\">Courtesy of Olivier Helenon, MD, Hopital Necker, Paris.</div><div id=\"graphicVersion\">Graphic 51469 Version 3.0</div></div></div>"},"51470":{"type":"graphic_table","displayName":"GBS antigens for vaccine use","title":"Potential antigens of group B streptococcus for use as vaccines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential antigens of group B streptococcus for use as vaccines</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Antigen</td> <td class=\"subtitle1\" rowspan=\"2\">Virulence factor</td> <td class=\"subtitle1\" colspan=\"2\">Studies performed with prototype vaccines:</td> </tr> <tr> <td class=\"subtitle2\">Preclinical</td> <td class=\"subtitle2\">Clinical</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Carbohydrates</td> </tr> <tr> <td class=\"indent1\">group B antigen</td> <td>no</td> <td>yes</td> <td>no</td> </tr> <tr> <td class=\"indent1\">Ia CPS</td> <td>yes</td> <td>yes</td> <td>Phases 1 and 2</td> </tr> <tr> <td class=\"indent1\">Ib CPS</td> <td>yes</td> <td>yes</td> <td>Phases 1 and 2</td> </tr> <tr> <td class=\"indent1\">II CPS</td> <td>yes</td> <td>yes</td> <td>Phases 1 and 2</td> </tr> <tr> <td class=\"indent1\">III CPS</td> <td>yes</td> <td>yes</td> <td>Phases 1 and 2</td> </tr> <tr> <td class=\"indent1\">V CPS</td> <td>yes</td> <td>yes</td> <td>Phase 1</td> </tr> <tr> <td class=\"indent1\">VI CPS</td> <td>yes</td> <td>yes</td> <td>no</td> </tr> <tr> <td class=\"indent1\">VIII CPS</td> <td>yes</td> <td>yes</td> <td>no</td> </tr> <tr> <td class=\"indent1\">IX CPS&nbsp;</td> <td>?</td> <td>no&nbsp;</td> <td>no&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Proteins</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"4\">C proteins </td> </tr> <tr> <td class=\"sublist2\">alpha</td> <td class=\"sublist_other\">yes </td> <td class=\"sublist_other\">yes</td> <td class=\"sublist_other\">no</td> </tr> <tr> <td class=\"sublist2\">beta</td> <td class=\"sublist_other\">?</td> <td class=\"sublist_other\">yes</td> <td class=\"sublist_other\">no</td> </tr> <tr> <td class=\"sublist2\">epsilon</td> <td class=\"sublist_other\">?</td> <td class=\"sublist_other\">no</td> <td class=\"sublist_other\">no</td> </tr> <tr> <td class=\"indent1\">Rib</td> <td>?</td> <td>yes</td> <td>no</td> </tr> <tr> <td class=\"indent1\">R-proteins</td> <td>?</td> <td>no</td> <td>no</td> </tr> <tr> <td class=\"indent1\">Type V/VIII alpha-like proteins</td> <td>?</td> <td>yes</td> <td>no</td> </tr> <tr> <td class=\"indent1\">C5a peptidase</td> <td>?</td> <td>yes</td> <td>no</td> </tr> <tr> <td class=\"indent1\">Sip</td> <td>?</td> <td>yes</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">LrrG&nbsp;</td> <td>yes&nbsp;</td> <td>yes&nbsp;</td> <td>no&nbsp;</td> </tr> <tr> <td class=\"indent1\">Pili</td> <td>yes&nbsp;</td> <td>yes&nbsp;</td> <td>no&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CPS: capsular polysaccharide.</div><div id=\"graphicVersion\">Graphic 51470 Version 3.0</div></div></div>"},"51471":{"type":"graphic_picture","displayName":"Negri bodies in rabies","title":"Negri body in rabies","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Negri body in rabies</div><div class=\"cntnt\"><img style=\"width:539px; height:215px;\" src=\"images/ID/51471_Negri_bodies_in_rabies.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A shows a neuron without Negri bodies, while panel B shows a Negri body in infected neuron (arrow). Panel C shows a Negri body in Sellers stained brain tissue with dark blue basophilic granules in the inclusion.</div><div class=\"graphic_reference\">Reproduced from: http://www.cdc.gov/ncidod/dvrd/rabies/diagnosis/diagnosi.htm. Centers for Disease Control and Prevention.</div><div id=\"graphicVersion\">Graphic 51471 Version 1.0</div></div></div>"},"51472":{"type":"graphic_movie","displayName":"TEE LA thrombus and spontaneous echo contrast","title":"Transesophageal echocardiogram (TEE) showing left atrial (LA) thrombus and spontaneous echo contrast","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiogram (TEE) showing left atrial (LA) thrombus and spontaneous echo contrast</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/51472_teelatt2conv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:259px; height:226px;\" src=\"images/CARD/51472_teelatt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram shows a large thrombus in the left atrium. Spontaneous echo contrast can also be seen in the left atrium.</div><div id=\"graphicVersion\">Graphic 51472 Version 4.0</div></div></div>"},"51473":{"type":"graphic_figure","displayName":"Predicted survival of PD pts according to KtV","title":"Graph showing predicted probability of survival among CAPD patients according to weekly Kt/V","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Graph showing predicted probability of survival among CAPD patients according to weekly Kt/V</div><div class=\"cntnt\"><img style=\"width:481px; height:327px;\" src=\"images/NEPH/51473_PDsurvivalandKtV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Predicted probability of survival in patients treated with continuous peritoneal dialysis according to the weekly Kt/V. A progressive decline in two-year survival is noted at lower values for Kt/V. The values were 81% at a Kt/V of 2.3 versus only 66% at a Kt/V of 1.5.</div><div class=\"graphic_footnotes\">CAPD: continuous ambulatory peritoneal dialysis.</div><div class=\"graphic_reference\">Data from CANADA-USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes.&nbsp;J Am Soc Nephrol 1996; 7:198.</div><div id=\"graphicVersion\">Graphic 51473 Version 5.0</div></div></div>"},"51474":{"type":"graphic_diagnosticimage","displayName":"Cavum septum pellucidum","title":"Cavum septum pellucidum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cavum septum pellucidum</div><div class=\"cntnt\"><img style=\"width:432px; height:283px;\" src=\"images/OBGYN/51474_Cavum_septum_pellucidum_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial view of the fetal head at the level used to measure the biparietal diameter and head circumference. The cavum septum pellucidum (large arrow) and slit-like third ventricle (short arrow) are indicated.</div><div class=\"graphic_footnotes\">HC: head circumference.</div><div class=\"graphic_reference\">Courtesy of Andrew P MacKenzie, MD.</div><div id=\"graphicVersion\">Graphic 51474 Version 5.0</div></div></div>"},"51475":{"type":"graphic_picture","displayName":"Gastric xanthoma CPC Light","title":"Gastric xanthoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric xanthoma</div><div class=\"cntnt\"><img style=\"width:385px; height:567px;\" src=\"images/GAST/51475_Gastric_xanthoma_CPC_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At low power (upper panel), the lamina propria of the surface/foveolar zone is expanded by a cellular infiltrate. The epithelium is normal. At high power (lower panel), the infiltrate consists of cells with small central benign nuclei and copious faintly basophilic cytoplasm. On immunostaining, these cells are CD68-positive, thus defining them as macrophages. The cytoplasm contains phagocytized lipid material. The appearance is typical of a gastric xanthoma. Similar endoscopic findings are seen in granular cell tumors and muciphages. Gastric xanthomas are sessile, yellow nodules, usually diminutive (&lt;5 mm) in size, confined to the mucosa. This represents accumulation of lipid in macrophages. Gastric xanthomas have no malignant potential.</div><div class=\"graphic_reference\">Courtesy of Heather Crowley, MD and Donald Antonioli, MD.</div><div id=\"graphicVersion\">Graphic 51475 Version 2.0</div></div></div>"},"51478":{"type":"graphic_picture","displayName":"Normal marrow aspirate low","title":"Normal bone marrow aspirate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal bone marrow aspirate</div><div class=\"cntnt\"><img style=\"width:372px; height:252px;\" src=\"images/HEME/51478_Normal_marrow_aspirate_low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate smear from a normal individual, as seen under low power (60x). The majority of cells in this field belong to the granulocyte series. (Wright Giemsa stain).</div><div class=\"graphic_reference\">Courtesy of David S Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 51478 Version 1.0</div></div></div>"},"51479":{"type":"graphic_picture","displayName":"Gross phyllodes tumor","title":"Cut surface of phyllodes tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cut surface of phyllodes tumor</div><div class=\"cntnt\"><img style=\"width:390px; height:273px;\" src=\"images/SURG/51479_Gross_phyllodes_tumor.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51479 Version 2.0</div></div></div>"},"51480":{"type":"graphic_diagnosticimage","displayName":"Hypoechoic nodule","title":"Hypoechoic nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypoechoic nodule</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/ENDO/51480_Hypoechoic_nodule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a transverse view of the thyroid gland (T) that shows a 3.2&nbsp;x 1.2 cm hypoechoic, pre-tracheal nodule (+ --- +) in the right lobe/isthmus (I). A tracheal cartilage (TC) is seen anterior to air-artifact in the trachea, which obscures the image and the structures deep to it. Muscles (M)&nbsp;are seen. A 14.0 MHz transducer was used.</div><div id=\"graphicVersion\">Graphic 51480 Version 3.0</div></div></div>"},"51481":{"type":"graphic_figure","displayName":"MUNE incremental stimulation","title":"Motor unit number estimation (MUNE) by the incremental stimulation method","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Motor unit number estimation (MUNE) by the incremental stimulation method</div><div class=\"cntnt\"><img style=\"width:523px; height:463px;\" src=\"images/NEURO/51481_MUNE-incremental-stimulation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Setup for recording from the biceps brachii with proximal stimulation of the musculocutaneous nerve (right). Superimposed waveforms, obtained following a series of progressively increasing stimuli (top left), are shown with the full CMAP (bottom left). The amplitudes of each waveform increment are measured and then averaged to obtain the average SMUAP amplitude. The full CMAP amplitude is then divided by the average SMUAP amplitude to derive the MUNE.</div><div class=\"graphic_footnotes\">MUNE: motor unit number estimation; CMAP: compound muscle action potential; SMUAP: single motor unit action potential.</div><div class=\"graphic_reference\">Courtesy of Jeremy Shefner, MD, PhD.</div><div id=\"graphicVersion\">Graphic 51481 Version 4.0</div></div></div>"},"51482":{"type":"graphic_figure","displayName":"Random effects model","title":"Random effects model","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">Random effects model</div><div class=\"cntnt\"><img style=\"width:620px; height:452px;\" src=\"images/PC/51482_Random_effects_model_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This model assumes that there are multiple treatment effects and that each trial provides an estimate of its own true effect.</div><div class=\"graphic_footnotes\">RD: risk difference; OR: odds ratio; RR: relative risk.</div><div class=\"graphic_reference\">Courtesy of Joseph Lau, MD.</div><div id=\"graphicVersion\">Graphic 51482 Version 4.0</div></div></div>"},"51483":{"type":"graphic_figure","displayName":"Tricuspid regurg outcome HF","title":"Tricuspid regurgitation predicts poorer outcome in HF","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Tricuspid regurgitation predicts poorer outcome in HF</div><div class=\"cntnt\"><img style=\"width:457px; height:286px;\" src=\"images/CARD/51483_Tricuspid_regurg_outcome_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 117 patients with heart failure (HF), the presence of tricuspid regurgitation (TR) on echocardiography was associated with a lower one year event free survival (30 versus 68 percent in the absence of TR, p = 0.002).</div><div class=\"graphic_reference\">Data from: Hung J, Koelling T, Semigran MJ, et al. Am J Cardiol 1998; 82:1301.</div><div id=\"graphicVersion\">Graphic 51483 Version 2.0</div></div></div>"},"51484":{"type":"graphic_algorithm","displayName":"Initial burn management","title":"Initial burn management","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Initial burn management</div><div class=\"cntnt\"><img style=\"width:572px; height:732px;\" src=\"images/EM/51484_Initial_burn_management.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* ABCDE: Airway, Breathing, Circulation, Disability (neurologic evaluation), Exposure.<br />&#182; Refer to topics on the emergency care of moderate to severe burns.</div><div class=\"graphic_reference\">Data from: Practice Guidelines for burn care. J Burn Care Rehabil 2001.</div><div id=\"graphicVersion\">Graphic 51484 Version 3.0</div></div></div>"},"51485":{"type":"graphic_figure","displayName":"Nerves of the male perineum","title":"Nerves of the male perineum","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Nerves of the male perineum</div><div class=\"cntnt\"><img style=\"width:540px; height:539px;\" src=\"images/PC/51485_Nerves_perineum_male.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51485 Version 2.0</div></div></div>"},"51486":{"type":"graphic_figure","displayName":"Tissue specific knockout const","title":"Schematic of tissue-specific knockout mouse construction","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Schematic of tissue-specific knockout mouse construction</div><div class=\"cntnt\"><img style=\"width:489px; height:347px;\" src=\"images/PC/51486_Tissue_specific_knockout_co.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Robert D Blank, MD, PhD.</div><div id=\"graphicVersion\">Graphic 51486 Version 1.0</div></div></div>"},"51488":{"type":"graphic_diagnosticimage","displayName":"Interstitial sarcoidosis CT","title":"Sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Sarcoidosis</div><div class=\"cntnt\"><img style=\"width:503px; height:233px;\" src=\"images/PULM/51488_Interstitial_sarcoidosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left: The chest radiograph shows interstitial disease (multiple small nodules in the mid-to-upper zones) with shrinking hilar nodes (Stage III). Right: HRCT shows the beaded or irregular thickening of the bronchovascular bundles, with nodules along bronchi, vessels, and subpleural regions.</div><div class=\"graphic_footnotes\">HRCT: high resolution computed tomography.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 51488 Version 3.0</div></div></div>"},"51489":{"type":"graphic_diagnosticimage","displayName":"Sand bronchogram CXR","title":"Sand tracheobronchogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sand tracheobronchogram</div><div class=\"cntnt\"><img style=\"width:371px; height:276px;\" src=\"images/PULM/51489_Sand_bronchogram_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postmortem chest radiograph from a surfer shows high attenuation material outlining the tracheobronchial tree.</div><div id=\"graphicVersion\">Graphic 51489 Version 2.0</div></div></div>"},"51490":{"type":"graphic_table","displayName":"Predictors of complications at the time of coronary angiography","title":"Multivariate predictors of major complications of coronary angiography (based on 58,332 procedures)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Multivariate predictors of major complications of coronary angiography (based on 58,332 procedures)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Variable</td>\n\n      <td class=\"subtitle1\">Odds ratio</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Moribund</td>\n\n      <td>10.22</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Shock</td>\n\n      <td>6.52</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acute MI &#60;24 h</td>\n\n      <td>4.03</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Renal insufficiency</td>\n\n      <td>3.30</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiomyopathy </td>\n\n      <td>3.29</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Aortic valve disease</td>\n\n      <td>2.72</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mitral valve disease </td>\n\n      <td>2.33</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Heart failure </td>\n\n      <td>2.33</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">New York Heart Association Functional</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Class I</td>\n\n      <td class=\"sublist_other\">1.00</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Class II</td>\n\n      <td class=\"sublist_other\">1.15</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Class III</td>\n\n      <td class=\"sublist_other\">1.32</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Class IV </td>\n\n      <td class=\"sublist_other\">1.52</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hypertension</td>\n\n      <td>1.45</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Unstable angina</td>\n\n      <td>1.42</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Outpatient/inpatient</td>\n\n      <td>0.63</td>\n\n    </tr>\n\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">2.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=7279&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Predictors_complications_an.htm</title></head></div><div class=\"graphic_lgnd\">Moribund indicates a patient who responds poorly due to a life threatening condition.</div><div class=\"graphic_footnotes\">MI: myocardial infarction.</div><div class=\"graphic_reference\">Redrawn from: Scanlon, PJ, Faxon, DP, Audet, AM, et al, J Am Coll Cardiol 1999; 33:1756.</div><div id=\"graphicVersion\">Graphic 51490 Version 3.0</div></div></div>"},"51492":{"type":"graphic_waveform","displayName":"ECG Mobitz II heart block","title":"II ECG of mobitz II second degree heart block","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">II ECG of mobitz II second degree heart block</div><div class=\"cntnt\"><img style=\"width:538px; height:123px;\" src=\"images/CARD/51492_ECG_Mobitz_II_heart_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lead II rhythm strip shows four sinus beats with P wave followed by a QRS complex; the fifth P wave is not followed by a QRS complex and represents second degree heart block. There is no change in the PR interval prior to or after the blocked P wave and thus this is Mobitz II second degree heart block. A second episode of second degree heart block can be seen after the seventh QRS complex.</div><div class=\"graphic_reference\">Reproduced with permission by Samuel Levy, MD.</div><div id=\"graphicVersion\">Graphic 51492 Version 2.0</div></div></div>"},"51493":{"type":"graphic_picture","displayName":"Armpit stretch PI","title":"Armpit stretch","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Armpit stretch</div><div class=\"cntnt\"><img style=\"width:305px; height:335px;\" src=\"images/PI/51493_Armpit_stretch_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Use your good arm to lift the affected arm onto a shelf, dresser, or other object that is chest high. Gently bend at the knees, so that your armpit stretches open. Try to push the arm up a little bit farther with each stretch. Repeat this stretch 10 to 20 times.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 51493 Version 3.0</div></div></div>"},"51494":{"type":"graphic_figure","displayName":"Holoprosencephaly development","title":"Holoprosencephaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Holoprosencephaly</div><div class=\"cntnt\"><img style=\"width:378px; height:340px;\" src=\"images/PEDS/51494_Holoprosencephaly_developme.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Kawamoto HK Jr, Pravin-Kumar KP, Atypical facial clefts. In: Pediatric Plastic Surgery, Bentz M (Ed), Appleton Lange, Stamford, CT 1998. p.184. Copyright &copy;1998 The McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 51494 Version 2.0</div></div></div>"},"51495":{"type":"graphic_diagnosticimage","displayName":"Scimitar syndrome","title":"Magnetic resonance angiogram of scimitar syndrome","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance angiogram of scimitar syndrome</div><div class=\"cntnt\"><img style=\"width:485px; height:615px;\" src=\"images/PEDS/51495_Scimitar_syndrome_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) View from the front of the patient.<br> (B) View from the back of the patient.<br> (C) Reconstruction of the scimitar vein and its relationship to the pulmonary arteries.</div><div class=\"graphic_reference\">Courtesy of Brian Soriano, MD.</div><div id=\"graphicVersion\">Graphic 51495 Version 4.0</div></div></div>"},"51497":{"type":"graphic_picture","displayName":"NASH Light","title":"Nonalcoholic steatohepatitis on biopsy","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Nonalcoholic steatohepatitis on biopsy</div><div class=\"cntnt\"><img style=\"width:543px; height:165px;\" src=\"images/GAST/51497_NASH_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histologic changes in nonalcoholic steatohepatitis (NASH). Left panel: The hepatocyte in the center contains a large vacuole of fat and deeply staining eosinophilic strands of cytoplasmic hyalin. Numerous neutrophils and phagocytic cells containing golden brown pigmented material (bile components and cellular debris) are present in the sinusoids. Right panel: NASH with cirrhosis. Trichrome stain shows regenerating nodules with fat surrounded by fibrous tissue.</div><div id=\"graphicVersion\">Graphic 51497 Version 2.0</div></div></div>"},"51498":{"type":"graphic_figure","displayName":"Use of calcium channel blockers","title":"Increasing use of longer-acting dihydropyridines","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Increasing use of longer-acting dihydropyridines</div><div class=\"cntnt\"><img style=\"width:410px; height:280px;\" src=\"images/NEPH/51498_Use_of_calcium_channel_bloc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Introduction and growth of new prescriptions of differing formulations of nifedipine and of amlodipine since 1986. Nifedipine was only available in the United States as a short-acting formulation in the late 1980s. The slow-release GITS (gastrointestinal therapeutic system) formulation of nifedipine was not introduced until 1989, and its usage did not increase appreciably until 1991-1992; the usage of amlodipine began to increase in 1993.</div><div class=\"graphic_reference\">Data from Epstein, M, Am J Hypertens 1996;9:110.</div><div id=\"graphicVersion\">Graphic 51498 Version 1.0</div></div></div>"},"51502":{"type":"graphic_waveform","displayName":"Electrical alternans tutorial","title":"Electrical alternans","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Electrical alternans</div><div class=\"cntnt\"><img style=\"width:504px; height:123px;\" src=\"images/CARD/51502_Electrical_alternans_tutori.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Every other QRS complex has a reduced amplitude alternating with a higher amplitude.</div><div id=\"graphicVersion\">Graphic 51502 Version 2.0</div></div></div>"},"51504":{"type":"graphic_table","displayName":"Guidelines pacemaker type","title":"Guidelines for choice of pacemaker generator in selected indications for pacing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for choice of pacemaker generator in selected indications for pacing</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type of pacemaker</td> <td class=\"subtitle1\">Sinus node dysfunction</td> <td class=\"subtitle1\">AV block</td> <td class=\"subtitle1\">Neurally-mediated syncope or carotid sinus hypersensitivity</td> </tr> <tr> <td>Single-chamber atrial</td> <td>No suspected abnormality of AV conduction and not at increased risk for future AV block<br /> <br /> Maintenance of AV synchrony during pacing desired<br /> <br /> Rate response available if desired</td> <td>Not appropriate</td> <td>Not appropriate (unless AV block systematically excluded)</td> </tr> <tr> <td>Single-chamber ventricular</td> <td>Maintenance of AV synchrony during pacing not necessary<br /> <br /> Rate response available if desired</td> <td>Chronic atrial fibrillation or other atrial tachyarrhythmia or maintenance of AV synchrony during pacing not necessary<br /> <br /> Rate response available if desired</td> <td>Chronic atrial fibrillation or other atrial tachyarrhythmia<br /> <br /> Rate response available if desired</td> </tr> <tr> <td>Dual-chamber</td> <td>AV synchrony during pacing desired<br /> <br /> Suspected abnormality of AV conduction or increased risk for future AV block<br /> <br /> Rate response available if desired</td> <td>AV synchrony during pacing desired<br /> <br /> Atrial pacing desired<br /> <br /> Rate response available if desired</td> <td>Sinus mechanism present<br /> <br /> Rate response available if desired</td> </tr> <tr> <td>Single-lead, atrial-sensing ventricular</td> <td>Not appropriate</td> <td>Normal sinus node function and no need for atrial pacing<br /> <br /> Desire to limit number of pacemaker leads</td> <td>Not appropriate</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AV: atrioventricular.</div><div class=\"graphic_reference\">Data from Gregoratos G, Cheitlin MD, Conill A, et al. Circulation 1998; 97:1325.</div><div id=\"graphicVersion\">Graphic 51504 Version 3.0</div></div></div>"},"51505":{"type":"graphic_diagnosticimage","displayName":"Retropharyngeal abscess CT","title":"Retro- and parapharyngeal abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retro- and parapharyngeal abscess</div><div class=\"cntnt\"><img style=\"width:340px; height:302px;\" src=\"images/PEDS/51505_Retropharyngeal_abscess_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This contrast-enhanced&nbsp;computed tomography of the neck&nbsp;shows retro- and parapharyngeal abscess (A, B)&nbsp;as indicated by&nbsp;a low-density core, soft-tissue swelling, obliterated fat planes, mass effect, and rim enhancement.</div><div id=\"graphicVersion\">Graphic 51505 Version 4.0</div></div></div>"},"51507":{"type":"graphic_figure","displayName":"Needle aspiration of an auricular hematoma","title":"Needle aspiration of an auricular hematoma","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Needle aspiration of an auricular hematoma</div><div class=\"cntnt\"><img style=\"width:536px; height:283px;\" src=\"images/EM/51507_Needleaspiration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After cleansing and provision of local anesthesia, the most flucutant part of the hematoma is identified and aspirated using an 18 gauge needle while simultaneously milking the hematoma to ensure complete drainage (A) OR, for large hematomas or those that are over 24 hours but less than seven days old, incise along the curvature of the auricle at the base of the hematoma (B)&nbsp;and use curved hemostats to completely evacuate the hematoma and any clots (C).</div><div id=\"graphicVersion\">Graphic 51507 Version 5.0</div></div></div>"},"51512":{"type":"graphic_table","displayName":"Causes of wide QRS tachycardia","title":"Causes of a wide QRS complex tachycardia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of a wide QRS complex tachycardia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Ventricular tachycardia (VT)</td> </tr> <tr> <td class=\"sublist1_start\">Any type of supraventricular tachycardia (SVT) with a preexistent bundle branch block or a rate-related (functional) bundle branch block</td> </tr> <tr> <td class=\"sublist1\">Sinus tachycardia</td> </tr> <tr> <td class=\"sublist1\">Atrial tachycardia</td> </tr> <tr> <td class=\"sublist1\">Atrial flutter</td> </tr> <tr> <td class=\"sublist1\">Atrioventricular nodal reentrant tachycardia</td> </tr> <tr> <td class=\"sublist1\">Atrioventricular reentrant tachycardia (orthodromic)</td> </tr> <tr> <td>Any SVT which occurs in a patient receiving an antiarrhythmic drug, primarily class IA or IC, or in a patient with severe hyperkalemia</td> </tr> <tr> <td class=\"sublist1_start\">Any SVT with antegrade conduction via an accessory pathway (Wolff-Parkinson-White syndrome)</td> </tr> <tr> <td class=\"sublist1\">Sinus tachycardia</td> </tr> <tr> <td class=\"sublist1\">Atrial tachycardia</td> </tr> <tr> <td class=\"sublist1\">Atrial flutter </td> </tr> <tr> <td class=\"sublist1\">Atrioventricular reentrant tachycardia (antidromic)</td> </tr> <tr> <td>Electronic pacemaker in certain specific settings</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51512 Version 2.0</div></div></div>"},"51513":{"type":"graphic_table","displayName":"Clin features Crohns children","title":"Presenting signs and symptoms in the patient with Crohn disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Presenting signs and symptoms in the patient with Crohn disease</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Intestinal\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Growth failure/pubertal delay</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Weight loss</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Diarrhea</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Abdominal pain</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Abdominal mass</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Rectal bleeding</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Perianal fissures/fistulae</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Extraintestinal\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Arthritis/arthralgia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Erythema nodosum</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Fever</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Oral ulcers</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Anemia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Clubbing</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Oxalate kidney stones</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Abnormal liver function tests</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Eye inflammation (uveitis)</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 51513 Version 1.0</div></div></div>"},"51514":{"type":"graphic_figure","displayName":"Potential source GH excess","title":"Potential sources of growth hormone excess within the GH axis","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Potential sources of growth hormone excess within the GH axis</div><div class=\"cntnt\"><img style=\"width:521px; height:552px;\" src=\"images/PEDS/51514_Potential_source_GH_excess.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) normal axis; (B) increased hypothalamic GHRH secretion; (C) increased pituitary GH secretion; (D) decreased somatostatin tone.</div><div class=\"graphic_footnotes\">GHRH: growth-hormone releasing hormone; SS: somatostatin; GH: growth hormone; IGF-1: insulin-like growth factor-1.</div><div class=\"graphic_reference\">Courtesy of Erica A Eugster, MD and Ora H Pescovitz, MD.</div><div id=\"graphicVersion\">Graphic 51514 Version 2.0</div></div></div>"},"51517":{"type":"graphic_picture","displayName":"Focal lymphangioma of the tongue","title":"Focal lymphangioma of the tongue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Focal lymphangioma of the tongue</div><div class=\"cntnt\"><img style=\"width:396px; height:329px;\" src=\"images/PEDS/51517_Tongue_lymphangioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Raised area of central tongue caused by infiltration of tongue muscle by dilated lymphatic channels.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 51517 Version 3.0</div></div></div>"},"51520":{"type":"graphic_figure","displayName":"Transureteroureterostomy","title":"Transureteroureterostomy","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Transureteroureterostomy</div><div class=\"cntnt\"><img style=\"width:466px; height:581px;\" src=\"images/SURG/51520_Transureteroureterostomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure represents an end-to-side transureteroureterostomy. The injury occured in the middle portion of the ureter, and the ureter is brought across the midline for an anastomosis into an uninterrupted ureter. </div><div id=\"graphicVersion\">Graphic 51520 Version 3.0</div></div></div>"},"51521":{"type":"graphic_picture","displayName":"Chair stand exercise","title":"Strength exercise: Chair stand","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Strength exercise: Chair stand</div><div class=\"cntnt\"><img style=\"width:371px; height:306px;\" src=\"images/PC/51521_Chair_stand_exercise_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This exercise, which strengthens your abdomen and thighs, will make it easier to get in and out of the car. If you have knee or back problems, talk with your doctor before trying this exercise. <ol> <li>Sit toward the front of a sturdy, armless chair with knees bent and feet flat on floor, shoulder-width apart. </li> <li>Lean back with your hands crossed over your chest. Keep your back and shoulders straight throughout exercise. Breathe in slowly. </li> <li>Breathe out and bring your upper body forward until sitting upright. </li> <li>Extend your arms so they are parallel to the floor and slowly stand up. </li> <li>Breathe in as you slowly sit down. </li> <li>Repeat 10 to 15 times. </li> <li>Rest; then repeat 10 to 15 more times. </li> </ol> People with back problems should start the exercise from the sitting upright position.</div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 51521 Version 2.0</div></div></div>"},"51522":{"type":"graphic_picture","displayName":"Small bowel leiomyosarc Light","title":"Small intestinal leiomyosarcoma","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Small intestinal leiomyosarcoma</div><div class=\"cntnt\"><img style=\"width:530px; height:192px;\" src=\"images/GAST/51522_Small_bowel_leiomyosarc_Lig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low (left panel) and high power (right panel) images of a small bowel leiomyosarcoma. The high power view reveals pleiomorphic spindle cells with nuclear atypia, hypercellularity, and several mitotic figures.</div><div class=\"graphic_reference\">Courtesy of Dr. Saint Aufranc.</div><div id=\"graphicVersion\">Graphic 51522 Version 1.0</div></div></div>"},"51523":{"type":"graphic_table","displayName":"Candida spp MICs","title":"In vitro susceptibility of <em>Candida</em> spp to systemically active antifungal agents determined by CLSI M27-A3 broth microdilution MIC methods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">In vitro susceptibility of <em>Candida</em> spp to systemically active antifungal agents determined by CLSI M27-A3 broth microdilution MIC methods</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"18%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Species</td> <td class=\"subtitle1\" rowspan=\"2\">Antifungal agents</td> <td class=\"subtitle1\" rowspan=\"2\">Number of<br /> isolates tested</td> <td class=\"subtitle1\" colspan=\"3\">MIC, mcg/mL</td> </tr> <tr> <td class=\"subtitle2\">Range</td> <td class=\"subtitle2\">50 percent*</td> <td class=\"subtitle2\">90 percent*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"10\"><em>Candida albicans</em></td> <td>Amphotericin B<sup>&#182;</sup></td> <td>2728</td> <td>0.016 to 4</td> <td>0.5</td> <td>0.5</td> </tr> <tr> <td>Flucytosine</td> <td>5208</td> <td>0.12 to 128</td> <td>0.25</td> <td>1</td> </tr> <tr> <td>Fluconazole</td> <td>5827</td> <td>0.12 to 128</td> <td>0.25</td> <td>0.5</td> </tr> <tr> <td>Isavuconazole</td> <td>671</td> <td>&#60;0.008 to 0.5</td> <td>0.015</td> <td>0.03</td> </tr> <tr> <td>Itraconazole</td> <td>3895</td> <td>0.03 to 8</td> <td>0.06</td> <td>0.12</td> </tr> <tr> <td>Posaconazole</td> <td>5827</td> <td>0.007 to 2</td> <td>0.015</td> <td>0.06</td> </tr> <tr> <td>Voriconazole</td> <td>5826</td> <td>0.007 to 4</td> <td>0.007</td> <td>0.015</td> </tr> <tr> <td>Anidulafungin</td> <td>2869</td> <td>0.007 to 2</td> <td>0.03</td> <td>0.06</td> </tr> <tr> <td>Caspofungin</td> <td>2869</td> <td>0.007 to 0.5</td> <td>0.03</td> <td>0.06</td> </tr> <tr class=\"divider_bottom\"> <td>Micafungin</td> <td>2869</td> <td>0.007 to 1</td> <td>0.015</td> <td>0.03</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"10\"><em>C. glabrata</em></td> <td>Amphotericin B<sup>&#182;</sup></td> <td>949</td> <td>0.03 to 16</td> <td>2</td> <td>4</td> </tr> <tr> <td>Flucytosine</td> <td>1267</td> <td>0.12 to 128</td> <td>0.12</td> <td>0.12</td> </tr> <tr> <td>Fluconazole</td> <td>1517</td> <td>0.25 to 128</td> <td>8</td> <td>32</td> </tr> <tr> <td>Isavuconazole</td> <td>291</td> <td>0.015 to 8</td> <td>0.5</td> <td>2</td> </tr> <tr> <td>Itraconazole</td> <td>1054</td> <td>0.03 to 8</td> <td>1</td> <td>2</td> </tr> <tr> <td>Posaconazole</td> <td>1517</td> <td>0.03 to &#62;8</td> <td>1</td> <td>2</td> </tr> <tr> <td>Voriconazole</td> <td>1516</td> <td>0.007 to 8</td> <td>0.25</td> <td>1</td> </tr> <tr> <td>Anidulafungin</td> <td>747</td> <td>0.015 to 4</td> <td>0.06</td> <td>0.12</td> </tr> <tr> <td>Caspofungin</td> <td>747</td> <td>0.015 to &#62;8</td> <td>0.03</td> <td>0.06</td> </tr> <tr class=\"divider_bottom\"> <td>Micafungin</td> <td>747</td> <td>0.007 to 1</td> <td>0.015</td> <td>0.015</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"10\"><em>C. parapsilosis</em></td> <td>Amphotericin B<sup>&#182;</sup></td> <td>666</td> <td>0.25 to 16</td> <td>1</td> <td>2</td> </tr> <tr> <td>Flucytosine</td> <td>1047</td> <td>0.12 to 128</td> <td>0.12</td> <td>0.25</td> </tr> <tr> <td>Fluconazole</td> <td>1542</td> <td>0.12 to 128</td> <td>0.5</td> <td>2</td> </tr> <tr> <td>Isavuconazole</td> <td>236</td> <td>&#60;0.008 to 0.25</td> <td>0.03</td> <td>0.12</td> </tr> <tr> <td>Itraconazole</td> <td>1028</td> <td>0.03 to 2</td> <td>0.25</td> <td>0.5</td> </tr> <tr> <td>Posaconazole</td> <td>1542</td> <td>0.007 to 1</td> <td>0.06</td> <td>0.12</td> </tr> <tr> <td>Voriconazole</td> <td>1541</td> <td>0.007 to 8</td> <td>0.015</td> <td>0.06</td> </tr> <tr> <td>Anidulafungin</td> <td>759</td> <td>0.03 to 4</td> <td>2</td> <td>2</td> </tr> <tr> <td>Caspofungin</td> <td>759</td> <td>0.015 to 4</td> <td>0.25</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>Micafungin</td> <td>759</td> <td>0.015 to 2</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"10\"><em>C. tropicalis</em></td> <td>Amphotericin B<sup>&#182;</sup></td> <td>528</td> <td>0.06 to 32</td> <td>1</td> <td>2</td> </tr> <tr> <td>Flucytosine</td> <td>759</td> <td>0.12 to 128</td> <td>0.25</td> <td>1</td> </tr> <tr> <td>Fluconazole</td> <td>1198</td> <td>0.12 to 128</td> <td>0.5</td> <td>2</td> </tr> <tr> <td>Isavuconazole</td> <td>122</td> <td>&#60;0.008 to 4</td> <td>0.06</td> <td>0.12</td> </tr> <tr> <td>Itraconazole</td> <td>839</td> <td>0.03 to 8</td> <td>0.12</td> <td>0.25</td> </tr> <tr> <td>Posaconazole</td> <td>1198</td> <td>0.015 to 2</td> <td>0.06</td> <td>0.12</td> </tr> <tr> <td>Voriconazole</td> <td>1197</td> <td>0.007 to 8</td> <td>0.03</td> <td>0.06</td> </tr> <tr> <td>Anidulafungin</td> <td>625</td> <td>0.007 to 2</td> <td>0.03</td> <td>0.06</td> </tr> <tr> <td>Caspofungin</td> <td>625</td> <td>0.007 to &#62;8</td> <td>0.03</td> <td>0.06</td> </tr> <tr class=\"divider_bottom\"> <td>Micafungin</td> <td>625</td> <td>0.007 to 1</td> <td>0.03</td> <td>0.06</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"10\"><em>C. krusei</em></td> <td>Amphotericin B<sup>&#182;</sup></td> <td>143</td> <td>0.03 to 16</td> <td>4</td> <td>8</td> </tr> <tr> <td>Flucytosine</td> <td>184</td> <td>0.12 to 128</td> <td>16</td> <td>32</td> </tr> <tr> <td>Fluconazole</td> <td>305</td> <td>8 to 128</td> <td>32</td> <td>64</td> </tr> <tr> <td>Isavuconazole</td> <td>32</td> <td>0.12 to 2</td> <td>0.5</td> <td>0.5</td> </tr> <tr> <td>Itraconazole</td> <td>206</td> <td>0.06 to 4</td> <td>0.5</td> <td>1</td> </tr> <tr> <td>Posaconazole</td> <td>305</td> <td>0.03 to 4</td> <td>0.25</td> <td>1</td> </tr> <tr> <td>Voriconazole</td> <td>305</td> <td>0.06 to 4</td> <td>0.25</td> <td>0.5</td> </tr> <tr> <td>Anidulafungin</td> <td>136</td> <td>0.015 to 0.5</td> <td>0.06</td> <td>0.06</td> </tr> <tr> <td>Caspofungin</td> <td>136</td> <td>0.015 to 1</td> <td>0.12</td> <td>0.25</td> </tr> <tr class=\"divider_bottom\"> <td>Micafungin</td> <td>136</td> <td>0.015 to 0.25</td> <td>0.06</td> <td>0.12</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"10\"><em>C. guilliermondii</em></td> <td>Amphotericin B<sup>&#182;</sup></td> <td>102</td> <td>0.06 to 32</td> <td>0.25</td> <td>1</td> </tr> <tr> <td>Flucytosine</td> <td>100</td> <td>0.12 to 4</td> <td>0.12</td> <td>0.5</td> </tr> <tr> <td>Fluconazole</td> <td>138</td> <td>0.5 to 32</td> <td>4</td> <td>8</td> </tr> <tr> <td>Isavuconazole</td> <td>14</td> <td>0.12 to 4</td> <td>0.5</td> <td>1</td> </tr> <tr> <td>Itraconazole</td> <td>90</td> <td>0.06 to 4</td> <td>0.5</td> <td>1</td> </tr> <tr> <td>Posaconazole</td> <td>138</td> <td>0.015 to 2</td> <td>0.25</td> <td>0.5</td> </tr> <tr> <td>Voriconazole</td> <td>138</td> <td>0.015 to 2</td> <td>0.06</td> <td>0.12</td> </tr> <tr> <td>Anidulafungin</td> <td>61</td> <td>0.12 to 4</td> <td>1</td> <td>2</td> </tr> <tr> <td>Caspofungin</td> <td>61</td> <td>0.03 to &#62;8</td> <td>0.5</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>Micafungin</td> <td>61</td> <td>0.015 to 2</td> <td>0.5</td> <td>1</td> </tr> <tr> <td rowspan=\"10\"><em>C. lusitaniae</em></td> <td>Amphotericin B<sup>&#182;</sup></td> <td>103</td> <td>0.06 to 16</td> <td>0.25</td> <td>1</td> </tr> <tr> <td>Flucytosine</td> <td>82</td> <td>0.12 to 128</td> <td>0.12</td> <td>0.5</td> </tr> <tr> <td>Fluconazole</td> <td>133</td> <td>0.12 to 64</td> <td>0.5</td> <td>1</td> </tr> <tr> <td>Isavuconazole</td> <td>24</td> <td>&#60;0.008 to 0.12</td> <td>0.03</td> <td>0.06</td> </tr> <tr> <td>Itraconazole</td> <td>89</td> <td>0.03 to 1</td> <td>0.12</td> <td>0.25</td> </tr> <tr> <td>Posaconazole</td> <td>133</td> <td>0.015 to 1</td> <td>0.03</td> <td>0.12</td> </tr> <tr> <td>Voriconazole</td> <td>133</td> <td>0.007 to 1</td> <td>0.007</td> <td>0.015</td> </tr> <tr> <td>Anidulafungin</td> <td>58</td> <td>0.06 to 1</td> <td>0.5</td> <td>0.5</td> </tr> <tr> <td>Caspofungin</td> <td>58</td> <td>0.03 to 1</td> <td>0.25</td> <td>0.5</td> </tr> <tr> <td>Micafungin</td> <td>58</td> <td>0.03 to 1</td> <td>0.12</td> <td>0.25</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CLSI: Clinical and Laboratory Standards Institute; MIC: minimum inhibitory concentration.<br />* MIC encompassing 50 percent and 90 percent of isolates tested, respectively.<br />¶ Amphotericin B MICs determined by Etest.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Pfaller, MA, Boyken, L, Hollis, RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46:150. </li>&#xD;&#xA;    <li>Pfaller, MA, Messer, SA, Boyken, L, et al. In vitro activities of 5-fluorocytosine against 8803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 2002; 46:3518. </li>&#xD;&#xA;    <li>Pfaller, MA, Messer, SA, Boyken, L, et al. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J Clin Microbiol 2004; 42:3137. </li>&#xD;&#xA;    <li>Pfaller, MA, Boyken, L, Hollis, RJ, et al. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9359 isolates tested by Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol 2005; 43: 3807. </li>&#xD;&#xA;    <li>Pfaller, MA, Messer, SA, Boyken, L, et al. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol 2008; 46:551. </li>&#xD;&#xA;    <li>Castanheira M, Messer SA, Rhomberg PR, et al. Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: Application of new CLSI clinical breakpoints and epidemiological cutoff values. Mycopathologia 2014; 178: 1.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 51523 Version 5.0</div></div></div>"},"51524":{"type":"graphic_waveform","displayName":"Basic case 13","title":"Basic case 13","html":"<div class=\"graphic normal\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Basic case 13</div><div class=\"cntnt\"><img style=\"width:518px; height:267px;\" src=\"images/CARD/51524_Basic_case_13.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51524 Version 3.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"51526":{"type":"graphic_picture","displayName":"Light microscopy of acute tubular necrosis II","title":"Light microscopy of acute tubular necrosis II","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Light microscopy of acute tubular necrosis II</div><div class=\"cntnt\"><img style=\"width:504px; height:328px;\" src=\"images/NEPH/51526_Acute_tubular_necrosis_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph in recovery phase of acute tubular necrosis showing multiple mitoses (arrows) indicative of regenerating tubular cells.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD</div><div id=\"graphicVersion\">Graphic 51526 Version 2.0</div></div></div>"},"51528":{"type":"graphic_diagnosticimage","displayName":"Long axis poststenotic dilation","title":"Aortic dilation in aortic stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic dilation in aortic stenosis</div><div class=\"cntnt\"><img style=\"width:229px; height:395px;\" src=\"images/CARD/51528_Long_axis_poststenotic_dila.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aortic pathology can be better seen by imaging the ascending aorta one interspace above the usual long axis precordial window. The normal appearance of the sinuses and ascending aorta (Asc Ao) is seen in panel A. For comparison, panel B shows poststenotic dilatation which is quite typical and almost always found in aortic stenosis.</div><div class=\"graphic_footnotes\">AV: aortic valve; LA: left atrium; LV: left ventricle.</div><div id=\"graphicVersion\">Graphic 51528 Version 2.0</div></div></div>"},"51529":{"type":"graphic_waveform","displayName":"ECG ventricular bigeminy tutorial","title":"Electrocardiogram (ECG) showing ventricular bigeminy","html":"<div class=\"graphic normal\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) showing ventricular bigeminy</div><div class=\"cntnt\"><img style=\"width:529px; height:220px;\" src=\"images/CARD/51529_Ventricular_bigeminy_tutori.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A ventricular premature beat (VPB) follows each sinus beat, and the coupling interval between the VPB and the previous sinus QRS complex is constant (fixed coupling interval). The resulting pattern is referred to as ventricular bigeminy.</div><div id=\"graphicVersion\">Graphic 51529 Version 4.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"51530":{"type":"graphic_table","displayName":"Articles containing latex","title":"Articles used during surgery or procedures and likelihood of clinically significant latex content","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Articles used during surgery or procedures and likelihood of clinically significant latex content</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Items which may contain natural rubber latex:</td> </tr> <tr> <td class=\"indent1\">Gloves (sterile and exam)</td> </tr> <tr> <td class=\"indent1\">Drains (Penrose and others)</td> </tr> <tr> <td class=\"indent1\">Catheters (indwelling, straight, and condom)</td> </tr> <tr> <td class=\"subtitle2_left\">Items which are now usually latex-free:</td> </tr> <tr> <td class=\"indent1\">Ambu-bag, airway masks</td> </tr> <tr> <td class=\"indent1\">Catheter leg bag straps</td> </tr> <tr> <td class=\"indent1\">Elastic bandages</td> </tr> <tr> <td class=\"indent1\">Electrode pads</td> </tr> <tr> <td class=\"indent1\">Endotracheal tubes</td> </tr> <tr> <td class=\"indent1\">Intravenous bags, ports, infusion sets</td> </tr> <tr> <td class=\"indent1\">Self-adhesive bandages and adhesive tape</td> </tr> <tr> <td class=\"indent1\">Suction catheters</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Chacko T, Ledford D. Peri-anesthetic anaphylaxis. Immunol Allergy Clin N Am 2007; 27:213. Copyright &copy; 2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 51530 Version 6.0</div></div></div>"},"51531":{"type":"graphic_figure","displayName":"Reclassification of presumed NLPHL","title":"Reclassification of presumed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) ","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Reclassification of presumed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) </div><div class=\"cntnt\"><img style=\"width:502px; height:310px;\" src=\"images/HEME/51531_Reclassification_NLPHL.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After careful review of 426 cases originally classified as NLPHL, morphologic and immunophenotypic studies confirmed the diagnosis in 51 percent while the rest were reclassified.</div><div class=\"graphic_footnotes\">NLPHL: nodular lymphocyte-predominant Hodgkin lymphoma; LRCHL: lymphocyte-rich classical Hodgkin lymphoma; CHL: classical Hodgkin lymphoma; NHL: non-Hodgkin lymphoma.</div><div class=\"graphic_reference\">Modified from: Diehl V, Sextro M, Franklin J. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999; 17:776.</div><div id=\"graphicVersion\">Graphic 51531 Version 3.0</div></div></div>"},"51533":{"type":"graphic_table","displayName":"Common cold treatments in pregnancy 3","title":"Agents used to treat the common cold and its symptoms, their efficacy and their safety in pregnancy, continued","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Agents used to treat the common cold and its symptoms, their efficacy and their safety in pregnancy, continued</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Effect in randomly controlled trial<br /> (not pregnant)</td> <td class=\"subtitle1\">Pregnancy data</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antihistamines</td> </tr> <tr> <td class=\"indent1\"> <p>Diphenhydramine</p> <p>Chlorpheniramine</p> <p>Fexofenadine</p> <p>Loratidine</p> <p>Clemastine</p> Brompheniramine</td> <td>Clemastine and brompheniramine (and loratadine in conjunction with pseuedoephedrine) decrease sneezing and nasal discharge but have no effect on sore throat, cough, headache and malaise. No antihistamine effects total symptom score or duration for the common cold.</td> <td> <p>Chlorpheniramine and diphenhydramine have mostly reassuring pregnancy data and should be considered the preferred antihistamines in pregnancy.</p> <p>Most of the older antihistamines are not considered to increase the incidence of congenital malformations in humans. Although some antihistamines have been associated with oral clefts in retrospective studies others have found no significant increase in the incidence of major or minor malformations and one study even found that significantly fewer infants with malformations were exposed to antihistamines while in utero than were controls.</p> <p>There are limited human pregnancy data on the newer antihistamines fexofenadine, cetirizine, and loratadine. Therefore, they should not be used as first line agents in pregnancy.</p> Use of antihistamine with women in pre-term labor was associated in one study with an increased risk of retrolental fibroplasias and should be avoided in this setting.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cough medicine</td> </tr> <tr> <td class=\"indent1\"> <p>Codeine</p> <p>Dextromethorphan</p> <p>Guaifenisin</p> <p>Benzonatate</p> Hydrocodone</td> <td>Uniformly ineffective in the setting of cough from common cold.</td> <td> <p>Animal data for codeine, dextromethorphan and hydrocodone conflicting.</p> <p>Human data for all these agents are poor. Guaifenisin was associated with inguinal hernias in one study only. A large case-control study observed an association between first trimester use of opioids and various congenital anomalies.</p> <p>Neonatal withdrawal has been reported in babies born both to addicted and non-addicted women who took codeine in the days prior to delivery. Codeine ingestion near the time of labor can produce respiratory depression in the newborn.</p> The lack of efficacy of these agents suggests their use is not justifiable in pregnancy for the common cold especially given questions about the safety of some of these agents in pregnancy.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51533 Version 8.0</div></div></div>"},"51535":{"type":"graphic_picture","displayName":"Patho nerve sheath A","title":"Intradural nerve sheath tumor: Alternating compact Antoni A areas traversed by a vertical band of looser Antoni B tissue","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Intradural nerve sheath tumor: Alternating compact Antoni A areas traversed by a vertical band of looser Antoni B tissue</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/ONC/51535_Patho_nerve_sheath_A.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51535 Version 2.0</div></div></div>"},"51536":{"type":"graphic_table","displayName":"Examination clues IEM","title":"Physical examination findings as clues to inborn errors of metabolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical examination findings as clues to inborn errors of metabolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Finding</td> <td class=\"subtitle1\">Potential inborn error</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">General</td> </tr> <tr> <td class=\"indent1\">Tall, long-limbed body habitus</td> <td>Homocystinuria</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Head</td> </tr> <tr> <td class=\"indent1\">Coarse facial features (eg, hirsuitism, prominent brow ridge, and gingival hypertrophy)</td> <td>Oligosaccharidoses, mucopolysaccharidoses, mucolipidoses</td> </tr> <tr> <td class=\"indent1\">Microcephaly</td> <td>Untreated phenylketonuria (PKU), maternal PKU syndrome, congenital disorders of glycosylation, leukodystrophies (late), organic acidemias, urea cycle disorders, maple syrup urine disease</td> </tr> <tr> <td class=\"indent1\">Macrocephaly</td> <td>Canavan disease, glutaric acidemia type I, oligosaccharidoses, mucopolysaccharidoses, mucolipidoses, Tay-Sachs (early)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Hair</td> </tr> <tr> <td class=\"indent1\">Alopecia</td> <td>Biotinidase deficiency, Vitamin D resistant rickets</td> </tr> <tr> <td class=\"indent1\">Sparse</td> <td>Biotinidase deficiency, Menkes</td> </tr> <tr> <td class=\"indent1\">Kinky, brittle</td> <td>Argininosuccinic aciduria and citrullinemia (due to arginine deficiency), Menkes, mucopolysaccharidoses</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Eyes</td> </tr> <tr> <td class=\"indent1\">Cataracts</td> <td>Oligosaccharidoses, Fabry disease, neuronal ceroid lipofuscinosis, galactosemia, Smith-Lemli-Opitz syndrome peroxisome biogenesis defects, rhizomelic chondrodysplasia punctata, Wilson disease, mitochondrial disorders, Lowe syndrome</td> </tr> <tr> <td class=\"indent1\">Cherry red spot</td> <td>Tay-Sachs disease, Sandhoff disease, Sialidosis type I and type II, GM1-gangliosidosis, Niemann-Pick disease type A, Gaucher disease type 2, metachromatic leukodystrophy, galactosialidosis</td> </tr> <tr> <td class=\"indent1\">Corneal clouding</td> <td>Oligosaccharidoses, mucopolysaccharidoses, mucolipidoses, Tangier, sialidosis</td> </tr> <tr> <td class=\"indent1\">Corneal opacity</td> <td>Oligosaccharidoses, Fabry disease, steroid sulfatase deficiency (X-linked ichthyosis), Tangier, molybdenum cofactor deficiency, sulfite oxidase deficiency</td> </tr> <tr> <td class=\"indent1\">Dislocated lens</td> <td>Homocystinuria, sulfite oxidase deficiency</td> </tr> <tr> <td class=\"indent1\">Kayser-Fleischer rings</td> <td>Wilson disease</td> </tr> <tr> <td class=\"indent1\">Retitinitis pigmentosa</td> <td>Abetalipoproteinemia, peroxisome biogenesis disorders, congenital disorders of glycosylation, fatty acid oxidation defects, mitochondrial disorders, mucopolysaccharidoses, Krabbe disease, Menkes disease, disorders of cobalamin (vitamin B12) transport and synthesis, ornithine aminotransferase deficiency</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Ears</td> </tr> <tr> <td class=\"indent1\">Hearing loss</td> <td>Peroxisomal disorders, mitochondrial disorders, lysosomal storage disorders, mucopolysaccharidoses</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Mouth</td> </tr> <tr> <td class=\"indent1\">Gingival hyperplasia</td> <td>Oligosaccharidoses, mucopolysaccharidoses, mucolipidoses</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Chest</td> </tr> <tr> <td class=\"indent1\">Inverted nipples</td> <td>Congenital disorders of&nbsp;glycosylation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Abdomen</td> </tr> <tr> <td class=\"indent1\">Hepatosplenomegaly</td> <td>Lysosomal storage disorders</td> </tr> <tr> <td class=\"indent1\">Hepatomegaly</td> <td>Glycogen storage diseases, carnitine palmitoyltransferase II deficiency (infantile form), peroxisomal disorders, mitochondrial DNA depletion disorders, tyrosinemia type I (hepatorenal), mucolipidoses, congenital disorders of glycosylation, longer chain fatty acid oxidation disorders.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Musculoskeletal</td> </tr> <tr> <td class=\"indent1\">Arthritis</td> <td>Farber disease, purine metabolism disorders</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neurologic</td> </tr> <tr> <td class=\"indent1\">Dystonia</td> <td>Glutaric acidemia I, organic acidemias, Wilson disease, mitochondrial disorders</td> </tr> <tr> <td class=\"indent1\">Myopathy</td> <td>Fatty acid oxidation defects, mitochondrial disorders, Pompe disease and other glycogen storage diseases</td> </tr> <tr> <td class=\"indent1\">Paresthesia</td> <td>Fabry disease, sialidosis</td> </tr> <tr> <td class=\"indent1\">Peripheral neuropathy</td> <td>Congenital disorders of protein glycosylation, leukodystrophies, peroxisomal disorders, Tangier disease</td> </tr> <tr> <td class=\"indent1\">Psychoses</td> <td>Adult Tay-Sachs, homocystinuria, porphyrias, purine metabolism disorders</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Skin</td> </tr> <tr> <td class=\"indent1\">Hypopigmentation or absent pigment</td> <td>Cystinosis, Menkes disease, phenylketonuria, sialidosis</td> </tr> <tr> <td class=\"indent1\">Angiokeratoma</td> <td>Fabry, fucosidosis, galactosialidosis, beta-mannosidosis, sialidosis</td> </tr> <tr> <td class=\"indent1\">Dermatitis</td> <td>Biotinidase deficiency, Hartnup disease, phenylketonuria, prolidase deficiency</td> </tr> <tr> <td class=\"indent1\">Edema</td> <td>GM1 gangliosidosis, prolidase deficiency</td> </tr> <tr> <td class=\"indent1\">Hirsutism</td> <td>Oligosaccharidoses, mucopolysaccharidoses, mucolipidoses</td> </tr> <tr> <td class=\"indent1\">Ichthyosis</td> <td>Multiple sulfatase deficiency, isolated steroid sulfatase deficiency</td> </tr> <tr> <td class=\"indent1\">Photosentization</td> <td>Porphyrias</td> </tr> <tr> <td class=\"indent1\">Xanthomas</td> <td>Hyperlipoproteinemias and other disorders of lipoproteins</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GM1: monosialotetrahexosylganglioside.</div><div class=\"graphic_reference\">Adapted from Wappner RS, Hainline BE. Inborn errors of metabolism. In: Oski's Pediatrics. Principles and Practice, 3rd ed, McMillan JA, DeAngelis CD, Feigin RD, Warshaw, JB (Eds), Lippincott, Williams and Wilkins, Philadelphia, 1999. p. 1823 and Saudubray JM, Chappentier C. Clinical phenotypes: Diagnosis/algorithms. In: Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York, 2001. p. 1327 and Lindor NM, Karnes PS. Initial assessment of infants and children with suspected inborn errors of metabolism. Mayo Clin Proc 1995; 70:987 and Cleary MA, Green A. Developmental delay: when to suspect and how to investigate for an inborn error of metabolism. Arch Dis Child 2005; 90:1128.</div><div id=\"graphicVersion\">Graphic 51536 Version 6.0</div></div></div>"},"51538":{"type":"graphic_figure","displayName":"Peripheral blood analysis by flow cytometry II","title":"Peripheral blood analysis by flow cytometry","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral blood analysis by flow cytometry</div><div class=\"cntnt\"><img style=\"width:385px; height:336px;\" src=\"images/ALLRG/51538_Periph_blood_anal_II.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of immunophenotyping of peripheral blood by staining with antibodies specific to monocytes (CD14) and neutrophils (CD15).</div><div id=\"graphicVersion\">Graphic 51538 Version 2.0</div></div></div>"},"51539":{"type":"graphic_table","displayName":"Effects diabetes bone","title":"The effects of type 1 and type 2 diabetes on bone","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The effects of type 1 and type 2 diabetes on bone</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Type 1</td> <td class=\"subtitle1\">Type 2</td> </tr> <tr> <td rowspan=\"4\"><strong>Pathology</strong></td> <td rowspan=\"3\">Insulin deficiency</td> <td>Insulin resistance</td> </tr> <tr> <td>Hyperinsulinemia</td> </tr> <tr> <td>Raised IGF-1</td> </tr> <tr> <td>Raised blood glucose</td> <td>Raised blood glucose</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Age of onset</strong></td> <td>Younger</td> <td>Older</td> </tr> <tr> <td>May affect peak bone mass</td> <td>Usually maturity onset</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>BMI</strong></td> <td rowspan=\"4\">May be low</td> <td>Usually high</td> </tr> <tr> <td>Increased load on skeleton</td> </tr> <tr> <td>May protect against impact</td> </tr> <tr> <td>Increased estrogen, leptin, and adiponectin production in adipose tissue</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Mechanism</strong></td> <td>Hyperglycemia may cause increased urine calcium loss and inhibit bone formation</td> <td>Hyperglycemia may cause increased urine calcium loss and inhibit bone formation</td> </tr> <tr> <td>Bone turnover is usually low</td> <td>Bone turnover is usually low</td> </tr> <tr> <td>Advanced glycosylation end products may affect bone fragility</td> <td>Advanced glycosylation end products may affect bone fragility</td> </tr> <tr> <td>&nbsp;</td> <td>Anabolic effect of insulin resistance</td> </tr> <tr class=\"divider_top\"> <td><strong>BMD</strong></td> <td>May be low</td> <td>May be increased</td> </tr> <tr class=\"divider_top\"> <td><strong>Fracture risk</strong></td> <td>Increased</td> <td>Increased</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Treatment</strong></td> <td rowspan=\"2\">Insulin has anabolic effect</td> <td>Different effects of drugs on fracture risk (reduction with metformin, increase with thiazolidinediones)</td> </tr> <tr> <td>Insulin has anabolic effect but use marks longstanding or severe diabetes</td> </tr> <tr class=\"divider_top\"> <td><strong>Complications</strong></td> <td colspan=\"2\">Micro- and macrovascular complications may increase fracture risk by effects on bone (eg, by metabolic effects of nephropathy) or by association with an increased risk of falling (eg, secondary to visual loss, cerebrovascular disease, or neuropathy). Neuropathy-related local bone loss may increase fracture risk at the foot and ankle.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IGF-1: insulin-like growth factor-1; BMI: body mass index; BMD: bone mineral density.</div><div class=\"graphic_reference\">Sources:<br /><ol>&#xD;&#xA;    <li>Rakel A, Sheehy O, Rahme E, LeLorier J. Osteoporosis among patients with type 1 and type 2 diabetes. Diabetes Metab 2008; 34:193.</li>&#xD;&#xA;    <li>Adami S. Bone health in diabetes: considerations for clinical management. Curr Med Res Opin 2009; 25:1057.</li>&#xD;&#xA;    <li>Epstein S, Leroith D. Diabetes and fragility fractures - a burgeoning epidemic? Bone 2008; 43:3.</li>&#xD;&#xA;    <li>McCulloch D. Thiazolidinediones in the treatment of diabetes mellitus. In: UpToDate, Basow DS (Ed), UpToDate, Waltham, MA, 2013.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 51539 Version 6.0</div></div></div>"},"51540":{"type":"graphic_diagnosticimage","displayName":"Manometry PSS DM","title":"Manometry of the stomach and small intestine differentiates neuropathic and myopathic disorders","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Manometry of the stomach and small intestine differentiates neuropathic and myopathic disorders</div><div class=\"cntnt\"><img style=\"width:517px; height:265px;\" src=\"images/GAST/51540_Manometry_PSS_DM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postprandial gastrointestinal motility in a patient with systemic sclerosis (myopathic disorder, left panel) is characterized by low amplitude contractions at all levels compared with controls. By comparison, a neuropathic disorder such as diabetes mellitus (right panel) is characterized by normal contraction amplitude, but abnormal organization of the contractile response. Specifically, there is a lack of distal antral contractions, pyloric tonic, and phasic pressure activity, and persistence of migrating motor complex-like activity postprandially (proximal jejunum rows 2 and 3) despite the ingestion of a solid-liquid meal.</div><div class=\"graphic_reference\">Adapted from: Camilleri M. Medical treatment of chronic intestinal pseudo-obstruction. Pract Gastroenterol 1991; 15:10.</div><div id=\"graphicVersion\">Graphic 51540 Version 6.0</div></div></div>"},"51541":{"type":"graphic_diagnosticimage","displayName":"Endometrial stripe normal","title":"Transvaginal sagittal image of a premenopausal normal uterus and cervix","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transvaginal sagittal image of a premenopausal normal uterus and cervix</div><div class=\"cntnt\"><img style=\"width:381px; height:176px;\" src=\"images/OBGYN/51541_Endometrial_stripe_normal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The uterus is in the follicular phase of the menstrual cycle with a trilaminar appearance of the endometrium. The cervix is indicated by the long arrow. The short arrows demonstrated the correct placement of the calipers for assessing the thickness of the endometrial stripe.</div><div class=\"graphic_reference\">Courtesy of Thomas D Shipp, MD.</div><div id=\"graphicVersion\">Graphic 51541 Version 2.0</div></div></div>"},"51542":{"type":"graphic_picture","displayName":"Aspiration radiohumeral joint","title":"Aspiration of the radiohumeral joint","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Aspiration of the radiohumeral joint</div><div class=\"cntnt\"><img style=\"width:452px; height:311px;\" src=\"images/EM/51542_Aspiration_radiohumeral_joi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aspiration of the radiohumeral joint is performed to differentiate traumatic hemarthrosis from inflammatory arthritis and the rare case of septic arthritis. The patient is supine with the elbow flexed to 90 degrees. A triangle is made with points at the lateral epicondyle, radial head, and olecranon process. Ethyl chloride or a comparable agent&nbsp;is&nbsp;applied to the skin for anesthesia. A 1 inch (2.5 cm), 21 or 22 gauge needle is inserted in the center of the triangle, perpendicular to the skin and parallel to the radial head, 3/4 to 1 inch (2 to 2.5 cm)&nbsp;deep. 0.5 mL of lidocaine is injected subcutaneously, and 0.5 mL is injected at 3/4 inches (2 cm)&nbsp;or adjacent to the bone.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 51542 Version 4.0</div></div></div>"},"51543":{"type":"graphic_figure","displayName":"Airway remodeling","title":"Airway remodeling in asthma","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Airway remodeling in asthma</div><div class=\"cntnt\"><img style=\"width:594px; height:421px;\" src=\"images/PULM/51543_Airway_remodeling.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ET-1: endothelin-1; FGF-2: fibroblast growth factor; IGF-1: insulin-like growth factor-1; IL: interleukin; Th2 lymphocyte: T-helper 2 lymphocyte; TSLP: thymic stromal lymphopoietin; LTB4: leukotriene B4; LTC4: leukotriene C4; MMP-9: matrix metalloproteinase-9; PDGF: platelet-derived growth factor; TGF-β: transforming growth factor β; TNF-α: tumor necrosis factor α; TIMP-1: tissue inhibitor of metalloproteinase-1; EGF: epidermal growth factor; GM-CSF: granulocyte macrophage colony stimulating factor; PGD2: prostaglandin D2; VEGF: vascular endothelial growth factor.</div><div id=\"graphicVersion\">Graphic 51543 Version 4.0</div></div></div>"},"51544":{"type":"graphic_table","displayName":"Features of hemorrhage II","title":"Pathologic features of major causes of immune or idiopathic alveolar hemorrhage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pathologic features of major causes of immune or idiopathic alveolar hemorrhage</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Disorder</td> <td class=\"subtitle1\" colspan=\"2\">Glomerular pathology</td> <td class=\"subtitle1\" colspan=\"2\">Pulmonary pathology</td> </tr> <tr> <td class=\"subtitle2\">Histopathology</td> <td class=\"subtitle2\">IF/EM</td> <td class=\"subtitle2\">Histopathology</td> <td class=\"subtitle2\">IF/EM</td> </tr> <tr> <td rowspan=\"3\">ABMA disease</td> <td rowspan=\"3\">Variable - segmental necrosis, crescents common</td> <td rowspan=\"3\">Linear IgG by IF</td> <td>Alveolar hemorrhage</td> <td rowspan=\"3\">Linear IgG by IF along alveolar capillary basement membrane</td> </tr> <tr> <td>Chronic inflammation</td> </tr> <tr> <td>No evidence of vasculitis</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">SLE</td> <td rowspan=\"3\">Variable - segmental necrosis, crescents in minority</td> <td rowspan=\"3\">Granular IgG by IF, electron dense deposits by EM</td> <td>Alveolar hemorrhage</td> <td rowspan=\"3\">Granular IgG by IF along alveolar capillary walls</td> </tr> <tr> <td>Vasculitis of small arteries and veins</td> </tr> <tr> <td>Capillaritis</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">WG</td> <td rowspan=\"2\">Segmental necrosis, crescents</td> <td rowspan=\"2\">Negative (granular IF in minority)</td> <td>Cavitary nodular parenchymal disease</td> <td rowspan=\"2\">Negative</td> </tr> <tr> <td>Necrotizing vasculitis with granulomatous inflammation of the parenchyma</td> </tr> <tr class=\"divider_top\"> <td>Nonspecific systemic necrotizing vasculitis (microscopic polyarteritis, polyangiitis, overlap syndrome)</td> <td>Segmental necrosis, crescents</td> <td>Negative (granular IF in minority)</td> <td>Small vessel arteritis and capillaritis</td> <td>Negative</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Idiopathic pulmonary hemosiderosis</td> <td rowspan=\"3\">Normal</td> <td rowspan=\"3\">Negative</td> <td>Alveolar hemorrhage</td> <td rowspan=\"3\">Negative</td> </tr> <tr> <td>Interstitial fibrosis</td> </tr> <tr> <td>Hemosiderin-laden macrophages</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IF: immunofluorescence; EM: electron microscopy; ABMA: antibasement membrane antibody; SLE: systemic lupus erythematosus; WG: granulomatosis with polyangiitis (Wegener's); ANA: antinuclear antibody; ANCA: antineutrophil cytoplasmic antibody; p-ANCA: perinuclear ANCA; GN: glomerulonephritis.</div><div class=\"graphic_reference\">Redrawn from: Leatherman JL. In: Immunologically Mediated Pulmonary Diseases, Lynch JP, DeRemee RA (Eds), JB Lippincott, Philadelphia, 1991, p.490.</div><div id=\"graphicVersion\">Graphic 51544 Version 4.0</div></div></div>"},"51546":{"type":"graphic_waveform","displayName":"WPW radiofrequency ablation","title":"Radiofrequency ablation for WPW syndrome","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Radiofrequency ablation for WPW syndrome</div><div class=\"cntnt\"><img style=\"width:451px; height:329px;\" src=\"images/CARD/51546_WPWradiofrequencyablation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surface ECG and intracardiac electrograms from a patient with Wolff-Parkinson-White syndrome (WPW) and a right lateral accessory pathway are simultaneously recorded. The patient is initially being paced from the high right atrium (HRA) at a cycle length of 500 msec to maximize preexcitation. The accessory pathway is localized to an area of the tricuspid annulus (Ta), and radiofrequency (RF) current is delivered via a deflectable tip ablation catheter. Preexcitation disappears (*) within 1.2 seconds.</div><div id=\"graphicVersion\">Graphic 51546 Version 3.0</div></div></div>"},"51547":{"type":"graphic_picture","displayName":"Jaw-thrust maneuver","title":"Jaw-thrust maneuver","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Jaw-thrust maneuver</div><div class=\"cntnt\"><img style=\"width:412px; height:343px;\" src=\"images/EM/51547_Jaw_thrust_maneuver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The jaw-thrust&nbsp;maneuver is used to relieve upper airway obstruction by moving the tongue anteriorly with the mandible, minimizing the tongue's ability to obstruct the airway. With the patient supine and the clinician standing at the head of the bed, the technique is performed by placing the heels of both hands on the parieto-occipital areas on each side of the patient's head, then grasping the angles of the mandible with the index and long fingers, and displacing the jaw anteriorly. The jaw-thrust maneuver&nbsp;may be&nbsp;used in the patient in whom cervical spine injury is a concern.</div><div id=\"graphicVersion\">Graphic 51547 Version 6.0</div></div></div>"},"51548":{"type":"graphic_diagnosticimage","displayName":"Radiograph pulm sporotrich","title":"Pulmonary sporotrichosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary sporotrichosis</div><div class=\"cntnt\"><img style=\"width:398px; height:257px;\" src=\"images/ID/51548_Radiograph_pulm_sporotrich.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiographs of a 52-year-old man with prior diabetes mellitus, alcoholism, and chronic obstructive pulmonary disease, and pulmonary sporotrichosis.<br />Left panel: PA film shows extensive bilateral upper cavitary lesions.<br />Right panel: Lateral radiograph of the same patient showing extensive upper lobe cavitary infiltration.</div><div class=\"graphic_footnotes\">PA: Posteroanterior.</div><div class=\"graphic_reference\">Courtesy of Carol A Kauffman, MD.</div><div id=\"graphicVersion\">Graphic 51548 Version 3.0</div></div></div>"},"51550":{"type":"graphic_picture","displayName":"Maternal vascular malperfusion","title":"Maternal vascular malperfusion","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Maternal vascular malperfusion</div><div class=\"cntnt\"><img style=\"width:540px; height:384px;\" src=\"images/OBGYN/51550_Chronicplacentaunderperfu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preterm placenta from a pregnancy complicated by severe preterm preeclampsia. The arrows show areas of accelerated maturity of the villi (short arrow) and a central infarct (long arrow).</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 51550 Version 3.0</div></div></div>"},"51551":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image of normal bowel","title":"Normal bowel","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal bowel</div><div class=\"cntnt\"><img style=\"width:403px; height:254px;\" src=\"images/OBGYN/51551_Ultrasound_normal_bowel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this longitudinal image, the echotexture of the fetal bowel is homogenous, and is considerably less echodense than fetal bone at low gain settings.</div><div class=\"graphic_reference\">Courtesy of Stephen Chasen, MD.</div><div id=\"graphicVersion\">Graphic 51551 Version 2.0</div></div></div>"},"51553":{"type":"graphic_picture","displayName":"Autoeczematous reaction","title":"Autoeczematous reaction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Autoeczematous reaction</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/PC/51553_Autoeczematous_reaction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Several areas of autoeczematization on the leg and thigh of a patient with venous insufficiency and stasis dermatitis.</div><div class=\"graphic_reference\">Courtesy of Patrick C Alguire, MD.</div><div id=\"graphicVersion\">Graphic 51553 Version 2.0</div></div></div>"},"51556":{"type":"graphic_table","displayName":"Estimating body fat","title":"Methods of estimating body fat and its distribution","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Methods of estimating body fat and its distribution</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Method</td>\n\n      <td class=\"subtitle1\">Cost</td>\n\n      <td class=\"subtitle1\">Ease of Use</td>\n\n      <td class=\"subtitle1\">Accuracy</td>\n\n      <td class=\"subtitle1\">Measures Regional Fat</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Height and weight</td>\n\n      <td>$</td>\n\n      <td>Easy</td>\n\n      <td>High</td>\n\n      <td>No</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Skin folds</td>\n\n      <td>$</td>\n\n      <td>Easy</td>\n\n      <td>Low</td>\n\n      <td>Yes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Circumferences</td>\n\n      <td>$</td>\n\n      <td>Easy</td>\n\n      <td>Moderate</td>\n\n      <td>Yes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ultrasound</td>\n\n      <td>$$</td>\n\n      <td>Moderate</td>\n\n      <td>Moderate</td>\n\n      <td>Yes</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"5\" rowspan=\"1\" class=\"sublist1_start\">Density</td>\n\n      \n\n      \n\n      \n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Immersion</td>\n\n      <td class=\"sublist_other\">$</td>\n\n      <td class=\"sublist_other\">Moderate</td>\n\n      <td class=\"sublist_other\">High</td>\n\n      <td class=\"sublist_other\">No</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Plethysmograph</td>\n\n      <td class=\"sublist_other\">$$$</td>\n\n      <td class=\"sublist_other\">Difficult</td>\n\n      <td class=\"sublist_other\">High</td>\n\n      <td class=\"sublist_other\">No</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"5\" rowspan=\"1\" class=\"sublist1_start\">Heavy water</td>\n\n      \n\n      \n\n      \n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Tritiated*</td>\n\n      <td class=\"sublist_other\">$$</td>\n\n      <td class=\"sublist_other\">Moderate</td>\n\n      <td class=\"sublist_other\">High</td>\n\n      <td class=\"sublist_other\">No</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Deuterium oxide or heavy oxygen</td>\n\n      <td class=\"sublist_other\">$$$</td>\n\n      <td class=\"sublist_other\">Moderate</td>\n\n      <td class=\"sublist_other\">High</td>\n\n      <td class=\"sublist_other\">No</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Potassium isotope (40K)</td>\n\n      <td>$$$$</td>\n\n      <td>Difficult </td>\n\n      <td>High</td>\n\n      <td>No</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Total body electrical conductivity</td>\n\n      <td>$$$</td>\n\n      <td>Moderate</td>\n\n      <td>High</td>\n\n      <td>No</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bioelectric impedance (BIA)</td>\n\n      <td>$$</td>\n\n      <td>Easy</td>\n\n      <td>High</td>\n\n      <td>No</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Absorptiometry (dual energy X-ray = DEXA; dual photon = DPA)</td>\n\n      <td>$$$</td>\n\n      <td>Easy</td>\n\n      <td>High</td>\n\n      <td>No</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Computed tomography*</td>\n\n      <td>$$$$</td>\n\n      <td>Difficult</td>\n\n      <td>High</td>\n\n      <td>Yes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Magnetic resonance imaging</td>\n\n      <td>$$$$</td>\n\n      <td>Difficult</td>\n\n      <td>High</td>\n\n      <td>Yes</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Radiation involved.</div><div id=\"graphicVersion\">Graphic 51556 Version 1.0</div></div></div>"},"51557":{"type":"graphic_picture","displayName":"Nuclear cataract","title":"Nuclear cataract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nuclear cataract</div><div class=\"cntnt\"><img style=\"width:288px; height:265px;\" src=\"images/PC/51557_Nuclear_cataract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Slit-lamp photo of a nuclear cataract reveals an opaque nucleus, manifested as a yellow-brown hazy structure at the center of the lens (arrows).</div><div class=\"graphic_reference\">Courtesy of Deborah S Jacobs, MD.</div><div id=\"graphicVersion\">Graphic 51557 Version 3.0</div></div></div>"},"51558":{"type":"graphic_figure","displayName":"Afferent nerve subtypes","title":"Afferent nerve subtypes innervating the airways and lungs of rats","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Afferent nerve subtypes innervating the airways and lungs of rats</div><div class=\"cntnt\"><img style=\"width:535px; height:372px;\" src=\"images/PULM/51558_Afferent_nerve_subtypes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subtypes can be identified based on their responsiveness to chemical stimuli such as capsaicin, their activity during eupneic breathing, and their response to sustained lung inflation. Three broad classes of airway afferent nerves have been identified. A) Bronchopulmonary C-fibers are relatively unresponsive to mechanical stimulation but are activated by noxious chemical stimuli such as capsaicin, acid, hypertonic saline and inflammatory mediators including bradykinin and serotonin (5-HT). B) and C) Airway mechanoreceptors are exquisitely sensitive to the dynamic and sustained mechanical forces put upon the lung during respiration. Subtypes of airway mechanoreceptors can be identified based on their adaptation to sustained lung inflation. Activation of airway C-fibers and rapidly adapting mechanoreceptors reflexly increases airway parasympathetic nerve activity and regulates airway defensive reflexes such as cough. By contrast, activation of slowly adapting mechanoreceptors reflexly reduces airway parasympathetic nerve activity and may play only a modulatory role in cough. Slowly adapting receptors also play a primary role in regulating respiratory pattern.</div><div class=\"graphic_reference\">Reproduced with permission from: Ho, CY, Gu, O, Lin, YS, Lee, LY. Sensitivity of vagal afferent endings to chemical irritants in the rat lung. Respir Physiol 2001; 127:113. Copyright &#169; 2001 Elsevier.</div><div id=\"graphicVersion\">Graphic 51558 Version 1.0</div></div></div>"},"51559":{"type":"graphic_algorithm","displayName":"Congenital syphilis evaluation and management","title":"Congenital syphilis: Evaluation and management","html":"<div class=\"graphic\"><div style=\"width: 635px\" class=\"figure\"><div class=\"ttl\">Congenital syphilis: Evaluation and management</div><div class=\"cntnt\"><img style=\"width:615px; height:697px;\" src=\"images/PEDS/51559_Congen_syph_algo_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RPR: rapid plasma reagin; VDRL: Venereal Disease Research Laboratory; TP-PA: <EM>Treponema pallidum</EM> particle agglutination; FTA-ABS: fluorescent treponema antibody absorption; TP-EIA: <EM>T. pallidum</EM> enzyme immunoassay; MHA-TP: microhemagglutination test for antibodies to <EM>T. pallidum</EM>.<br />* This algorithm does not apply if maternal samples are screened in reverse order (ie, treponemal test is performed before the RPR/VDRL). For a discussion of interpretation of reverse sequence testing, please refer to UpToDate topic on diagnosis of syphilis.<br />¶ TP-PA, FTA-ABS, TP-EIA, or MHA-TP.<br />Δ Test for human immunodeficiency virus (HIV) antibody. Infants of HIV-infected mothers do not require different evaluation or treatment.<br /><FONT class=lozenge>◊</FONT> A fourfold change in titer is the same as a change of 2 dilutions. For example, a titer of 1:64 is fourfold greater than a titer of 1:16, and a titer of 1:4 is fourfold lower than a titer of 1:16.<br />§ Women who maintain a VDRL titer 1:2 or less or an RPR 1:4 or less beyond 1 year after successful treatment are considered serofast.<br />¥ Complete blood cell (CBC) and platelet count; cerebrospinal fluid (CSF) examination for cell count, protein, and quantitative VDRL; other tests as clinically indicated (eg, chest radiographs, long-bone radiographs, eye examination, liver function tests, neuroimaging, and auditory brainstem response).<br />‡ Some experts would consider a single intramuscular injection of benzathine penicillin (Treatment Option 2), particularly if follow-up is not certain.<br />† Treatment (Option 1 or Option 2, above) with many experts recommending Treatment Option 1. If a single dose of benzathine penicillin G is used, then the infant must be fully evaluated, full evaluation must be normal, and follow-up must be certain. If any part of the infant's evaluation is abnormal or not performed, or if the CSF analysis is rendered uninterpretable, then a 10-day course of penicillin is required.</div><div class=\"graphic_reference\">From: American Academy of Pediatrics. Syphilis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. Copyright © 2012 American Academy of Pediatrics. Used with permission. The contents of this figure remain unchanged in the Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed.</div><div id=\"graphicVersion\">Graphic 51559 Version 17.0</div></div></div>"},"51560":{"type":"graphic_picture","displayName":"Tattoo sarcoidosis","title":"Sarcoidosis involving a tattoo","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Sarcoidosis involving a tattoo</div><div class=\"cntnt\"><img style=\"width:469px; height:540px;\" src=\"images/DERM/51560_Tattoo_sarcoidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biopsy proven sarcoidosis involving only the tattooed skin. Firm papules are present within the tattooed areas.</div><div id=\"graphicVersion\">Graphic 51560 Version 3.0</div></div></div>"},"51561":{"type":"graphic_picture","displayName":"Pinguecula","title":"Pinguecula","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pinguecula</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PC/51561_Pinguecula_new.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Image created by Christopher J. Rapuano, MD. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51561 Version 5.0</div></div></div>"},"51562":{"type":"graphic_diagnosticimage","displayName":"Severe spinal stenosis in Paget disease","title":"Severe spinal stenosis in Paget disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe spinal stenosis in Paget disease</div><div class=\"cntnt\"><img style=\"width:253px; height:540px;\" src=\"images/RHEUM/51562_Severe_spinal_sten_Paget.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paget disease affecting L4 and L5, with overgrowth of L4, extension of pagetic changes into the posterior elements of the spine, and compression. This man presented with severe spinal stenosis.</div><div class=\"graphic_reference\">Courtesy of Margaret Seton, MD.</div><div id=\"graphicVersion\">Graphic 51562 Version 2.0</div></div></div>"},"51563":{"type":"graphic_table","displayName":"Available rabies biologics","title":"Currently available rabies biologics - United States, 2008","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Currently available rabies biologics - United States, 2008</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Human rabies vaccine</td> <td class=\"subtitle1\">Product name</td> <td class=\"subtitle1\">Manufacturer</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Route</td> <td class=\"subtitle1\">Indications</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Human diploid cell vaccine</td> <td class=\"divider_bottom\" rowspan=\"3\">Imovax&#174; Rabies*</td> <td>sanofi Pasteur</td> <td class=\"divider_bottom\" rowspan=\"3\">1 mL</td> <td class=\"divider_bottom\" rowspan=\"3\">Intramuscular</td> <td class=\"divider_bottom\" rowspan=\"3\">Pre-exposure or postexposure</td> </tr> <tr> <td>Phone: 800-822-2463</td> </tr> <tr> <td class=\"divider_bottom\">Website: http://www.vaccineplace.com/products/</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Purified chick embryo cell vaccine</td> <td class=\"divider_bottom\" rowspan=\"3\">RabAvert&#174;</td> <td>Novartis Vaccines and Diagnostics</td> <td class=\"divider_bottom\" rowspan=\"3\">1 mL</td> <td class=\"divider_bottom\" rowspan=\"3\">Intramuscular</td> <td class=\"divider_bottom\" rowspan=\"3\">Pre-exposure or postexposure</td> </tr> <tr> <td>Phone: 800-244-7668</td> </tr> <tr> <td class=\"divider_bottom\">Website: http://www.rabavert.com</td> </tr> <tr> <td rowspan=\"7\">Rabies immune globulin</td> <td rowspan=\"3\">Imogam&#174; Rabies-HT</td> <td>sanofi Pasteur</td> <td rowspan=\"3\">20 IU/kg</td> <td rowspan=\"3\">Local<sup>&#182;</sup></td> <td rowspan=\"3\">Postexposure only</td> </tr> <tr> <td>Phone: 800-822-2463</td> </tr> <tr> <td>Website: http://www.vaccineplace.com/products/</td> </tr> <tr> <td rowspan=\"4\">HyperRab&#174; S/D</td> <td>Talecris Biotherapeutics</td> <td rowspan=\"4\">20 IU/kg</td> <td rowspan=\"4\">Local<sup>&#182;</sup></td> <td rowspan=\"4\">Posteexposure only</td> </tr> <tr> <td>Bayer Biological Products</td> </tr> <tr> <td>Phone: 800-243-4153</td> </tr> <tr> <td>Website: http://www.talecris-pi.info</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Imovax rabies I.D., administered intradermally, is no longer available in the United States.<br />&para; As much of the product as is anatomically feasible should be infiltrated into and around the wound. Any remaining product should be administered intramuscularly in the deltoid or quadriceps (at a location other than that used for vaccine inoculation to minimize potential interference).</div><div class=\"graphic_reference\">Adapted from: Manning, SE, Rupprecht, CE, Fishbein, D, et al. Human rabies prevention-United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008; 57:1.</div><div id=\"graphicVersion\">Graphic 51563 Version 4.0</div></div></div>"},"51565":{"type":"graphic_table","displayName":"Benefits physical activity","title":"Benefits of regular physical activity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Benefits of regular physical activity</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Reduces the risk of dying prematurely</td> </tr> <tr> <td>Reduces the risk of dying from heart disease</td> </tr> <tr> <td>Reduces the risk of stroke</td> </tr> <tr> <td>Reduces the risk of developing diabetes</td> </tr> <tr> <td>Reduces the risk of developing high blood pressure</td> </tr> <tr> <td>Helps reduce blood pressure in people who already have high blood pressure</td> </tr> <tr> <td>Reduces the risk of developing colon cancer</td> </tr> <tr> <td>Reduces feelings of depression and anxiety</td> </tr> <tr> <td>Helps control weight</td> </tr> <tr> <td>Helps build and maintain healthy bones, muscles, and joints</td> </tr> <tr> <td>Helps older adults become stronger and better able to move about without falling</td> </tr> <tr> <td>Promotes psychological wellbeing</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51565 Version 2.0</div></div></div>"},"51568":{"type":"graphic_picture","displayName":"Necrotizing scleritis in RA","title":"Necrotizing scleritis in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Necrotizing scleritis in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:401px; height:265px;\" src=\"images/RHEUM/51568_Necrotizing_scleritis_in_RA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Necrotizing scleritis in a patient with rheumatoid arthritis has resulted in extreme scleral thinning with prolapse of the underlying uvea.</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 51568 Version 3.0</div></div></div>"},"51569":{"type":"graphic_table","displayName":"Fat soluble vitamin supplements for biliary atresia","title":"Fat soluble vitamin deficiencies and supplementation for patients with biliary atresia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fat soluble vitamin deficiencies and supplementation for patients with biliary atresia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Fat-soluble vitamin</td> <td class=\"subtitle1\">How to monitor</td> <td class=\"subtitle1\">Standard oral treatment recommendation</td> <td class=\"subtitle1\">Signs and symptoms of deficiency</td> <td class=\"subtitle1\">Recommended supplementation in setting of deficiency</td> </tr> <tr> <td>Vitamin A</td> <td> <p>Measure serum or plasma Retinol and Retinol Binding Protein (RBP)</p> <p>Interpretation: Normal range for retinol 19 to 77 &#181;g/dL; Retinol:RBP &#60;0.8 mol/mol defines deficiency when Retinol &#60;20 &#181;g/dL</p> </td> <td>Liquid vitamin A, 3000 IU/day</td> <td> <p>Keratinization of the skin and mucous membranes; ocular effects such as xerophthalmia, night blindness, xerosis, and bitot spots</p> <p>Retinol:RBP molar ratio &#60;0.8 and serum retinol &#60;20 &#181;g/dL</p> </td> <td> <p>Liquid vitamin A 5000 IU/day by mouth; recheck levels in&nbsp;one month</p> <p><strong>OR</strong></p> <p>25,000 to 50,000 IU/day by mouth for&nbsp;one to&nbsp;four&nbsp;weeks; recheck levels weekly</p> <p><strong>OR</strong></p> <p>50,000 IU IM once/month up to&nbsp;two months; recheck levels monthly</p> </td> </tr> <tr class=\"divider_top\"> <td>Vitamin D</td> <td> <p>Measure serum 25-OH-D</p> <p>Interpretation: Optimal levels &#62;30 ng/ml</p> </td> <td>Cholecalciferol or ergocalciferol, 800 IU/d</td> <td> <p>Rickets; fractures; osteomalacia</p> <p>25-OH-D &#60;15 ng/mL</p> </td> <td> <p>Cholecalciferol or ergocalciferol 1200 to 4000 IU/day by mouth; recheck levels in&nbsp;one month</p> <p>If child remains deficient, give 4000 to 8000 IU/day; recheck levels in one month</p> <p><strong>OR</strong></p> <p>Give 1,25 OH<sub>2</sub>D, 0.05 to 0.2 &#181;g/kg/day; recheck serum 1,25 OH<sub>2</sub>D levels in&nbsp;one month</p> </td> </tr> <tr class=\"divider_top\"> <td>Vitamin E</td> <td> <p>Measure serum vitamin E and total lipids</p> <p>Interpretation: Normal vitamin E:total lipid ratio &#62;0.6 mg/g (age &#60;1 year) or &#62;0.8 mg/g (age &#62;1 year)</p> </td> <td>25 IU/kg/day of TPGS</td> <td> <p>Peripheral neuropathy, ataxia; ophthalmoplegia</p> <p>Vit. E:total lipid ratio: &#60;0.6 mg/g (age &#60;1 year) or &#60;0.8 mg/g (age &#62;1 year) is deficient</p> </td> <td>If deficient, 50 IU/kg/day of TPGS - recheck levels in&nbsp;one month</td> </tr> <tr class=\"divider_top\"> <td>Vitamin K</td> <td>Measure PT, INR, and PIVKA-II</td> <td>Vitamin K<sub>1</sub>, 2.5 mg twice weekly, or up to 5.0 mg daily</td> <td>Prolonged prothrombin time, increased INR (INR &#62;1.2); elevated PIVKA-II; coagulopathy; bruising; bleeding</td> <td>If INR &#62;1.5 and &#8804;1.8: give 5 mg vitamin K<sub>1</sub> daily by mouth and/or 2 to 5 mg vitamin K intramuscularly one time; recheck PT/INR in&nbsp;one to&nbsp;two&nbsp;days</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IU: international units; 25-OH-D: 25-hydroxyvitamin D; 1,25-OH<SUB>2</SUB>D: 1,25 dihydroxyvitamin D; TPGS: Tocopherol polyethylene glycol succinate (water miscible form of vitamin E); PT: prothrombin time; INR: international normalized ratio; PIVKA-II: protein induced by vitamin K absence II; Vitamin K<SUB>1</SUB>: phytonadione.</div><div id=\"graphicVersion\">Graphic 51569 Version 3.0</div></div></div>"},"51571":{"type":"graphic_diagnosticimage","displayName":"Expiratory Arteriogram Celiac Artery Compression Syndrome","title":"Expiratory Arteriogram Celiac Artery Compression Syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Expiratory Arteriogram Celiac Artery Compression Syndrome</div><div class=\"cntnt\"><img style=\"width:287px; height:360px;\" src=\"images/GAST/51571_Celiac_artery_expiration_An.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lateral arteriogram in the same patient upon end-expiration. There is a notable region of stenosis not seen on the previous film (arrowhead). Beyond this region of stenosis, there is post-stenotic dilatation (arrow) signifying a region of significant and persistent proximal narrowing.</div><div class=\"graphic_reference\">Courtesy of Sherry Scovell, MD.</div><div id=\"graphicVersion\">Graphic 51571 Version 4.0</div></div></div>"},"51572":{"type":"graphic_picture","displayName":"Transgastric double-pigtail plastic stents","title":"Transgastric pigtail stents to drain a pancreatic pseudocyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transgastric pigtail stents to drain a pancreatic pseudocyst</div><div class=\"cntnt\"><img style=\"width:360px; height:343px;\" src=\"images/GAST/51572_Transgastrpigtailstents.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of two 10F transgastric double-pigtail, plastic&nbsp;stents.</div><div class=\"graphic_reference\">Courtesy of Dr. Raj J Shah, MD.</div><div id=\"graphicVersion\">Graphic 51572 Version 4.0</div></div></div>"},"51573":{"type":"graphic_diagnosticimage","displayName":"Red marrow sickle cell","title":"Distribution of bone marrow in a child with sickle cell disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distribution of bone marrow in a child with sickle cell disease</div><div class=\"cntnt\"><img style=\"width:430px; height:434px;\" src=\"images/HEME/51573_Red_marrow_sickle_cell.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The scintigram on the left shows the distribution of erythropoietic (red) marrow in a child with sickle cell disease, as demonstrated by the uptake of transferrin-bound radioactive iron three hours after injection. The child's whole body outline is shown in the photo on the right for localization purposes. Note the marked uptake of isotope in the spine, pelvis, and ribs, a pattern also seen in the adult. Unlike the adult, however, there is also erythropoietic marrow in the skull, jaws, arms, and legs. The latter uptake is most prominent in the region of the knee and ankle joints. The child was not having a painful crisis at the time of this study.</div><div class=\"graphic_reference\">Provided by Stephen A. Landaw, MD.</div><div id=\"graphicVersion\">Graphic 51573 Version 2.0</div></div></div>"},"51574":{"type":"graphic_diagnosticimage","displayName":"Mediastinal widening inhalation anthrax","title":"A chest radiograph showing mediastinal widening in a patient with inhalation anthrax","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">A chest radiograph showing mediastinal widening in a patient with inhalation anthrax</div><div class=\"cntnt\"><img style=\"width:350px; height:289px;\" src=\"images/ID/51574_Mediastinal_widening_inhala.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">http://www.bt.cdc.gov/agent/anthrax/anthrax-images/inhalational.asp.</div><div id=\"graphicVersion\">Graphic 51574 Version 4.0</div></div></div>"},"51575":{"type":"graphic_movie","displayName":"Left ventricular thrombus five chamber echocardiogram","title":"Left ventricular thrombus","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular thrombus</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/51575_5chlvthrconv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:279px; height:189px;\" src=\"images/CARD/51575_5chlvthr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Five chamber view from a 2-D echocardiogram with close up of the left ventricle shows a large thrombus at the left ventricular apex and interventricular septum. The apex and apical portion of the septum are akinetic, suggesting a prior myocardial infarction.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 51575 Version 3.0</div></div></div>"},"51577":{"type":"graphic_table","displayName":"Platinum desens","title":"Platinum desensitization (example)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Platinum desensitization (example)</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_left\" colspan=\"8\">Desensitization protocol instructions: </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\" colspan=\"8\">1. Confirm written consent is in medical record. Initial desensitization is performed in the medical ICU. </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\" colspan=\"8\">2. Please ensure preceding dose of beta-blockers was held, unless otherwise advised by supervising physician. </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\" colspan=\"8\">3. Obtain IV access, and vital signs (temperature, HR, BP, RR, oxygen saturation, peak flow). </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\" colspan=\"8\">4. Have at bedside: Epinephrine 0.3 mg (for adult) for IM injection, peak flow meter, and BP cuff. </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\" colspan=\"8\">5. A nurse must closely observe the patient throughout the protocol (one-to-one). </td>\r\n                </tr>\r\n                <tr>\r\n                    <td colspan=\"8\">\r\n                    <p><strong>Premedications:&nbsp;</strong>&nbsp;Give diphenhydramine (25 mg IV) and ranitidine (50 mg IV) 20 minutes before starting protocol. For patients with flushing during their initial hypersensitivity reaction, give aspirin (325 mg po) the night before and the morning of the protocol. For patients with respiratory symptoms during their initial reaction, give montelukast (10 mg po) the night before and the morning of the protocol. </p>\r\n                    </td>\r\n                </tr>\r\n                <tr>\r\n                    <td colspan=\"8\"><strong>Administration:</strong> Hang each solution successively, changing the rate every 15 minutes, per protocol. The IV tubing should be pre-flushed with the appropriate solution (1, 2, or 3) and attached at the IV hub, prior to starting infusion with each bag. There is no reason to wait between bags. Vital signs should be taken and recorded every 15 minutes, and every 30 minutes during the last step (step 12). </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_left\" colspan=\"5\">Name of medication: </td>\r\n                    <td colspan=\"3\"><strong>Carboplatin</strong> </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_left\" colspan=\"5\">Target dose, mg </td>\r\n                    <td colspan=\"3\"><strong>400</strong> </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_left\" colspan=\"5\">Standard volume per bag, mL </td>\r\n                    <td colspan=\"3\"><strong>250</strong> </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_left\" colspan=\"5\">Final rate of infusion, mL/hr </td>\r\n                    <td colspan=\"3\"><strong>75</strong> </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist_other\" colspan=\"8\">&nbsp; </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_left\" colspan=\"5\">Calculated target concentration, mg/mL </td>\r\n                    <td colspan=\"3\"><strong>1.6</strong> </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_left\" colspan=\"5\">Standard time of infusion, minutes </td>\r\n                    <td colspan=\"3\"><strong>200</strong> </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist_other\" colspan=\"8\">&nbsp; </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_left\" colspan=\"6\">&nbsp; </td>\r\n                    <td class=\"subtitle1_left\">Total mg per bag </td>\r\n                    <td class=\"subtitle1_left\">Amount of bag infused, mL </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"3\">Solution 1 </td>\r\n                    <td>250</td>\r\n                    <td>mL of</td>\r\n                    <td>0.016 mg/mL</td>\r\n                    <td>4.000</td>\r\n                    <td>8.67</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"3\">Solution 2 </td>\r\n                    <td>250</td>\r\n                    <td>mL of</td>\r\n                    <td>0.160 mg/mL</td>\r\n                    <td>40.000</td>\r\n                    <td>17.58</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"3\">Solution 3 </td>\r\n                    <td>250</td>\r\n                    <td>mL of</td>\r\n                    <td><strong>1.588 mg/mL</strong></td>\r\n                    <td>397.049</td>\r\n                    <td>250.00</td>\r\n                </tr>\r\n                <tr>\r\n                    <td colspan=\"8\"><strong>PLEASE NOTE:</strong> The total volume and dose dispensed are more than the final dose given to patient because the initial solutions are <em>not completely infused</em> </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Step </td>\r\n                    <td class=\"subtitle1\">Solution </td>\r\n                    <td class=\"subtitle1\">Rate, mL/hr </td>\r\n                    <td class=\"subtitle1\">Time, min </td>\r\n                    <td class=\"subtitle1\">Volume infused per step, mL </td>\r\n                    <td class=\"subtitle1\">Dose administered with this step, mg </td>\r\n                    <td class=\"subtitle1\">Cumulative dose, mg </td>\r\n                    <td class=\"subtitle1\">Fold increase per step </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>1</td>\r\n                    <td>1</td>\r\n                    <td>1.9</td>\r\n                    <td>15</td>\r\n                    <td>0.47</td>\r\n                    <td>0.0075</td>\r\n                    <td>0.0075</td>\r\n                    <td>-</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>2</td>\r\n                    <td>1</td>\r\n                    <td>4.7</td>\r\n                    <td>15</td>\r\n                    <td>1.17</td>\r\n                    <td>0.0188</td>\r\n                    <td>0.0263</td>\r\n                    <td>2.5</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>3</td>\r\n                    <td>1</td>\r\n                    <td>9.4</td>\r\n                    <td>15</td>\r\n                    <td>2.34</td>\r\n                    <td>0.0375</td>\r\n                    <td>0.0638</td>\r\n                    <td>2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>4</td>\r\n                    <td>1</td>\r\n                    <td>18.8</td>\r\n                    <td>15</td>\r\n                    <td>4.69</td>\r\n                    <td>0.0750</td>\r\n                    <td>0.1388</td>\r\n                    <td>2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>5</td>\r\n                    <td>2</td>\r\n                    <td>4.7</td>\r\n                    <td>15</td>\r\n                    <td>1.17</td>\r\n                    <td>0.1875</td>\r\n                    <td>0.3263</td>\r\n                    <td>2.5</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>6</td>\r\n                    <td>2</td>\r\n                    <td>9.4</td>\r\n                    <td>15</td>\r\n                    <td>2.34</td>\r\n                    <td>0.3750</td>\r\n                    <td>0.7013</td>\r\n                    <td>2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>7</td>\r\n                    <td>2</td>\r\n                    <td>18.8</td>\r\n                    <td>15</td>\r\n                    <td>4.69</td>\r\n                    <td>0.7500</td>\r\n                    <td>1.4513</td>\r\n                    <td>2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>8</td>\r\n                    <td>2</td>\r\n                    <td>37.5</td>\r\n                    <td>15</td>\r\n                    <td>9.38</td>\r\n                    <td>1.5000</td>\r\n                    <td>2.9513</td>\r\n                    <td>2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>9</td>\r\n                    <td>3</td>\r\n                    <td>9.4</td>\r\n                    <td>15</td>\r\n                    <td>2.34</td>\r\n                    <td>3.7223</td>\r\n                    <td>6.6736</td>\r\n                    <td>2.481554688</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>10</td>\r\n                    <td>3</td>\r\n                    <td>18.8</td>\r\n                    <td>15</td>\r\n                    <td>4.69</td>\r\n                    <td>7.4447</td>\r\n                    <td>14.1182</td>\r\n                    <td>2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>11</td>\r\n                    <td>3</td>\r\n                    <td>37.5</td>\r\n                    <td>15</td>\r\n                    <td>9.38</td>\r\n                    <td>14.8893</td>\r\n                    <td>29.0076</td>\r\n                    <td>2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>12</td>\r\n                    <td>3</td>\r\n                    <td><strong>75.0</strong></td>\r\n                    <td>186.875</td>\r\n                    <td>233.59</td>\r\n                    <td>370.9924</td>\r\n                    <td>400.0000</td>\r\n                    <td>2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td colspan=\"8\"><strong>Total time: 351.875 minutes = 5.86 hours</strong> </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_left\" colspan=\"8\">Monitoring and charting during desensitization: </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\" colspan=\"8\">Please clearly document any reaction, including: </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\" colspan=\"8\">a. Patient's symptoms, vital signs, and physical findings; </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\" colspan=\"8\">b. Exactly when the reaction occurred (ie, what step, how many minutes into that step); </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\" colspan=\"8\">c. Treatment administered, how and when the reaction resolved, and when the protocol was restarted. </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_left\" colspan=\"8\">Treatment of allergic reactions: </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\" colspan=\"8\">1. <strong>For mild reactions:</strong> In case of isolated itching, flushing, hives, mild chest tightness, nausea, abdominal pain, or back pain, with normal vital signs, stop the infusion and treat with IV diphenhydramine. Observe patient until the reaction subsides, and then resume the protocol at the last step that was tolerated. </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\" colspan=\"8\">2. <strong>For severe reactions:</strong> In case of hypotension, throat swelling, wheezing/respiratory distress, or decreased oxygen saturation, stop the infusion and treat with Epinephrine 0.3 mg IM x 1, diphenhydramine and methylprednisolone IV, oxygen, nebulized albuterol for bronchospasm, and IV fluids (normal saline), per AHA guidelines. Place patient in a recumbent position if hypotensive. Consider glucagon 1-2 mg IV bolus if patient has taken beta-blockers, followed by infusion at 1-5 mg/hr. <strong>Immediately alert the housestaff and supervising physician.</strong> When the patient is stable, the protocol will be resumed as instructed by the supervising physician. <em>Patient should be discharged with prescription for an epinephrine auto injector.</em> </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\" colspan=\"8\"><strong>Contact the supervising physician for ANY severe or prolonged reaction, or any questions regarding the protocol, reactions, and appropriate management.</strong> </td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=47503&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_reference\">Courtesy of Mariana C Castells, MD, PhD.</div><div id=\"graphicVersion\">Graphic 51577 Version 2.0</div></div></div>"},"51578":{"type":"graphic_picture","displayName":"Subconjunctival hemorrhage","title":"Subconjunctival hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subconjunctival hemorrhage</div><div class=\"cntnt\"><img style=\"width:322px; height:213px;\" src=\"images/PC/51578_Subconjunctivalhemorrhage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extravasated blood in the inferior conjunctiva.</div><div class=\"graphic_reference\">Reproduced with permission from: Trobe JD, Hackel RE. Field Guide to the Eyes. Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 51578 Version 10.0</div></div></div>"},"51579":{"type":"graphic_table","displayName":"Asthma severity 5 to 11 yrs","title":"Classifying asthma severity in children 5 to 11 years of age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classifying asthma severity in children 5 to 11 years of age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\" colspan=\"2\">Components of severity</td> <td class=\"subtitle1\" colspan=\"4\">Classification of asthma severity (children 5 to 11 years of age)</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\">Intermittent</td> <td class=\"subtitle2\" colspan=\"4\">Persistent</td> </tr> <tr> <td class=\"subtitle3\">Mild</td> <td class=\"subtitle3\">Moderate</td> <td class=\"subtitle3\">Severe</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Impairment</td> <td>Symptoms</td> <td>&#8804;2 days/week</td> <td>&#62;2 days/week, but not daily</td> <td>Daily</td> <td>Throughout the day</td> </tr> <tr> <td>Nighttime awakenings</td> <td>&#8804;2 times/month</td> <td>3 to 4 times/month</td> <td>&#62;1 time/week, but not nightly</td> <td>Often 7 times/week</td> </tr> <tr> <td>Short-acting beta<sub>2</sub>-agonist use for symptom control (not prevention of EIB)</td> <td>&#8804;2 days/week</td> <td>&#62;2 days/week, but not daily</td> <td>Daily</td> <td>Several times per day</td> </tr> <tr> <td>Interference with normal activity</td> <td>None</td> <td>Minor limitation</td> <td>Some limitation</td> <td>Extremely limited</td> </tr> <tr class=\"divider_bottom\"> <td>Lung function</td> <td> <ul> <li>Normal FEV<sub>1</sub> between exacerbations </li> <li>FEV<sub>1</sub> &#62;80% predicted </li> <li>FEV<sub>1</sub>/FVC &#62;85%</li> </ul> </td> <td> <ul> <li>FEV<sub>1</sub> = &#62;80% predicted </li> <li>FEV<sub>1</sub>/FVC &#62;80%</li> </ul> </td> <td> <ul> <li>FEV<sub>1</sub> = 60 to 80% predicted </li> <li>FEV<sub>1</sub>/FVC = 75 to 80%</li> </ul> </td> <td> <ul> <li>FEV<sub>1</sub> &#60;60% predicted </li> <li>FEV<sub>1</sub>/FVC &#60;75%</li> </ul> </td> </tr> <tr> <td rowspan=\"4\">Risk</td> <td rowspan=\"4\"><strong>Exacerbations requiring oral systemic glucocorticoids</strong></td> <td><strong>0 to 1/year (see footnote)</strong></td> <td colspan=\"3\"><strong>&#8805;2 in one year (see footnote)</strong></td> </tr> <tr> <td colspan=\"4\"><strong>Consider severity and interval since last exacerbation</strong></td> </tr> <tr> <td colspan=\"4\"><strong>Frequency and severity may fluctuate over time for patients in any severity category</strong></td> </tr> <tr> <td colspan=\"4\"><strong>Relative annual risk of exacerbations may be related to FEV<sub>1</sub></strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>Classifying severity in children who are not currently taking long-term control medication.</strong> Level of severity is determined by both impairment and risk. Assess impairment domain by patient's/caregiver's recall of the previous two to four weeks and spirometry. Assign severity to the most severe category in which any feature occurs. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate greater underlying disease severity. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic glucocorticoids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.</div><div class=\"graphic_footnotes\">EIB: exercise-induced bronchoconstriction; FEV<sub>1</sub>: forced expiratory volume in one second; ICU: intensive care unit.</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 51579 Version 7.0</div></div></div>"},"51581":{"type":"graphic_table","displayName":"Prevention of outdoor fire ant infestation","title":"Prevention of outdoor fire ant infestation at health care facilities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevention of outdoor fire ant infestation at health care facilities</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>The first 25 to 50 feet around the outside of a building should be considered a critical zone and regularly surveyed for fire ant infestation.</td> </tr> <tr> <td>Allow 18 to 20 inches of clear air space between the building and the mature height and width of ornamental plants.</td> </tr> <tr> <td>If irrigation is used, make sure sprinkler heads are pointed away from the building and not positioned so as to wet the building, thus providing moisture for insect infestation.</td> </tr> <tr> <td>Keep the soil grade sloping away from the building to prevent accumulation of water against the foundation.</td> </tr> <tr> <td>If rain gutters are used, make sure that down spouts are clear and water runs freely away from the facility.</td> </tr> <tr> <td>Contract with a pest control service to routinely inspect and (if appropriate) apply insecticides to keep the perimeter of health care facilities free of fire ant infestation.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Goddard J, Jarratt J, deShazo RD. Recommendations for prevention and management of fire ant infestation of health care facilities. South Med J 2002; 95:627. Copyright © 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51581 Version 14.0</div></div></div>"},"51582":{"type":"graphic_table","displayName":"Short stature versus delay of growth","title":"Differential features of familial short stature and constitutional delay of growth and puberty","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential features of familial short stature and constitutional delay of growth and puberty</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Feature </td> <td class=\"subtitle1\">Familial short stature </td> <td class=\"subtitle1\">Constitutional delay </td> </tr> <tr> <td>Parents' stature</td> <td>Small (one or both)</td> <td>Average</td> </tr> <tr> <td>Parents' puberty</td> <td>Usual timing</td> <td>Often delayed</td> </tr> <tr> <td>Birth length</td> <td>Normal or low-normal</td> <td>Normal</td> </tr> <tr> <td>Growth (zero to&nbsp;two years)</td> <td>Normal</td> <td>Slow from mid-infancy to mid-childhood</td> </tr> <tr> <td>Growth (two years to puberty)</td> <td>Normal</td> <td>Slow</td> </tr> <tr> <td>Bone age</td> <td>Normal</td> <td>Delayed</td> </tr> <tr> <td>Timing of puberty</td> <td>Normal</td> <td>Delayed</td> </tr> <tr> <td>Pubertal growth</td> <td>Rate low-normal</td> <td>Growth spurt delayed; rate slightly diminished</td> </tr> <tr> <td>Adult height</td> <td>Short</td> <td>Normal</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51582 Version 5.0</div></div></div>"},"51583":{"type":"graphic_picture","displayName":"Chronic anal fissure","title":"Chronic anal fissure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic anal fissure</div><div class=\"cntnt\"><img style=\"width:377px; height:252px;\" src=\"images/GAST/51583_Chronic_anal_fissure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph of a chronic anal fissure in the posterior midline (arrow), which is the most common site of fissure formation. The raised edges and fibrotic appearance at the base of this fissure distinguish it from an acute anal fissure, which appears like a fresh laceration.</div><div class=\"graphic_reference\">Reproduced by permission from the American Society of Colon and Rectal Surgeons.</div><div id=\"graphicVersion\">Graphic 51583 Version 3.0</div></div></div>"},"51584":{"type":"graphic_picture","displayName":"Familial colon cancer","title":"Familial colon cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Familial colon cancer</div><div class=\"cntnt\"><img style=\"width:372px; height:344px;\" src=\"images/GAST/51584_Familial_colon_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These images are from a 38-year-old man who was found to have heme positive stool. His father and two uncles died of colon cancer before the age of fifty. Panel A: The initial study was a barium enema (although a colonoscopy is more commonly used as the initial diagnostic study for heme positive stools). The barium enema reveals a filling defect in the cecum (arrow). Panels B and C: A CT scan of the abdomen shows a large exophytic mass (colored in pink in panel C) involving the cecum (arrows). Panel D: Colonoscopy reveals that the large exophytic lesion occupies most of the cecum. Adenocarcinoma was confirmed by biopsy. Despite the size of the lesion, the tumor had not spread beyond the colonic wall.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 51584 Version 2.0</div></div></div>"},"51585":{"type":"graphic_figure","displayName":"Nutrition label fiber PI","title":"Nutrition label","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Nutrition label</div><div class=\"cntnt\"><img style=\"width:546px; height:558px;\" src=\"images/PI/51585_NutrlabelfiberPIedt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an example of a nutrition label. To know how much fiber is in a food, look at the line that reads \"dietary fiber.\" This product has 3 grams of fiber in each serving.</div><div class=\"graphic_footnotes\">%: percent.</div><div id=\"graphicVersion\">Graphic 51585 Version 6.0</div></div></div>"},"51586":{"type":"graphic_diagnosticimage","displayName":"Normal gallbladder EUS","title":"Radial endoscopic ultrasound image of a normal gallbladder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radial endoscopic ultrasound image of a normal gallbladder</div><div class=\"cntnt\"><img style=\"width:322px; height:317px;\" src=\"images/GAST/51586_Normal_gallbladder_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The gallbladder (GB) comes into view when the transducer is in the antrum. It appears as an anechoic structure with a three-layered wall.</div><div class=\"graphic_reference\">Courtesy of Lyndon V. Hernandez, MD and Manoop S. Bhutani, MD.</div><div id=\"graphicVersion\">Graphic 51586 Version 3.0</div></div></div>"},"51592":{"type":"graphic_picture","displayName":"Extragenital lichen sclerosus in dark skin","title":"Extragenital lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Extragenital lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/51592_Extragen_lich_scl_dark_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrophic plaques with mottled hyperpigmentation are present on the shoulder and arm.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51592 Version 3.0</div></div></div>"},"51595":{"type":"graphic_table","displayName":"Coagulation factor levels required for hemostasis","title":"Coagulation factor levels required for hemostasis and plasma half-life","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Coagulation factor levels required for hemostasis and plasma half-life</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Factor </td> <td class=\"subtitle1\">Plasma half-life </td> <td class=\"subtitle1\">Hemostatic level* </td> </tr> <tr> <td>Fibrinogen</td> <td>2 to 4 days</td> <td>50 to&nbsp;100 mg/dL</td> </tr> <tr> <td>Prothrombin (factor II)</td> <td>3 to 4 days</td> <td>20 to 30%</td> </tr> <tr> <td>Factor V</td> <td>36 hours</td> <td>15 to 20%</td> </tr> <tr> <td>Factor VII</td> <td>4 to 6 hours</td> <td>15 to 20%</td> </tr> <tr> <td>Factor X</td> <td>40 to 60 hours</td> <td>15 to 20%</td> </tr> <tr> <td>Factor XI</td> <td>40 to 70 hours</td> <td>15 to 20%</td> </tr> <tr> <td>Factor XIII</td> <td>11 to 14 days</td> <td>10 to 15%</td> </tr> <tr> <td>Factor V + factor VIII combined deficiency</td> <td>36 hours for factor V and 10 to 14 hours for factor VIII</td> <td>15 to 20%<span style=\"font-size: 13px;\"><sup>&#182;</sup></span></td> </tr> <tr> <td>Multiple vitamin K-dependent factor deficiencies (factors II, VII, IX, X)</td> <td>​Refer to individual factor half-lives above</td> <td>15 to 20<span style=\"font-size: 13px;\">%</span></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on factor XI&nbsp;deficiency, rare inherited coagulation disorders, and fibrinogen disorders for details. </div><div class=\"graphic_footnotes\">* Level of factor activity generally required for hemostasis, expressed as a percent of normal except for fibrinogen, which is expressed in mg/dL.<br />¶&nbsp;Higher levels of factor VIII needed post-surgery.</div><div class=\"graphic_reference\">Adapted from: Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104:1243. Copyright © 2004 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 51595 Version 10.0</div></div></div>"},"51596":{"type":"graphic_table","displayName":"Stool electrolytes","title":"Interpretation of stool electrolytes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interpretation of stool electrolytes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"3\">Calculation of the osmotic gap </td> </tr> <tr> <td colspan=\"3\">Stool osmotic gap = 290 - estimated stool osmolality </td> </tr> <tr> <td colspan=\"3\">Estimated stool osmolality = 2 x ([Na<sub>stool</sub> + K<sub>stool</sub>]) </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"3\">Laboratory tests aiding the differentiation between secretory and osmotic diarrhea </td> </tr> <tr> <td class=\"subtitle2_single\">Laboratory tests </td> <td class=\"subtitle2_single\">Secretory </td> <td class=\"subtitle2_single\">Osmotic </td> </tr> <tr> <td class=\"indent1\">Osmotic gap </td> <td class=\"indent1\">&#60;50 mOsm/kg </td> <td class=\"indent1\">&#62;75 mOsm/kg </td> </tr> <tr> <td class=\"indent1\">pH </td> <td class=\"indent1\">Often &#62;6.0 </td> <td class=\"indent1\">Often &#60;6.0</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Richard Kellermayer, MD, PhD and Robert J Shulman, MD.</div><div id=\"graphicVersion\">Graphic 51596 Version 2.0</div></div></div>"},"51598":{"type":"graphic_diagnosticimage","displayName":"Comminuted metacarpal head fractures","title":"Comminuted metacarpal head fractures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comminuted metacarpal head fractures</div><div class=\"cntnt\"><img style=\"width:270px; height:360px;\" src=\"images/EM/51598_Metacarp_head_fx_commin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal appearance of the second metacarpal head can be compared to the comminuted fractures of the third (arrow) and fourth (arrowhead) metacarpal heads. There is also proximal displacement of two of the fragments of the third metacarpal.</div><div class=\"graphic_reference\">Courtesy of Kevin Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 51598 Version 6.0</div></div></div>"},"51599":{"type":"graphic_figure","displayName":"Open hernia groin incision","title":"Incision for open inguinal hernia repair","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Incision for open inguinal hernia repair</div><div class=\"cntnt\"><img style=\"width:462px; height:604px;\" src=\"images/SURG/51599_Open_hernia_groin_incision.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51599 Version 1.0</div></div></div>"},"51600":{"type":"graphic_waveform","displayName":"Retrograde atrial beat tutorial","title":"Retrograde atrial activation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retrograde atrial activation</div><div class=\"cntnt\"><img style=\"width:273px; height:102px;\" src=\"images/CARD/51600_Retrograde_atrial_beat_tuto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This rhythm strip of a junctional rhythm demonstrates negative P waves following the QRS complex as a result of retrograde atrial activation through the atrioventricular node.</div><div id=\"graphicVersion\">Graphic 51600 Version 2.0</div></div></div>"},"51601":{"type":"graphic_movie","displayName":"Ultrasound traumatic neuroma","title":"Ultrasound traumatic neuroma","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound traumatic neuroma</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/NEURO/51601_UStraumaticneuromaconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:448px; height:596px;\" src=\"images/NEURO/51601_UStraumaticneuroma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a real-time image of the median nerve at the wrist in a woman who had old self-inflected slash wounds on the wrist. Months after this, a small palpable cyst like structure developed that was sensitive to touch causing median nerve distribution paresthesias. Ultrasound shows a normal median nerve (N) distal and proximal to this enlarged cystic traumatic neuroma (TN), with demonstrable continuity both in the axial (first segment) and sagittal (second segment) plane as the probe is moved from the wrist proximally over the cystic structure.</div><div class=\"graphic_reference\">Courtesy of Francis O Walker, MD.</div><div id=\"graphicVersion\">Graphic 51601 Version 3.0</div></div></div>"},"51602":{"type":"graphic_figure","displayName":"Low sodium diet A","title":"Low-sodium diet","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Low-sodium diet</div><div class=\"cntnt\"><img style=\"width:580px; height:774px;\" src=\"images/GAST/51602_Low_sodium_diet_A.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51602 Version 2.0</div></div></div>"},"51604":{"type":"graphic_diagnosticimage","displayName":"Neuroblastoma","title":"Fetal neuroblastoma at 18 weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fetal neuroblastoma at 18 weeks of gestation</div><div class=\"cntnt\"><img style=\"width:396px; height:348px;\" src=\"images/OBGYN/51604_Neuroblastoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse view of fetal abdomen at gestational age of 18 weeks shows an echogenic mass adjacent to the spine. The differential diagnosis for a lesion in this location with this appearance is neuroblastoma or sequestration.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 51604 Version 2.0</div></div></div>"},"51605":{"type":"graphic_diagnosticimage","displayName":"MRI breast cancer","title":"Breast MRI","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Breast MRI</div><div class=\"cntnt\"><img style=\"width:461px; height:212px;\" src=\"images/ONC/51605_MRI_breast_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Staging breast magnetic resonance image (MRI) for invasive carcinoma poorly assessed on mammography. (A) Preconstrast 3-D FSPGR MRI image with fat suppression. (B) Postcontrast MRI delineates the extent of the invasive carcinoma as well as several clinically and mammographically occult satelite lesions (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Stomper, PC. Breast Imaging. In: Atlas of Breast Cancer, 2nd edition, Hayes, DF (Ed), Mosby, New York 2000. Copyright © 2000 Elsevier.</div><div id=\"graphicVersion\">Graphic 51605 Version 2.0</div></div></div>"},"51607":{"type":"graphic_table","displayName":"Static tests adrenal insufficiency","title":"Normal values for blood and urinary steroid hormone levels (unstimulated)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal values for blood and urinary steroid hormone levels (unstimulated)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Test</td> <td class=\"subtitle1\" colspan=\"2\">Normal values*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Serum cortisol<sup>&#182;</sup></td> <td class=\"subtitle2_left\" colspan=\"2\">micrograms/dL</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Premature infants (day 4)</td> <td>26 to 28 weeks</td> <td class=\"indent1\" colspan=\"2\">1 to 11 (6)</td> </tr> <tr> <td>31 to 35 weeks</td> <td class=\"indent1\" colspan=\"2\">2.5 to 9.1 (6.4)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Full-term infants</td> <td>3 days</td> <td class=\"indent1\" colspan=\"2\">1.7 to 14 (6.2)</td> </tr> <tr> <td>7 days</td> <td class=\"indent1\" colspan=\"2\">2 to 11 (4.4)</td> </tr> <tr> <td>31 days to 11 months</td> <td class=\"indent1\" colspan=\"2\">2.8 to 23 (9.4)</td> </tr> <tr> <td class=\"indent1\">Children</td> <td>12 months to 15 years (8:00 AM)</td> <td class=\"indent1\" colspan=\"2\">3 to 21 (9.8)</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Adults</td> <td>8:00 AM</td> <td class=\"indent1\" colspan=\"2\">8 to 19 (11)</td> </tr> <tr class=\"divider_bottom\"> <td>4:00 PM</td> <td class=\"indent1\" colspan=\"2\">4 to 11 (5.9)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Urinary 17-hydroxycorticosteroids (17-OHCS)</td> <td class=\"subtitle2_left\">mg/g creatinine</td> <td class=\"subtitle2_left\">mg/24 hours</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Prepubertal children</td> <td>1 to 4 years</td> <td class=\"indent1\">1.7 to 6.4 (4.1)</td> <td class=\"indent1\">0.2 to 2.5 (0.8)</td> </tr> <tr> <td>5 to 9 years</td> <td class=\"indent1\">2.2 to 6 (3.5)</td> <td class=\"indent1\">0.5 to 2.5 (1.2)</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Pubertal children and adults</td> <td>Male</td> <td class=\"indent1\">2.4 to 4.3 (3.2)</td> <td class=\"indent1\">3 to 10 (6.4)</td> </tr> <tr class=\"divider_bottom\"> <td>Female</td> <td class=\"indent1\">1.6 to 3.6 (2.3)</td> <td class=\"indent1\">2 to 6 (2.8)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Urinary free cortisol</td> <td class=\"subtitle2_left\">micrograms/g creatinine</td> <td class=\"subtitle2_left\">micrograms/24 hours</td> </tr> <tr> <td class=\"indent1\">Prepubertal children</td> <td>&nbsp;</td> <td class=\"indent1\">7 to 25 (15)</td> <td class=\"indent1\">3 to 9 (5.2)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Adults</td> <td>Male</td> <td class=\"indent1\">7 to 45 (21)</td> <td class=\"indent1\">11 to 84 (40)</td> </tr> <tr> <td>Female</td> <td class=\"indent1\">9 to 32 (19)</td> <td class=\"indent1\">10 to 34 (20)</td> </tr> <tr> <td>Pregnancy</td> <td class=\"indent1\">14 to 59 (38)</td> <td class=\"indent1\">16 to 60 (47)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Normal ranges and means (in parentheses) are based on reference ranges from Esoterix Laboratories, Calabasas Hills, California, and are used with permission. In other laboratories, plasma rather than serum cortisol may be measured, but the reference ranges are similar.<br />&para; Stress (physiological or psychological) may cause elevation of cortisol levels above the reference range.</div><div id=\"graphicVersion\">Graphic 51607 Version 3.0</div></div></div>"},"51608":{"type":"graphic_figure","displayName":"Reversible benefit ERT on BMD","title":"Reversible benefit of estrogen replacement therapy","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Reversible benefit of estrogen replacement therapy</div><div class=\"cntnt\"><img style=\"width:534px; height:260px;\" src=\"images/ENDO/51608_Reversible_benefit_ERT_on_B.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone mineral content in postmenopausal women during three years of treatment: the first two years with either placebo (red) or with estradiol cyclically combined with a small dose of norethisterone (blue); the women were then rerandomized to continued therapy or the other regimen in the third year. Estrogen therapy increased bone density when given as initial therapy (upper curve) and after two years of placebo. Replacement of estrogen with placebo led to a decline in bone density.</div><div class=\"graphic_reference\">Data from: Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981; 1:459.</div><div id=\"graphicVersion\">Graphic 51608 Version 2.0</div></div></div>"},"51611":{"type":"graphic_table","displayName":"Radiation toxicity hematopoietic","title":"Levels of hematopoietic toxicity following radiation exposure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Levels of hematopoietic toxicity following radiation exposure</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Degree</td> <td class=\"subtitle1\">ALC</td> <td class=\"subtitle1\">ANC</td> <td class=\"subtitle1\">Platelet count</td> <td class=\"subtitle1\">Bleeding and anemia</td> </tr> <tr> <td>0*</td> <td>1400 to 3500</td> <td>4000 to 9000</td> <td>140 to 400,000</td> <td>None</td> </tr> <tr> <td rowspan=\"2\">1</td> <td rowspan=\"2\">&#8805;1500</td> <td rowspan=\"2\">&#8805;2000</td> <td rowspan=\"2\">&#8805;100,000</td> <td>Petechie, bruising</td> </tr> <tr> <td>Normal Hgb level</td> </tr> <tr> <td rowspan=\"2\">2</td> <td rowspan=\"2\">1000 to 1500</td> <td rowspan=\"2\">1000 to 2000</td> <td rowspan=\"2\">50 to 100,000</td> <td>Mild blood loss</td> </tr> <tr> <td>&#60;10 percent decrease in Hgb</td> </tr> <tr> <td rowspan=\"2\">3</td> <td rowspan=\"2\">500 to 1000</td> <td rowspan=\"2\">500 to 1000</td> <td rowspan=\"2\">20 to 50,000</td> <td>Gross blood loss</td> </tr> <tr> <td>10 to 20 percent decrease in Hgb</td> </tr> <tr> <td rowspan=\"2\">4</td> <td rowspan=\"2\">&#60;500</td> <td rowspan=\"2\">&#60;500</td> <td rowspan=\"2\">&#60;20,000</td> <td>Spontaneous bleeding</td> </tr> <tr> <td>&#62;20 percent decrease in Hgb</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">7</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">8/26/2004 Perm requested Pull if no perm by 12.3 9/7/2004 Perm granted 6/3/2005 renewal requested 6/17/2005 they emailed for more info 6/28/2005 granted - need to note in each renewal the waselenko is the author since they don't carry over this info 7/24/2006 Renewal Requested 8/21/2006 bugged - informed that they only grant for one version at a time 8/21/2006 renewal granted (renew 15.1) 10/6/2006 renewal requested 10/11/2006 renewal granted for one year 11/28/2007--renewal requested. EM 1/8/2008--renewal granted. EM 12/30/2008--Requested renewal (JD). 1/14/2009--Renewal invoice recevied, to Susan; awaiting formal grant of permission (JD). 1/22/2009--Grant of permission received (JD). 2/4/2010--Renewal requested (JD). 2/12/2010--Renewal granted, paid on my AMEX (JD). The total fee of $&amp;quot;120.00&amp;quot;was originally charged to Radiation_tox_gastrointest Radiation_tox_hematopoietic Radiation_tox_cerebrovascular Radiation_biodosimetry Rx_guide_radiation_exposure Cytokines_radiation_exposure Military_triage_radiation</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=26438&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">ALC: absolute lymphocyte count in cells/microL; ANC: absolute neutrophil count in cells/microL; Platelet count: platelet count in cells/microL; Hgb: hemoglobin concentration.<BR>* Degree 0 represents normal reference values.</div><div class=\"graphic_reference\">Modified with permission from: Waselenko JK, MacVittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: Recommendations of the strategic national stockpile radiation working group. Ann Intern Med 2004; 140:1037. Copyright © 2004 American College of Physicians.</div><div id=\"graphicVersion\">Graphic 51611 Version 17.0</div></div></div>"},"51613":{"type":"graphic_picture","displayName":"Mononeuritis multiplex MPA","title":"Muscle wasting caused by nerve infarctions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Muscle wasting caused by nerve infarctions</div><div class=\"cntnt\"><img style=\"width:396px; height:261px;\" src=\"images/RHEUM/51613_Mononeuritis_multiplex_MPA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral atrophy of the muscle in the web space between the first and second metacarpal bones. The underlying diagnosis is microscopic polyangiitis.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 51613 Version 1.0</div></div></div>"},"51616":{"type":"graphic_waveform","displayName":"Electrocardiographic characteristics of the short QT syndrome","title":"Electrocardiographic characteristics of the short QT syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrocardiographic characteristics of the short QT syndrome</div><div class=\"cntnt\"><img style=\"width:426px; height:593px;\" src=\"images/CARD/51616_Electrocard_char_short_QT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A 12-lead ECG showing ECG characteristic of SQT1.<br> (B) A 12-lead ECG showing ECG characteristic of SQT4 displaying combined ECG phenotype of Brugada and short QT syndromes. Note that ECG shows Brugada type ST elevation in V1 and V2 after administration of ajmaline in addition to short QT intervals.</div><div class=\"graphic_reference\">Reproduced with permission from: Patel C, Yan GX, Antzelevitch C. Short QT syndrome: from bench to bedside. Circ Arrhythm Electrophysiol 2010; 3:401. Copyright © 2010 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51616 Version 6.0</div></div></div>"},"51617":{"type":"graphic_diagnosticimage","displayName":"Bipartite lateral (fibular) sesamoid","title":"Bipartite lateral (fibular) sesamoid (white arrow)","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Bipartite lateral (fibular) sesamoid (white arrow)</div><div class=\"cntnt\"><img style=\"width:480px; height:342px;\" src=\"images/EM/51617_Bipartite_lateral_sesamoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the rounded contour of the line separating the two pieces of the sesamoid, and the rounded corners of the distal piece. Cortication of the proximal edge of the distal piece can also be seen.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 51617 Version 3.0</div></div></div>"},"51618":{"type":"graphic_picture","displayName":"IPH dilatation portal vein","title":"Idiopathic portal hypertension (IPH)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Idiopathic portal hypertension (IPH)</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/GAST/51618_IPH_dilatation_portal_vein.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Masson's trichrome stain of a liver biopsy specimen in a patient with IPH showing marked abnormal dilatation of a portal vein radicle. The dilation is evident when comparing the portal vein radicle to the relatively small bile duct (BD) and hepatic artery (HA) in the portal triad.</div><div class=\"graphic_reference\">Courtesy of Rosa Miquel, MD.</div><div id=\"graphicVersion\">Graphic 51618 Version 2.0</div></div></div>"},"51620":{"type":"graphic_table","displayName":"Frequency of detection of carrier partners ","title":"Frequency of detection of carrier partners ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of detection of carrier&nbsp;partners </div><div class=\"cntnt\"><table style=\"width: 578px; height: 321px;\" cellspacing=\"0\">\n<tbody><tr>\n<td rowspan=\"2\" colspan=\"1\" class=\"subtitle1\">Cystic fibrosis mutations detectable,\npercent</td><td class=\"subtitle1\" rowspan=\"1\" colspan=\"3\">Detection\nof carrier status, percent</td>\n</tr>\n<tr>\n<td class=\"subtitle2\">Both parents</td>\n<td class=\"subtitle2\">One parent</td>\n<td class=\"subtitle2\">Neither parent</td>\n</tr><tr>\n<td>70</td>\n<td>49.0</td>\n<td>42.0</td>\n<td>9.0</td>\n</tr><tr>\n<td>75</td>\n<td>56.3</td>\n<td>37.5</td>\n<td>6.2</td>\n</tr><tr>\n<td>80</td>\n<td>64.0</td>\n<td>32.0</td>\n<td>4.0</td>\n</tr><tr>\n<td>85</td>\n<td>72.3</td>\n<td>25.5</td>\n<td>2.2</td>\n</tr><tr>\n<td>90</td>\n<td>81.0</td>\n<td>18.0</td>\n<td>1.0</td>\n</tr><tr>\n<td>95</td>\n<td>90.3</td>\n<td>9.5</td>\n<td>0.2</td>\n</tr></tbody>\n</table>\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=42214&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>CF_risk_couples_based_scree.htm</title></head></div><div class=\"graphic_lgnd\">The risk of having a child with cystic fibrosis (CF) is reduced, but not eliminated, when both members of the couple are tested and no CF mutations are identified. This table shows the proportion of high-risk couples (couples in which each member carries a CF gene) that are correctly identified according to the percentage of CF cases accounted for by the mutations in the screening panel. If each member of the couple is tested only for ΔF508, which accounts for 75 percent of all CF cases, 56 percent of couples who are truly at risk of having a child with CF will be correctly identified; if each member is tested for mutations that account for 90 percent of all CF cases (the screening panel that is most commonly used), 81 percent of at-risk couples will be correctly identified.</div><div class=\"graphic_reference\">Reproduced with permission from: Elias S, Annas GJ, Simpson JL. Carrier screening for cystic fibrosis: Implications for obstetric and gynecologic practice. Am J Obstet Gynecol 1991; 164:1077. Copyright © 1991 Mosby, Inc.</div><div id=\"graphicVersion\">Graphic 51620 Version 3.0</div></div></div>"},"51621":{"type":"graphic_algorithm","displayName":"Classification of unconjugated hyperbilirubinemia in children","title":"Classification of unconjugated hyperbilirubinemia in children and infants beyond the neonatal period","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Classification of unconjugated hyperbilirubinemia in children and infants beyond the neonatal period</div><div class=\"cntnt\"><img style=\"width:556px; height:467px;\" src=\"images/PEDS/51621_Class_unconj_hyperbili.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">G6PD: glucose-6-phosphate dehydrogenase deficiency.</div><div id=\"graphicVersion\">Graphic 51621 Version 4.0</div></div></div>"},"51622":{"type":"graphic_table","displayName":"Acquired dystonia","title":"Causes of acquired dystonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of acquired dystonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Perinatal brain injury</td> </tr> <tr> <td class=\"indent1\">Delayed-onset dystonia</td> </tr> <tr> <td class=\"indent1\">Dystonic cerebral palsy</td> </tr> <tr> <td class=\"subtitle1_single\">Cerebrovascular</td> </tr> <tr> <td class=\"indent1\">Ischemia</td> </tr> <tr> <td class=\"indent1\">Hemorrhage</td> </tr> <tr> <td class=\"indent1\">Arteriovenous malformation and aneurysm</td> </tr> <tr> <td class=\"subtitle1_left\">Brain injury</td> </tr> <tr> <td class=\"indent1\">Head trauma</td> </tr> <tr> <td class=\"indent1\">Brain surgery (including stereotactic ablations)</td> </tr> <tr> <td class=\"indent1\">Electrical injury</td> </tr> <tr> <td class=\"subtitle1_single\">Drug</td> </tr> <tr> <td class=\"indent1\">Anticonvulsants</td> </tr> <tr> <td class=\"indent1\">Calcium channel blockers</td> </tr> <tr> <td class=\"indent1\">Dopamine agonists</td> </tr> <tr> <td class=\"indent1\">Levodopa</td> </tr> <tr> <td class=\"indent1\">Neuroleptics/antiemetics (dopamine receptor blocking drugs) including metoclopramide</td> </tr> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td class=\"indent1\">Encephalitis lethargica</td> </tr> <tr> <td class=\"indent1\">Human immunodeficiency virus (HIV) infection</td> </tr> <tr> <td class=\"indent1\">Subacute sclerosing panencephalitis</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"indent1\">Viral encephalitis</td> </tr> <tr> <td class=\"subtitle1_single\">Neoplastic</td> </tr> <tr> <td class=\"indent1\">Brain tumor</td> </tr> <tr> <td class=\"indent1\">Paraneoplastic encephalitis</td> </tr> <tr> <td class=\"subtitle1_single\">Toxic</td> </tr> <tr> <td class=\"indent1\">3-nitropropionic acid</td> </tr> <tr> <td class=\"indent1\">Carbon disulfide</td> </tr> <tr> <td class=\"indent1\">Cobalt</td> </tr> <tr> <td class=\"indent1\">Cyanide</td> </tr> <tr> <td class=\"indent1\">Disulfiram</td> </tr> <tr> <td class=\"indent1\">Manganese</td> </tr> <tr> <td class=\"indent1\">Methanol</td> </tr> <tr> <td class=\"subtitle1_single\">Psychogenic (functional)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013; 28:863.</div><div id=\"graphicVersion\">Graphic 51622 Version 3.0</div></div></div>"},"51623":{"type":"graphic_table","displayName":"Local sx CNS tumor child","title":"Signs and symptoms of pediatric central nervous system tumors based on tumor location","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms of pediatric central nervous system tumors based on tumor location</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Tumor location</td> <td class=\"subtitle1\">Presenting signs/symptoms</td> </tr> <tr> <td>Cerebral cortex</td> <td>Headache, seizures, hemiparesis, hyperreflexia, clonus, sensory loss, speech disturbances, memory deficits, personality changes</td> </tr> <tr> <td>Posterior fossa</td> <td>Nausea and vomiting, headache, abnormal gait and coordination, papilledema, abnormal eye movements</td> </tr> <tr> <td>Brain stem</td> <td>Cranial nerve deficits, gait and coordination disturbances, nystagmus, focal motor weakness, signs of increased ICP including headache and papilledema</td> </tr> <tr> <td>Spinal cord</td> <td>Radicular pain and/or weakness (symptoms correspond to level of lesion); loss of bowel/bladder control; gait abnormalities</td> </tr> <tr> <td>Optic pathway</td> <td>Visual disturbances; proptosis; nystagmus</td> </tr> <tr> <td>Hypothalamus</td> <td>Endocrine disturbances including diabetes insipidus and growth failure</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICP: intracranial pressure.</div><div id=\"graphicVersion\">Graphic 51623 Version 2.0</div></div></div>"},"51624":{"type":"graphic_diagnosticimage","displayName":"Atlanto occipital disassociation","title":"Atlanto-occipital disassociation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atlanto-occipital disassociation</div><div class=\"cntnt\"><img style=\"width:360px; height:368px;\" src=\"images/EM/51624_Atlanto_occipital_dissoctn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe flexion injuries involving the atlas (C1) can cause an atlanto-occipital dislocation or disassociation.</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD.</div><div id=\"graphicVersion\">Graphic 51624 Version 3.0</div></div></div>"},"51625":{"type":"graphic_figure","displayName":"Thumbs up sign","title":"Thumb's up sign","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Thumb's up sign</div><div class=\"cntnt\"><img style=\"width:531px; height:218px;\" src=\"images/EM/51625_Thumbs_up_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This thumb motion indicates intact radial nerve motor function.</div><div id=\"graphicVersion\">Graphic 51625 Version 1.0</div></div></div>"},"51629":{"type":"graphic_picture","displayName":"Squamous CA lung cytology","title":"Squamous cell carcinoma of the lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Squamous cell carcinoma of the lung</div><div class=\"cntnt\"><img style=\"width:397px; height:263px;\" src=\"images/PULM/51629_Squamous_CA_lung_cytology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cytology specimen showing the typical appearance of squamous cell carcinoma of the lung. The malignant cell has an enlarged hyperchromatic nucleus and darkly staining cytoplasm with an irregular configuration including a cytoplasmic tail (arrow).</div><div class=\"graphic_reference\">Courtesy of Jeffrey Myers, MD.</div><div id=\"graphicVersion\">Graphic 51629 Version 1.0</div></div></div>"},"51630":{"type":"graphic_figure","displayName":"Interscalene brachial plexus block","title":"Interscalene brachial plexus block","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Interscalene brachial plexus block</div><div class=\"cntnt\"><img style=\"width:506px; height:506px;\" src=\"images/SURG/51630_Interscalenebpblock.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sternal notch, sternal and clavicular heads of sternocleidomastoid muscle, and clavicle are identified and marked. The groove between the anterior and middle scalene muscles is palpated. For ultrasound-guided block, the ultrasound probe is placed as shown by the rectangle in this graphic. For either&nbsp;ultrasound-guided block or nerve stimulator-guided block, the needle insertion site is approximated by the red dot. See the text for description of block technique.</div><div id=\"graphicVersion\">Graphic 51630 Version 4.0</div></div></div>"},"51631":{"type":"graphic_picture","displayName":"Storz pediatric video laryngoscope","title":"Storz pediatric video laryngoscope","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Storz pediatric video laryngoscope</div><div class=\"cntnt\"><img style=\"width:294px; height:540px;\" src=\"images/EM/51631_Storz_ped_laryn.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Copyright &#169; 2011. Photo courtesy of KARL STORZ Endoscopy-America, Inc.</div><div id=\"graphicVersion\">Graphic 51631 Version 1.0</div></div></div>"},"51632":{"type":"graphic_picture","displayName":"Pyogenic flexor tenosynovitis","title":"Pyogenic flexor tenosynovitis","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Pyogenic flexor tenosynovitis</div><div class=\"cntnt\"><img style=\"width:548px; height:366px;\" src=\"images/SURG/51632_Pyogenic_flexor_tenosyn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In patients with pyogenic flexor tenosynovitis, four classic signs are described (Kanavel signs) including fusiform swelling of the whole finger, partially flexed posture of the finger, tenderness limited to the course of the flexor tendon sheath, and disproportionate pain on passive extension of the finger. The photographs illustrate the fusiform swelling of the finger and the partially flexed posture of the finger.</div><div id=\"graphicVersion\">Graphic 51632 Version 2.0</div></div></div>"},"51633":{"type":"graphic_figure","displayName":"Histologic image of cortical and cancellous bone","title":"Histologic image of cortical and cancellous bone","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Histologic image of cortical and cancellous bone</div><div class=\"cntnt\"><img style=\"width:548px; height:374px;\" src=\"images/ENDO/51633_Histoimgcorticalcancel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two-dimensional histologic images of cortical and cancellous bone from iliac bone biopsies taken from a normal individual (left panel) and a patient with osteoporosis (right panel). Please note that in the osteoporotic patient, the cortices are thinner and more porous and the trabeculae are fewer, thinner, disconnected, and further apart.</div><div class=\"graphic_reference\">Courtesy of Dr. Robert Weinstein, University of Arkansas for Medical Sciences.</div><div id=\"graphicVersion\">Graphic 51633 Version 3.0</div></div></div>"},"51634":{"type":"graphic_figure","displayName":"Spondylolysis","title":"Spondylolysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spondylolysis</div><div class=\"cntnt\"><img style=\"width:429px; height:427px;\" src=\"images/PEDS/51634_Spondylolysis_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oblique radiographs in patients with spondylolysis reveal the defect at the pars interarticularis as a crack or collar on the neck of the &quot;Scotty dog.&quot;</div><div class=\"graphic_reference\">Reproduced with permission from: Smith JA, Hu SS. Management of spondylolysis and spondylolsisthesis in the pediatric and adolescent population. Orthop Clin North Am 1999; 30:487. Copyright &#169; 1999 Elsevier.</div><div id=\"graphicVersion\">Graphic 51634 Version 4.0</div></div></div>"},"51635":{"type":"graphic_figure","displayName":"Fat content of oils","title":"Fat content of oils","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Fat content of oils</div><div class=\"cntnt\"><img style=\"width:463px; height:358px;\" src=\"images/PC/51635_Fat_content_of_oils_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When fats are needed for cooking, spreads, and other uses, oils with higher amounts of monounsaturated and/or polyunsaturated fatty acids should be used, such as canola oil and olive oil. Those oils that are higher in n-3 polyunsaturated fats (alpha-linolenic acid [ALA]), such as walnut oil and, to a lesser extent, soybean oil, are also beneficial. Linoleic acid (LA) is an n-6 polyunsaturated fatty acid.</div><div id=\"graphicVersion\">Graphic 51635 Version 9.0</div></div></div>"},"51636":{"type":"graphic_figure","displayName":"Schematic diagram mammogram","title":"Schematic diagram of a mammogram","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Schematic diagram of a mammogram</div><div class=\"cntnt\"><img style=\"width:502px; height:530px;\" src=\"images/PC/51636_Schematic_diagram_mammogram.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51636 Version 2.0</div></div></div>"},"51638":{"type":"graphic_figure","displayName":"Cobb angles","title":"Cobb angles in kyphoscoliosis","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Cobb angles in kyphoscoliosis</div><div class=\"cntnt\"><img style=\"width:463px; height:322px;\" src=\"images/PULM/51638_Cobbangles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematized posteroanterior chest radiograph (left) demonstrates the lines constructed to measure the Cobb angle of scoliosis. Schematized lateral chest roentgenogram (right) shows the Cobb angle of kyphosis.</div><div class=\"graphic_reference\">Adapted from McCool, FD, Rochester, DF. The lungs and chest Wall diseases. In: Textbook of Respiratory Medicine, 2nd ed, Vol 2, Murray, JF, Nadel, JA (Eds), W.B. Saunders, Philadelphia 1994.</div><div id=\"graphicVersion\">Graphic 51638 Version 1.0</div></div></div>"},"51639":{"type":"graphic_picture","displayName":"Lung transplant rejection","title":"Chronic lung transplant rejection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic lung transplant rejection</div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/PULM/51639_Lung_transplant_rejection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peribronchiolar fibrosis in chronic lung transplant rejection. Photomicrograph demonstrating fibrosis around the lumen of a small airway.</div><div class=\"graphic_reference\">Courtesy of L Kobzik, MD.</div><div id=\"graphicVersion\">Graphic 51639 Version 1.0</div></div></div>"},"51644":{"type":"graphic_table","displayName":"ESC risk stratification WPW","title":"Recommendations for risk stratification for sudden cardiac death proposed by the European Society of Cardiology (ESC): Wolff-Parkinson-White syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for risk stratification for sudden cardiac death proposed by the European Society of Cardiology (ESC): Wolff-Parkinson-White syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Finding</td> <td class=\"subtitle1_single\">Recommendations</td> </tr> <tr> <td>Short (&#60;250 ms) RR interval during atrial fibrillation</td> <td>Class IIa</td> </tr> <tr> <td>Short (&#60;270 ms) anterograde refractory period of the accessory pathway</td> <td>Class IIa</td> </tr> <tr> <td>Multiple accessory pathways</td> <td>Class IIa</td> </tr> <tr> <td>Loss of pre-excitation ajmaline or procainamide test (lower risk)</td> <td>Class IIb</td> </tr> <tr> <td>Syncope</td> <td>Class III</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Classification</td> </tr> <tr> <td colspan=\"2\"><strong>Class I:</strong> Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Class II:</strong> Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\"><strong>Class IIa:</strong> Weight of evidence/opinion is in favor of usefulness/efficacy.</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\"><strong>Class IIb:</strong> Usefulness/efficacy less well established by evidence/opinion.</td> </tr> <tr> <td colspan=\"2\"><strong>Class III:</strong> Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Recommendations from the European Society of Cardiology for additional risk stratification for sudden cardiac death in patients with specific clinical findings in the setting of Wolff-Parkinson-White syndrome.</div><div class=\"graphic_reference\">Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Eur Heart J 2001; 22:1374.</div><div id=\"graphicVersion\">Graphic 51644 Version 3.0</div></div></div>"},"51645":{"type":"graphic_algorithm","displayName":"SVT chronic management","title":"Overview of the chronic management of supraventricular tachycardia in children","html":"<div class=\"graphic\"><div style=\"width: 666px\" class=\"figure\"><div class=\"ttl\">Overview of the chronic management of&nbsp;supraventricular tachycardia in children</div><div class=\"cntnt\"><img style=\"width:646px; height:679px;\" src=\"images/PEDS/51645_ChronicSVTmanagementchil.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">This algorithm is intended for use in conjunction with additional UpToDate content on SVT in children. Refer to UpToDate topics on the management of SVT in children for additional details of our approach to treatment and the overall efficacy of these treatments.<br />SVT: supraventricular tachycardia; WPW: Wolff-Parkinson-White; RFA: radiofrequency ablation.<br />* Infants &lt;1 year old with recurrent and/or refractory SVT present a management challenge. An overview of initial treatment options is provided here. For additional details, refer to UpToDate content on SVT in infancy.<br />¶ Digoxin should not be used in patients with WPW syndrome because it can accelerate conduction across the accessory pathway.<br />Δ In expectant management, no specific treatment is provided. The child is monitored for at least 24 hours and the parents are taught to recognize SVT and to terminate episodes using vagal maneuvers (eg, applying an ice bag to the face, performing the Valsalva maneuver, assuming a head-down position, inducing the gag reflex).</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>​Philip Saul J, Kanter RJ, Abrams D, et al. PACES/HRS expert consensus statement on the use of catheter ablation in children and patients with congenital heart disease: Developed in partnership with the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American Academy of Pediatrics (AAP), the American Heart Association (AHA), and the Association for European Pediatric and Congenital Cardiology (AEPC). Heart Rhythm 2016; 13:e251.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 51645 Version 3.0</div></div></div>"},"51646":{"type":"graphic_table","displayName":"Secretory products gastrin","title":"Secretory granule products derived from preprogastrin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Secretory granule products derived from preprogastrin</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Progastrin</td>\n</tr>\n<tr>\n<td>Glycine-extended gastrin-17</td>\n</tr>\n<tr>\n<td>Glycine-extended gastrin-34</td>\n</tr>\n<tr>\n<td>Gastrin-71</td>\n</tr>\n<tr>\n<td>Gastrin-34</td>\n</tr>\n<tr>\n<td>Gastrin-17</td>\n</tr>\n<tr>\n<td>Gastrin-6</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 51646 Version 1.0</div></div></div>"},"51647":{"type":"graphic_table","displayName":"Examination of disabled women","title":"Facilitating the gynecologic examination of disabled women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Facilitating the gynecologic examination of disabled women</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td>Make modifications in office layout and equipment and train staff to meet the physical and informational needs of disabled patients. In particular, the office should be accessible; communication should be possible despite cognitive or sensory impairment; and staff should be trained in safe techniques for transfer of the patient to the examining table.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Ask if the woman feels her disability affects her reproductive functions. Address all gynecologic issues, as appropriate: sexual activity, contraception, menstrual cycles, cancer screening, preconceptional issues, menopause, and osteoporosis.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Understand the medical issues of patients with disabilities</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Allow extra time for the appointment and have extra staff available, if needed</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Inquire about a history of physical or sexual abuse as these women are at increased risk</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>A frog-legged or lateral position may be easier to achieve than the lithotomy position for examination. If examination is still not possible, use of ultrasonography, sedation, or anesthesia are options.</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_reference\">Adapted from American College of Obstetricians and Gynecologists. Women with Disabilities. In: Guidelines for Women's Health Care. 2nd edition, Washington, DC, 2002.</div><div id=\"graphicVersion\">Graphic 51647 Version 2.0</div></div></div>"},"51649":{"type":"graphic_figure","displayName":"Predicting platelet recovery","title":"Predicting recovery of the platelet count post chemotherapy","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Predicting recovery of the platelet count post chemotherapy</div><div class=\"cntnt\"><img style=\"width:500px; height:283px;\" src=\"images/HEME/51649_Predicting_platelet_recover.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graph indicates the ability of two different measurements of \"reticulated\" platelets to predict spontaneous recovery of platelet counts following chemotherapy. The two measurements shown are percent reticulated platelets (x-axis) and the mean fluorescence of reticulated platelets (platelet maturation index, y-axis). Patients with at least a 20,000/microL increase in platelet count over the ensuing 48 hours without platelet transfusion are shown as closed red circles, while those not showing spontaneous recovery within this time period are shown as open blue circles. When both parameters were normal or low (ie, data points falling within the box outlined with dashes) spontaneous recovery within the next 48 hours was not seen, with a negative predictive value of 91 percent. When one or both parameters were increased (ie, data points falling outside of the box), recovery within 48 hours was predicted with a postive predictive value of 82 percent.</div><div class=\"graphic_reference\">Data from:&nbsp;Wang C, Smith BR, Ault KA, Rinder HM. Reticulated platelets predict platelet count recovery following chemotherapy. Transfusion 2002; 42:368.</div><div id=\"graphicVersion\">Graphic 51649 Version 2.0</div></div></div>"},"51651":{"type":"graphic_picture","displayName":"Flanged mouthpiece for pulmonary function testing","title":"Flanged mouthpiece for pulmonary function testing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flanged mouthpiece for pulmonary function testing</div><div class=\"cntnt\"><img style=\"width:400px; height:348px;\" src=\"images/PULM/51651_flang_mouth_pulm_funct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An example of a flanged rubber mouthpiece for pulmonary function testing. For patients with spinal cord injury a flanged mouthpiece can be used for tests of inspiratory muscle strength.</div><div id=\"graphicVersion\">Graphic 51651 Version 2.0</div></div></div>"},"51652":{"type":"graphic_figure","displayName":"Powers ratio for cervical spine","title":"Powers ratio for cervical spine","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Powers ratio for cervical spine</div><div class=\"cntnt\"><img style=\"width:501px; height:516px;\" src=\"images/EM/51652_Powers-ratio-for-cervical-spine.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51652 Version 4.0</div></div></div>"},"51653":{"type":"graphic_table","displayName":"Kinetics of common first generation antipsychotics","title":"Kinetics of common first generation antipsychotic medications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Kinetics of common first generation antipsychotic medications</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Drug\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Time to peak serum level after oral dosing (hours)\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Elimination half-life (hours)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Chlorpromazine</td>\r\n  \r\n   <td>3</td>\r\n  \r\n   <td>6 (range: 2 to 119)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Haloperidol</td>\r\n  \r\n   <td>--</td>\r\n  \r\n   <td>10 to 38</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hydroxyzine</td>\r\n  \r\n   <td>--</td>\r\n  \r\n   <td>3 to 20</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Perphenazine</td>\r\n  \r\n   <td>--</td>\r\n  \r\n   <td>8 to 12</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Prochlorperazine</td>\r\n  \r\n   <td>2 to 4*</td>\r\n  \r\n   <td>7 to 9</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Promethazine</td>\r\n  \r\n   <td>--</td>\r\n  \r\n   <td>7 to 15</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Thioridazine</td>\r\n  \r\n   <td>--</td>\r\n  \r\n   <td>21 to 24</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Thiothixene</td>\r\n  \r\n   <td>1 to 2</td>\r\n  \r\n   <td>34</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Trifluoperazine</td>\r\n  \r\n   <td>2 to 4</td>\r\n  \r\n   <td>24</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">* Longer if sustained-release formulation is ingested.</div><div id=\"graphicVersion\">Graphic 51653 Version 2.0</div></div></div>"},"51655":{"type":"graphic_algorithm","displayName":"Initial approach to pediatric tachycardia","title":"Initial approach to the child with tachycardia*","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Initial approach to the child with tachycardia*</div><div class=\"cntnt\"><img style=\"width:504px; height:305px;\" src=\"images/EM/51655_Tachycardia_initial_app.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HF: heart failure; SVT: supraventricular tachycardia; VT: ventricular tachycardia.<br>* Also see Algorithm 2: Pediatric advanced life support, Algorithm 3: Causes of shock, and Algorithm 4: Tachycardia, no shock.<br>&#8226; Causes of VT/torsades de pointes include prolonged QT syndrome, drug toxicity (cyclic antidepressants), myocarditis, structural heart disease, and electrolyte disturbance (hyperkalemia, hypokalemia, hypocalcemia, hypomagnesemia).<br>&#916; Causes of SVT include structural heart disease, WPW, and drugs (eg, sympathomimetics).</div><div id=\"graphicVersion\">Graphic 51655 Version 2.0</div></div></div>"},"51656":{"type":"graphic_algorithm","displayName":"Evaluation of a child with CP","title":"Algorithm for the evaluation of the child with cerebral palsy (CP)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for the evaluation of the child with cerebral palsy (CP)</div><div class=\"cntnt\"><img style=\"width:381px; height:753px;\" src=\"images/PEDS/51656_EvaluationCP.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CP: cerebral palsy; EEG: electroencephalogram; MRI: magnetic resonance imaging; CT: computed tomography, TORCH: toxoplasmosis, other, rubella, cytomegalovirus, herpes simplex virus.<br />* CP is generally classified into one of several subtypes based upon the type and distribution of motor abnormalities, which often correlate to location of injury. However, it is important to recognize that there is substantial overlap in these classifications and clinical features often change over time. For further details, refer to separate UpToDate topics on clinical features of CP.<br />¶ For details of laboratory evaluation for thrombophilia, refer to separate UpToDate content on screening for inherited thrombophilia in children.<br />Δ Metabolic and genetic testing are generally warranted if there are atypical symptoms, atypical MRI findings, or if no etiology is identified by clinical history and neuroimaging. Findings that might suggest a metabolic or genetic etiology include deterioration or episodes of metabolic decompensation, dysmorphic features, and/or a family history or childhood neurologic disorder associated with CP. For additional details, refer to UpToDate topic on evaluation and diagnosis of CP and separate topics on inborn errors of metabolism.<br />◊ For details of evaluation for suspected congenital infection, refer to separate UpToDate content on TORCH infections and individual topics on each infection.</div><div class=\"graphic_reference\">Modified with permission from: Ashwal S, Russman BS, Blasco PA, et al. Practice Parameter: Diagnostic assessment of the child with cerebral palsy: Report of the Quality Standards Subcommittee of the American Neurology and the Practice Committee of the Child Neurology Society. Neurology 2004; 62:851. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51656 Version 12.0</div></div></div>"},"51657":{"type":"graphic_diagnosticimage","displayName":"Left upper lobe atelectasis A","title":"Left upper lobe atelectasis in a child with cystic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Left upper lobe atelectasis in a child with cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:573px; height:332px;\" src=\"images/PEDS/51657_Left_upper_lobe_atelectasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiographs of an eight-year-old girl with cystic fibrosis, recent wheezing, increased cough and secretions, and diminished breath sounds in left upper lobe. Upright frontal radiograph reveals relatively increased opacity of the left lung and indistinctness of the left mediastinal border. The lateral view shows anterior displacement of the major fissure caused by left upper lobe atelectasis.</div><div id=\"graphicVersion\">Graphic 51657 Version 3.0</div></div></div>"},"51658":{"type":"graphic_table","displayName":"Mechanism exercise on mortality","title":"Possible biologic mechanisms for exercise-induced reductions in all-cause and cardiac mortality","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Possible biologic mechanisms for exercise-induced reductions in all-cause and cardiac mortality</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Cardiovascular influences</td>\n</tr>\n<tr>\n<td>Reduction of resting and exercise heart rate</td>\n</tr>\n<tr>\n<td>Reduction of resting and exercise blood pressure</td>\n</tr>\n<tr>\n<td>Reduction of myocardial oxygen demand at submaximal levels of physical activity</td>\n</tr>\n<tr>\n<td>Expansion of plasma volume</td>\n</tr>\n<tr>\n<td>Increase in myocardial contractility</td>\n</tr>\n<tr>\n<td>Increase in peripheral venous tone</td>\n</tr>\n<tr>\n<td>Favorable changes in fibrinolytic system</td>\n</tr>\n<tr>\n<td>Increased endothelium-dependent vasodilation</td>\n</tr>\n<tr>\n<td>Increased gene expression for nitric oxide synthase</td>\n</tr>\n<tr>\n<td>Enhanced parasympathetic tone</td>\n</tr>\n<tr>\n<td>Possible increases in coronary blood flow, coronary collateral vessels, and myocardial capillary density</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Metabolic influences</td>\n</tr>\n<tr>\n<td>Reduction of obesity</td>\n</tr>\n<tr>\n<td>Enhanced glucose tolerance</td>\n</tr>\n<tr>\n<td>Improved lipid profile</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Lifestyle influences</td>\n</tr>\n<tr>\n<td>Decreased liklihood of smoking</td>\n</tr>\n<tr>\n<td>Possible reduction of stress</td>\n</tr>\n<tr>\n<td>Short-term reduction of appetite</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">2.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=6202&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Mechanism_exercise_on_morta.htm</title></head></div><div class=\"graphic_reference\">Data from: Shepard RJ, Balady GJ. Circulation 1999; 99:963.</div><div id=\"graphicVersion\">Graphic 51658 Version 3.0</div></div></div>"},"51659":{"type":"graphic_diagnosticimage","displayName":"Lymph node enlargement CT","title":"Supraclavicular lymph node enlargement","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Supraclavicular lymph node enlargement</div><div class=\"cntnt\"><img style=\"width:543px; height:213px;\" src=\"images/PULM/51659_Lymph_node_enlargement_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows left (left panel) and right (right panel) supraclavicular node enlargement (N) in patients with bronchogenic carcinoma. Spread to the supraclavicular lymph nodes indicates N3 involvement.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 51659 Version 3.0</div></div></div>"},"51660":{"type":"graphic_diagnosticimage","displayName":"Pleural effusion decubitus","title":"Free layering pleural effusion","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Free layering pleural effusion</div><div class=\"cntnt\"><img style=\"width:567px; height:288px;\" src=\"images/PULM/51660_Pleural_effusion_decubitus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A shows blunting of the right costophrenic sulcus (arrow) on an upright chest radiograph due to the presence of a pleural effusion. Panel B shows a right lateral decubitus radiograph from the same patient, and reveals layering of pleural effusion (arrowhead). Effusions thicker than 1 cm on decubitus views are usually large enough for sampling with thoracentesis.</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 51660 Version 3.0</div></div></div>"},"51661":{"type":"graphic_picture","displayName":"Stellate lesions II","title":"Pulmonary Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:399px; height:263px;\" src=\"images/PULM/51661_Stellate_lesions_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph shows a stellate lesion that is characteristic of pulmonary Langerhans cell histiocytosis.</div><div class=\"graphic_reference\">From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.</div><div id=\"graphicVersion\">Graphic 51661 Version 1.0</div></div></div>"},"51666":{"type":"graphic_figure","displayName":"Timing of onset of postoperative infection and fever","title":"Timing of onset of postoperative infection and fever","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Timing of onset of postoperative infection and fever</div><div class=\"cntnt\"><img style=\"width:408px; height:502px;\" src=\"images/SURG/51666_Timing_of_postop_fever.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The timing of fever after surgery is one of the most important characteristics in ordering the differential diagnosis of fever in postoperative patients.</div><div class=\"graphic_reference\">Data from: Garibaldi RA, Brodine S, Matsumiya S, Coloman M, Infect Control 1985; 6:273.</div><div id=\"graphicVersion\">Graphic 51666 Version 5.0</div></div></div>"},"51668":{"type":"graphic_picture","displayName":"Escharotomies dorsal hand","title":"Escharotomies of the burned hand","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Escharotomies of the burned hand</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/SURG/51668_Escharotomies_dorsal_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Escharotomies have been made in the dorsal right hand to release the constriction and restore blood flow to the hand and digits. The longitudinal full thickness incisions are made in the intermetacarpal spaces, avoiding exposure of the tendons and joints. The radial and ulnar incisions are carried proximally onto the wrist.</div><div id=\"graphicVersion\">Graphic 51668 Version 2.0</div></div></div>"},"51669":{"type":"graphic_table","displayName":"Primary palliative care assessment components","title":"Primary palliative care assessment components","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Primary palliative care assessment components</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Pain/symptom assessment</td> </tr> <tr> <td>Are there distressing physical or psychological symptoms?</td> </tr> <tr> <td class=\"subtitle1_single\">Social/spiritual assessment</td> </tr> <tr> <td>Are there significant social or spiritual concerns affecting daily life?</td> </tr> <tr> <td class=\"subtitle1_single\">Understanding of illness/prognosis and treatment options</td> </tr> <tr> <td>Does the patient/family/surrogate understand the current illness, prognostic trajectory, and treatment options?</td> </tr> <tr> <td class=\"subtitle1_single\">Identification of patient-centered goals of care</td> </tr> <tr> <td>What are the goals for care, as identified by the patient/family/surrogate?</td> </tr> <tr> <td>Are treatment options matched to informed patient-centered goals?</td> </tr> <tr> <td>Has the patient participated in an advance care planning process?</td> </tr> <tr> <td>Has the patient completed an advance care planning document?</td> </tr> <tr> <td class=\"subtitle1_single\">Transition of care post-discharge</td> </tr> <tr> <td>What are the key considerations for a safe and sustainable transition from one setting to another?</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Weissman DE, Meier DE. Identifying patients in need of a palliative care assessment in the hospital setting. J Palliat Med 2011; 14:17. Copyright &#169; 2011 Mary Ann Liebert, Inc.</div><div id=\"graphicVersion\">Graphic 51669 Version 2.0</div></div></div>"},"51670":{"type":"graphic_figure","displayName":"AF remodeling","title":"AF remodeling","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">AF remodeling</div><div class=\"cntnt\"><img style=\"width:575px; height:471px;\" src=\"images/CARD/51670_AF_remodeling.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mechanisms underlying ATR. Rapid atrial rates increase potentially cytotoxic Ca<SUP>2+</SUP> loading. Autoprotective I<SUB>Ca,L</SUB> reductions occur via rapidly developing functional changes (I<SUB>Ca,L</SUB> inactivation) and more slowly developing changes in gene and protein expression. Decreased I<SUB>Ca,L</SUB> reduces Ca<SUP>2+</SUP> loading but decreases APD. Diminished APD shortens refractoriness and reduces the wavelength (WL), which allows for smaller and more atrial reentry circuits, thus making AF unlikely to terminate. Atrial tachycardia also increases inward-rectifier currents such as I<SUB>K1</SUB> and I<SUB>K,ACh,c</SUB>, which further reduces APD and promotes AF.</div><div class=\"graphic_footnotes\">RP: refractory period; WL: wavelength.</div><div class=\"graphic_reference\">Reproduced with permission from: Nattel S, Burstein B, Dobrev D. Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications. Circ Arrhythm Electrophysiol 2008; 1:62. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51670 Version 8.0</div></div></div>"},"51671":{"type":"graphic_table","displayName":"Activation criteria for rapid response systems","title":"Examples of published activation criteria for rapid response systems","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of published activation criteria for rapid response systems</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Bellomo calling criteria<sup>[1]</sup></td> </tr> <tr> <td class=\"subtitle2_single\">If one of these is present:</td> </tr> <tr> <td class=\"indent1\">Staff member is worried about the patient</td> </tr> <tr> <td class=\"indent1\">Acute change in heart rate to &#60;40 or &#62;130 beats/min</td> </tr> <tr> <td class=\"indent1\">Acute change in systolic blood pressure to &#60;90 mmHg</td> </tr> <tr> <td class=\"indent1\">Acute change in respiratory rate &#60;8 or &#62;30 breaths/min</td> </tr> <tr> <td class=\"indent1\">Acute change in pulse oximetry saturation to &#60;90 percent despite oxygen administration</td> </tr> <tr> <td class=\"indent1\">Acute change in conscious state</td> </tr> <tr> <td class=\"indent1\">Acute change in urine output to &#60;50 mL in 4 hours</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">MERIT calling criteria<sup>[2]</sup></td> </tr> <tr> <td class=\"subtitle2_single\">Airway:</td> </tr> <tr> <td class=\"indent1\">If threatened</td> </tr> <tr> <td class=\"subtitle2_single\">Breathing:</td> </tr> <tr> <td class=\"indent1\">All respiratory arrests</td> </tr> <tr> <td class=\"indent1\">Respiratory rate &#60;5 breaths/min</td> </tr> <tr> <td class=\"indent1\">Respiratory rate &#62;36 breaths/min</td> </tr> <tr> <td class=\"subtitle2_single\">Circulation:</td> </tr> <tr> <td class=\"indent1\">All cardiac arrests</td> </tr> <tr> <td class=\"indent1\">Pulse rate &#60;40 beats/min</td> </tr> <tr> <td class=\"indent1\">Pulse rate &#62;140 beats/min</td> </tr> <tr> <td class=\"indent1\">Systolic blood pressure &#60;90 mmHg</td> </tr> <tr> <td class=\"subtitle2_single\">Neurology:</td> </tr> <tr> <td class=\"indent1\">Sudden fall in level of consciousness (fall in Glasgow coma scale of &#62;2 points)</td> </tr> <tr> <td class=\"indent1\">Repeated or extended seizures</td> </tr> <tr> <td class=\"subtitle2_single\">Other:</td> </tr> <tr> <td class=\"indent1\">Any patient you are seriously worried about that does not fit the above criteria</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Pittsburgh calling criteria<sup>[3]</sup></td> </tr> <tr> <td class=\"subtitle2_single\">Respiratory:</td> </tr> <tr> <td class=\"indent1\">Rate &#60;8 or &#62;36 breaths/min</td> </tr> <tr> <td class=\"indent1\">New onset difficult breathing</td> </tr> <tr> <td class=\"indent1\">New pulse oximeter reading less than 85 percent for more than five minutes (unless patient known to have chronic hypoxemia)</td> </tr> <tr> <td class=\"subtitle2_single\">Heart rate:</td> </tr> <tr> <td class=\"indent1\">&#60;40 or &#62;140 with symptoms or any rate &#62;160 beats/min</td> </tr> <tr> <td class=\"subtitle2_single\">Blood pressure:</td> </tr> <tr> <td class=\"indent1\">&#60;80 or &#62;200 systolic or 110 mmHg diastolic with symptoms</td> </tr> <tr> <td class=\"subtitle2_single\">Acute neurological change:</td> </tr> <tr> <td class=\"indent1\">Acute loss of consciousness</td> </tr> <tr> <td class=\"indent1\">New-onset lethargy or Narcan use without immediate response</td> </tr> <tr> <td class=\"indent1\">Seizure (outside of seizure monitoring unit)</td> </tr> <tr> <td class=\"indent1\">Sudden loss of movement (or weakness) of face, arm, or leg</td> </tr> <tr> <td class=\"subtitle2_single\">Other:</td> </tr> <tr> <td class=\"indent1\">Chest pain unresponsive to nitroglycerine or doctor unavailable</td> </tr> <tr> <td class=\"indent1\">Color change (of patient or extremity): pale, dusky, gray, or blue</td> </tr> <tr> <td class=\"indent1\">Unexplained agitation for more than 10 minutes</td> </tr> <tr> <td class=\"indent1\">Suicide attempt</td> </tr> <tr> <td class=\"indent1\">Uncontrolled bleeding</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br> <ol> <li>Bellomo R, et al. Prospective controlled trial of effect of medical emergency team on postoperative morbidity and mortality rates. Critical care 2004; 32:916. </li> <li>Hillman K, et al. Introduction of the medical emergency team (MET) system: a cluster-randomised controlled trial. Lancet 2005; 365:2091. </li> <li>DeVita MA, et al. Use of medical emergency team responses to reduce hospital cardiopulmonary arrests. Quality &amp; safety in health care 2004; 13:251. </li> </ol></div><div id=\"graphicVersion\">Graphic 51671 Version 2.0</div></div></div>"},"51672":{"type":"graphic_table","displayName":"T4 concentration in preterm","title":"T4 concentrations in preterm infants at birth, by birth weight (heel-stick samples obtained at 2 to 5 days of age)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">T4 concentrations in preterm infants at birth, by birth weight (heel-stick samples obtained at 2 to 5 days of age)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Weight, grams</td> <td class=\"subtitle1\">T4, &#181;g/dL</td> <td class=\"subtitle1\">T4, nmol/L</td> </tr> <tr> <td>&#60;1000</td> <td>5.6 &#177; 3.0</td> <td>72 &#177; 38</td> </tr> <tr> <td>1000-1500</td> <td>7.7 &#177; 2.7</td> <td>100 &#177; 35</td> </tr> <tr> <td>1500-2000</td> <td>9.6 &#177; 2.7</td> <td>124 &#177; 32</td> </tr> <tr> <td>2000-2500</td> <td>11.2 &#177; 2.4</td> <td>144 &#177; 31</td> </tr> <tr> <td>&#62;2500</td> <td>12.0 &#177; 2.0</td> <td>154 &#177; 26</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Frank, JE, Faix, JE, Hermos, RJ, et al, J Pediatr 1996; 128:548.</div><div id=\"graphicVersion\">Graphic 51672 Version 3.0</div></div></div>"},"51673":{"type":"graphic_diagnosticimage","displayName":"Gastric cancer UGI","title":"Gastric cancer","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric cancer</div><div class=\"cntnt\"><img style=\"width:327px; height:288px;\" src=\"images/GAST/51673_Gastric_cancer_UGI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A double contrast upper GI study demonstrates a gastric cancer infiltrating the wall of the gastric antrum producing an apple core lesion (arrow).</div><div class=\"graphic_footnotes\">GI: gastrointestinal.</div><div class=\"graphic_reference\">Courtesy of Jonthan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 51673 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal upper GI series</div><div class=\"cntnt\"><img style=\"width:286px; height:330px;\" src=\"images/GAST/81537_Normal_upper_GI_series.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal air-contrast upper gastrointestinal (GI)&nbsp;study showing normal gastric folds and small intestinal anatomy, and no masses.</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy III, MD.</div><div id=\"graphicVersion\">Graphic 81537 Version 4.0</div></div></div>"},"51674":{"type":"graphic_picture","displayName":"Bullous Vibrio vulnificus","title":"Severe <EM>Vibrio vulnificus </EM>infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe <EM>Vibrio vulnificus </EM>infection</div><div class=\"cntnt\"><img style=\"width:398px; height:255px;\" src=\"images/ID/51674_Bullous_Vibrio_vulnificus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bullous lesions and hemorrhagic necrosis of the hand and forearm were caused by <EM>Vibrio Vulnificus</EM> in this immunocompromised patient.</div><div class=\"graphic_reference\">Courtesy of Rolando E Saenz, MD.</div><div id=\"graphicVersion\">Graphic 51674 Version 4.0</div></div></div>"},"51676":{"type":"graphic_table","displayName":"Adult coma evaluation and treatment","title":"Emergent evaluation and management of stupor and coma in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Emergent evaluation and management of stupor and coma in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Evaluation</td> </tr> <tr> <td>Vital signs and general examination</td> </tr> <tr> <td>Neurologic examination and GCS</td> </tr> <tr> <td>Screening laboratories (CBC, glucose selectrolyes, BUN, creatinine, PT, PTT, ABG, LFTs, drug screen)</td> </tr> <tr> <td>ECG</td> </tr> <tr> <td>Head CT scan: prioritize emergent if focal neurologic signs, papilledema, fever</td> </tr> <tr> <td>Lumbar puncture: prioritize emergent after CT scan if fever, elevated WBC, meningismus; otherwise do according to level of suspicion for diagnosis or if cause remains obscure</td> </tr> <tr> <td>EEG: for possible nonconvulsive seizure, or if diagnosis remains obscure</td> </tr> <tr> <td>Other laboratory tests: blood cultures, adrenal and thyroid tests, coagulation tests, carboxyhemoglobin, specific drug concentrations - do according to level of suspicion for diagnosis or if cause remains obscure</td> </tr> <tr> <td>Brain MRI with DWI, if cause remains obscure</td> </tr> <tr> <td class=\"subtitle1_single\">Management</td> </tr> <tr> <td class=\"subtitle2_single\">ABCs:</td> </tr> <tr> <td class=\"indent1\">Intubate if GCS &#8804;8</td> </tr> <tr> <td class=\"indent1\">Stabilize CSpine</td> </tr> <tr> <td class=\"indent1\">Supplement O2</td> </tr> <tr> <td class=\"indent1\">IV access</td> </tr> <tr> <td class=\"indent1\">Blood pressure support as needed</td> </tr> <tr> <td class=\"subtitle2_single\">Glucose 50 percent IV 50 mL (after blood drawn, before results back)</td> </tr> <tr> <td class=\"subtitle2_single\">Thiamine 100 mg IV</td> </tr> <tr> <td class=\"subtitle2_single\">Treat definite seizures with phenytoin or equivalent</td> </tr> <tr> <td class=\"subtitle2_single\">Consider empiric treatments:</td> </tr> <tr> <td class=\"sublist2_start\">For possible infection:</td> </tr> <tr> <td class=\"sublist2\">Ceftriaxone and Vancomycin</td> </tr> <tr> <td class=\"sublist2\">Acyclovir</td> </tr> <tr> <td class=\"sublist2_start\">For possible ingestion:</td> </tr> <tr> <td class=\"sublist2\">Naloxone</td> </tr> <tr> <td class=\"sublist2\">Flumazenil</td> </tr> <tr> <td class=\"sublist2\">Gastric lavage/activated charcoal</td> </tr> <tr> <td class=\"sublist2_start\">For possible increased ICP:</td> </tr> <tr> <td class=\"sublist2\">Mannitol</td> </tr> <tr> <td class=\"sublist2_start\">For possible nonconvulsive status:</td> </tr> <tr> <td class=\"sublist2\">Lorazepam</td> </tr> <tr> <td class=\"sublist2\">Phenytoin or equivalent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GCS: Glasgow coma scale; CBC: complete blood count; BUN: blood urea nitrogen; PT: prothrombin time; PTT: partial thromboplastin time; ABG: arterial blood gas; LFT: liver function tests; ECG: electrocardiogram; CT: computed tomography; WBC: white blood cells; EEG: electroencephalography; MRI: magnetic resonance imaging; DWI: diffusion weighted imaging; ICP: intracranial pressure.</div><div id=\"graphicVersion\">Graphic 51676 Version 5.0</div></div></div>"},"51680":{"type":"graphic_algorithm","displayName":"Traumatic ear pain in children","title":"Traumatic diagnoses associated with ear pain in children","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traumatic diagnoses associated with ear pain in children</div><div class=\"cntnt\"><img style=\"width:316px; height:643px;\" src=\"images/EM/51680_Traumatic_dx_ear_pain.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TM: tympanic membrane.</div><div id=\"graphicVersion\">Graphic 51680 Version 4.0</div></div></div>"},"51681":{"type":"graphic_picture","displayName":"CLL lymph node","title":"Lymph node biopsy from a patient with chronic lymphocytic leukemia","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Lymph node biopsy from a patient with chronic lymphocytic leukemia</div><div class=\"cntnt\"><img style=\"width:514px; height:196px;\" src=\"images/HEME/51681_CLLlymphnode.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymph node biopsy from a patient with chronic lymphocytic leukemia. At low magnification (A), there is a vaguely nodular (pseudofollicular) pattern. Higher magnification (B) shows a predominance of small lymphocytes with scattered larger cells known as prolymphocytes and paraimmunoblasts.</div><div class=\"graphic_reference\">Reproduced with permission from: Armitage JO, Mauch PM, Harris NL, et al. Non-Hodgkin Lymphomas, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 51681 Version 11.0</div></div></div>"},"51683":{"type":"graphic_picture","displayName":"Arthritis mutilans in psoriasis","title":"Arthritis mutilans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arthritis mutilans</div><div class=\"cntnt\"><img style=\"width:360px; height:286px;\" src=\"images/RHEUM/51683_Arthritis_mutilans_in_psori.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arthritis mutilans in psoriatic arthritis with marked deformity and destruction of digits.</div><div class=\"graphic_reference\">Courtesy of Peter H Schur, MD.</div><div id=\"graphicVersion\">Graphic 51683 Version 1.0</div></div></div>"},"51684":{"type":"graphic_picture","displayName":"Eyelid and skin amyloid","title":"AL amyloidosis affecting facial skin and eyelids","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">AL amyloidosis affecting facial skin and eyelids</div><div class=\"cntnt\"><img style=\"width:574px; height:382px;\" src=\"images/RHEUM/51684_Periorbitalamyloidpurpura.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this patient with AL amyloidosis, amyloid deposits are seen below the nose, around the lips, and on the eyelids. These lesions are waxy and raised, and they show characteristic hemorrhage. This patient also had severe amyloid arthritis and eventually developed a malignant plasma cell dyscrasia.</div><div class=\"graphic_reference\">Copyright © 2017 American College of Rheumatology. Used with permission.</div><div id=\"graphicVersion\">Graphic 51684 Version 21.0</div></div></div>"},"51685":{"type":"graphic_picture","displayName":"Posterior vaginal prolapse","title":"Evaluation of posterior vaginal wall prolapse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Evaluation of posterior vaginal wall prolapse</div><div class=\"cntnt\"><img style=\"width:346px; height:462px;\" src=\"images/OBGYN/51685_Vaginal_prolapse.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: RG Rogers, MD, Division of Female Pelvic Medicine and Reconstructive Surgery, University of New Mexico Health Sciences Center, Albuquerque, NM.</div><div id=\"graphicVersion\">Graphic 51685 Version 1.0</div></div></div>"},"51687":{"type":"graphic_table","displayName":"Diagnostic laboratory evaluation for neutropenia","title":"Diagnostic laboratory evaluation for neutropenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic laboratory evaluation for neutropenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Serial complete blood counts with differential</td> <td>Observation over time of the complete blood count and absolute neutrophil count&nbsp;is often the best approach.</td> </tr> <tr> <td>Sedimentation rate (ESR), C-reactive protein (CRP)</td> <td>Elevations of the ESR and/or CRP in the absence of any overt infection may suggest underlying inflammation due to neutropenia or presence of autoimmune disease.</td> </tr> <tr> <td>ANA, C3, C4, anti-DNA</td> <td>Screening tests for the presence of collagen vascular disease.</td> </tr> <tr> <td>B12, methylmalonic acid, homocysteine, copper, ceruloplasmin, pyridoxine</td> <td>Indicate abnormality in micronutrients that can be associated with marrow failure. High methylmalonic acid and/or homocysteine suggest B12 or folate deficiency even if serum levels are normal. Low ceruloplasmin is associated with neutropenia or pancytopenia and corrects with copper replacement.</td> </tr> <tr> <td>Bone marrow aspirate and biopsy with cytogenetics</td> <td>Testing to address possibility of underlying hematologic malignancy, myelodysplastic syndrome, maturation arrest.</td> </tr> <tr> <td>CD3/CD16,56,57, immunoglobulins, tetanus titers</td> <td>Natural killer cells/cytotoxic T cell subsets. A clone of &#62;20 percent suggests large granular lymphocyte disease; immunodeficiency can present with neutropenia.</td> </tr> <tr> <td>Genetic testing</td> <td>Specific gene tests are available for several of the congenital neutropenias.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ANA: antinuclear antibodies.</div><div id=\"graphicVersion\">Graphic 51687 Version 6.0</div></div></div>"},"51688":{"type":"graphic_picture","displayName":"Postinfectious glomerulonephritis light microscopy","title":"Postinfectious glomerulonephritis light microscopy","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Postinfectious glomerulonephritis light microscopy</div><div class=\"cntnt\"><img style=\"width:499px; height:373px;\" src=\"images/NEPH/51688_Postinfectglomerlight2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The most common morphologic pattern of bacterial infection-associated glomerulonephritis is diffuse and global endocapillary proliferative glomerulonephritis. The glomerular capillaries in this glomerulus are globally occluded by numerous intracapillary infiltrating neutrophils and proliferation of glomerular mesangial and endothelial cells (H&amp;E).</div><div class=\"graphic_reference\">Provided by Samih H Nasr, MD.</div><div id=\"graphicVersion\">Graphic 51688 Version 3.0</div></div></div>"},"51689":{"type":"graphic_diagnosticimage","displayName":"MRI multifocal vasculop","title":"MRI scan of a patient with multifocal vasculopathy","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">MRI scan of a patient with multifocal vasculopathy</div><div class=\"cntnt\"><img style=\"width:495px; height:296px;\" src=\"images/ID/51689_MRI_mltfcl_vsclp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Brain MRI scanning shows multiple areas of infarction in both hemispheres, primarily involving white matter and gray-white matter junctions.<br />(B) Cerebral angiogram shows focal areas of stenosis (arrows) and post-stenotic dilatation (arrowheads) involving the right posterior cerebral artery.</div><div class=\"graphic_footnotes\">MRI: Magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Don Gilden, MD.</div><div id=\"graphicVersion\">Graphic 51689 Version 7.0</div></div></div>"},"51690":{"type":"graphic_movie","displayName":"Correction of hyperopia","title":"Hyperopia corrected with refractive convergent lens","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hyperopia corrected with refractive convergent lens</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/51690_hyprrefconv.mp4\" style=\"width:336px;height:226px\"></div><img style=\"width:334px; height:208px;\" src=\"images/CARD/51690_hyprref.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperopia is corrected with convergent (convex) lenses which move the focus onto the retina from a point of focus behind the retina.</div><div class=\"graphic_reference\">Reproduced with permission from: The University of Michigan Kellogg Eye Center, www.kellogg.umich.edu.</div><div id=\"graphicVersion\">Graphic 51690 Version 3.0</div></div></div>"},"51694":{"type":"graphic_picture","displayName":"Acute urticaria child PI","title":"Hives that have merged","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hives that have merged</div><div class=\"cntnt\"><img style=\"width:297px; height:211px;\" src=\"images/PI/51694_Coalescing_urti_les_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hives are sometimes so widespread that they start to merge together.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig S, Baskin MN. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51694 Version 8.0</div></div></div>"},"51697":{"type":"graphic_table","displayName":"Rapid overview: Management of hypothermia","title":"Rapid overview: Management of hypothermia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid overview: Management of hypothermia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">General </td> </tr> <tr> <td class=\"sublist1_start\">Definition: core temperature lower than 35&#176;C (95&#176;F) </td> </tr> <tr> <td class=\"sublist1\">&#8226; Mild: 32-35&#176;C (90-95&#176;F) </td> </tr> <tr> <td class=\"sublist1\">&#8226; Moderate: 28-32&#176;C (82-90&#176;F) </td> </tr> <tr> <td class=\"sublist1\">&#8226; Severe: Below 28&#176;C (82&#176;F) </td> </tr> <tr> <td>Use a low-reading core thermometer if hypothermia suspected; standard oral thermometers do not read below 34&#176;C (93&#176;F)</td> </tr> <tr> <td>Hypothermia secondary to other disease (infection, hypoglycemia, adrenal insufficiency, hypothyroidism, overdose, many others) must be considered</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical aspects </td> </tr> <tr> <td class=\"sublist1_start\">Physical examination </td> </tr> <tr> <td class=\"sublist1\">&#8226; Vital signs </td> </tr> <tr> <td class=\"sublist2\">Mild hypothermia: tachypnea, tachycardia, hyperventilation </td> </tr> <tr> <td class=\"sublist2\">Moderate hypothermia: expect bradycardia; tachycardia suggests hypoglycemia, hypovolemia, or overdose </td> </tr> <tr> <td class=\"sublist2\">Severe hypothermia: hypotension, cardiovascular collapse </td> </tr> <tr> <td class=\"sublist1\">&#8226; Neurological examination </td> </tr> <tr> <td class=\"sublist2\">Mild hypothermia: ataxia, dysarthria, impaired judgement; suspect CNS pathology if patient comatose </td> </tr> <tr> <td class=\"sublist2\">Moderate hypothermia: CNS depression </td> </tr> <tr> <td class=\"sublist2\">Severe hypothermia: areflexia, coma </td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory evaluation </td> </tr> <tr> <td class=\"sublist1_start\">Obtain coagulation studies, complete blood count, basic electrolytes, BUN and creatinine </td> </tr> <tr> <td class=\"sublist1\">&#8226; Clinical coagulopathy present despite normal measured coagulation times </td> </tr> <tr> <td class=\"sublist1\">&#8226; Increased hematocrit may reflect hemoconcentration </td> </tr> <tr> <td class=\"sublist1\">&#8226; May see low bicarbonate, suggesting anion-gap acidosis; if so, obtain arterial blood gas </td> </tr> <tr> <td class=\"sublist1_start\">Electrocardiogram </td> </tr> <tr> <td class=\"sublist1\">&#8226; Rhythm abnormalities (atrial fibrillation, sinus bradycardia) may be present </td> </tr> <tr> <td class=\"sublist1\">&#8226; Intervals (PR, QRS and QTc) may be prolonged </td> </tr> <tr> <td class=\"sublist1\">&#8226; Osborn J waves characteristic of hypothermia </td> </tr> <tr> <td class=\"sublist2\">Occurs at junction of QRS and ST segments, most prominent in V2-V5 </td> </tr> <tr> <td class=\"sublist2\">Distortion of the earliest phase of membrane depolarization </td> </tr> <tr> <td class=\"sublist2\">Computer misinterprets as ischemic injury pattern </td> </tr> <tr> <td class=\"subtitle1_single\">Treatment </td> </tr> <tr> <td>Endotracheal intubation may be necessary in obtunded patients and those with bronchorrhea</td> </tr> <tr> <td>Treat hypotension with warmed crystalloid (42&#176;C) initially, dopamine if necessary</td> </tr> <tr> <td>Avoid rough movements and activity, which may induce ventricular fibrillation</td> </tr> <tr> <td class=\"sublist1_start\">Rewarming techniques are based on degree of hypothermia </td> </tr> <tr> <td class=\"sublist1\">&#8226; Mild hypothermia: passive external rewarming </td> </tr> <tr> <td class=\"sublist2\">Remove wet clothing, cover with blankets </td> </tr> <tr> <td class=\"sublist1\">&#8226; Moderate hypothermia: active external and internal rewarming </td> </tr> <tr> <td class=\"sublist2\">Warmed humidified oxygen, forced air warming systems </td> </tr> <tr> <td class=\"sublist2\">Beware of initial paradoxical drop in core temperature due to return of cold blood from extremities to core circulation </td> </tr> <tr> <td class=\"sublist2\">Rewarm trunk first to minimize risk of core temperature afterdrop </td> </tr> <tr> <td class=\"sublist1\">&#8226; Severe hypothermia: active internal rewarming (active core rewarming) and active external rewarming </td> </tr> <tr> <td class=\"sublist2\">Warmed humidified oxygen, warmed IV fluids (42&#176;C) </td> </tr> <tr> <td class=\"sublist2\">Pleural and peritoneal irrigation with warm saline (40-42&#176;C) </td> </tr> <tr> <td class=\"sublist2\">Extracorporeal options: continuous venovenous rewarming, hemodialysis, continuous arteriovenous rewarming, and cardiopulmonary bypass </td> </tr> <tr> <td class=\"sublist1_start\">Treatment of arrhythmias </td> </tr> <tr> <td class=\"sublist1\">&#8226; Arrhythmias may persist until patient rewarmed </td> </tr> <tr> <td class=\"sublist1\">&#8226; Ignore atrial arrhythmias with slow ventricular response </td> </tr> <tr> <td class=\"sublist1\">&#8226; Ventricular fibrillation a common rhythm </td> </tr> <tr> <td class=\"sublist2\">May be precipitated by physical jostling </td> </tr> <tr> <td class=\"sublist2\">Manage according to ACLS protocol </td> </tr> <tr> <td class=\"sublist2\">Electrical defibrillation may be attempted but is rarely successful until core temperature is above 30&#176;C </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; IV: intravenous; ACLS: advanced cardiac life support.</div><div id=\"graphicVersion\">Graphic 51697 Version 3.0</div></div></div>"},"51698":{"type":"graphic_algorithm","displayName":"Diagnostic approach to hypercalcemia","title":"Diagnostic approach to hypercalcemia","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to hypercalcemia</div><div class=\"cntnt\"><img style=\"width:764px; height:792px;\" src=\"images/ENDO/51698_Diag_approach_hypercalcemia.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PTH: parathyroid hormone; FHH: familial hypocalciuric hypercalcemia; PTHrp: parathyroid hormone-related peptide; SPEP: serum protein electrophoresis; UPEP: urine protein electrophoresis.<br />* Serum PTH typically ranging from 35 to 65 pg/mL in an assay whose normal range is 10 to 60 pg/mL.<br />&para; Serum 25-hydroxyvitamin D must be markedly elevated before hypercalcemia develops. Although the serum concentration of 25-hydroxyvitamin D at which hypercalcemia typically occurs is undefined, many experts define vitamin D intoxication as a value &gt;150 ng/mL (374 nmol/L).<br />&Delta; Refer to UpToDate content on primary hyperparathyroidism.<br /><span class=\"lozenge\">&loz;</span> Refer to UpToDate content on primary hyperparathyroidism and familial hypocalciuric hypercalcemia for details.<br />&sect; Additional work-up is warranted to identify malignancy.</div><div id=\"graphicVersion\">Graphic 51698 Version 4.0</div></div></div>"},"51703":{"type":"graphic_figure","displayName":"Ibutilide sotalol AF flutter","title":"Ibutilide is more effective than sotalol for acute reversion of atrial tachyarrhythmias","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ibutilide is more effective than sotalol for acute reversion of atrial tachyarrhythmias</div><div class=\"cntnt\"><img style=\"width:407px; height:252px;\" src=\"images/CARD/51703_Ibutilide_sotalol_AF_flutte.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 281 patients with atrial fibrillation or atrial flutter randomized to intravenous ibutilide or intravenous sotalol, both doses of ibutilide were more effective than sotalol for reverting atrial flutter. Among the patients with atrial fibrillation, only the higher dose of ibutilide was significantly more effective than sotalol for restoring sinus rhythm.</div><div class=\"graphic_footnotes\">* p &lt;0.05 compared with sotalol.<BR>• p &lt;0.05 compared with 1 mg ibutilide.</div><div class=\"graphic_reference\">Data from: Vos MA, Golitsyn SR, Stangl K, et al. for the Ibutilide/Sotalol Comparator Study Group, Heart 1998; 79:568.</div><div id=\"graphicVersion\">Graphic 51703 Version 3.0</div></div></div>"},"51704":{"type":"graphic_picture","displayName":"Human skin mast cell ","title":"Human skin mast cell","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Human skin mast cell</div><div class=\"cntnt\"><img style=\"width:471px; height:321px;\" src=\"images/ALLRG/51704_Mast_cell_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mast cells may be round to spindle-shaped with eccentrically positioned unilobed nuclei. Mast cells contain numerous large granules containing proteases. The granules of mast cells in the skin predominantly contain tryptase and chymase (TC).</div><div class=\"graphic_reference\">Courtesy of Mariana Castells, MD PhD, Lawrence B Schwartz, MD, and Shirley Craig, PhD.</div><div id=\"graphicVersion\">Graphic 51704 Version 4.0</div></div></div>"},"51705":{"type":"graphic_picture","displayName":"Gastric B cell lymphoma CPC Endosc","title":"Gastric B cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Gastric B cell lymphoma</div><div class=\"cntnt\"><img style=\"width:536px; height:190px;\" src=\"images/GAST/51705_B_cell_lymphoma_CPC_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper endoscopy showing a single 2 cm by 3 cm ulcerated lesion of malignant appearance in the gastric body.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 51705 Version 2.0</div></div></div>"},"51710":{"type":"graphic_picture","displayName":"Candidiasis vulva2","title":"Candidiasis vulva","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Candidiasis vulva</div><div class=\"cntnt\"><img style=\"width:376px; height:371px;\" src=\"images/OBGYN/51710_Candidiasis_vulva2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from&#160;Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 51710 Version 2.0</div></div></div>"},"51711":{"type":"graphic_figure","displayName":"Prop gen model peri chondro","title":"Proposed multistep genetic model for peripheral chondrosarcoma development and potential targets for treatment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proposed multistep genetic model for peripheral chondrosarcoma development and potential targets for treatment</div><div class=\"cntnt\"><img style=\"width:422px; height:475px;\" src=\"images/ONC/51711_Prop_gen_model_peri_chondro.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrow shows candidate adjuvant treatment strategies based on identification of molecular changes during chondrosarcoma progression.</div><div class=\"graphic_reference\">Modified from: Bov&#233;e JV, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2006; 6:599. All rights reserved.</div><div id=\"graphicVersion\">Graphic 51711 Version 4.0</div></div></div>"},"51713":{"type":"graphic_picture","displayName":"Intertriginous erythrasma","title":"Erythrasma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythrasma</div><div class=\"cntnt\"><img style=\"width:311px; height:432px;\" src=\"images/DERM/51713_Erythrasma_groin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red-brown plaques of erythrasma in the groin.</div><div class=\"graphic_reference\">Reproduced with permission from John L Aeling, MD.</div><div id=\"graphicVersion\">Graphic 51713 Version 7.0</div></div></div>"},"51714":{"type":"graphic_figure","displayName":"Spore shapes","title":"Spore shapes","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Spore shapes</div><div class=\"cntnt\"><img style=\"width:542px; height:407px;\" src=\"images/ALLRG/51714_Spore_shapes.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from Burge HA, Burge W, Muilenberg ML, et al. Airborne pollen and fungus spore identification: Hands On Workshop, Postgraduate Course, University of Michigan Medical School, Ann Arbor, MI, May 1990.</div><div id=\"graphicVersion\">Graphic 51714 Version 2.0</div></div></div>"},"51715":{"type":"graphic_diagnosticimage","displayName":"Annular pancreas CT","title":"Annular pancreas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Annular pancreas</div><div class=\"cntnt\"><img style=\"width:427px; height:356px;\" src=\"images/GAST/51715_Annular_pancreas_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial image from an abdominal CT scan showing the annulus encircling the duodenum (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Dr. Darren Brennan, Department of Radiology, Beth Israel Deaconess Medical Center.</div><div id=\"graphicVersion\">Graphic 51715 Version 3.0</div></div></div>"},"51717":{"type":"graphic_diagnosticimage","displayName":"HDR cerv brachyther plan","title":"High dose rate (HDR) cervical brachytherapy planning","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">High dose rate (HDR) cervical brachytherapy planning</div><div class=\"cntnt\"><img style=\"width:349px; height:606px;\" src=\"images/OBGYN/51717_HDR_cerv_brachyther_plan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Orthogonal radiographs, (A) and (B), depicting placement of intrauterine tandem and vaginal ovoids. The images show the instruments in place in the uterus and vagina. In addition, there is barium contrast in the rectum, contrast in the Foley catheter balloon and radiopaque vaginal packing.</div><div class=\"graphic_reference\">Courtesy of Kristin Bradley, MD and Derek McHaffie, MD.</div><div id=\"graphicVersion\">Graphic 51717 Version 2.0</div></div></div>"},"51718":{"type":"graphic_figure","displayName":"Accidental loss of FB","title":"Potential complications of foreign body extraction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Potential complications of foreign body extraction</div><div class=\"cntnt\"><img style=\"width:325px; height:300px;\" src=\"images/PULM/51718_Accidental_loss_of_FB.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">1. Foreign body becomes wedged distally, leading to postobstructive atelectasis 2. Loss of the foreign body complicated by 3. Obstruction of the contralateral mainstem bronchus or central airway, potentially causing asphyxia.</div><div id=\"graphicVersion\">Graphic 51718 Version 1.0</div></div></div>"},"51720":{"type":"graphic_picture","displayName":"Amalgam tattoo","title":"Amalgam tattoo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amalgam tattoo</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/51720_Amalgam_tattoo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This area of blue-black pigment in the oral cavity is consistent with an amalgam tattoo.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51720 Version 3.0</div></div></div>"},"51721":{"type":"graphic_diagnosticimage","displayName":"Fusarium pneumonia CT","title":"<EM>Fusarium</EM> pneumonia computed tomography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Fusarium</EM> pneumonia computed tomography</div><div class=\"cntnt\"><img style=\"width:400px; height:377px;\" src=\"images/ID/51721_Fusarium_CT_ed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right-sided lung nodule caused by <EM>Fusarium</EM> spp. The patient was a 43-year-old male with acute myelogenous leukemia who had undergone allogeneic hematopoietic cell transplantation and presented with persistent fevers while neutropenic despite broad-spectrum antibiotics.</div><div class=\"graphic_reference\">Reproduced from: Garnica M, Nucci M. Emerging fungal infections. In: Pulmonary involvement in patients with hematological malignancies, 1st Ed, Azoulay E (Ed), Springer-Verlag, Berlin Heidelberg 2011, with kind permission from Springer Science + Business Media B.V. Copyright © 2011.</div><div id=\"graphicVersion\">Graphic 51721 Version 7.0</div></div></div>"},"51722":{"type":"graphic_diagnosticimage","displayName":"Healing toddlers fracture","title":"Healing toddler's fracture in an 18-month-old child","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Healing toddler's fracture in an 18-month-old child</div><div class=\"cntnt\"><img style=\"width:520px; height:417px;\" src=\"images/EM/51722_Healing_toddlers_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 18-month-old child had a limp but no fever or signs of infection. The radiograph shows a left distal tibial toddler's fracture with mild associated sclerosis and periosteal reaction (arrow).</div><div class=\"graphic_reference\">Courtesy of Jennifer Chapman, MD.</div><div id=\"graphicVersion\">Graphic 51722 Version 4.0</div></div></div>"},"51723":{"type":"graphic_table","displayName":"Sulfonylurea with renally-eliminated active metabolites","title":"Sulfonylureas with significant renally-eliminated, active metabolites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sulfonylureas with significant renally-eliminated, active metabolites</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Sulfonylurea</td>\n\t\t\t\t\t<td class=\"subtitle1\">Active, renally-eliminated metabolite</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Acetohexamide</td>\n\t\t\t\t\t<td>Hydroxyhexamide, 65 percent</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Chlorpropamide</td>\n\t\t\t\t\t<td><p>Chlorpropamide, 20 percent</p>\n\t\t\t\t\t\t<p>2-Hydroxychlorpropamide, 55 percent</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Tolazamide</td>\n\t\t\t\t\t<td><p>Hydroxytolazamide, 35 percent</p>\n\t\t\t\t\t\t<p>Tolazamide, 7 percent</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Tolbutamide</td>\n\t\t\t\t\t<td>Hydroxytolbutamide, 30 percent</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Glimepiride</td>\n\t\t\t\t\t<td>Cyclohexylhydroxymethyl derivative, 63 percent</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Glyburide</td>\n\t\t\t\t\t<td>4-hydroxyglyburide, 36 percent</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from: Bosse, GM. Antidiabetes and Hypoglycemics. In: Goldfrank's Toxicologic Emergencies, 8th Edition, Goldfrank, LR, Flomenbaum, NE, Hoffman, RS, et al (Eds), McGraw Hill, New York 2006. p. 749.</div><div id=\"graphicVersion\">Graphic 51723 Version 2.0</div></div></div>"},"51725":{"type":"graphic_diagnosticimage","displayName":"Brain MRI age 4 years juvenile Alexander disease","title":"Early brain MRIs in a patient with presumed juvenile Alexander disease, obtained at the age of four years","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early brain MRIs in a patient with presumed juvenile Alexander disease, obtained at the age of four years</div><div class=\"cntnt\"><img style=\"width:398px; height:226px;\" src=\"images/NEURO/51725_MRI_juv_4yr_Alex_Dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive cerebral white matter abnormalities are seen on these T2-weighted images (B), with sparing of the occipital U fibers (arrows, B). The signal abnormality is more pronounced in the frontal than in the occipital white matter. There is an irregular periventricular rim of low signal intensity (arrowheads, B). The basal ganglia and thalamus have a mildly increased signal intensity. Within the posterior fossa, signal abnormalities are seen in the central part of the medulla, the hilus of the dentate nucleus, and the cerebellar hemispheric white matter, characteristically with the normal dentate nucleus prominently visible in between (A).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: van der Knaap, MS, Naidu, S, Breiter, SN, et al. Alexander disease: diagnosis with MR imaging. AJNR Am J Neuroradiol 2001; 22:541. Copyright &copy;2001 American Society of Neuroradiology.</div><div id=\"graphicVersion\">Graphic 51725 Version 3.0</div></div></div>"},"51726":{"type":"graphic_diagnosticimage","displayName":"Dandy Walker malformation","title":"Dandy-Walker malformation at 27 postmenstrual weeks","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Dandy-Walker malformation at 27 postmenstrual weeks</div><div class=\"cntnt\"><img style=\"width:455px; height:273px;\" src=\"images/OBGYN/51726_Dandy_Walker_malform_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panels A-D) Panels A through D are serial coronal sections going from anterior to posterior showing the dilated lateral ventricles, the large cisterna magna and the small cerebellum with the missing vermis.<br> (Panel E) Axial section showing the large posterior fossa cyst and the cerebellar hemispheres widely splayed out.<br> (Panel F) Oblique section showing hydrocephaly.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 51726 Version 4.0</div></div></div>"},"51727":{"type":"graphic_picture","displayName":"Eruption hematoma","title":"Eruption hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eruption hematoma</div><div class=\"cntnt\"><img style=\"width:350px; height:258px;\" src=\"images/PEDS/51727_Eruption_hematoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An eruption hematoma over an erupting maxillary permanent central incisor.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, MD, Ludwig W, MD, Baskin MN, MD. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51727 Version 1.0</div></div></div>"},"51728":{"type":"graphic_diagnosticimage","displayName":"Large right pneumothorax","title":"Posterior-anterior (PA) chest radiographs showing a large right pneumothorax","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Posterior-anterior (PA) chest radiographs showing a large right pneumothorax</div><div class=\"cntnt\"><img style=\"width:547px; height:320px;\" src=\"images/PEDS/51728_Large_right_pneumothorax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left-hand image represents a conventional radiograph. A large right pneumothorax is demonstrated. The visceral pleural line is marked by red arrows. The lack of vascular and pulmonary markings in the periphery should be noted. The right-hand image represents the negative image of the film on the left. The pneumothorax is more clearly seen in this view.</div><div id=\"graphicVersion\">Graphic 51728 Version 3.0</div></div></div>"},"51729":{"type":"graphic_table","displayName":"Carb counting getting started","title":"Carbohydrate counting: getting started","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Carbohydrate counting: getting started</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Step 1: Know the goal\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Eating about the same amount of carbohydrate at meals and snacks each day will help to keep blood glucose levels from getting too high or too low.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Focus on keeping the amount of carbohydrate intake moderate to keep your blood glucose levels from going too high. Remember, it is not healthy to cut out all carbohydrate foods; the body, especially your brain, needs some every day.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Step 2: Monitoring intake and blood glucose\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Keeping a daily food and blood glucose record will help inform what affects blood glucose levels.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Measuring or weighing foods is helpful in the beginning to learn what common food portions look like.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Step 3: Methods of counting carbohydrate\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   To count carbohydrates, there are two methods. Patients may also blend the two methods.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   <strong>Read food labels:</strong> Look at the grams of total carbohydrate on the label. Remember, the nutrition information on food labels is for the standard serving size. If the portion is larger or smaller, it is necessary to adjust the carbohydrate information.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   <strong>Use the exchange system:</strong> Estimation of carbohydrate content can be broken down into food groups that are standardized for carbohydrate content according to particular portions. For example, one serving from the Bread/Starch, Fruit, or Milk group each contains between 12 and 15 grams of carbohydrate. Most vegetables do not contain a significant number of carbohydrates and do not need to be counted, although there are exceptions (eg, corn, potatoes).\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=57758&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Carb_counting_getting_start.htm</title></head></div><div id=\"graphicVersion\">Graphic 51729 Version 2.0</div></div></div>"},"51730":{"type":"graphic_figure","displayName":"Transection of redundant sigmoid colon AP view","title":"Transection of redundant sigmoid colon AP view","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Transection of redundant sigmoid colon AP view</div><div class=\"cntnt\"><img style=\"width:502px; height:639px;\" src=\"images/SURG/51730_Trans_red_sigmoid_col.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the anterior posterior view of the transection of redundant sigmoid colon in preparation for a rectopexy for rectal procidentia.</div><div id=\"graphicVersion\">Graphic 51730 Version 1.0</div></div></div>"},"51731":{"type":"graphic_diagnosticimage","displayName":"Spiculated carcinoma CT","title":"Spiculated solitary pulmonary nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spiculated solitary pulmonary nodule</div><div class=\"cntnt\"><img style=\"width:364px; height:353px;\" src=\"images/PULM/51731_Spiculated_carcinoma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Irregular border in a poorly differentiated bronchogenic carcinoma presenting as a solitary pulmonary nodule in the left lower lobe.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 51731 Version 2.0</div></div></div>"},"51733":{"type":"graphic_diagnosticimage","displayName":"Tibiotalar arthritis in HH","title":"Hemochromatosis of the ankle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemochromatosis of the ankle</div><div class=\"cntnt\"><img style=\"width:222px; height:288px;\" src=\"images/RHEUM/51733_Tibiotalar_arthritis_in_HH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain radiograph of the ankle in a 45-year-old man with hemochromatosis shows marked destruction of the tibiotalar joint space, with loss of joint space and erosions of adjacent bone surfaces (arrows).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 51733 Version 2.0</div></div></div>"},"51734":{"type":"graphic_figure","displayName":"Partial colpocleisis","title":"Le Fort partial colpocleisis","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Le Fort partial colpocleisis</div><div class=\"cntnt\"><img style=\"width:514px; height:565px;\" src=\"images/OBGYN/51734_Partial_colpocleisis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A-C) In Le Fort colpocleisis, rectangles of vaginal mucosa are removed from the anterior and posterior vaginal walls.<br> (D, E) The denuded areas are then sutured together, leaving (F) channels on each side open.</div><div class=\"graphic_reference\">Reproduced with permission from: Mattingly, RF, Thompson, JD. TeLinde's Operative Gynecology, Sixth Edition. Philadelphia: JB Lippincott Co, 1985:562. Copyright &#169; 1985 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51734 Version 1.0</div></div></div>"},"51735":{"type":"graphic_figure","displayName":"Nasal bridle","title":"Nasal bridle","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Nasal bridle</div><div class=\"cntnt\"><img style=\"width:452px; height:491px;\" src=\"images/SURG/51735_Nasal-bridle edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A flexible piece of material is looped around the nasal septum from one nostril to the other as a bridle. The nasoenteric tube is secured to the bridle which prevents movement or dislodgement of the tube.</div><div class=\"graphic_reference\">Reproduced with permission from: Mulholland MW, Maier RV, et al. Greenfield's Surgery: Scientific Principles and Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51735 Version 2.0</div></div></div>"},"51737":{"type":"graphic_table","displayName":"Prev HD cath infection","title":"Prevention of infection with central hemodialysis catheters","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevention of infection with central hemodialysis catheters</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Replacement and relocation of catheter</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Do not routinely replace hemodialysis catheters.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Replacement of catheter-site dressing</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Replace dressing when the catheter is removed or replaced, or when the dressing becomes damp, loosened, or soiled. Replace dressings more frequently in diaphoretic patients.</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>There is no need to remove a gauze or opaque dressing if the patient has no clinical signs of infection.</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Replacement of administration sets</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Use hemodialysis catheters solely for hemodialysis. Use of hemodialysis catheters for other purposes (eg, administration of fluids, blood/blood products, or parenteral nutrition) should be restricted to circumstances where no alternative vascular access is feasible.</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Hang time for parenteral fluids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Use hemodialysis catheters solely for hemodialysis. Use of hemodialysis catheters for other purposes (eg, administration of fluids, blood/blood products, or parenteral nutrition) should be restricted to circumstances where no alternative vascular access is feasible.</td>\n\n    </tr>\n\n\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 51737 Version 1.0</div></div></div>"},"51740":{"type":"graphic_picture","displayName":"Melanoma in transit met","title":"Cutaneous melanoma: management of in transit metastases","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Cutaneous melanoma: management of in transit metastases</div><div class=\"cntnt\"><img style=\"width:572px; height:429px;\" src=\"images/ONC/51740_Melanoma_in_transit_met.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In transit metastasis. A) Prior to treatment. B) Six weeks after isolated limb infusion. C) Three months after isolated limb infusion.</div><div class=\"graphic_reference\">Courtesy of Douglas Tyler, MD.</div><div id=\"graphicVersion\">Graphic 51740 Version 3.0</div></div></div>"},"51741":{"type":"graphic_table","displayName":"Absorbable sutures","title":"Absorbable sutures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Absorbable sutures</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Suture material</td> <td class=\"subtitle1\">Knot security</td> <td class=\"subtitle1\">Wound tensile strength</td> <td class=\"subtitle1\">Security (days)*</td> <td class=\"subtitle1\">Tissue reactivity</td> <td class=\"subtitle1\">Anatomic site</td> </tr> <tr> <td>Fast-absorbing gut</td> <td>Poor</td> <td>Least</td> <td>4 to 6</td> <td>Most</td> <td>Face</td> </tr> <tr> <td>Vicryl Rapide</td> <td>Good</td> <td>Fair</td> <td>5 to 7</td> <td>Minimal</td> <td>Face, scalp, under cast/splint</td> </tr> <tr> <td>Surgical gut</td> <td>Poor</td> <td>Fair</td> <td>5 to 7</td> <td>Most</td> <td>Face (rarely used)</td> </tr> <tr> <td>Poliglecaprone 25 (Monocryl)</td> <td>Good</td> <td>Fair</td> <td>7 to 10</td> <td>Minimal</td> <td>Face, consider in contaminated wounds needing deep closure</td> </tr> <tr> <td>Chromic gut</td> <td>Fair</td> <td>Fair</td> <td>10 to 14</td> <td>Most</td> <td>Mouth, tongue, nailbed</td> </tr> <tr> <td>Polyglactin (Vicryl)</td> <td>Good</td> <td>Good</td> <td>30</td> <td>Minimal</td> <td>Deep closure, nailbed, mouth</td> </tr> <tr> <td>Polyglycolic acid (Dexon)</td> <td>Best</td> <td>Good</td> <td>30</td> <td>Minimal</td> <td>Deep closure</td> </tr> <tr> <td>Polydioxanone (PDS)</td> <td>Fair</td> <td>Best</td> <td>45 to 60</td> <td>Least</td> <td>Deep closure</td> </tr> <tr> <td>Polyglyconate (Maxon)</td> <td>Fair</td> <td>Best</td> <td>45 to 60</td> <td>Least</td> <td>Deep closure</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Retention of 50 percent of tensile strength.</div><div class=\"graphic_reference\">Adapted with permission from: Hollander, JE, Singer, AJ. Laceration management. Ann Emerg Med 1999; 34:356. Copyright © 1999 The American College of Emergency Physicians.</div><div id=\"graphicVersion\">Graphic 51741 Version 2.0</div></div></div>"},"51743":{"type":"graphic_diagnosticimage","displayName":"CT of depressed skull fracture","title":"Depressed skull fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Depressed skull fracture</div><div class=\"cntnt\"><img style=\"width:396px; height:360px;\" src=\"images/EM/51743_Skull_fx_depressed_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan showing a depressed skull fracture in the right frontal region (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright &#169; 2008.</div><div id=\"graphicVersion\">Graphic 51743 Version 2.0</div></div></div>"},"51750":{"type":"graphic_picture","displayName":"MDI with counter","title":"Metered dose inhaler with counter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metered dose inhaler with counter</div><div class=\"cntnt\"><img style=\"width:396px; height:325px;\" src=\"images/PULM/51750_MDI_with_counter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Some MDIs are now manufactured with built-in dose counters.</div><div class=\"graphic_footnotes\">MDI: metered dose inhaler.</div><div id=\"graphicVersion\">Graphic 51750 Version 4.0</div></div></div>"},"51751":{"type":"graphic_figure","displayName":"Induced pluripotent stem cells in therapy","title":"Induced pluripotent stem cells (iPS) in cellular replacement therapy","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Induced pluripotent stem cells (iPS) in cellular replacement therapy</div><div class=\"cntnt\"><img style=\"width:487px; height:318px;\" src=\"images/PC/51751_iPS_cell_replacement.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Principle of use of induced pluripotent stem cells (iPS) in cellular replacement therapy. Patient cells, ie skin fibroblasts, can be obtained and reprogrammed to pluripotency ex vivo, generating iPS. These iPS can subsequently be differentiated to specific cell types which can be used for autologous transplantation. In monogenic diseases, it may be possible to correct the disease gene in iPS before transplantation.</div><div id=\"graphicVersion\">Graphic 51751 Version 3.0</div></div></div>"},"51752":{"type":"graphic_diagnosticimage","displayName":"Mycoplasma chest x-ray","title":"<em>Mycoplasma</em> pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Mycoplasma</em> pneumonia</div><div class=\"cntnt\"><img style=\"width:400px; height:378px;\" src=\"images/ID/51752_Mycoplasmachestxray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows poorly defined nodular opacities in the right lower lung zone. The patient was a 30-year-old woman with <em>Mycoplasma pneumoniae</em> pneumonia.</div><div class=\"graphic_reference\">Reproduced with permission from: Viruses, Mycoplasma, and Chlamydia. In: Imaging of Pulmonary Infections, M&uuml;ller NL, Franquet T, Lee KS (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 51752 Version 10.0</div></div></div>"},"51753":{"type":"graphic_picture","displayName":"Endoscopy - strongyloidiasis","title":"Endoscopy - strongyloidiasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopy - strongyloidiasis</div><div class=\"cntnt\"><img style=\"width:419px; height:432px;\" src=\"images/ID/51753_Endosc_strongyloidiasis_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Colonoscopic view of multiple 2 mm diameter nodules with surrounding erythema.</div><div class=\"graphic_reference\">Reproduced from: Goh S-K, Chow P, Chung AY, et al. Strongyloides colitis in a patient with Cushing's syndrome. Gastrointest Endosc 2004; 59:738. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 51753 Version 1.0</div></div></div>"},"51758":{"type":"graphic_table","displayName":"Medical conditions with RPLS","title":"Medical conditions associated with reversible posterior leukoencephalopathy syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical conditions associated with reversible posterior leukoencephalopathy syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Hypertensive encephalopathy</td> </tr> <tr> <td>Acute or chronic renal diseases</td> </tr> <tr> <td>Thrombotic thrombocytopenic purpura</td> </tr> <tr> <td>Hemolytic and uremic syndrome</td> </tr> <tr> <td>Eclampsia</td> </tr> <tr> <td class=\"sublist1_start\">Vasculitis </td> </tr> <tr> <td class=\"sublist1\">Systemic lupus erythematosus </td> </tr> <tr> <td class=\"sublist1\">Polyarteritis nodosa </td> </tr> <tr> <td class=\"sublist1\">Cryoglobulinemia </td> </tr> <tr> <td class=\"sublist1\">Wegener's granulomatosis </td> </tr> <tr> <td class=\"sublist1_start\">Immunosuppressive, immunomodulatory, and chemotherapeutic drugs </td> </tr> <tr> <td class=\"sublist1\">Bevacizumab </td> </tr> <tr> <td class=\"sublist1\">Cisplatin and other platinum-based agents </td> </tr> <tr> <td class=\"sublist1\">Combination chemotherapy </td> </tr> <tr> <td class=\"sublist1\">Cyclosporine A </td> </tr> <tr> <td class=\"sublist1\">Cytarabine </td> </tr> <tr> <td class=\"sublist1\">Gemcitabine </td> </tr> <tr> <td class=\"sublist1\">Interferon-alpha </td> </tr> <tr> <td class=\"sublist1\">Intravenous immunoglobulin </td> </tr> <tr> <td class=\"sublist1\">Ipilimumab</td> </tr> <tr> <td class=\"sublist1\">Methotrexate </td> </tr> <tr> <td class=\"sublist1\">Rituximab </td> </tr> <tr> <td class=\"sublist1\">Sirolimus </td> </tr> <tr> <td class=\"sublist1\">Tacrolimus </td> </tr> <tr> <td class=\"sublist1\">Tyrosine kinase inhibitors (pazopanib), sorafenib, sunitinib&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Vincristine </td> </tr> <tr> <td>Porphyria</td> </tr> <tr> <td>Hypercalcemia, hypomagnesmia</td> </tr> <tr> <td>Blood transfusion</td> </tr> <tr> <td>Contrast media exposure (cerebral, coronary angiography)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51758 Version 3.0</div></div></div>"},"51759":{"type":"graphic_picture","displayName":"Condyloma acuminatum 3","title":"Condyloma acuminatum involving vulva, vagina, and perianal region","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Condyloma acuminatum involving vulva, vagina, and perianal region</div><div class=\"cntnt\"><img style=\"width:400px; height:491px;\" src=\"images/OBGYN/51759_Condyloma_acuminatum3.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51759 Version 7.0</div></div></div>"},"51760":{"type":"graphic_figure","displayName":"C1 burst fracture","title":"Burst (Jefferson) fracture of C1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Burst (Jefferson) fracture of C1</div><div class=\"cntnt\"><img style=\"width:293px; height:213px;\" src=\"images/EM/51760_C1_burst_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Jefferson fracture of C1 is highly unstable and occurs when a vertical compression force is transmitted through the occipital condyles to the lateral masses of the atlas.</div><div id=\"graphicVersion\">Graphic 51760 Version 4.0</div></div></div>"},"51761":{"type":"graphic_picture","displayName":"Macintosh blade in the vallecula","title":"Macintosh blade in the vallecula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Macintosh blade in the vallecula</div><div class=\"cntnt\"><img style=\"width:432px; height:396px;\" src=\"images/EM/51761_MacLscopeposition.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this cadaver, the Macintosh blade is shown with the tip in the vallecula.</div><div class=\"graphic_reference\">Reproduced with permission from: Orebaugh SL. Retraction blades for direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 51761 Version 11.0</div></div></div>"},"51763":{"type":"graphic_table","displayName":"Prevalence vs PPV and NPV","title":"Prevalence vs PPV and NPV","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence vs PPV and NPV</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr><td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">Disease prevalence = 10 percent</td></tr><tr class=\"subtitle2\">\n\n\n      <td class=\"subtitle2\">&nbsp;<br /></td>\n\n\n\n      <td class=\"subtitle2\">Disease present</td>\n\n\n      <td class=\"subtitle2\">Disease absent</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Test positive</td>\n\n\n\n      <td> 99</td>\n\n\n      <td> 90</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Test negative</td>\n\n\n\n      <td> 1</td>\n\n\n      <td> 810</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td rowspan=\"1\" colspan=\"3\">Sensitivity = 99 percent; specificity = 90 percent </td>\n\n\n\n      \n\n\n      \n\n\n    </tr>\n\n\n    <tr>\n\n      <td colspan=\"3\" rowspan=\"1\">Positive predictive value (99/189 = 53 percent) </td>\n\n      \n\n      \n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"3\" rowspan=\"1\">Negative predictive value (810/811 = 100 percent) </td>\n\n      \n\n      \n\n    </tr>\n\n\n    <tr><td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">Disease Prevalence = 1 percent</td></tr><tr>\n\n\n      <td class=\"subtitle2\">&nbsp;</td>\n\n\n\n      <td class=\"subtitle2\">Disease present</td>\n\n\n      <td class=\"subtitle2\">Disease absent</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Test positive</td>\n\n\n\n      <td>9.9</td>\n\n\n      <td>99</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Test negative</td>\n\n\n\n      <td>0.1</td>\n\n\n      <td>891</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td rowspan=\"1\" colspan=\"3\">Sensitivity = 99 percent; specificity = 90 percent&nbsp;&nbsp;</td>\n\n\n\n      \n\n\n      \n\n\n    </tr>\n\n\n    <tr>\n\n      <td colspan=\"3\" rowspan=\"1\">Positive predictive value (9.9/108.9 = 9 percent)</td>\n\n      \n\n      \n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"3\" rowspan=\"1\">Negative predictive value (891/891.1 = 100 percent)</td>\n\n      \n\n      \n\n    </tr>\n\n\n    <tr><td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">Disease Prevalence = 0.1 percent</td></tr><tr>\n\n\n      <td class=\"subtitle2\">&nbsp;</td>\n\n\n\n      <td class=\"subtitle2\">Disease present</td>\n\n\n      <td class=\"subtitle2\"> Disease absent</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Test positive</td>\n\n\n\n      <td> 0.99</td>\n\n\n      <td> 100</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Test negative</td>\n\n\n\n      <td> 0.01</td>\n\n\n      <td> 899</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td rowspan=\"1\" colspan=\"3\">Sensitivity = 99 percent; specificity = 90 percent</td>\n\n\n\n      \n\n\n      \n\n\n    </tr>\n\n\n    <tr>\n\n      <td colspan=\"3\" rowspan=\"1\">Positive predictive value (0.99/100.99 = 1 percent)</td>\n\n      \n\n      \n\n    </tr>\n\n    <tr>\n\n\n      <td colspan=\"3\" rowspan=\"1\">Negative predictive value (899/899.01 = 100 percent)</td>\n\n    </tr>\n\n\n  \n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 51763 Version 1.0</div></div></div>"},"51765":{"type":"graphic_picture","displayName":"Reversible cirrhosis thalassemia major","title":"Reversibility of cirrhosis in thalassemia following hematopoietic cell transplantation","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Reversibility of cirrhosis in thalassemia following hematopoietic cell transplantation</div><div class=\"cntnt\"><img style=\"width:536px; height:361px;\" src=\"images/HEME/51765_Reversible_cirrhosis_thal_m.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serial liver biopsies illustrating reversibility of cirrhosis in a 25-year-old-female with thalassemia major, transfusional iron overload, and anti-hepatitis C virus antibodies. Panels A and B were obtained at the time of diagnosis of cirrhosis, four years after hematopoietic cell transplantation. Panel A (Masson trichrome stain) shows cirrhosis and active hepatitis; panel B (Perl's Prussian Blue reaction) shows severe iron overload (23 mg/g of liver dry weight). The liver biopsy shown on panels C and D was obtained 10 years after transplantation, four years following completion of phlebotomy treatment; abnormal aminotransferase levels normalized without antiviral treatment. It shows regression of cirrhosis, marked improvement of hepatitis, and absent iron overload (0.9 mg/g).</div><div class=\"graphic_reference\">Reproduced with permission from: Muretto P, Angelucci E, Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med 2002; 136:667. Copyright © 2002 American College of Physicians-American Society of Internal Medicine.</div><div id=\"graphicVersion\">Graphic 51765 Version 3.0</div></div></div>"},"51767":{"type":"graphic_figure","displayName":"Primary hyperfibrinolysis","title":"Primary hyperfibrinolysis as assessed by thromboelastography","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Primary hyperfibrinolysis as assessed by thromboelastography</div><div class=\"cntnt\"><img style=\"width:593px; height:273px;\" src=\"images/SURG/51767_Primary_hyperfibrinolysis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Citrated rapid thromboelastography study&#160;(rapid-TEG)&#160;showing primary hyperfibrinolysis. The red tracing indicates a normal study.<br> This study has a normal ACT, normal R time, normal K time, and normal alpha angle; low MA and G, reflecting significant fibrinolysis prior to achieving maximal clot strength; high LY30 reflecting hyperfibrinolysis.</div><div class=\"graphic_footnotes\">R (reaction time): time from sample placement or activation until the tracing amplitude reaches 2 mm; K (clot formation time): time elapsed between the R-time and the point where the tracing amplitude reaches 20 mm; alpha angle: angle between the middle line of the tracing and a tangential line to the developing &quot;body&quot; of the tracing; MA (maximal amplitude): the maximal amplitude reached after clot initiation; G: a calculated measure of total clot strength based on amplitude; LY30: the amount of clot lysis detected 30 minutes after the maximal amplitute (MA) is reached; SP (split point): time from sample placement (or activation with an exogenous procoagulant) until the earliest detectable resistance.</div><div id=\"graphicVersion\">Graphic 51767 Version 5.0</div></div></div>"},"51768":{"type":"graphic_figure","displayName":"Endoscopic classification of biliary atresia","title":"Endoscopic classification of biliary atresia","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Endoscopic classification of biliary atresia</div><div class=\"cntnt\"><img style=\"width:506px; height:539px;\" src=\"images/PEDS/51768_ERCP-biliary-atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classification of biliary atresia according to appearance on endoscopic retrograde cholangiopancreatography (ERCP). In ERCP type 1, present in approximately 30 percent of patients, there is no visualization of the entire biliary tree. In ERCP type 2, present in approximately 50 percent of patients, there is visualization of the common bile duct and gallbladder, but not of the hepatic duct. In ERCP type 3, present in approximately 20 percent of patients, there is visualization of the common bile duct and gallbladder, with visualization of biliary lakes at the porta hepatis (type 3a) or of both hepatic ducts (type 3b). Improper positioning of the catheter during ERCP can lead to misclassification. Note that this ERCP classification of biliary atresia is different from the Kasai classification of biliary atresia, which is based on anatomy at operation.</div><div class=\"graphic_reference\">Data from: Guelrud M, Jaen D, Mendoza S, et al. ERCP in the diagnosis of extrahepatic biliary atresia. Gastrointest Endosc 1991; 37:522.</div><div id=\"graphicVersion\">Graphic 51768 Version 4.0</div></div></div>"},"51769":{"type":"graphic_picture","displayName":"Mohs surgery 1","title":"Mohs surgery of squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Mohs surgery of squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:584px; height:517px;\" src=\"images/DERM/51769_Mohs_surgery_1_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Biopsy proven squamous cell carcinoma of the left preauricular area.<br> (B) After delineation of the clinical lesion, a curette is used to debulk the lesion.<br> (C) Using a blade angled at 45 degrees, a saucerized excision is performed with reference nicks at 12 and 6 o'clock.</div><div id=\"graphicVersion\">Graphic 51769 Version 1.0</div></div></div>"},"51770":{"type":"graphic_picture","displayName":"Palpable purpura from vasculitis","title":"Palpable purpura","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Palpable purpura</div><div class=\"cntnt\"><img style=\"width:492px; height:504px;\" src=\"images/RHEUM/51770_Palpable_purpura_vasc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Non-blanching, palpable purpuric skin lesions found over the lower extremity of a patient with a small-vessel vasculitis affecting the skin.</div><div class=\"graphic_reference\">Courtesy of Joseph F Merola, MD.</div><div id=\"graphicVersion\">Graphic 51770 Version 2.0</div></div></div>"},"51771":{"type":"graphic_figure","displayName":"VLDL metabolism","title":"Endogenous pathway of lipid metabolism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endogenous pathway of lipid metabolism</div><div class=\"cntnt\"><img style=\"width:448px; height:294px;\" src=\"images/CARD/51771_VLDL_metabolism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The endogenous pathway begins with the synthesis in the liver of nascent VLDL particles, containing apolipoproteins (apo) B-100 and E. Cholesteryl esters and other apolipoproteins, some of which are derived from HDL catabolism, are added to form the mature VLDL particle. The lipolytic action of lipoprotein lipase (for which apo C-II is the primary ligand) cleaves VLDL into smaller VLDL remnants that are enriched in apo B-100 and E. The remnants are either cleared by the LDL and remnant receptors in the liver or hydrolyzed by hepatic triglyceride lipase to yield LDL particles containing apo B-100.</div><div id=\"graphicVersion\">Graphic 51771 Version 1.0</div></div></div>"},"51774":{"type":"graphic_table","displayName":"Six Ts of TBNA","title":"Six essential \"T's\" of transbronchial needle aspiration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Six essential &quot;T's&quot; of transbronchial needle aspiration</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Tomographic (CT) evaluation</td>\n</tr>\n<tr>\n<td>Type of needle</td>\n</tr>\n<tr>\n<td>Technique</td>\n</tr>\n<tr>\n<td>Tissue preparation</td>\n</tr>\n<tr>\n<td>Tissue interpretation</td>\n</tr>\n<tr>\n<td>Trained assistant</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research-Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.</div><div id=\"graphicVersion\">Graphic 51774 Version 1.0</div></div></div>"},"51775":{"type":"graphic_picture","displayName":"Blue sclerae","title":"Blue sclerae in osteogenesis imperfecta","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Blue sclerae in osteogenesis imperfecta</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ALLRG/51775_Blue_sclerae_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blue sclera in a child with osteogenesis imperfecta.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51775 Version 6.0</div></div></div>"},"51776":{"type":"graphic_diagnosticimage","displayName":"Norm ad sagital knee MRI","title":"Normal patellar tendon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal patellar tendon</div><div class=\"cntnt\"><img style=\"width:384px; height:384px;\" src=\"images/RHEUM/51776_Norm_ad_sagital_knee_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This sagittal proton density magnetic resonance image of the knee demonstrates the normal low signal of an intact patellar tendon (arrow).</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 51776 Version 2.0</div></div></div>"},"51778":{"type":"graphic_picture","displayName":"Obstructed umbilical cord","title":"Umbilical cord obstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Umbilical cord obstruction</div><div class=\"cntnt\"><img style=\"width:396px; height:364px;\" src=\"images/OBGYN/51778_Obstructed_umbilical_cord.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The umbilical cord is excessively long (&gt;85 cm), hypertwisted (&gt;5 coils/cm), and shows red discoloration due to degenerative changes accompanying fetal death.</div><div class=\"graphic_reference\">Courtesy of Raymond W. Redline, MD.</div><div id=\"graphicVersion\">Graphic 51778 Version 1.0</div></div></div>"},"51779":{"type":"graphic_table","displayName":"Evaluation and management of suspected encephalitis in children","title":"Initial evaluation and management of suspected encephalitis in children older than one month of age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial evaluation and management of suspected encephalitis in children older than one month of age</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">History</td> </tr> <tr> <td class=\"indent1\">Symptoms: Altered mental status; decreased level of consciousness; lethargy; personality change; fever; seizure; ataxia</td> </tr> <tr> <td class=\"indent1\">Travel</td> </tr> <tr> <td class=\"indent1\">Exposure (animals, insects, freshwater swimming, toxins)</td> </tr> <tr> <td class=\"indent1\">Immunizations</td> </tr> <tr> <td class=\"indent1\">Immune status</td> </tr> <tr> <td class=\"subtitle1_single\">Physical findings</td> </tr> <tr> <td class=\"indent1\">Vital signs and general examination</td> </tr> <tr> <td class=\"indent1\">Neurologic examination, particularly for focal findings and GCS</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory studies</td> </tr> <tr> <td class=\"indent1\">Screening laboratories: CBC, glucose, electrolytes, BUN, creatinine, coagulation studies, ammonia, blood pH, blood cultures, LFTs, urine drug screen; save a sample of acute serum</td> </tr> <tr> <td class=\"indent1\">Lumbar puncture: perform after neuroimaging if a focal lesion is suspected;&nbsp;send CSF for cell count/differential, glucose, protein, bacterial culture, HSV PCR, enterovirus PCR; save a sample of CSF</td> </tr> <tr> <td class=\"indent1\">Other laboratory tests to consider: influenza testing during influenza season; tests for toxic metabolic encephalopathy and inborn errors of metabolism;* antibody studies for NMDAR and VGKC*</td> </tr> <tr> <td class=\"subtitle1_single\">Ancillary studies</td> </tr> <tr> <td class=\"indent1\">Neuroimaging: MRI preferred, but CT if MRI not promptly available, impractical, or cannot be performed</td> </tr> <tr> <td class=\"indent1\">EEG: as soon as is feasible</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"subtitle2_single\">Stabilization</td> </tr> <tr> <td class=\"indent1\">Support airway, breathing and circulation</td> </tr> <tr> <td class=\"indent1\">Endotracheal intubation for GCS &#8804;8 or compromised airway</td> </tr> <tr> <td class=\"indent1\">Fluid resuscitation with normal saline (20 mL/kg, initial bolus) for signs of hypovolemia or shock</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Treat seizures with lorazepam (0.1 mg/kg IV) </td> </tr> <tr> <td class=\"subtitle2_single\">Empiric therapy (initial dose)<sup><span style=\"font-size: 13px;\">&#182;</span></sup></td> </tr> <tr> <td class=\"indent1\">Administer acyclovir<sup><span style=\"font-size: 13px;\">&#916;</span></sup> (&#62;28 days to &#60;3 months: 20 mg/kg IV; &#8805;3 months to &#60;12 years: 10 to 15 mg/kg IV; &#8805;12 years: 10 mg/kg IV) to patients with suspected viral encephalitis (ie, encephalopathy [altered mental status, focal deficits, seizures] with laboratory and/or radiographic evidence of CNS inflammation [eg,&nbsp;CSF pleocytosis,&nbsp;abnormal neuroimaging or EEG])&nbsp;without another identified etiology.</td> </tr> <tr> <td class=\"indent1\">Treat for bacterial meningitis if CSF pleocytosis or other clinical concerns (eg, vancomycin [15 mg/kg IV] <strong>plus either</strong> ceftriaxone [50 mg/kg IV] <strong>or</strong> cefotaxime [100 mg/kg IV])<sup><span style=\"font-size: 13px;\">&#9674;</span></sup></td> </tr> <tr> <td class=\"indent1\">Treat for influenza, as indicated based on clinical findings and season (Oseltamivir [dose&nbsp;according to age and weight: 0 to 3 months: 12 mg orally; 4 to 5 months: 17 mg orally; 6 to 11 months: 24 mg orally; &#8805;12 months and &#8804;15 kg: 30 mg orally; 15 to 23 kg: 45 mg orally; 23 to 40 kg: 60 mg orally; &#62;40 kg and/or &#62;12 years old: 75 mg orally])</td> </tr> <tr> <td class=\"indent1\">Treat for rickettsial infection (eg, Rocky Mountain spotted fever, Q fever) or ehrlichiosis in children at risk (doxycycline [2.2 mg/kg IV or orally])<sup>&#167;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GCS: Glasgow coma scale; CBC: complete blood count; BUN: blood urea nitrogen; LFT: liver function tests; CSF: cerebrospinal fluid; HSV: herpes simplex virus; PCR: polymerase chain reaction; NMDAR: anti-N-methyl-D-aspartate receptor; VGKC: voltage-gated potassium channel; MRI: magnetic resonance imaging; CT: computed tomography; EEG: electroencephalography; IV: intravenous;&nbsp;CNS: central nervous system.<br />* Refer to UpToDate content on the evaluation and management of encephalitis in children.<br />¶ The medication doses listed in the section on \"Empiric therapy\" are <STRONG>initial</STRONG> doses. Please <FONT color=black>refer to&nbsp;UpToDate content on encephalitis in children&nbsp;for information about ongoing dosing and care.</FONT><br />Δ&nbsp;Presumptive treatment for herpes simplex virus.<br />◊ For patients in whom bacterial meningitis cannot be excluded.<br />§&nbsp;Exposure to ticks in endemic regions; exposure to cats, sheep, goats; blood smear characteristic of ehrlichiosis.</div><div id=\"graphicVersion\">Graphic 51779 Version 14.0</div></div></div>"},"51780":{"type":"graphic_diagnosticimage","displayName":"IVP megaureter","title":"Intravenous pyelogram of bilateral congenital megaureter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intravenous pyelogram of bilateral congenital megaureter</div><div class=\"cntnt\"><img style=\"width:269px; height:370px;\" src=\"images/PEDS/51780_IVP_megaureter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intravenous pyelogram of a congenital nonrefluxing nonobstructive megaureter.</div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 51780 Version 3.0</div></div></div>"},"51782":{"type":"graphic_diagnosticimage","displayName":"CT subdural hemorrhage and cerebral edema","title":"Head CT of subdural hemorrhage and cerebral edema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Head CT of subdural hemorrhage and cerebral edema</div><div class=\"cntnt\"><img style=\"width:306px; height:331px;\" src=\"images/PEDS/51782_Subdural_bleed_cerebral_ede.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT image (axial view) of acute-hyperacute right subdural hemorrhage (arrows) and asymmetric cerebral edema in an eight-month-old male infant who sustained nonaccidental injury (child abuse).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 51782 Version 4.0</div></div></div>"},"51786":{"type":"graphic_table","displayName":"Clinical features of common optic neuropathies","title":"Clinical features of more common optic neuropathies*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of more common optic neuropathies*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Optic neuritis</td> <td class=\"subtitle1\">Non-arteritic ischemic optic neuropathy</td> <td class=\"subtitle1\">Arteritic ischemic optic neuropathy</td> <td class=\"subtitle1\">Leber's hereditary optic neuropathy</td> <td class=\"subtitle1\">Neuroretinitis</td> </tr> <tr> <td><strong>Age</strong></td> <td>20 to 50 years</td> <td>&#62;50 years</td> <td>&#62;70 years</td> <td>25 to 40 years</td> <td>Children</td> </tr> <tr> <td><strong>Gender</strong></td> <td>2:1 female</td> <td>Equal</td> <td>3.5:1 female</td> <td>80 to 90 percent male</td> <td>Equal</td> </tr> <tr> <td><strong>Pain</strong></td> <td>Present in &#62;90 percent</td> <td>Present in &#60;10 percent</td> <td>Headache, scalp tenderness, jaw claudication</td> <td>Not present</td> <td>Variable</td> </tr> <tr> <td><strong>Onset</strong></td> <td>Hours to days</td> <td>Sudden</td> <td>Sudden</td> <td>Weeks to months</td> <td>Hours to days</td> </tr> <tr> <td><strong>Unilateral or bilateral</strong></td> <td>Usually unilateral</td> <td>Usually unilateral; low chance may recur in other eye years later</td> <td>May occur in both eyes in rapid sequence</td> <td>Bilateral - but presentation often unilateral</td> <td>Often bilateral</td> </tr> <tr> <td><strong>Funduscopic examination</strong></td> <td>Papillitis present in one-third</td> <td>Papillitis present in most</td> <td>Pale swelling of disc; fundus may also be normal (posterior ischemic optic neuropathy - indicates giant cell arteritis)</td> <td>Disc hyperemia but no swelling; peripapillary telangiectasia</td> <td>Papillitis, macular edema, exudates</td> </tr> <tr> <td><strong>Visual field defect</strong></td> <td>Central scotoma</td> <td>Altitudinal (usually inferior) defect</td> <td>Altitudinal or generalized constriction</td> <td>Central or cecocentral defect</td> <td>Variable</td> </tr> <tr> <td><strong>Magnetic resonance imaging: optic nerve</strong></td> <td>Inflammation of optic nerve in most (one-third to one-half will have other demyelinating lesions)</td> <td>Often normal</td> <td>May show enhancement</td> <td>Normal</td> <td>Variably abnormal</td> </tr> <tr> <td><strong>Prognosis</strong></td> <td>Begins within two to four weeks, most achieve 20/40 or better</td> <td>Over several months, only 40 percent improve by three or more lines</td> <td>Poor once vision loss has occurred; may cause rapid blindness untreated</td> <td>One-third achieve some improvement</td> <td>Most recover fully</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Other diagnoses are described in the text \"Optic neuropathies.\"</div><div id=\"graphicVersion\">Graphic 51786 Version 3.0</div></div></div>"},"51787":{"type":"graphic_table","displayName":"Outcome of IVF by maternal age","title":"Outcomes from in vitro fertilization using fresh embryos from non-donor oocytes (2009)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outcomes from in vitro fertilization using fresh embryos from non-donor oocytes (2009)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">&#60;35</td> <td class=\"subtitle1\">35-37</td> <td class=\"subtitle1\">38-40</td> <td class=\"subtitle1\">41-42</td> <td class=\"subtitle1\">43-44</td> </tr> <tr> <td>Number of cycles</td> <td>56,843</td> <td>29,822</td> <td>29,907</td> <td>14,261</td> <td>8745</td> </tr> <tr> <td>Percentage of cycles resulting in pregnancies</td> <td>47</td> <td>39</td> <td>30</td> <td>20</td> <td>11</td> </tr> <tr> <td>Percentage of cycles resulting in live births</td> <td>41</td> <td>32</td> <td>22</td> <td>12</td> <td>5</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Centers for Disease Control and Prevention (CDC). Society for Assisted Reproductive Technology, American Society for Reproductive Medicine. Assisted reproductive technology success rates. National summary and fertility clinic reports for 2009. Available at: <A spellcheck=true href=\"http://www.cdc.gov/art/pdf/archived/art_2009_full.pdf\" target=_blank>http://www.cdc.gov/art/pdf/archived/art_2009_full.pdf</A> (Accessed July 24, 2015).</div><div id=\"graphicVersion\">Graphic 51787 Version 4.0</div></div></div>"},"51795":{"type":"graphic_diagnosticimage","displayName":"Coccidioidomycosis chest CT","title":"Chest computed tomograph of a patient with coccidioidomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest computed tomograph of a patient with coccidioidomycosis</div><div class=\"cntnt\"><img style=\"width:400px; height:268px;\" src=\"images/ID/51795_CoccidioidomycosisCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-resolution computed tomography (CT) image (1.5-mm collimation) shows thin-walled cavity in right upper lobe. The diagnosis of coccidioidomycosis was made at surgical resection. The patient was a 44-year-old man who developed coccidioidomycosis following travel to an endemic area.</div><div class=\"graphic_reference\">Reproduced with permission from: Fungal and parasitic infections. In: Imaging of pulmonary infections. Muller NL, Franquet T, Kyung SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 51795 Version 9.0</div></div></div>"},"51796":{"type":"graphic_picture","displayName":"Night splint PI","title":"Night splint to treat a bunion","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Night splint to treat a bunion</div><div class=\"cntnt\"><img style=\"width:502px; height:364px;\" src=\"images/PI/51796_Night_splint_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">If you have a bunion, wearing a night splint might help straighten your big toe.</div><div class=\"graphic_reference\">Courtesy of Jill Ferrari, PhD, BSc.</div><div id=\"graphicVersion\">Graphic 51796 Version 1.0</div></div></div>"},"51797":{"type":"graphic_table","displayName":"Classification of adverse drug reactions","title":"Classification of adverse drug reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of adverse drug reactions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug reaction</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Type A: Reactions occurring in most normal patients, given sufficient dose and duration of therapy: Common and predictable</td> </tr> <tr> <td class=\"indent1\">Overdose</td> <td> <p>Hepatic failure (acetaminophen)</p> Metabolic acidosis (aspirin)</td> </tr> <tr> <td class=\"indent1\">Side effects</td> <td> <p>Nausea, headache (with methylxanthines)</p> <p>Oral thrush or vaginal candidiasis (with glucocorticoids)</p> Nephrotoxicity (with aminoglycosides)</td> </tr> <tr> <td class=\"indent1\">Secondary or indirect effects</td> <td> <p>Diarrhea due to alteration in GI bacteria after antibiotics</p> Phototoxicity (with doxycycline or thiazide diuretics)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Drug interactions</td> <td>Macrolide antibiotics increasing theophylline, digoxin, or statin blood levels</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Type B: Drug hypersensitivity reactions restricted to a small subset of the general population: Rare and mostly unpredictable</td> </tr> <tr> <td class=\"indent1\">Intolerance*</td> <td>Tinnitus after a single aspirin tablet</td> </tr> <tr> <td class=\"indent1\">Idiosyncrasy<sup>&#182;</sup> (pharmacogenetics)</td> <td> <p>G6PD deficiency: Hemolytic anemia after antioxidant drugs (eg, dapsone)<sup>&#916;</sup></p> <p>TMPT deficiency: Toxicity during azathioprine therapy<sup>&#916;</sup></p> Pseudoallergic reaction (with NSAIDs)</td> </tr> <tr> <td class=\"indent1\">Immunologic drug reactions (allergy)</td> <td> <p>Anaphylaxis from beta-lactam antibiotics</p> <p>Photoallergy with quinidine</p> <p>Immune-mediated thrombocytopenia (with heparin)</p> <p>Serum sickness (with antivenom preparations)</p> <p>Vasculitis (with phenytoin)</p> <p>Stevens-Johnson syndrome (with trimethoprim-sulfamethoxazole)</p> Drug-induced hypersensitivity syndrome (with allopurinol in HLA-B*58:01 individuals)<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GI: gastrointestinal; G6PD: glucose-6-phosphate dehydrogenase; TPMT: thiopurine methyltransferase; NSAIDs: nonsteroidal anti-inflammatory drugs.<br />* Side effects at subtherapeutic doses.<br />¶ Drug effect not attributable to known pharmacologic properties of drug and not immune-mediated.<br />Δ This is an example of a type B reaction that is predictable.</div><div class=\"graphic_reference\">Modified with permission from: Celik G, Pichler WJ, Adkinson NF Jr. Drug Allergy. In: Middleton's Allergy Principles &amp; Practice, 7th ed, Adkinson NF, et al (Ed), Mosby Elsevier, Philadelphia 2009. p.1205-1226. Illustration used with permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 51797 Version 10.0</div></div></div>"},"51798":{"type":"graphic_picture","displayName":"Bilateral septal hematoma","title":"Bilateral septal hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral septal hematoma</div><div class=\"cntnt\"><img style=\"width:324px; height:308px;\" src=\"images/EM/51798_Septal_hematoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Handler SD, Myer CM. Atlas of ear, nose and throat disorders in children. Ontario, Canada: BC Decker; 1998:52. Copyright © 1998 PMPH-USA, Ltd.</div><div id=\"graphicVersion\">Graphic 51798 Version 2.0</div></div></div>"},"51802":{"type":"graphic_picture","displayName":"Histol radial growth melanoma","title":"Radial growth phase melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radial growth phase melanoma</div><div class=\"cntnt\"><img style=\"width:371px; height:276px;\" src=\"images/ONC/51802_Histol_radial_growth_melano.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power light photomicrograph of an in-situ superficial spreading melanoma. Note the lack of large atypical nests or mitoses in the dermis.</div><div class=\"graphic_reference\">Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.</div><div id=\"graphicVersion\">Graphic 51802 Version 1.0</div></div></div>"},"51803":{"type":"graphic_table","displayName":"Causes thyroid nodules PI","title":"Causes of thyroid nodules","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of thyroid nodules</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Benign </td> </tr> <tr> <td>Multinodular (sporadic) goiter (\"colloid adenoma\")</td> </tr> <tr> <td>Hashimoto's (chronic lymphocytic) thyroiditis</td> </tr> <tr> <td>Cysts: colloid, simple, or hemorrhagic</td> </tr> <tr> <td class=\"sublist1_start\">Follicular adenomas </td> </tr> <tr> <td class=\"sublist1\">Macrofollicular adenomas </td> </tr> <tr> <td class=\"sublist1\">Microfollicular or cellular adenomas </td> </tr> <tr> <td class=\"sublist1_start\">H&#252;rthle cell (oxyphil cell) adenomas </td> </tr> <tr> <td class=\"sublist1\">Macro- or microfollicular patterns </td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Malignant </td> </tr> <tr> <td>Papillary carcinoma</td> </tr> <tr> <td class=\"sublist1_start\">Follicular carcinoma </td> </tr> <tr> <td class=\"sublist1\">Minimally or widely invasive </td> </tr> <tr> <td class=\"sublist1\">Oxyphilic (H&#252;rthle cell) type </td> </tr> <tr> <td>Medullary carcinoma</td> </tr> <tr> <td>Anaplastic carcinoma</td> </tr> <tr> <td>Primary thyroid lymphoma</td> </tr> <tr> <td>Metastatic carcinoma (breast, renal cell, others)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51803 Version 2.0</div></div></div>"},"51805":{"type":"graphic_figure","displayName":"Saphenous vein cutdown dissection and cannulation","title":"Saphenous vein cutdown: dissection and cannulation","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Saphenous vein cutdown: dissection and cannulation</div><div class=\"cntnt\"><img style=\"width:540px; height:558px;\" src=\"images/EM/51805_Saphenous_cutdown_techniq1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Isolate the saphenous vein by blunt dissection using a curved hemostat (proximal to distal, paralleling the course of the vein). Take care to separate the vein from the surrounding tissue because a sensory nerve is located just anterior to it. Place a small silk suture around the distal end of the vein and anchor it with a clamp. <br />(B) Apply traction to the vein with the distal suture. Insert the point of a No. 11 scalpel blade into the upper third of the vessel perpendicular to the long axis of the vein to produce a flap halfway through the vein.<br />(C) Hold the vein flap open with a curved hook. Insert a beveled catheter into the vein opening.<br />(D) Advance the catheter into the vein. The catheter may be easier to advance when fluid is running through it.</div><div id=\"graphicVersion\">Graphic 51805 Version 4.0</div></div></div>"},"51806":{"type":"graphic_table","displayName":"Perioperative anaphylaxis versus general anaphylaxis","title":"Differences between perioperative/perianesthesia anaphylaxis and anaphylaxis in other settings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differences between perioperative/perianesthesia anaphylaxis and anaphylaxis in other settings</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Manifestations of anaphylaxis</td> <td class=\"subtitle1\">In other settings</td> <td class=\"subtitle1\">In perioperative settings</td> </tr> <tr class=\"divider_bottom\"> <td>Upper respiratory tract/laryngeal edema</td> <td>Throat tightness, change in voice quality</td> <td>Difficulty with intubation</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Lower respiratory tract/bronchospasm</td> <td class=\"divider_bottom\" rowspan=\"3\">Shortness of breath, wheezing, repetitive cough</td> <td>Increase in ventilatory pressure needed to inflate lungs</td> </tr> <tr> <td>Increase in end-tidal CO<sub>2</sub></td> </tr> <tr class=\"divider_bottom\"> <td>Decrease in arterial oxygen saturation</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Cardiovascular system/hypotension</td> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Dizziness, tunnel vision</p> Collapse without warning signs uncommon</td> <td>Cardiovascular collapse common (first detected manifestation in one-half of cases)</td> </tr> <tr class=\"divider_bottom\"> <td>Arrhythmias and cardiac arrest are more common</td> </tr> <tr> <td rowspan=\"2\">Skin</td> <td rowspan=\"2\">Flushing, itching, or urticaria (present in &#62;90% of cases)</td> <td>Cutaneous signs and symptoms may be absent or present but hidden by surgical drapes</td> </tr> <tr> <td>Patient cannot report itching</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In the perioperative setting, patients are usually sedated or anesthetized and unable to report some of the milder and earlier signs of an allergic reaction. In addition, many exposures are intravenous. For these reasons, patients are more likely to present with cardiopulmonary symptoms, rather than cutaneous symptoms.</div><div id=\"graphicVersion\">Graphic 51806 Version 9.0</div></div></div>"},"51808":{"type":"graphic_figure","displayName":"Pericentric inversion","title":"Pericentric inversion of chromosome 7","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pericentric inversion of chromosome 7</div><div class=\"cntnt\"><img style=\"width:396px; height:313px;\" src=\"images/HEME/51808_Pericentric_inversion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a pericentric inversion, the inverted chromosome segment involves part of both chromosome arms and spans the centromere. This patient (GTG stained chromosome on the right) has a pericentric inversion of chromosome 7. The boxed area corresponds to the area between the two red arrows in the normal chromosome 7 (center) and to the indicated bands on the representation of chromosome 17 (left). The black bar to the left of both GTG banded chromosomes shows the location of the centromere. This pericentric inversion changed the position of the centromere.</div><div class=\"graphic_footnotes\">GTG: G-banding with trypsin and Giemsa</div><div id=\"graphicVersion\">Graphic 51808 Version 2.0</div></div></div>"},"51809":{"type":"graphic_waveform","displayName":"Incomplete RBBB tutorial","title":"Incomplete right bundle branch block","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Incomplete right bundle branch block</div><div class=\"cntnt\"><img style=\"width:470px; height:134px;\" src=\"images/CARD/51809_Incomplete_RBBB_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Delayed conduction through the right bundle branch does not affect the initial portion of the QRS complex (septal activation), but alters the terminal portion. There is an rsR' pattern in leads aVR and V1, and a qRs morphology in leads I and V6. The width of the QRS complex is only slightly prolonged, between 0.10 and 0.12 seconds.</div><div id=\"graphicVersion\">Graphic 51809 Version 4.0</div></div></div>"},"51814":{"type":"graphic_figure","displayName":"Larynx innervation","title":"Innervation of the larynx","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Innervation of the larynx</div><div class=\"cntnt\"><img style=\"width:524px; height:536px;\" src=\"images/EM/51814_Airwayanatinnervation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Innervation of the larynx.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 51814 Version 11.0</div></div></div>"},"51816":{"type":"graphic_picture","displayName":"Labial hypertrophy","title":"Hypertrophy of the labia minora","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypertrophy of the labia minora</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/OBGYN/51816_Labialhypertrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral labia minor hypertrophy fully extended.</div><div class=\"graphic_reference\">Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds). Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 51816 Version 15.0</div></div></div>"},"51818":{"type":"graphic_waveform","displayName":"Intermediate case 11","title":"Intermediate case 11","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intermediate case 11</div><div class=\"cntnt\"><img style=\"width:337px; height:253px;\" src=\"images/CARD/51818_Intermediate_case_11.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51818 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"51819":{"type":"graphic_figure","displayName":"Pathogenesis C diff diarrhea","title":"Pathogenesis of <EM>Clostridium difficile </EM>diarrhea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of <EM>Clostridium difficile </EM>diarrhea</div><div class=\"cntnt\"><img style=\"width:331px; height:238px;\" src=\"images/GAST/51819_Pathogenesis_C_diff_diarrhe.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51819 Version 3.0</div></div></div>"},"51820":{"type":"graphic_table","displayName":"Epidemiology of HBV","title":"Epidemiology and modes of transmission of hepatitis B virus infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epidemiology and modes of transmission of hepatitis B virus infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">High</td> <td class=\"subtitle1\">Intermediate</td> <td class=\"subtitle1\">Low</td> </tr> <tr> <td>Carrier rate</td> <td>&#8805;8 percent</td> <td>2 to 7 percent</td> <td>&#8804;1 percent</td> </tr> <tr> <td>Geographic distribution*</td> <td>Parts of sub-Saharan Africa (eg, Western Africa, South Sudan)</td> <td>Mediterranean basin; Eastern Europe; Central Asia; Southeast Asia; China; Japan; parts of Latin and South America (eg, Peru, Colombia); Middle East</td> <td>United States; Canada; Western Europe; Mexico; Australia; New Zealand</td> </tr> <tr> <td>Predominant age at infection</td> <td>Perinatal and early childhood</td> <td>Early childhood</td> <td>Adult</td> </tr> <tr> <td>Predominant mode of infection</td> <td>Mother to child; percutaneous</td> <td>Percutaneous; sexual</td> <td>Percutaneous; sexual</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*For updated data, refer to <A spellcheck=true href=\"http://www.cdc.gov/\">the United States Centers for Disease Control and Prevention website</A>.</div><div class=\"graphic_reference\">References: <br /><br /><OL>&#xD;&#xA;<LI>Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30:2212. </LI>&#xD;&#xA;<LI>Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection:&nbsp;A systematic review of data published between 1965 and 2013. Lancet 2015; 386:1546.</LI>&#xD;&#xA;<LI>HIV, viral hepatitis and sexually transmissible infections in Australia: Annual Surveillance Report 2013. Sydney: The Kirby Institute, The University of New South Wales; 2013.</LI>&#xD;&#xA;<LI>New Zealand Society of Gastroenterology. www.nzsg.org.nz/cms2/research/hepatitis/hepatitis b/ (accessed 12/31/2015).</LI></OL></div><div id=\"graphicVersion\">Graphic 51820 Version 6.0</div></div></div>"},"51824":{"type":"graphic_table","displayName":"Triggers autonomic dysreflexia","title":"Triggers of autonomic dysreflexia in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Triggers of autonomic dysreflexia in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td><strong>Pelvis:</strong> manipulation of the vagina or cervix, bimanual examination, insertion of a vaginal speculum, swabbing the cervix or posterior fornix, or uterine contractions.</td>\n</tr>\n<tr>\n<td><strong>Genitourinary:</strong> manipulation of urinary catheters, catheter insertion, catheter obstruction, vesico-ureteral reflux, or renal colic.</td>\n</tr>\n<tr>\n<td><strong>Gastrointestinal:</strong> constipation, biliary colic, various gastrointestinal pathologies.</td>\n</tr>\n<tr>\n<td><strong>Dermatologic:</strong> decubitus ulcers, temperature variation below the level of the spinal cord lesion such as immersion of feet in cold or hot water, or placement of feet in cold stirrups.</td>\n</tr>\n<tr>\n<td><strong>Other:</strong> sexual activity</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Pereira, L. Obstet Gynecol Surv 2003; 58:678.</div><div id=\"graphicVersion\">Graphic 51824 Version 1.0</div></div></div>"},"51825":{"type":"graphic_picture","displayName":"Tick comparison PI","title":"Tick comparison","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tick comparison</div><div class=\"cntnt\"><img style=\"width:346px; height:295px;\" src=\"images/PI/51825_Tick_comparison_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The top row shows deer ticks. These are the kind of tick that can cause Lyme disease. The first tick on the left in the top row is a \"nymph,\" an immature tick. Next are an adult male, an adult female, and an adult female that has been feeding and is full of blood (called \"engorged\").<br />The bottom row shows dog ticks, which do not cause Lyme disease. From left to right, the ticks on the bottom row are an adult male, an adult female, and an engorged adult female. Adult dog ticks are larger than adult deer ticks and have white markings on their back.</div><div class=\"graphic_reference\">Reproduced with permission from: Lyme Disease Research Laboratory, Maine Medical Center Research Institute, 13 Charles Street, Portland, ME 04102.</div><div id=\"graphicVersion\">Graphic 51825 Version 8.0</div></div></div>"},"51826":{"type":"graphic_figure","displayName":"Anterior peritoneal reflection","title":"Identification of the anterior peritoneal reflection during vaginal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Identification of the anterior peritoneal reflection during vaginal hysterectomy</div><div class=\"cntnt\"><img style=\"width:425px; height:385px;\" src=\"images/OBGYN/51826_Anterior_peritoneal_reflect.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51826 Version 2.0</div></div></div>"},"51828":{"type":"graphic_table","displayName":"Oral antipsychotics cost comparison","title":"Oral antipsychotics cost comparison in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral antipsychotics cost comparison in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Usual oral dose in adults*</td> <td class=\"subtitle1\">Cost of 30 day supply (United States dollars)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">First-generation<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Chlorpromazine</td> <td>200 mg twice daily</td> <td>53.</td> </tr> <tr> <td class=\"indent1\">Fluphenazine</td> <td>10 mg once daily</td> <td>10.</td> </tr> <tr> <td class=\"indent1\">Haloperidol</td> <td>5 mg twice daily</td> <td>4.</td> </tr> <tr> <td class=\"indent1\">Loxapine</td> <td>50 to 100 mg in two to four divided doses</td> <td>10.</td> </tr> <tr> <td class=\"indent1\">Perphenazine</td> <td>24 mg per day in two or three divided doses</td> <td>20.</td> </tr> <tr> <td class=\"indent1\">Thioridazine</td> <td>100 to 200 mg twice daily</td> <td>10.</td> </tr> <tr> <td class=\"indent1\">Thiothixene</td> <td>10 mg twice daily</td> <td>14 to 30.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trifluoperazine</td> <td>10 mg twice daily</td> <td>22 to 30.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Second-generation<sup>&#916;</sup></td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Aripiprazole</td> </tr> <tr> <td class=\"sublist2\">Generic<sup>&#182;</sup></td> <td class=\"sublist_other\">10 to 30 mg once daily</td> <td class=\"sublist_other\">89 to 194.<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2\">Abilify</td> <td class=\"sublist_other\">10 to 30 mg once daily</td> <td class=\"sublist_other\">892.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Asenapine</td> </tr> <tr> <td class=\"sublist2\">Sublingual tablet: Saphris</td> <td class=\"sublist_other\">5 to 10 mg twice daily</td> <td class=\"sublist_other\">916.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Brexpiprazole</td> </tr> <tr> <td class=\"sublist2\">Rexulti</td> <td class=\"sublist_other\">2 to 4 mg once daily</td> <td class=\"sublist_other\">866.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Cariprazine</td> </tr> <tr> <td class=\"sublist2\">Vraylar</td> <td class=\"sublist_other\">1.5 to 6 mg once daily</td> <td class=\"sublist_other\">1006.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Clozapine</td> </tr> <tr> <td class=\"sublist2\">Generic<sup>&#182;</sup></td> <td class=\"sublist_other\">100 to 300 mg three times daily</td> <td class=\"sublist_other\">68 to 95.<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2\">Clozaril</td> <td class=\"sublist_other\">100 to 300 mg three times daily</td> <td class=\"sublist_other\">1126.</td> </tr> <tr> <td class=\"sublist2\" colspan=\"3\">Orally disintegrating tablet</td> </tr> <tr> <td class=\"sublist3\">Generic<sup>&#182;</sup></td> <td class=\"sublist_other\">100 to 300 mg three times daily</td> <td class=\"sublist_other\">285&nbsp;to 522.<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist3\">FazaClo</td> <td class=\"sublist_other\">100 to 300 mg three times daily</td> <td class=\"sublist_other\">1440.</td> </tr> <tr> <td class=\"sublist3\">Versacloz 50 mg/mL oral suspension</td> <td class=\"sublist_other\">100 to 300 mg three times daily</td> <td class=\"sublist_other\">1387.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Iloperidone</td> </tr> <tr> <td class=\"sublist2\">Fanapt</td> <td class=\"sublist_other\">6 to 12 mg twice daily</td> <td class=\"sublist_other\">1139.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Lurasidone</td> </tr> <tr> <td class=\"sublist2\">Latuda</td> <td class=\"sublist_other\">40 to 160 mg once daily</td> <td class=\"sublist_other\">922.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Olanzapine</td> </tr> <tr> <td class=\"sublist2\">Generic<sup>&#182;</sup></td> <td class=\"sublist_other\">10 to 20 mg once daily</td> <td class=\"sublist_other\">17.<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2\">Zyprexa</td> <td class=\"sublist_other\">10 to 20 mg once daily</td> <td class=\"sublist_other\">553.</td> </tr> <tr> <td class=\"sublist2\" colspan=\"3\">Orally disintegrating tablet</td> </tr> <tr> <td class=\"sublist3\">Generic<sup>&#182;</sup></td> <td class=\"sublist_other\">10 to 20 mg once daily</td> <td class=\"sublist_other\">190.</td> </tr> <tr> <td class=\"sublist3\">Zyprexa Zydis</td> <td class=\"sublist_other\">10 to 20 mg once daily</td> <td class=\"sublist_other\">583.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Paliperidone</td> </tr> <tr> <td class=\"sublist2\">Generic<sup>&#182;</sup></td> <td class=\"sublist_other\">3 to 12 mg once daily</td> <td class=\"sublist_other\">190. to 375.<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2\">Invega</td> <td class=\"sublist_other\">3 to 12 mg once daily</td> <td class=\"sublist_other\">934.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Quetiapine</td> </tr> <tr> <td class=\"sublist2\">Generic<sup>&#182;</sup></td> <td class=\"sublist_other\">150 to 750 mg in two or three divided doses</td> <td class=\"sublist_other\">4. to 12.<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2\">Seroquel</td> <td class=\"sublist_other\">150 to 750 mg in two or three divided doses</td> <td class=\"sublist_other\">600.</td> </tr> <tr> <td class=\"sublist2\">Seroquel XR</td> <td class=\"sublist_other\">400 to 800 mg once daily</td> <td class=\"sublist_other\">750.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Risperidone</td> </tr> <tr> <td class=\"sublist2\">Generic<sup>&#182;</sup></td> <td class=\"sublist_other\">4 to 8 mg once per day</td> <td class=\"sublist_other\">15. to 17.<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2\">Risperdal</td> <td class=\"sublist_other\">4 to 8 mg once per day</td> <td class=\"sublist_other\">714.</td> </tr> <tr> <td class=\"sublist2\" colspan=\"3\">Orally disintegrating tablet</td> </tr> <tr> <td class=\"sublist3\">Generic<sup>&#182;</sup></td> <td class=\"sublist_other\">4 to 8 mg once daily</td> <td class=\"sublist_other\">100. to 195.<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist3\">Risperdal M-Tab</td> <td class=\"sublist_other\">4 to 8 mg once daily</td> <td class=\"sublist_other\">857.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Ziprasidone</td> </tr> <tr> <td class=\"sublist2\">Generic<sup>&#182;</sup></td> <td class=\"sublist_other\">60 to 80 mg twice daily</td> <td class=\"sublist_other\">30. to 33.<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2\">Geodon</td> <td class=\"sublist_other\">60 to 80 mg twice daily</td> <td class=\"sublist_other\">880.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>Doses shown in this table are for cost comparison purposes <STRONG>only</STRONG>. For patient dosing recommendations, refer to the appropriate UpToDate treatment topics and Lexicomp monographs.</LI>&#xD;&#xA;<LI>Information about strategies to reduce cost of medicines is covered elsewhere. Refer to UpToDate topic: Reducing the costs of medicines (Beyond the Basics).</LI>&#xD;&#xA;<LI>Brand&nbsp;names of second-generation antipsychotics are for products available in the United States and some other countries.</LI></UL></div><div class=\"graphic_footnotes\">* Usual oral daily maintenance dose for schizophrenia in adults used for determining cost of 30 days treatment without prescription insurance coverage. <br />¶ Prices for generic preparations purchased at some large chain-store pharmacy departments in the United States without insurance; a store club membership or discount card may be required.<SUP>[1]</SUP><br />​Δ Approximate wholesale acquisition cost for 30 days' treatment with the lowest usual daily dose. Actual retail prices may differ.<SUP>[2]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>GoodRx website. Available at: http://www.goodrx.com/. Accessed on October 5, 2016.</LI>&#xD;&#xA;<LI>Adapted with special permission from The Medical Letter on Drugs and Therapeutics, April 25, 2016; Vol. 58 (1493):51-3. <A href=\"http://www.medicalletter.org/\" target=_blank>www.medicalletter.org</A>.</LI></OL></div><div id=\"graphicVersion\">Graphic 51828 Version 17.0</div></div></div>"},"51830":{"type":"graphic_figure","displayName":"Toxocariasis life cycle","title":"Toxocariasis life cycle","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Toxocariasis life cycle</div><div class=\"cntnt\"><img style=\"width:612px; height:460px;\" src=\"images/ID/51830_Toxocariasis_life_cycle_sharpened.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><em>Toxocara canis</em> accomplishes its life cycle in dogs, with humans acquiring the infection as accidental hosts. Unembryonated eggs are shed in the feces of the definitive host <strong>(1)</strong>. Eggs embryonate and become infective in the environment <strong>(2)</strong>. Following ingestion by dogs <strong>(3)</strong>, the infective eggs hatch and larvae penetrate the gut wall. In younger dogs, the larvae migrate through the lungs, bronchial tree, and esophagus; adult worms develop and oviposit in the small intestine <strong>(4)</strong>. In older dogs, patent infections can also occur, but larval encystment in tissues is more common. Encysted stages are reactivated in female dogs during late pregnancy and infect by the transplacental and transmammary routes the puppies <strong>(5)</strong>, in whose small intestine adult worms become established <strong>(6)</strong>. Puppies are a major source of environmental egg contamination. <em>Toxocara canis</em> can also be transmitted through ingestion of paratenic hosts: eggs ingested by small mammals (eg, rabbits) hatch and larvae penetrate the gut wall and migrate into various tissues where they encyst <strong>(7)</strong>. The life cycle is completed when dogs eat these hosts <strong>(8)</strong> and the larvae develop into egg-laying adult worms in the small intestine. Humans are accidental hosts who become infected by ingesting infective eggs in contaminated soil <strong>(9)</strong> or infected paratenic hosts <strong>(10)</strong>. After ingestion, the eggs hatch and larvae penetrate the intestinal wall and are carried by the circulation to a wide variety of tissues (liver, heart, lungs, brain, muscle, eyes) <strong>(11)</strong>. While the larvae do not undergo any further development in these sites, they can cause severe local reactions that are the basis of toxocariasis. The two main clinical presentations of toxocariasis are visceral larva migrans and ocular larva migrans. Diagnosis is usually made by serology or the finding of larvae in biopsy or autopsy specimens.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Toxocariasis. Available at: <A href=\"http://www.cdc.gov/parasites/toxocariasis/\">http://www.cdc.gov/parasites/toxocariasis/</A>.</div><div id=\"graphicVersion\">Graphic 51830 Version 4.0</div></div></div>"},"51831":{"type":"graphic_figure","displayName":"TW alternans and late potentials predict arrhythmias","title":"Repolarization alternans (RPA) and late potentials (LP) predict arrhythmic events following myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Repolarization alternans (RPA) and late potentials (LP) predict arrhythmic events following myocardial infarction</div><div class=\"cntnt\"><img style=\"width:490px; height:356px;\" src=\"images/CARD/51831_TWalternansLParrhythmia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 102 patients with a prior myocardial infarction (MI) followed for 13 months, the combination of repolarization alternans (RPA) and late potentials (LP) on a signal averaged ECG had a specificity and negative predictive value for an arrhythmic event of 91 and 92 percent, respectively. However, the positive predictive value was only 50 percent. The very low event rate in the group \"RPA negative and LP positive\" may be due to the small number of patients in this subset (n = 5).</div><div class=\"graphic_reference\">Data from Ikeda T, Sakata T, Takami M, et al, J Am Coll Cardiol 2000; 35:722.</div><div id=\"graphicVersion\">Graphic 51831 Version 3.0</div></div></div>"},"51832":{"type":"graphic_table","displayName":"Role of GLP-1 in glucose homeostasis","title":"The role of GLP-1 in glucose homeostasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The role of GLP-1 in glucose homeostasis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">GLP-1</td> </tr> <tr> <td><strong>Deficiency</strong></td> <td>Type 2 diabetes, +/&ndash; type 1</td> </tr> <tr> <td><strong>Site of synthesis</strong></td> <td>Small intestinal L cells</td> </tr> <tr> <td><strong>Glucose-dependent stimulation of insulin secretion</strong></td> <td>Yes</td> </tr> <tr> <td><strong>Reduction of gastric emptying</strong></td> <td>Yes</td> </tr> <tr> <td><strong>Reduction of inappropriate glucagon secretion</strong></td> <td>Yes</td> </tr> <tr> <td><strong>Weight loss</strong></td> <td>Yes</td> </tr> <tr> <td><strong>Beta cell proliferation/regeneration</strong></td> <td>Yes - in animals</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GLP-1: glucagon-like peptide-1.</div><div id=\"graphicVersion\">Graphic 51832 Version 4.0</div></div></div>"},"51833":{"type":"graphic_table","displayName":"Doses of IV abx for osteoarticular infections in children","title":"Doses of parenteral antibiotics commonly used in the treatment of osteoarticular infections in infants and children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Doses of parenteral antibiotics commonly used in the treatment of osteoarticular infections in infants and children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Intravenous agent</td> <td class=\"subtitle1\">Dose for infants 8 to 28 days of age and&nbsp;body weight &#62;2 kg</td> <td class=\"subtitle1\">Dose for children &#62;28 days&nbsp;of age</td> </tr> <tr> <td>Ampicillin</td> <td>100 to 200 mg/kg per day divided in 4 doses</td> <td>200 to 400 mg/kg per day divided in 4 doses; maximum dose 12 g/day</td> </tr> <tr> <td>Cefazolin</td> <td> <p>75 mg/kg per day divided in 3 doses&nbsp;</p> </td> <td>100 mg/kg per day divided in 3 doses; maximum dose 6 g/day</td> </tr> <tr> <td>Cefepime</td> <td>60 to 100 mg/kg per day divided in 2 doses</td> <td>100 to 150 mg/kg per day divided in 3 doses; maximum dose 6 g/day</td> </tr> <tr> <td>Cefotaxime</td> <td>150 to 200 mg/kg per day divided in 3 doses</td> <td>150 to 200 mg/kg per day divided in 3 or 4 doses; maximum dose 12 g/day</td> </tr> <tr> <td>Ceftazidime</td> <td>150 mg/kg per day divided in 3 doses</td> <td>125 to 150 mg/kg per day divided in 3 doses; maximum daily dose 6 g</td> </tr> <tr> <td>Ceftriaxone</td> <td>50 to 75 mg/kg per day in 1 dose</td> <td>80 to 100 mg/kg per day divided in 1 or 2 doses; maximum dose 4 g/day</td> </tr> <tr> <td>Clindamycin</td> <td>20 to 30 mg/kg per day divided in 4 doses</td> <td>25 to 40<sup>&#182;</sup> mg/kg per day divided in 3 or 4 doses; maximum dose 2.7 g/day</td> </tr> <tr> <td>Daptomycin<sup>&#916;</sup></td> <td>NA</td> <td> <p>1 through 6 years: 12 mg/kg per day in 1 dose</p> <p>7 through 11 years: 9 mg/kg per day in 1 dose</p> <p>12 through 17 years: 7 mg/kg per day in 1 dose</p> </td> </tr> <tr> <td>Gentamicin</td> <td>7.5 mg/kg per day divided in 3 doses</td> <td>7.5 mg/kg per day divided in 3 doses</td> </tr> <tr> <td rowspan=\"2\">Linezolid</td> <td rowspan=\"2\">30 mg/kg per day divided in 3 doses</td> <td>&#60;12 years: 30 mg/kg per day in 3 doses</td> </tr> <tr> <td>&#8805;12 years: 600 mg twice per day</td> </tr> <tr> <td>Nafcillin</td> <td> <p>100 mg/kg per day divided in 4 doses</p> </td> <td>150 to 200 mg/kg per day divided in 4 doses; maximum dose 12 g/day</td> </tr> <tr> <td>Oxacillin</td> <td> <p>100 mg/kg per day divided in 4 doses&nbsp;</p> </td> <td>150 to 200 mg/kg per day divided in 4 to 6 doses; maximum dose 12 g/day</td> </tr> <tr> <td>Penicillin</td> <td>100,000 to 200,000 units/kg per day divided in 4 doses</td> <td>250,000 to 400,000 units/kg per day divided in 4 to 6 doses; maximum dose 24 million units per day</td> </tr> <tr> <td>Vancomycin<sup>&#9674;</sup></td> <td>Initial dosing according to creatinine as follows: <ul class=\"decimal_heading\"> <li>&#60;0.7 mg/dL: 15 mg/kg every 12 hours </li> <li>0.7 to 0.9 mg/dL: 20 mg/kg every 24 hours </li> <li>1.0 to 1.2 mg/dL: 15 mg/kg every 24 hours </li> <li>1.3 to 1.6 mg/dL: 10 mg/kg every 24 hours </li> <li>&#62;1.6 mg/dL: 15 mg/kg every 48 hours </li> </ul> </td> <td>40 to 60 mg/kg per day divided in 3 doses; maximum dose 4 g/day</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NA: not available.<br />* Refer to UpToDate topics on management of osteomyelitis and septic arthritis in children for details regarding indications for particular drugs; recommended doses are for patients with normal renal function.<br />¶ 40 mg/kg per day is preferred for children ≥3 months of age.<br />Δ Daptomycin should not be used in children with concomitant pulmonary involvement <SPAN style=\"COLOR: black\">and is not recommended in children &lt;1 year of age because of the risk of potential effects on muscular, neuromuscular, and/or nervous systems (peripheral and/or central) observed in dogs. It is not approved for the treatment of&nbsp;osteoarticular infections&nbsp;in children; the appropriate dose for osteoarticular infections has not yet been established but is the subject of clinical trials. The doses provided above are those that are recommended for<EM> Staphylococcus aureus</EM> bacteremia in children</SPAN><SPAN style=\"COLOR: black\">.</SPAN><br />◊ Dosing algorithm for vancomycin based upon serum creatinine concentration in neonates born at gestational age &gt;28 weeks. A vancomycin dosing method based upon postnatal age and weight is provided as an alternative to the serum creatinine-based method listed above and may be useful in some clinical situations. This particular algorithm was provided in the 2009 edition of the Red Book.<SUP>[1]</SUP><br />Postnatal age &lt;7 days: <br /><UL>&#xD;&#xA;<LI>&lt;1200 g: 15 mg/kg IV every 24 hours</LI>&#xD;&#xA;<LI>1200 to 2000 g: 10 to 15 mg/kg IV every 12 or 18 hours</LI>&#xD;&#xA;<LI>&gt;1200 g: 10 to 15 mg/kg IV every 8 or 12 hours</LI></UL>Postnatal age ≥7 days: <br /><UL>&#xD;&#xA;<LI>&lt;1200 g: 15 mg/kg IV every 24 hours</LI>&#xD;&#xA;<LI>1200 to 2000 g: 10 to 15 mg/kg IV every 8 or 12 hours</LI>&#xD;&#xA;<LI>&gt;2000 g: 10 to 15 mg/kg IV every 6 or 8 hours</LI></UL></div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>American Academy of Pediatrics. Antibacterial drugs for newborn infants: Dose and frequency of administration. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28<SUP>th</SUP> ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.745.</LI>&#xD;&#xA;<LI>American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.881.</LI>&#xD;&#xA;<LI><FONT color=black>Cubicin (daptomycin for injection). United States Prescribing Information. Revised September, 2017. US Food&nbsp;and Drug Administration. (Available online at&nbsp;<A spellcheck=true href=\"http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm\" target=_blank>http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm</A> ((accessed&nbsp;September 7, 2017)).</FONT></LI></OL></div><div id=\"graphicVersion\">Graphic 51833 Version 20.0</div></div></div>"},"51834":{"type":"graphic_diagnosticimage","displayName":"Osteomyelitis limp fever","title":"Lytic lucency in osteomyelitis","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Lytic lucency in osteomyelitis</div><div class=\"cntnt\"><img style=\"width:506px; height:510px;\" src=\"images/PEDS/51834_Osteomyelitis_limp_fever.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A plain radiograph at the initial evaluation of a 9-year-old with fever and limp demonstrates a lytic lucency in the distal femoral metaphysis.<br />(B, C) Axial and coronal magnetic resonance (MR) images delineate the area of osteomyelitis and adjacent marrow edema.</div><div class=\"graphic_reference\">Reproduced with permission from Jeanne Chow, MD. Children's Hospital-Boston, Copyright &copy; Jeanne Chow, MD.</div><div id=\"graphicVersion\">Graphic 51834 Version 3.0</div></div></div>"},"51835":{"type":"graphic_picture","displayName":"Posterior labial fusion","title":"Posterior labial fusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior labial fusion</div><div class=\"cntnt\"><img style=\"width:390px; height:262px;\" src=\"images/PEDS/51835_Posterior_labial_fusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posterior labial fusion in the 46,XX patient with ovotesticular disorder of sex development (previously known as true hermaphroditism) who also has clitoromegaly and gonads palpable in the labioscrotal folds.</div><div class=\"graphic_reference\">Courtesy of Christopher P Houk, MD and Lynne L Levitsky, MD.</div><div id=\"graphicVersion\">Graphic 51835 Version 4.0</div></div></div>"},"51836":{"type":"graphic_picture","displayName":"Limbic keratoconjunctivitis","title":"Superior limbic keratoconjunctivitis in contact lens wearer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superior limbic keratoconjunctivitis in contact lens wearer</div><div class=\"cntnt\"><img style=\"width:290px; height:241px;\" src=\"images/PC/51836_Limbic_keratoconjunctivitis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51836 Version 2.0</div></div></div>"},"51842":{"type":"graphic_figure","displayName":"Defibrillation waveforms in ICDs","title":"Defibrillation waveforms in implantable cardioverter-defibrillators","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Defibrillation waveforms in implantable cardioverter-defibrillators</div><div class=\"cntnt\"><img style=\"width:551px; height:181px;\" src=\"images/CARD/51842_Defib_waveforms_in_ICD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figure A shows the monophasic, exponentially decaying pulse was the waveform used in the first generation of ICDs. Figure B shows the biphasic waveform which is generated with a single capacitor by switching the output polarity during discharge. Each division is two milliseconds.</div><div id=\"graphicVersion\">Graphic 51842 Version 2.0</div></div></div>"},"51843":{"type":"graphic_picture","displayName":"Acoustic neuroma Light","title":"Acoustic neuroma light","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Acoustic neuroma light</div><div class=\"cntnt\"><img style=\"width:567px; height:234px;\" src=\"images/ONC/51843_Acoustic_neuroma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acoustic neuroma. Low and high power magnification of acoustic neuroma with zones of alternately dense and sparse cellularity.</div><div class=\"graphic_reference\">Courtesy of Ivo P Janecka, MD, FACS.</div><div id=\"graphicVersion\">Graphic 51843 Version 1.0</div></div></div>"},"51844":{"type":"graphic_diagnosticimage","displayName":"Panc divisum normal duct","title":"Pancreas divisum and a normal appearing dorsal duct","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreas divisum and a normal appearing dorsal duct</div><div class=\"cntnt\"><img style=\"width:316px; height:509px;\" src=\"images/PEDS/51844_Panc_divisum_normal_duct.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: ERCP in Paediatric Practice: Diagnosis and Treatment, Isis Medical Media LTD, Oxford University Press, UK, 1997. Copyright ©1997 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 51844 Version 2.0</div></div></div>"},"51847":{"type":"graphic_algorithm","displayName":"HAAF","title":"Hypoglycemia-associated autonomic failure in diabetes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypoglycemia-associated autonomic failure in diabetes</div><div class=\"cntnt\"><img style=\"width:303px; height:421px;\" src=\"images/ENDO/51847_HAAF.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from: Cryer PE. Diverse causes of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2004; 350:2272.</div><div id=\"graphicVersion\">Graphic 51847 Version 6.0</div></div></div>"},"51848":{"type":"graphic_figure","displayName":"Transdermal versus oral ERT","title":"Transdermal and oral estrogen prevent bone loss","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Transdermal and oral estrogen prevent bone loss</div><div class=\"cntnt\"><img style=\"width:473px; height:248px;\" src=\"images/ENDO/51848_Transdermal_versus_oral_ERT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Percent changes in lumbar spine bone density in postmenopausal women treated with transdermal or oral&nbsp;ERT or not treated. Each estrogen regimen led to an equivalent increase in bone density which was statistically different from the loss of bone in untreated women.</div><div class=\"graphic_footnotes\">ERT: estrogen replacement therapy.</div><div class=\"graphic_reference\">Data from: Stevenson JC, Cust MP, Gangar KF, et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women.&nbsp;Lancet 1990; 336:265.</div><div id=\"graphicVersion\">Graphic 51848 Version 3.0</div></div></div>"},"51849":{"type":"graphic_table","displayName":"Contraceptive counseling","title":"Contraceptive counseling tool: The top 10 questions that facilitate contraceptive counseling","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraceptive counseling tool: The top 10 questions that facilitate contraceptive counseling</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>1. What are your contraceptive goals? Do you ever plan to get pregnant? When?</td>\n</tr>\n<tr>\n<td>2. Are you currently having sex with a male partner?</td>\n</tr>\n<tr>\n<td>3. Have you tried any contraceptive methods? If so, which one(s)?</td>\n</tr>\n<tr>\n<td>4. What did you like/dislike about the method(s)?</td>\n</tr>\n<tr>\n<td>5. Are you a good pill taker?</td>\n</tr>\n<tr>\n<td>6. For user-controlled methods, how often did you forget to use the method?</td>\n</tr>\n<tr>\n<td>7. Are there any methods you have heard about and would like to try?</td>\n</tr>\n<tr>\n<td>8. How important is spontaneity of use?</td>\n</tr>\n<tr>\n<td>9. Is protection from sexually transmitted infections important considering your life situation?</td>\n</tr>\n<tr>\n<td>10. Is cost an issue? Does your health insurance plan cover any contraceptive method?</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=22067&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Contraceptive_counseling.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from: Association of Reproductive Health Professionals. Clinical Proceedings: Periodic Well-Woman Visit: Individualized Contraceptive Care. Washington, DC; April 2004. Copyright © Association of Reproductive Health Professionals (ARHP).</div><div id=\"graphicVersion\">Graphic 51849 Version 2.0</div></div></div>"},"51853":{"type":"graphic_diagnosticimage","displayName":"Complex pleural effusion","title":"Complex pleural effusion on thoracic ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complex pleural effusion on thoracic ultrasound</div><div class=\"cntnt\"><img style=\"width:432px; height:294px;\" src=\"images/PULM/51853_Complexpleuraleffusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterolateral view of a complex septate pleural effusion. This pattern may be found in complicated parapneumonic effusion, empyema or hemothorax. The heart&nbsp;is seen in a short axis view (ie, cross-sectional or transverse) of the ventricle.</div><div id=\"graphicVersion\">Graphic 51853 Version 3.0</div></div></div>"},"51856":{"type":"graphic_picture","displayName":"Gloves and socks syndrome","title":"Gloves and socks syndrome secondary to parvovirus B19 infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gloves and socks syndrome secondary to parvovirus B19 infection</div><div class=\"cntnt\"><img style=\"width:432px; height:320px;\" src=\"images/ID/51856_Glove_and_sock_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papular-purpuric rash on the hands and feet of a patient with acute parvovirus B19 infection.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson DJ, Fangman W, Fowler VG, et al. A returning traveler with fever and rash. Clin Infect Dis 2005; 41:1453. Copyright &#169; 2005 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 51856 Version 2.0</div></div></div>"},"51857":{"type":"graphic_figure","displayName":"Plasmapheresis in recurrent FGS","title":"Graph showing effect on protein excretion of removal of a circulating factor in recurrent focal and segmental glomerulosclerosis","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Graph showing effect on protein excretion of removal of a circulating factor in recurrent focal and segmental glomerulosclerosis</div><div class=\"cntnt\"><img style=\"width:517px; height:234px;\" src=\"images/NEPH/51857_Plasmapheresis_in_recurrent.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean reduction in protein excretion following treatment with a protein adsorption column in eight patients with recurrent focal glomerulosclerosis after renal transplantation. Three patients also underwent plasma exchange at a different time. The degree of proteinuria fell with both modalities by the end of the treatment period and then began to return toward baseline. These findings suggest the presence of a circulating factor toxic to the glomerular capillary wall.</div><div class=\"graphic_reference\">Data from Dantal J, Bigot E, Bogers W, et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome.&nbsp;N Engl J Med 1994; 330:7.</div><div id=\"graphicVersion\">Graphic 51857 Version 3.0</div></div></div>"},"51859":{"type":"graphic_diagnosticimage","displayName":"Echogenic fetal intracardiac focus","title":"Echogenic fetal intracardiac focus","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Echogenic fetal intracardiac focus</div><div class=\"cntnt\"><img style=\"width:463px; height:582px;\" src=\"images/OBGYN/51859_Echogeniccardiacfocus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sonographic criteria for an echogenic intracardiac focus (arrow)&nbsp;is brightness equivalent to that of bone. Echogenic intracardiac foci usually occur as a single focus in the left ventricle, but multiple foci, biventricular foci, or a right ventricular location can also occur.</div><div class=\"graphic_reference\">Courtesy of Beryl R Benacerraf, MD.</div><div id=\"graphicVersion\">Graphic 51859 Version 3.0</div></div></div>"},"51860":{"type":"graphic_table","displayName":"Work and pregnancy outcome","title":"Working conditions and the risk of adverse pregnancy outcome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Working conditions and the risk of adverse pregnancy outcome</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Work parameter</td>\n<td class=\"subtitle1\">Odds ratio for preterm birth</td>\n<td class=\"subtitle1\">Odds ratio for SGA infant</td>\n<td class=\"subtitle1\">Confidence interval</td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"2\">Physically demanding work (lifting, load carrying, manual labor, or significant physical exertion)</td>\n<td colspan=\"1\" rowspan=\"1\">1.22</td>\n<td>&nbsp;</td>\n<td>1.15, 1.29</td>\n</tr>\n<tr>\n\n\n<td>&nbsp;</td><td>1.37</td>\n<td>1.30, 1.44</td>\n</tr>\n<tr>\n<td>Prolonged standing (&#62;3 hours/day)</td>\n<td>1.26</td>\n<td>&nbsp;</td>\n<td>1.13, 1.40</td>\n</tr>\n<tr>\n<td>Shift or night work</td>\n<td>1.24</td>\n<td>&nbsp;</td>\n<td>1.06, 1.46</td>\n</tr>\n<tr>\n<td>Long working hours</td>\n<td>1.03</td>\n<td>&nbsp;</td>\n<td>0.92, 1.16</td>\n</tr>\n<tr>\n<td>High cumulative work fatigue score</td>\n<td>1.63</td>\n<td>&nbsp;</td>\n<td>1.33, 1.98</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=45085&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Work_and_pregnancy_outcome.htm</title></head></div><div class=\"graphic_footnotes\">SGA: small for gestational age.</div><div class=\"graphic_reference\">Data from: Mozurkewich EL, Luke B, Avni M, Wolf FM. Working conditions and adverse pregnancy outcome: a meta-analysis. Obstet Gynecol 2000; 95:623.</div><div id=\"graphicVersion\">Graphic 51860 Version 2.0</div></div></div>"},"51862":{"type":"graphic_figure","displayName":"Thyroid hormones in serum","title":"Transport and metabolism of thyroid hormones","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transport and metabolism of thyroid hormones</div><div class=\"cntnt\"><img style=\"width:425px; height:448px;\" src=\"images/ENDO/51862_Thyroid_hormones_in_serum.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Forms of T4 and T3 in serum and pathways of T4 and T3 production and degradation.</div><div class=\"graphic_footnotes\">T3: triiodothyronine; T4: thyroxine; TBG: thyroxine-binding globulin; TTR: transthyretin.</div><div class=\"graphic_reference\">Adapted from: Utiger RD. The Thyroid: Physiology, thyrotoxicosis, hypothyroidism, and the painful thyroid. In: Endocrinology and Metabolism, 3rd ed, Felig, R, Baxter, JD, Frohman, LA (Eds), McGraw-Hill, 1995.</div><div id=\"graphicVersion\">Graphic 51862 Version 3.0</div></div></div>"},"51865":{"type":"graphic_picture","displayName":"Vitiligo - lips","title":"Vitiligo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vitiligo</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/51865_Vitiligolips.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Depigmented patches are present on the lips of this patient with vitiligo.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51865 Version 3.0</div></div></div>"},"51866":{"type":"graphic_picture","displayName":"Herpes zoster - palate","title":"Intraoral herpes zoster","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraoral herpes zoster</div><div class=\"cntnt\"><img style=\"width:325px; height:432px;\" src=\"images/DERM/51866_Herpes_zoster_palate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erosions are present on the palate in a unilateral distribution.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51866 Version 3.0</div></div></div>"},"51867":{"type":"graphic_diagnosticimage","displayName":"Medullary sponge kidney using multidetector row CT","title":"Medullary sponge kidney using multidetector row CT","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Medullary sponge kidney using multidetector row CT</div><div class=\"cntnt\"><img style=\"width:472px; height:363px;\" src=\"images/NEPH/51867_Med_sponge_kid_MDCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced maximum intensity projection 3-dimensional image from multidetector-row computed tomographic urogram shows characteristic papillary blush (arrows) associated with scattered calculi within the dilated collecting tubules. The computed tomographic demonstration is equivalent to the well-documented intravenous pyelography findings.</div><div class=\"graphic_reference\">Reproduced from: Maw AM, Megibow AJ, Grasso M, Goldfarb D. Diagnosis of Medullary Sponge Kidney by Computed Tomographic Urography. Am J Kid Dis 2007; 50:146. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 51867 Version 2.0</div></div></div>"},"51868":{"type":"graphic_picture","displayName":"Pemphigus vulgaris erosions","title":"Pemphigus vulgaris","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pemphigus vulgaris</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/51868_Pemph_vulgaris_erosions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erosions and small blisters are present in this image taken from a patient with pemphigus vulgaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51868 Version 3.0</div></div></div>"},"51869":{"type":"graphic_waveform","displayName":"ECG - ALCAPA","title":"Electrocardiogram in a 10-week-old infant with anomalous left coronary arising off the pulmonary artery (ALCAPA)","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram in a 10-week-old infant with anomalous left coronary arising off the pulmonary artery (ALCAPA)</div><div class=\"cntnt\"><img style=\"width:586px; height:314px;\" src=\"images/PEDS/51869_ECG_ALCAPA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram demonstrating deep q waves in inferior and lateral leads (I, aVL, and V5-V6) with ST segment and T wave abnormalities in a 10-week-old female with ALCAPA.</div><div id=\"graphicVersion\">Graphic 51869 Version 3.0</div></div></div>"},"51870":{"type":"graphic_table","displayName":"TMP-SMX - Nine-day oral desensitization ","title":"Oral ambulatory incremental regimen for patients sensitive to TMP-SMX (three doses given each day)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral ambulatory incremental regimen for patients sensitive to TMP-SMX (three doses given each day)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Day</td> <td class=\"subtitle1\">SMX concentration (mg/mL)</td> <td class=\"subtitle1\">Volume/dose (mL)</td> <td class=\"subtitle1\">SMX dose/day (mg)</td> </tr> <tr> <td>1</td> <td>0.00002</td> <td>1, then 3, then 7</td> <td>0.00022</td> </tr> <tr> <td>2</td> <td>0.0002</td> <td>1, then 3, then 7</td> <td>0.0022</td> </tr> <tr> <td>3</td> <td>0.002</td> <td>1, then 3, then 7</td> <td>0.022</td> </tr> <tr> <td>4</td> <td>0.02</td> <td>1, then 3, then 7</td> <td>0.22</td> </tr> <tr> <td>5</td> <td>0.2</td> <td>1, then 3, then 7</td> <td>2.2</td> </tr> <tr> <td>6</td> <td>2</td> <td>1, then 3, then 7</td> <td>22</td> </tr> <tr> <td>7</td> <td>20</td> <td>1, then 3, then 7</td> <td>220</td> </tr> <tr> <td>8</td> <td>40</td> <td>5, then 10, then 20</td> <td>1400</td> </tr> <tr> <td>9 and thereafter</td> <td colspan=\"3\">One TMP-SMX DS tab (160 mg TMP-SMX 800 mg)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SMX: sulfamethoxazole; TMP: trimethoprim; DS: double-strength.</div><div class=\"graphic_reference\">Adapted with permission from: Rich JD, Sullivan T, Greineder D, Kazanjian PH. Trimethoprim/suflamethoxazole incremental dose regimen in human immunodeficiency virus-infected persons. Ann Allergy Asthma Immunol 1997; 79:409. Copyright &copy;1997 American College of Allergy, Asthma, and Immunology.</div><div id=\"graphicVersion\">Graphic 51870 Version 5.0</div></div></div>"},"51871":{"type":"graphic_figure","displayName":"Model of inspiration","title":"Model of inspiration with respect to the volume/time cycle","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Model of inspiration with respect to the volume/time cycle</div><div class=\"cntnt\"><img style=\"width:486px; height:330px;\" src=\"images/PULM/51871_Model_of_inspiration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a patient breathing 20 breaths per minute with an I:E ratio of 1:2 and assuming no dwell time between breaths, the last 150 mL of inspired gas which fills the dead space requires about one-half the inspiratory time while the first part of the breath, representing about 0.5 seconds in this schematic, is the actual gas that reaches the alveoli and participates in gas exchange. Note that the very first gas in the airways is air that was exhaled from the alveoli. It is oxygen poor and CO<SUB>2</SUB> rich.</div><div class=\"graphic_footnotes\">V<sub>D</sub>: dead space; V<sub>A</sub>: volume of air that reaches the alveoli and participates in gas exchange; I:E: inspiratory:expiratory ratio.</div><div class=\"graphic_reference\">Data from: Tiep BL. Continuous flow oxygen therapy and basis for improving the efficiency of oxygen delivery. In: Portable Oxygen Therapy: Including Oxygen Conserving Methodology, Tiep BL (Ed), Futura Publishing, Mt Kisco, New York, 1991.</div><div id=\"graphicVersion\">Graphic 51871 Version 2.0</div></div></div>"},"51872":{"type":"graphic_figure","displayName":"Pathogenesis pseudomonas in CF","title":"Schematic model of the pathogenic events hypothesized to lead to chronic P. aeruginosa infection in airways of CF patients","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Schematic model of the pathogenic events hypothesized to lead to chronic P. aeruginosa infection in airways of CF patients</div><div class=\"cntnt\"><img style=\"width:505px; height:302px;\" src=\"images/PULM/51872_Pathogenesis_pseudomonas_in.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) On normal airway epithelia, a thin mucus layer resides atop the periciliary liquid layer (PCL),&nbsp;shown as clear. The presence of the low-viscosity PCL facilitates efficient mucociliary clearance (denoted by vector). A normal rate of epithelial O<SUB>2</SUB> consumption (Q<SUB>O2</SUB>; left) produces no O<SUB>2</SUB> gradients within this thin airway surface liquid (ASL) (denoted by bar). (B-F) CF airway epithelia. (B) Excessive CF volume depletion (denoted by vertical arrows) removes the PCL, mucus becomes adherent to epithelial surfaces, and mucus transport slows/stops (bidirectional vector). The raised O<SUB>2</SUB> consumption (left) associated with accelerated CF ion transport does not generate gradients in thin films of ASL. (C) Persistent mucus hypersecretion (denoted as mucus secretory gland/goblet cell units) with time increases the height of luminal mucus massages/plugs. The raised CF epithelial Q<SUB>O2</SUB> generates steep hypoxic gradients in thickened mucus masses. (D) P. aeruginosa bacteria deposited on mucus surfaces penetrate actively and/or passively (due to mucus turbulence) into hypoxic zones within the mucus masses. (E) P. aeruginosa adapts to hypoxic niches within mucus masses with increased alginate formation and the creation of macrocolonies. (F) Macrocolonies resist secondary defenses, including neutrophils, setting the stage for chronic infection. The presence of increased macrocolony density and, to a lesser extent neutrophils, render the now mucopurulent mass hypoxic.</div><div class=\"graphic_footnotes\">NL: normal; CF: cystic fibrosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Worlitzsch, D, Tarran, R, Ulrich, M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002; 109:317. Copyright &#169; 2002 Copyright Clearance Center.</div><div id=\"graphicVersion\">Graphic 51872 Version 2.0</div></div></div>"},"51874":{"type":"graphic_picture","displayName":"Cutaneous polyarteritis","title":"Cutaneous polyarteritis nodosa","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Cutaneous polyarteritis nodosa</div><div class=\"cntnt\"><img style=\"width:542px; height:243px;\" src=\"images/RHEUM/51874_Cutaneous_polyarteritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Different stages of cutaneous vasculitis lesions in polyarteritis nodosa, which are similar to those seen at extracutaneous sites.<br />(A) Involvement of a single small artery in the subcutis by a necrotizing vasculitis, which is neutrophilic rich at its inception and then evolves into a predominance of mononuclear cells.<br />(B) Inflammatory infiltrate in the adventitia with marked necrosis and fibrin deposition of the vascular wall.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 51874 Version 4.0</div></div></div>"},"51875":{"type":"graphic_diagnosticimage","displayName":"Stromelysin in synovium of RA","title":"Stromelysin in rheumatoid synovium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stromelysin in rheumatoid synovium</div><div class=\"cntnt\"><img style=\"width:431px; height:303px;\" src=\"images/RHEUM/51875_Stromelysin_in_synovium_of.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Darkfield photomicrograph of rheumatoid synovial tissue probed for expression of the gene encoding stromelysin (MMP-3). Bright white dots are localized to the synovial lining layer and represent areas of stromelysin expression.</div><div class=\"graphic_reference\">Courtesy of Ellen M Gravallese, MD.</div><div id=\"graphicVersion\">Graphic 51875 Version 2.0</div></div></div>"},"51876":{"type":"graphic_waveform","displayName":"Pressures tricuspid regurg pulm HTN","title":"Tricuspid regurgitation due to pulmonary hypertension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tricuspid regurgitation due to pulmonary hypertension</div><div class=\"cntnt\"><img style=\"width:437px; height:248px;\" src=\"images/CARD/51876_Pressurestricuspidregur1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressures, simultaneously recorded in the right atrium (RA) and right ventricle (RV), are markedly elevated in tricuspid regurgitation due to pulmonary hypertension, and there is a tall \"V\" wave in the RA.</div><div class=\"graphic_reference\">Redrawn from Kern MJ (Ed). Hemodynamic Rounds: Interpretation of Cardiac Pathophysiology from Pressure Waveform Analysis. Wiley-Liss, New York, 1993.</div><div id=\"graphicVersion\">Graphic 51876 Version 4.0</div></div></div>"},"51877":{"type":"graphic_table","displayName":"Studies of supplemental oxygen for dyspnea in advanced cancer","title":"Studies of supplemental oxygen for dyspnea in advanced cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Studies of supplemental oxygen for dyspnea in advanced cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Design</td> <td class=\"subtitle1\">Patients</td> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Measurement</td> <td class=\"subtitle1\">Results</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Hypoxemic</td> </tr> <tr> <td class=\"indent1\">Bruera 1992<sup>[1]</sup></td> <td>RDB, crossover</td> <td>n = 1, six trials of O<sub>2</sub> versus air</td> <td>5 L/min O<sub>2</sub> versus 5 L/min air for five mins</td> <td>- VAS</td> <td>- Significant improvement in VAS of O<sub>2</sub> over air. Both patient and investigator chose O<sub>2</sub> over air in five of six cases.</td> </tr> <tr> <td class=\"indent1\">Bruera 1993<sup>[2]</sup></td> <td>RDB, crossover</td> <td>n = 14, inpatients </td> <td>100 percent O<sub>2</sub> versus air at 5 L/min by nasal prongs at rest till SaO<sub>2</sub> stable for five min</td> <td> <p>- VAS</p> <p>- Degree of benefit (Likert scale)</p> <p>- Patient preference</p> </td> <td> <p>- Significant improvement from baseline in VAS dyspnea scores with O<sub>2</sub>, but not with air</p> <p>- 12 of 14 patients prefer O<sub>2</sub>; 12 of 14 patients rate degree of benefit with O<sub>2</sub> as moderate or greater</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Combined hypoxemic and non-hypoxemic</td> </tr> <tr> <td class=\"indent1\">Booth 1996<sup>[3]</sup></td> <td>Randomized, single-blind, crossover</td> <td>n = 45, inpatients, baseline SaO<sub>2</sub> range 80 to 99 percent</td> <td>100 percent O<sub>2</sub> versus air at 4 L/min by nasal prongs for 15 min at rest</td> <td>- VAS</td> <td> <p>- Both O<sub>2</sub> and air resulted in significant improvement from baseline, no statistical difference in magnitude of improvement between groups</p> <p>- Neither baseline oxygen saturation (SpO<sub>2</sub>), lung disease nor cardiac status predicted greater improvement with O<sub>2</sub></p> </td> </tr> <tr> <td class=\"indent1\">Philip 2006<sup>[4]</sup></td> <td>RDB, crossover</td> <td>n = 51, inpatients and outpatients, baseline SaO<sub>2</sub> range 70 to 98 percent</td> <td>100 percent O<sub>2</sub> versus air at 4 L/min for 15 min, then crossover to alternative</td> <td> <p>- Patient preference</p> <p>- VAS</p> </td> <td> <p>- No patient preference for oxygen</p> <p>- No difference in change in dyspnea VAS</p> <p>- No correlation between O<sub>2</sub> saturation and VAS score</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Non-hypoxemic</td> </tr> <tr> <td class=\"indent1\">Abernethy 2010<sup>[5]</sup></td> <td>RDB, separate placebo control group</td> <td>n = 239, outpatient adults, mixed diagnoses, multicenter (nine sites in three countries)</td> <td>100 percent O<sub>2</sub> or room air at 2 L/min via nasal prongs for seven days</td> <td> <p>- Dyspnea NRS</p> <p>- Dyspnea diary</p> </td> <td> <p>- No difference in breathlessness at any time</p> <p>- Similar proportions in both arms achieved &#8805;1 point reduction on NRS</p> </td> </tr> <tr> <td class=\"indent1\">Ahmedzai 2004<sup>[6]</sup></td> <td>RDB, crossover</td> <td>n = 12, outpatients</td> <td>HeO<sub>2</sub> 28 versus 28 percent O<sub>2</sub> versus air at 8 L/min by mask for duration of the six minute walk test</td> <td> <p>- Modified Borg scale</p> <p>- Distance walked</p> </td> <td> <p>- HeO<sub>2</sub> 28 &#62;28 percent O<sub>2</sub> &#62;air for distance walked</p> <p>- HeO<sub>2</sub> 28 &#62;air for Borg scale at end of six minute walk</p> <p>- Borg scale for 28 percent O<sub>2</sub> was better than non-enriched air, but did not achieve statistical significance</p> </td> </tr> <tr> <td class=\"indent1\">Bruera 2003<sup>[7]</sup></td> <td>Randomized, single-blind, crossover</td> <td>n = 33, outpatients</td> <td>100 percent O<sub>2</sub> versus air at 5 L/min by nasal prongs for six minute walk test</td> <td> <p>- Dyspnea NRS</p> <p>- Fatigue NRS</p> <p>- Distance walked</p> </td> <td>- No difference in dyspnea, fatigue or distance walked</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RDB: randomized double blind; VAS: visual analogue scale; NRS: numeric rating scale.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Bruera E, Schoeller T, MacEachern T. Symptomatic benefit of supplemental oxygen in hypoxemic patients with terminal cancer: the use of the N of 1 randomized controlled trial. J Pain Symptom Manage 1992; 7:365. </li>&#xD;&#xA;    <li>Bruera E, de Stoutz N, Velasco-Leiva A, et al. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet 1993; 342:13. </li>&#xD;&#xA;    <li>Booth S, Kelly MJ, Cox NP, et al. Does oxygen help dyspnea in patients with cancer? Am J Respir Crit Care Med 1996; 153:1515. </li>&#xD;&#xA;    <li>Philip J, Gold M, Milner A, Di Iulio J, Miller B, Spruyt O. A randomized, double-blind, crossover trial of the effect of oxygen on dyspnea in patients with advanced cancer. J Pain Symptom Manage 2006; 32:541. </li>&#xD;&#xA;    <li>Abernethy AP, McDonald CF, Frith PA, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: A double-blind randomized, controlled trial. Lancet 2010; 376:784. </li>&#xD;&#xA;    <li>Ahmedzai SH, Laude E, Robertson A, et al. A double-blind, randomised, controlled Phase II trial of Heliox28 gas mixture in lung cancer patients with dyspnoea on exertion. Br J Cancer 2004; 90:366. </li>&#xD;&#xA;    <li>Bruera E, Sweeney C, Willey J, et al. A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. Palliat Med 2003; 17:659. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 51877 Version 10.0</div></div></div>"},"51879":{"type":"graphic_figure","displayName":"Tilting stretch exercise","title":"Tilting stretch exercise for congenital muscular torticollis with a tight right sternocleidomastoid muscle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tilting stretch exercise for congenital muscular torticollis with a tight right sternocleidomastoid muscle</div><div class=\"cntnt\"><img style=\"width:446px; height:639px;\" src=\"images/PEDS/51879_Tiltingstretchexercisenew.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tilt the head away from the side of the shortened muscle (the infant's right) until the child's ear on the unaffected side (left) touches the shoulder of the unaffected side (left).</div><div id=\"graphicVersion\">Graphic 51879 Version 2.0</div></div></div>"},"51880":{"type":"graphic_picture","displayName":"Transthecal block","title":"Transthecal block","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transthecal block</div><div class=\"cntnt\"><img style=\"width:370px; height:278px;\" src=\"images/EM/51880_Transthecal_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transthecal block (or flexor tendon sheath digital block) is performed by infusing the flexor tendon sheath with an anesthetic solution through a single injection. The needle is inserted at a 45 degree angle just distal to the distal palmar crease. The black ink lines on the skin outline the flexor tendon.</div><div class=\"graphic_reference\">Courtesy of Robert Baldor, MD.</div><div id=\"graphicVersion\">Graphic 51880 Version 2.0</div></div></div>"},"51881":{"type":"graphic_table","displayName":"ECT consent acute phase","title":"Electroconvulsive Therapy (ECT) Consent Form: Acute Phase","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Electroconvulsive Therapy (ECT) Consent Form: Acute Phase</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"2\">\n   Name of Patient:\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"2\">\n   \t<p>My doctor, _____________________________________, has recommended that I receive treatment with electroconvulsive therapy (ECT). This treatment, including the risks and benefits that I may experience, has been fully described to me. I give my consent to be treated with ECT.</p>\n\t<p>Whether ECT or an alternative treatment, like medication or psychotherapy, is most appropriate for me depends on my prior experience with these treatments, the features of my illness, and other considerations. Why ECT has been recommended for me has been explained.</p>\n\t<p>ECT involves a series of treatments that may be given on an inpatient or outpatient basis. To receive each treatment I will come to a specially equipped area in this facility. The treatments are usually given in the morning. Because the treatments involve general anesthesia, I will have had nothing to eat or drink for several hours before each treatment. Before the treatment, a small needle will be placed in my vein so that I can be given medications. An anesthetic medication will be injected that will quickly put me to sleep. I will then be given another medication that will relax my muscles. Because I will be asleep, I will not experience pain or discomfort or remember the procedure. Other medications may also be given depending on my needs.</p>\n\t<p>To prepare for the treatment, monitoring sensors will be placed on my head and body. Blood pressure cuffs will be placed on an arm and leg. This monitoring involves no pain or discomfort. After I am asleep, a carefully controlled amount of electricity will be passed between two electrodes that have been placed on my head.</p>\n\t<p>I may receive bilateral ECT or unilateral ECT. In bilateral ECT, one electrode is placed on the left side of the head, the other on the right side. In unilateral ECT, both electrodes are placed on the same side of the head, usually the right side. Right unilateral ECT (electrodes on the right side) is likely to produce less memory difficulty than bilateral ECT. However, for some patients bilateral ECT may be a more effective treatment. My doctor will carefully consider the choice of unilateral or bilateral ECT.</p>\n\t<p>The electrical current produces a seizure in the brain. The amount of electricity used to produce the seizure will be adjusted to my individual needs, based on the judgment of the ECT physician. The medication used to relax my muscles will greatly soften the contractions in my body that would ordinarily accompany the seizure. I will be given oxygen to breathe. The seizure will last for approximately 1 minute. During the procedure, my heart, blood pressure, and brain waves will be monitored. Within a few minutes, the anesthetic medications will wear off and I will awaken. I will then be observed until it is time to leave the ECT area.</p>\n\t<p>The number of treatments that I will receive cannot be known ahead of time. A typical course of ECT is 6 to 12 treatments, but some patients may need fewer and some may need more. Treatments are usually given three times a week, but the frequency of treatment may also vary depending on my needs. If I need more than ________ treatments, my written consent will be reobtained.</p>\n\t<p>ECT is expected to improve my illness. However, I understand that I may recover completely, partially, or not at all. After ECT, my symptoms may return. How long I will remain well cannot be known ahead of time. To make the return of symptoms less likely after ECT, I will need additional treatment with medication, psychotherapy, and/or ECT. The treatment I will receive to prevent the return of symptoms will be discussed with me.</p>\n\t<p>Like other medical treatments, ECT has risks and side effects. To reduce the risk of complications, I will receive a medical evaluation before starting ECT. The medications I have been taking may be adjusted. However, in spite of precautions, it is possible that I will experience a medical complication. As with any procedure using general anesthesia, there is a remote possibility of death from ECT. The risk of death from ECT is very low, about 1 in 10,000 patients. This rate may be higher in patients with severe medical conditions.</p>\n\t<p>ECT very rarely results in serious medical complications, such as heart attack, stroke, respiratory difficulty, or continuous seizure. More often, ECT results in irregularities in heart rate and rhythm. These irregularities are usually mild and short lasting but in rare instances can be life threatening. With modem ECT technique, dental complications are infrequent and bone fractures or dislocations are very rare.</p>\n\t<p>If serious side effects occur, I understand that medical care and treatment will be instituted immediately and that facilities to handle emergencies are available. I understand, however, that neither the institution nor the treating physicians are required to provide long-term medical treatment. I shall be responsible for the cost of such treatment whether personally or through medical insurance or other medical coverage. I understand that no compensation will be paid for lost wages or other consequential damages.</p>\n\t<p>The minor side effects that are frequent include headache, muscle soreness, and nausea. These side effects usually respond to simple treatment.</p>\n\t<p>When I awaken after each treatment, I may be confused. This confusion usually goes away within 1 hour. During the treatment course I may have new difficulties in attention and concentration and other aspects of thinking. These problems rapidly go away after completion of ECT.</p>\n\t<p>I understand that memory loss is a common side effect of ECT. The memory loss with ECT has a characteristic pattern, including problems remembering past events and new information. The degree of memory problems is often related to the number and type of treatments given. A smaller number of treatments is likely to produce less memory difficulty than a larger number. Shortly following a treatment, the problems with memory are greatest. As time from treatment increases, memory improves.</p>\n\t<p>I may experience difficulties remembering events that happened before and while I received ECT. The spottiness in my memory for past events may extend back to several months before I received ECT, and, less commonly, for longer periods of time, sometimes several years or more. Although many of these memories should return during the first few months following my ECT course, I may be left with some permanent gaps in memory.</p>\n\t<p>For a short period following ECT, I may also experience difficulty in remembering new information. This difficulty in forming new memories should be temporary and typically disappears within several weeks following the ECT course.</p>\n\t<p>The majority of patients state that the benefits of ECT outweigh the problems with memory. Furthermore, most patients report that their memory is actually improved after ECT. Nonetheless, a minority of patients report problems in memory that remain for months or even years. The reasons for these reported long-lasting impairments are not fully understood. As with any medical treatment, people who receive ECT differ considerably in the extent to which they experience side effects.</p>\n\t<p>Because of the possible problems with confusion and memory, I should not make any important personal or business decisions during or immediately after the ECT course. During and shortly after the ECT course, and until discussed with my doctor, I should refrain from driving, transacting business, or other activities for which memory difficulties may be troublesome.</p>\n\t<p>The conduct of ECT at this facility is under the direction of Dr. ______________________. I may contact him/her at _______________________ if I have further questions.</p>\n\t<p>I am free to ask my doctor or members of the ECT treatment team questions about ECT at this time or at any time during or following the ECT course. My decision to agree to ECT is being made voluntarily, and I may withdraw my consent for further treatment at any time.</p>\n\t<p>I have been given a copy of this consent form to keep.</p>\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\">\n   Signature:\n   </td>\n   <td  class=\"subtitle2_left\">\n   Date:\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"2\">\n   Person Obtaining Consent:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\">\n   Name:\n   </td>\n   <td  class=\"subtitle2_left\">\n   Signature:\n   </td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">22.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">5/31/2010--Requested permission (JD). 6/2/2010--Permission granted; figures to Terrence, invoice to Jo (JD). The total fee of $&amp;quot;230.00&amp;quot;was originally charged to ECT_consent_acute_phase ECT_consent_continuation_rx</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=62116&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>ECT_consent_acute_phase.htm</title></head></div><div class=\"graphic_reference\">Reprinted with permission from the Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. Copyright © 2001 American Psychiatric Association.</div><div id=\"graphicVersion\">Graphic 51881 Version 10.0</div></div></div>"},"51884":{"type":"graphic_figure","displayName":"Vertebral body - transverse section","title":"Transverse section of a vertebral body","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Transverse section of a vertebral body</div><div class=\"cntnt\"><img style=\"width:488px; height:393px;\" src=\"images/ID/51884_Transverse_of_vertebral_bod.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51884 Version 3.0</div></div></div>"},"51887":{"type":"graphic_figure","displayName":"Schematic depiction of solute movement in dialysis","title":"Schematic depiction of solute movement in dialysis","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Schematic depiction of solute movement in dialysis</div><div class=\"cntnt\"><img style=\"width:511px; height:177px;\" src=\"images/NEPH/51887_Solute_movement_in_dialysis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the movement of solute from blood to dialysate across the dialysis membrane. Blood and dialysate move in opposite directions (ie, flow in a countercurrent fashion) to maximize the clearance of solute.</div><div id=\"graphicVersion\">Graphic 51887 Version 3.0</div></div></div>"},"51888":{"type":"graphic_table","displayName":"Nonmuscle features myotonic dystrophy I and II","title":"Extra-muscular characteristics of myotonic dystrophy (DM), types I and II","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Extra-muscular characteristics of myotonic dystrophy (DM), types I and II</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"4\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of DM</td> <td class=\"subtitle1\">Cataracts</td> <td class=\"subtitle1\">Cardiac abnormalities</td> <td class=\"subtitle1\">Cognitive impairment; personality disturbance</td> <td class=\"subtitle1\">Endocrine disturbance</td> <td class=\"subtitle1\">Gastrointestinal disorder</td> </tr> <tr> <td>DM I (Steinert's disease)</td> <td>Very common; almost universal late in course*</td> <td> <p>Conduction disturbances well recognized and common late in course*</p> Progressive cardiomyopathy also described</td> <td>Mental retardation (congenital form) is common; mild to moderate cognitive and personality defects in adult form</td> <td> <p>Glucose intolerance: well recognized and common late in course*</p> Hypogonadism: common and almost universal late in course*</td> <td>Irritable bowel symptoms; dysphagia; gall stones</td> </tr> <tr> <td>DM II (Proximal myotonic myopathy)</td> <td>Common (78% in subjects &#62;50 years)<sup>&#182;</sup></td> <td> <p>Conduction disturbances less problematic than DM I (19 percent when considered across age spectrum [21 - &#62;50]<sup>&#182;</sup>)</p> Progressive cardiomyopathy also described</td> <td>Mild cognitive impairment may be seen</td> <td> <p>Glucose intolerance: common, seen in 75 percent<sup>&#182;</sup></p> Hypogonadism: seen in 29 percent<sup>&#182;</sup></td> <td>Yes, but not as pronounced as in DM1; dysphagia common but relatively mild</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Information from Harper PS. Myotonic dystrophy, 2nd edition, WB Saunders, London, 1989.<br />&para; Information from Day JW, Ricker K, Jacobsen BS et al. Myotonic dystrophy type 2. Molecular, diagnostic and clinical spectrum. Neurology 2003; 60:657-664.</div><div id=\"graphicVersion\">Graphic 51888 Version 3.0</div></div></div>"},"51890":{"type":"graphic_diagnosticimage","displayName":"Neonatal femur fracture","title":"Neonatal femur fracture","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Neonatal femur fracture</div><div class=\"cntnt\"><img style=\"width:470px; height:484px;\" src=\"images/EM/51890_Neonatalfemurfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A) This infant had a birth-related left femoral fracture. Panel B) An anteroposterior splint was used but ended at the fracture site, only increasing the angulation. Panel C) A Pavlik harness reduced the fracture by flexing the distal fragment.</div><div class=\"graphic_reference\">Reproduced with permission from: Kasser JR, Beaty JH. Femoral Shaft Fractures. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 51890 Version 13.0</div></div></div>"},"51893":{"type":"graphic_diagnosticimage","displayName":"Leiomyoma gastric UGI","title":"Leiomyoma of the stomach","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leiomyoma of the stomach</div><div class=\"cntnt\"><img style=\"width:192px; height:264px;\" src=\"images/GAST/51893_Leiomyoma_gastric_UGI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper gastrointestinal study demonstrates a well circumscribed smooth-appearing mass (large arrows) arising from the wall of the proximal lesser curvature of the stomach. A small central ulcer crater filled with barium (small arrow) along with the well-defined margins of the mass are typically seen with leiomyomas.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 51893 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal upper GI series</div><div class=\"cntnt\"><img style=\"width:286px; height:330px;\" src=\"images/GAST/81537_Normal_upper_GI_series.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal air-contrast upper gastrointestinal (GI)&nbsp;study showing normal gastric folds and small intestinal anatomy, and no masses.</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy III, MD.</div><div id=\"graphicVersion\">Graphic 81537 Version 4.0</div></div></div>"},"51895":{"type":"graphic_table","displayName":"FAB classification of MDS","title":"French-American-British (FAB) cooperative group criteria for myelodysplastic syndrome subtypes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">French-American-British (FAB) cooperative group criteria for myelodysplastic syndrome subtypes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Bone marrow blasts, percent</td> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Peripheral blood blasts, percent</td> <td class=\"subtitle1\">Auer rods</td> <td class=\"subtitle1\">Monocytes &#62;1000/microL</td> <td class=\"subtitle1\">Ringed sideroblasts, &#62;15 percent of nucleated erythroid cells</td> </tr> <tr> <td>RA</td> <td>&#60;5</td> <td>&nbsp;</td> <td>&#8804;1</td> <td>No</td> <td>No</td> <td>No</td> </tr> <tr> <td>RARS</td> <td>&#60;5</td> <td>&nbsp;</td> <td>&#8804;1</td> <td>No</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>RAEB</td> <td>5 to 20</td> <td>&nbsp;</td> <td>&#60;5</td> <td>No</td> <td>No</td> <td>&#177;</td> </tr> <tr> <td>CMML</td> <td>&#8804;20</td> <td>&nbsp;</td> <td>&#60;5</td> <td>No</td> <td>Yes</td> <td>&#177;</td> </tr> <tr> <td>RAEB-T*</td> <td>21 to 30</td> <td><strong>OR</strong></td> <td>&#8805;5 </td> <td>&#177;</td> <td>&#177;</td> <td>&#177;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RA: refractory anemia; RARS: refractory anemia with ringed sideroblasts; RAEB: refractory anemia with excess blasts; CMML: chronic myelomonocytic leukemia; RAEB-T: refractory anemia with excess blasts in transformation. <br />* Editor's note: The World Health Organization (WHO) classification considers RAEB-T to represent either an evolving acute myeloid leukemia (AML) or AML with multilineage dysplasia.</div><div class=\"graphic_reference\">Adapted from Bennett, JM, Catovsky, D, Daniel, MT, et al. FAB Cooperative Group: Proposal for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51:189., and Greenberg, PL. The Myelodysplastic Syndromes. In: Hematology: Basic Principles and Practice, 2nd ed, Hoffman, R, Benz, E, Shattil, S (Eds), Churchill Livingstone, New York, 1994, p. 1098.</div><div id=\"graphicVersion\">Graphic 51895 Version 3.0</div></div></div>"},"51897":{"type":"graphic_figure","displayName":"Subacromial bursa injection in children","title":"Subacromial bursa injection in children","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subacromial bursa injection in children</div><div class=\"cntnt\"><img style=\"width:339px; height:273px;\" src=\"images/ALLRG/51897_Subacromial_bursa_injection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lateral or posterior approach can be used to inject the subacromial bursa. The lateral approach shown here is safer to perform since injection into the rotator cuff tendons is nearly impossible with this technique. The patient is to be sitting up, with the hands placed in the lap. The patient is asked to relax the shoulder and neck muscles. Traction applied to the flexed elbow may be necessary to open the subacromial space. The lateral edge of the acromion is located and its midpoint marked. The point of entry is 1 to 1 <FONT size=3 face=calibri>½</FONT>\" below the marked midpoint. The angle of entry should parallel the patient's own acromial angle (averaging 50 to 65 degrees). The depth will vary according to the patient's weight and muscle development (1 <FONT size=3 face=calibri>½</FONT>&nbsp;\" in an asthenic patient and up to 3 <FONT size=3 face=calibri>½</FONT>&nbsp;\" in an obese patient over 30 percent ideal body weight). Ethyl chloride is sprayed on the skin. Local anesthetic is placed in the deltoid muscle (1 mL) and the deep deltoid fascia (0.5 mL). The needle is advanced through the subcutaneous tissue and the deltoid muscle until the subtle resistance of the deep deltoid fascia is encountered. If firm or hard tissue resistance is encountered (deltoid tendon or periosteum, often painful), then the needle is withdrawn <FONT size=3 face=calibri>½</FONT>&nbsp;\" and the angle is redirected 5 to 10 degrees either up or down. A \"giving way\" or \"popping\" sensation is often appreciated when the subacromial bursa is entered. Following 1 to 2 mL of anesthesia and leaving the needle in position, the patient strength is tested again. If pain is reduced by 50 percent and the strength of abduction and external rotation are 75 to 80 percent of the unaffected side, then triamcinolone acetonide (1 mg/kg of 40 mg/mL suspension, maximum 40 mg) is injected. Note, never inject under moderate to high pressure. If high injection pressure is encountered, first try rotating the syringe 180 degrees. If tension is still high and the patient obviously anxious, ask the patient to take a deep breath and try to relax the shoulder muscles. If tension remains high, reposition the needle by <FONT size=3 face=calibri>¼</FONT>&nbsp;\" increments or by altering the angle of entry by 5 to 10 degrees. The subacromial bursa will accept only 2 to 3 mL of total volume before rupturing.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 51897 Version 4.0</div></div></div>"},"51898":{"type":"graphic_picture","displayName":"Endometrial polyps at hysteroscopy","title":"Hysteroscopic view of endometrial polyps","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Hysteroscopic view of endometrial polyps</div><div class=\"cntnt\"><img style=\"width:532px; height:547px;\" src=\"images/OBGYN/51898_Endometrial_polyps_hystero.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A large functional polyp covered with normal endometrium spread over the posterior wall of the uterine cavity. CO2 bubbles are seen above the polyp.<br> (B) An endometrial polyp with a thin pedicle tending to take the appearance of a nonfunctional lesion as it grows bigger.<br> (C) Polyp prolapsing through the internal cervical os.</div><div class=\"graphic_reference\">Reproduced with permission from: Baggish MS, Valle RF, Guedj H. Hysteroscopy: Visual Perspectives of Uterine Anatomy, Physiology and Pathology. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &#169; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51898 Version 1.0</div></div></div>"},"51899":{"type":"graphic_picture","displayName":"Glomus tumor nail dystrophy","title":"Subungual glomus tumor with nail dystrophy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Subungual glomus tumor with nail dystrophy</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/51899_Glomus_tum_nail_dys.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nail dystrophy caused by a subungual glomus tumor. The red subungual patch indicates the location of the tumor.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51899 Version 3.0</div></div></div>"},"51901":{"type":"graphic_figure","displayName":"Closing a corner of a flap","title":"Technique for closing the corner of a flap: half-buried horizontal mattress","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Technique for closing the corner of a flap: half-buried horizontal mattress</div><div class=\"cntnt\"><img style=\"width:587px; height:330px;\" src=\"images/EM/51901_Closing_a_corner_of_a_flap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The half-buried horizontal mattress suture combines elements of the horizontal mattress suture with a dermal skin closure and can be used to approximate the corner of a flap. The needle is introduced through the skin in the non-flap portion of the wound. In the dermal (or buried) portion of the suture, the corner of the flap is picked up horizontally through the dermis. The suture loop is completed by bringing the needle out through the skin on the opposite side of the non-flap portion.</div><div id=\"graphicVersion\">Graphic 51901 Version 2.0</div></div></div>"},"51903":{"type":"graphic_diagnosticimage","displayName":"Carmustine lung fibrosis PA","title":"Chest radiograph of patient with late onset carmustine lung fibrosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of patient with late onset carmustine lung fibrosis</div><div class=\"cntnt\"><img style=\"width:290px; height:398px;\" src=\"images/PULM/51903_Carmustine_lung_fibrosis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note hilar elevation and slight apical fibrosis but absence of obvious interstitial fibrotic changes.</div><div class=\"graphic_reference\">Courtesy of Ronan O'Driscoll, MD.</div><div id=\"graphicVersion\">Graphic 51903 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"51907":{"type":"graphic_picture","displayName":"Nasal packing sponge for anterior epistaxis","title":"Nasal packing sponge for anterior epistaxis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nasal packing&nbsp;sponge for anterior epistaxis</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/EM/51907_Merocel_sponge_ant_epis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;nasal sponge&nbsp;pack (eg, Merocel, Rhinocell)&nbsp;is inserted directly along the floor of the nasal cavity and can be reexpanded with 10 to 20 mL of saline. The pack dissolves without the need for removal.</div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 51907 Version 3.0</div></div></div>"},"51908":{"type":"graphic_figure","displayName":"Dorsoinferior transver lie2","title":"Dorsoinferior transverse lie","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dorsoinferior transverse lie</div><div class=\"cntnt\"><img style=\"width:418px; height:412px;\" src=\"images/OBGYN/51908_Dorsoinferior_transver_lie2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. Copyright 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51908 Version 2.0</div></div></div>"},"51910":{"type":"graphic_figure","displayName":"Side view knee PI","title":"Side view of the knee","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Side view of the knee</div><div class=\"cntnt\"><img style=\"width:447px; height:516px;\" src=\"images/PI/51910_Side_view_knee_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51910 Version 1.0</div></div></div>"},"51911":{"type":"graphic_diagnosticimage","displayName":"Plunging ranula","title":"Plunging ranula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plunging ranula</div><div class=\"cntnt\"><img style=\"width:432px; height:439px;\" src=\"images/PEDS/51911_Plunging_ranula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal computed tomography scan of a large ranula that extends through the mylohyoid musculature of the floor of the mouth.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 51911 Version 2.0</div></div></div>"},"51913":{"type":"graphic_table","displayName":"Intracorporeal blood gas values","title":"Cavernosal blood gas values for ischemic and non-ischemic priapism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cavernosal blood gas values for ischemic and non-ischemic priapism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp; </td> <td class=\"subtitle1\">pO<sub>2</sub>, mmHg </td> <td class=\"subtitle1\">pCO<sub>2</sub>, mmHg </td> <td class=\"subtitle1\">pH </td> </tr> <tr> <td>Ischemic priapism</td> <td>&#8804;40</td> <td>&#8805;60</td> <td>&#8804;7.25</td> </tr> <tr> <td>Nonischemic priapism</td> <td>&#8805;60</td> <td>&#8804;40</td> <td>&#62;7.25</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51913 Version 3.0</div></div></div>"},"51917":{"type":"graphic_algorithm","displayName":"Headache in ER II","title":"Management of headache in the emergency department-II","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Management of headache in the emergency department-II</div><div class=\"cntnt\"><img style=\"width:514px; height:650px;\" src=\"images/EM/51917_Headache_in_ER_II_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CNS: central nervous system; CSF: cerebrospinal fluid; CT: computed tomography scan; LP: lumbar puncture; RBC: red blood cell; WBC: white blood cell.</div><div id=\"graphicVersion\">Graphic 51917 Version 4.0</div></div></div>"},"51919":{"type":"graphic_table","displayName":"Dx vomiting children by age","title":"Common or critical causes of vomiting in the pediatric age range","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common or critical&nbsp;causes of vomiting in the pediatric age range</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Neonate</td> </tr> <tr> <td>Physiologic reflux or GERD*</td> </tr> <tr> <td>Dietary protein intolerance* or allergy&nbsp;(eg, milk protein-induced enteritis)&nbsp;</td> </tr> <tr> <td>Pyloric stenosis</td> </tr> <tr> <td>Necrotizing enterocolitis</td> </tr> <tr> <td>Malrotation with midgut volvulus</td> </tr> <tr> <td>Congenital atresias, stenoses, webs&nbsp;</td> </tr> <tr> <td>Gastroenteritis</td> </tr> <tr> <td>Hirschsprung disease</td> </tr> <tr> <td>Inborn errors of metabolism (eg, organic acidemias, urea cycle disorders, galactosemia, hereditary fructose intolerance) </td> </tr> <tr> <td>Feeding intolerance (may be associated with cardiac, pulmonary, renal, or neuromotor disorders)</td> </tr> <tr> <td>Adrenal crisis</td> </tr> <tr> <td>Hepatobiliary disease</td> </tr> <tr> <td>Medical child abuse&nbsp;</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infancy</td> </tr> <tr> <td>Physiologic reflux or GERD*</td> </tr> <tr> <td>Gastroenteritis*</td> </tr> <tr> <td>Dietary protein intolerance* or allergy&nbsp;(eg, milk protein-induced enteritis)</td> </tr> <tr> <td>Obstruction (eg, intussusception, malrotation, Hirschsprung disease, pyloric stenosis)</td> </tr> <tr> <td>Inborn errors of metabolism (eg, hereditary fructose intolerance, galactosemia, organic acidemias, urea cycle disorders)&nbsp;</td> </tr> <tr> <td>Infant rumination</td> </tr> <tr> <td>Otitis media&nbsp;</td> </tr> <tr> <td>Urinary tract infection</td> </tr> <tr> <td>Toxic ingestion</td> </tr> <tr> <td>Increased intracranial pressure (subdural hematoma from child abuse, hydrocephalus)</td> </tr> <tr> <td>Hepatobiliary disease</td> </tr> <tr> <td>Renal disease (obstructive uropathy, renal insufficiency)&nbsp;</td> </tr> <tr> <td>Pancreatitis</td> </tr> <tr> <td>Adrenal crisis&nbsp;</td> </tr> <tr> <td>Medical child abuse&nbsp;</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Childhood</td> </tr> <tr> <td>Gastroenteritis*</td> </tr> <tr> <td>Streptococcal pharyngitis*&nbsp;</td> </tr> <tr> <td>Posttussive* (asthma, infection, foreign body)&nbsp;</td> </tr> <tr> <td>Functional dyspepsia* </td> </tr> <tr> <td>GERD*&nbsp;</td> </tr> <tr> <td>Peptic ulcer</td> </tr> <tr> <td>Cyclic vomiting</td> </tr> <tr> <td>Psychogenic</td> </tr> <tr> <td>Increased intracranial pressure (tumor, hydrocephalus, subdural hematoma from child abuse)</td> </tr> <tr> <td>Otitis media&nbsp;</td> </tr> <tr> <td>Urinary tract infection</td> </tr> <tr> <td>Toxic ingestion</td> </tr> <tr> <td>Diabetic ketoacidosis&nbsp;</td> </tr> <tr> <td>Eosinophilic esophagitis</td> </tr> <tr> <td>Obstruction (eg, malrotation, intussusception, incarcerated hernia)</td> </tr> <tr> <td>Hepatobiliary disease</td> </tr> <tr> <td>Renal disease&nbsp;(renal insufficiency)&nbsp;</td> </tr> <tr> <td>Pancreatitis</td> </tr> <tr> <td>Gastroparesis</td> </tr> <tr> <td>Adrenal crisis&nbsp;</td> </tr> <tr> <td>Medical child abuse&nbsp;</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Adolescence</td> </tr> <tr> <td>Gastroenteritis*</td> </tr> <tr> <td>Posttussive* (asthma, infection, foreign body)</td> </tr> <tr> <td>Functional dyspepsia*&nbsp;</td> </tr> <tr> <td>GERD*&nbsp;</td> </tr> <tr> <td>Streptococcal pharyngitis&nbsp;</td> </tr> <tr> <td>Pregnancy&nbsp;</td> </tr> <tr> <td>Bulimia&nbsp;</td> </tr> <tr> <td>Drugs of abuse&nbsp;</td> </tr> <tr> <td>Suicide attempt&nbsp;</td> </tr> <tr> <td>Peptic ulcer</td> </tr> <tr> <td>Appendicitis</td> </tr> <tr> <td>Psychogenic</td> </tr> <tr> <td>Gastroparesis&nbsp;</td> </tr> <tr> <td>Intracranial mass</td> </tr> <tr> <td>Cyclic vomiting</td> </tr> <tr> <td>Eosinophilic gastroenteritis/esophagitis</td> </tr> <tr> <td>Diabetic ketoacidosis&nbsp;</td> </tr> <tr> <td>Obstruction (eg, malrotation, intussusception, incarcerated hernia)</td> </tr> <tr> <td>Hepatobiliary disease</td> </tr> <tr> <td>Renal disease (renal insufficiency) &nbsp;</td> </tr> <tr> <td>Pancreatitis</td> </tr> <tr> <td>Adolescent rumination syndrome</td> </tr> <tr> <td>Adrenal crisis&nbsp;</td> </tr> <tr> <td>Medical child abuse&nbsp;</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GERD: gastroesophageal reflux disease<br />*Common cause in this age group</div><div id=\"graphicVersion\">Graphic 51919 Version 13.0</div></div></div>"},"51920":{"type":"graphic_table","displayName":"Guidelines pharmacologic glucocorticoids","title":"Guidelines for pharmacological glucocorticoid therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for pharmacological glucocorticoid therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Initiate only if there is published evidence of objective therapeutic benefit</td> </tr> <tr> <td>Use only after other specific therapies fail</td> </tr> <tr> <td>Identify a specific therapeutic objective</td> </tr> <tr> <td>Use objective criteria of response</td> </tr> <tr> <td>Administer sufficient glucocorticoid for a sufficient time to achieve the desired response</td> </tr> <tr> <td>Administer glucocorticoid for no longer than is necessary to achieve the desired response</td> </tr> <tr> <td>Terminate if objective therapeutic benefit is not observed when expected, if complications arise, or if maximum benefit has been achieved</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51920 Version 3.0</div></div></div>"},"51921":{"type":"graphic_diagnosticimage","displayName":"CT IPMN parenchymal atrophy","title":"Computed tomography of intraductal papillary mucinous neoplasm with parenchymal atrophy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography of intraductal papillary mucinous neoplasm with parenchymal atrophy</div><div class=\"cntnt\"><img style=\"width:400px; height:249px;\" src=\"images/GAST/51921_CT_IPMN_parenchymal_atrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan of main duct intraductal papillary mucinous neoplasm, revealing a markedly dilated pancreatic duct with parenchymal atrophy.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Kevin McGrath, MD, and Asif Khalid, MD.</div><div id=\"graphicVersion\">Graphic 51921 Version 4.0</div></div></div>"},"51924":{"type":"graphic_table","displayName":"Clinician tasks","title":"The clinician's tasks during a patient visit","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The clinician's tasks during a patient visit</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Get the visit off to a good start</td> </tr> <tr> <td>Learn what the patient hopes to accomplish in the visit (the patient's agenda)</td> </tr> <tr> <td>Elicit the patient's complaints (symptoms), concerns, and requests</td> </tr> <tr> <td>Perform an appropriately focused physical examination</td> </tr> <tr> <td>Mentally test diagnostic hypotheses throughout the collection of historical and examination data</td> </tr> <tr> <td>Develop a differential diagnosis of the problem(s)</td> </tr> <tr> <td>Plan a cost-effective workup if needed</td> </tr> <tr> <td>Choose a therapeutic intervention if needed</td> </tr> <tr> <td>Discuss all of this with the patient in terms that are easily understood</td> </tr> <tr> <td>Check the patient's understanding</td> </tr> <tr> <td>Negotiate differences of opinion the patient and doctor may have about the nature of the problem, its evaluation, and its treatment</td> </tr> <tr> <td>Assure that attention is given to disease prevention strategies appropriate to the patient's age, gender, habits, and genetic and socioeconomic risk factors</td> </tr> <tr> <td>Make plans for follow-up of the problem and its treatment</td> </tr> <tr> <td>Conclude the visit</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 51924 Version 3.0</div></div></div>"},"51925":{"type":"graphic_diagnosticimage","displayName":"Atypical hydropneumothorax CT","title":"CT scan of an atypical hydropneumothorax","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of an atypical hydropneumothorax</div><div class=\"cntnt\"><img style=\"width:324px; height:314px;\" src=\"images/PULM/51925_Atypical_hydropneumothorax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atypical right hydropneumothorax in patient with previous sclerotherapy. CT scan shows dorsal gas-liquid level with the right lung adherent to the anterior chest wall.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 51925 Version 4.0</div></div></div>"},"51926":{"type":"graphic_picture","displayName":"p65 subunit of NF kB in RA","title":"p65 subunit of nuclear factor-kappa B (NF-kB) in rheumatoid synovium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">p65 subunit of nuclear factor-kappa B (NF-kB) in rheumatoid synovium</div><div class=\"cntnt\"><img style=\"width:430px; height:277px;\" src=\"images/RHEUM/51926_p65_subunit_of_NF_kB_in_RA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Localization of p65 subunit of nuclear factor-kappa B by immunohistochemistry. Brown staining indicates nuclei containing this subunit. These are present in the synovial lining layer and in the sublining (hematoxylin counterstain).</div><div class=\"graphic_reference\">Courtesy of Ellen M Gravallese, MD.</div><div id=\"graphicVersion\">Graphic 51926 Version 2.0</div></div></div>"},"51927":{"type":"graphic_figure","displayName":"Neurologic disorders brain PI","title":"Dementia caused by changes in the brain ","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Dementia caused by changes in the brain </div><div class=\"cntnt\"><img style=\"width:470px; height:556px;\" src=\"images/PI/51927_Neurologic_disorders_brain_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Different forms of dementia are linked to changes in the brain. Alzheimer disease causes many parts of the brain to shrink. Parkinson disease damages parts of the brain involved in movement. Vascular dementia happens when the blood vessels that supply the brain are diseased.</div><div id=\"graphicVersion\">Graphic 51927 Version 2.0</div></div></div>"},"51930":{"type":"graphic_picture","displayName":"Mid-borderline leprosy","title":"Mid-borderline leprosy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mid-borderline leprosy</div><div class=\"cntnt\"><img style=\"width:288px; height:370px;\" src=\"images/ID/51930_Mid-borderline_leprosy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tuberculoid-like lesion of mid-borderline leprosy with hypopigmentation and anesthesia. The raised border is prominent in this case.</div><div class=\"graphic_reference\">Reproduced with permission from McDougall AC, Yuasa Y. A New Atlas of leprosy, Sasakawa Memorial Health Foundation, Tokyo, 2000, and Guinto RS, Abalos RM, Cellopna RV, Fajardo TT. An Atlas of Leprosy, Sasakawa Memorial Health Foundation, Tokyo, 1983.</div><div id=\"graphicVersion\">Graphic 51930 Version 3.0</div></div></div>"},"51932":{"type":"graphic_figure","displayName":"Drug effect on AV node","title":"Effect of drugs on AV function in AF","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Effect of drugs on AV function in AF</div><div class=\"cntnt\"><img style=\"width:461px; height:227px;\" src=\"images/CARD/51932_Drug_effect_on_AV_node.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Various drugs can slow conduction through the atrioventricular node in atrial fibrillation by altering its physiology. The calcium (Ca++) channel blockers, primarily diltiazem and verapamil, block the influx of calcium and therefore slow conduction by reducing the upstroke of the action potential; digoxin, carotid massage, Valsalva maneuver, and edrophonium are vagotonic and slow conduction by increasing parasympathetic effects on the node; beta blockers slow conduction by offsetting sympathetic inputs; and adenosine slows conduction only transiently by increasing potassium conduction and decreasing calcium influx.</div><div id=\"graphicVersion\">Graphic 51932 Version 1.0</div></div></div>"},"51934":{"type":"graphic_figure","displayName":"Bogalusa threshold boys","title":"Thresholds for defining cardiovascular risk in boys, Bogalusa Heart Study","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Thresholds for defining cardiovascular risk in boys, Bogalusa Heart Study</div><div class=\"cntnt\"><img style=\"width:540px; height:186px;\" src=\"images/PEDS/51934_Bogalusa_threshold_boys.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Smoothed body mass index (BMI) and waist circumference thresholds for predicting risk factor clustering among male children and adolescents in the Bogalusa Heart Study (1992-1994). Each curve defines the optimal BMI or waist circumference which predicts having three or more cardiovascular risk factors (high blood pressure; low high-density lipoprotein cholesterol concentration; or high low-density lipoprotein cholesterol, triglyceride, glucose, or insulin concentration, adjusted for age) at a given age.</div><div class=\"graphic_reference\">Data from: Katzmarzyk PT, Srinivasan SR, Chen W, et al. Body mass index, waist circumference, and clustering of cardiovascular disease risk factors in a biracial sample of children and adolescents. Pediatrics 2004; 114:e198.</div><div id=\"graphicVersion\">Graphic 51934 Version 4.0</div></div></div>"},"51937":{"type":"graphic_figure","displayName":"Nuss repair pectus","title":"Nuss repair of pectus excavatum","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Nuss repair of pectus excavatum</div><div class=\"cntnt\"><img style=\"width:515px; height:701px;\" src=\"images/PEDS/51937_Nuss_repair_pectus.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 51937 Version 1.0</div></div></div>"},"51938":{"type":"graphic_picture","displayName":"Talar tilt test","title":"Talar tilt test","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Talar tilt test</div><div class=\"cntnt\"><img style=\"width:512px; height:282px;\" src=\"images/EM/51938_Talar_tilt_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The talar tilt test is for integrity of the calcaneofibular ligament. With the ankle in the neutral position, a gentle inversion force is applied to the affected ankle, and the degree of inversion is observed and compared to the uninjured side.</div><div id=\"graphicVersion\">Graphic 51938 Version 2.0</div></div></div>"},"51940":{"type":"graphic_table","displayName":"Oxidized LDL in atherosclerosis","title":"Role of oxidized LDL in atherosclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Role of oxidized LDL in atherosclerosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Endothelial damage</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Alteration in vascular tone</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Monocyte/macrophage recruitment</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Increased uptake of LDL by macrophages, with foam cell formation</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Induction of growth factors</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Increased platelet aggregation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Formation of autoantibodies to oxidized LDL</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 51940 Version 1.0</div></div></div>"},"51941":{"type":"graphic_table","displayName":"TIMI flow grades","title":"Thrombolysis in myocardial infarction (TIMI) flow grading system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Thrombolysis in myocardial infarction (TIMI) flow grading system</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td>\nGrade 0 - Complete occlusion of the infarct-related artery</td>\n\n    </tr>\n\n    <tr>\n\n      <td>\nGrade 1 - Some penetration of contrast material beyond the point of\nobstruction but without perfusion of the distal coronary bed </td>\n\n    </tr>\n\n    <tr>\n\n      <td>\nGrade 2 - Perfusion of the entire infarct vessel into the distal bed\nbut with delayed flow compared with a normal artery </td>\n\n    </tr>\n\n    <tr>\n\n      <td>\nGrade 3 - Full perfusion of the infarct vessel with normal flow</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">From Chesebro JH, Knatterud G, Roberts R, et al. Circulation 1987; 76:142.</div><div id=\"graphicVersion\">Graphic 51941 Version 2.0</div></div></div>"},"51942":{"type":"graphic_picture","displayName":"Forced air rewarming","title":"Forced air rewarming","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Forced air rewarming</div><div class=\"cntnt\"><img style=\"width:363px; height:432px;\" src=\"images/EM/51942_Forcedairrewarming.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Child in a forced air warming device.</div><div class=\"graphic_reference\">Reproduced with permission from: Hickey R, de Caen A. Warming procedures. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 51942 Version 10.0</div></div></div>"},"51943":{"type":"graphic_waveform","displayName":"Advanced case 3 with answer","title":"Right ventricular hypertrophy","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Right ventricular hypertrophy</div><div class=\"cntnt\"><img style=\"width:576px; height:378px;\" src=\"images/CARD/51943_Advanced_case_3_with_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right ventricular hypertrophy due, in this case, to primary pulmonary hypertension. The characteristic features include marked right axis deviation (+210º which is equal to -150º), tall R wave in V1 (as part of a qR complex), delayed precordial transition zone with prominent S waves in leads V5 and V6, inverted T waves and ST depression in V1 to V3 consistent with right ventricular overload (&quot;strain&quot; pattern), and peaked P waves in lead II consistent with concomitant right atrial abnormality.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 51943 Version 2.0</div></div></div>"},"51944":{"type":"graphic_table","displayName":"Chemoprophylaxis meningococcus","title":"Recommended chemoprophylaxis regimens for protection against meningococcal disease — Advisory Committee on Immunization Practices (ACIP), United States, 2012","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended chemoprophylaxis regimens for protection against meningococcal disease &mdash; Advisory Committee on Immunization Practices (ACIP), United States, 2012</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Age group</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Duration and route of administration*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Rifampin<sup>&#182;</sup></td> <td>Children aged &#60;1 month</td> <td>5 mg/kg every 12 hours</td> <td>Two days</td> </tr> <tr> <td>Children aged &#8805;1 month</td> <td>10 mg/kg every 12 hours</td> <td>Two days</td> </tr> <tr class=\"divider_bottom\"> <td>Adults</td> <td>600 mg every 12 hours</td> <td>Two days</td> </tr> <tr class=\"divider_bottom\"> <td>Ciprofloxacin<sup>&#916;</sup></td> <td>Adults</td> <td>500 mg</td> <td>Single dose</td> </tr> <tr class=\"divider_bottom\"> <td>Ceftriaxone</td> <td>Children age &#60;15 years</td> <td>125 mg</td> <td>Single IM dose</td> </tr> <tr> <td>Ceftriaxone</td> <td>Adults</td> <td>250 mg</td> <td>Single IM dose</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IM: intramuscular.<br />* Oral administration unless indicated otherwise.<br />¶ Rifampin is not recommended for pregnant women because the drug is teratogenic in laboratory animals. Because the reliability of oral contraceptives might be affected by rifampin therapy, consideration should be given to using alternative contraceptive measures while rifampin is being administered.<br />Δ Ciprofloxacin is not generally recommended for persons aged &lt;18 years or for pregnant and lactating women because the drug causes cartilage damage for immature laboratory animals. However, ciprofloxacin may be used for chemoprophylaxis of children when no acceptable alternative therapy is available. A review identified no reports of irreversible cartilage toxicity or age-associated adverse events in children and adolescents<SUP>[1]</SUP>.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Burstein GR, Berman SM, Blumer JL, Moran JS. Ciprofloxacin for the treatment of uncomplicated gonorrhea infection in adolescents: does the benefit outweigh the risk? Clin Infect Dis 2002; 35:S191</LI></OL>Reproduced from: Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1.</div><div id=\"graphicVersion\">Graphic 51944 Version 4.0</div></div></div>"},"51947":{"type":"graphic_diagnosticimage","displayName":"MRA moyamoya","title":"Magnetic resonance angiography (MRA) of a patient with moyamoya disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance angiography (MRA) of a patient with moyamoya disease</div><div class=\"cntnt\"><img style=\"width:389px; height:183px;\" src=\"images/NEURO/51947_MRA_moyamoya.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) There is severe narrowing of the distal part of the both carotid arteries (arrows). In addition, there is markedly reduced flow in the left middle cerebral artery and absence of both anterior cerebral arteries. B) Lateral projection MRA demonstrates severe narrowing of the distal internal carotid artery (arrow).</div><div class=\"graphic_reference\">Courtesy of Nijasri Suwanwela, MD.</div><div id=\"graphicVersion\">Graphic 51947 Version 2.0</div></div></div>"},"51949":{"type":"graphic_table","displayName":"Enzymes hepatic GSD","title":"Clinical and laboratory features of hepatic enzyme deficiencies of glycogen/glucose metabolism in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical and laboratory features of hepatic enzyme deficiencies of glycogen/glucose metabolism in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Enzyme deficiency</td> <td class=\"subtitle1\">Lactic acid</td> <td class=\"subtitle1\">Uric acid</td> <td class=\"subtitle1\">Ketosis</td> <td class=\"subtitle1\">Serum lipids</td> <td class=\"subtitle1\">Response to glucagon</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Glycogen synthase (GSD 0)</td> <td class=\"divider_bottom\" rowspan=\"3\">&#8593;*</td> <td class=\"divider_bottom\" rowspan=\"3\">&#8593;</td> <td class=\"divider_bottom\" rowspan=\"3\">+</td> <td class=\"divider_bottom\" rowspan=\"3\">&#8593;</td> <td class=\"divider_bottom\" rowspan=\"3\">&#8595;</td> <td>Normal liver size</td> </tr> <tr> <td>Neonatal onset</td> </tr> <tr class=\"divider_bottom\"> <td>Severe fasting hypoglycemia, but postprandial hyperglycemia and lactic acidosis</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Glucose-6-phosphatase (GSD I)</td> <td class=\"divider_bottom\" rowspan=\"4\">&#8593;</td> <td class=\"divider_bottom\" rowspan=\"4\">&#8593;</td> <td class=\"divider_bottom\" rowspan=\"4\">+</td> <td class=\"divider_bottom\" rowspan=\"4\">&#8593;</td> <td class=\"divider_bottom\" rowspan=\"4\">&#8595;</td> <td>Hepatomegaly</td> </tr> <tr> <td>Neonatal onset</td> </tr> <tr> <td>Severe fasting hypoglycemia</td> </tr> <tr class=\"divider_bottom\"> <td>Some patients have neutropenia, platelet dysfunction, renal disease or hypertension</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Glycogen debrancher (GSD III)</td> <td class=\"divider_bottom\" rowspan=\"5\">Normal or &#8593;</td> <td class=\"divider_bottom\" rowspan=\"5\">Normal</td> <td class=\"divider_bottom\" rowspan=\"5\">+</td> <td class=\"divider_bottom\" rowspan=\"5\">Normal or &#8593;</td> <td class=\"divider_bottom\" rowspan=\"5\">Normal two hours after glucose meal, but absent after fast</td> <td>Hepatomegaly</td> </tr> <tr> <td>Onset in infancy</td> </tr> <tr> <td>Mild fasting hypoglycemia</td> </tr> <tr> <td>May have cardiac or skeletal muscle manifestations (eg, elevated CK)</td> </tr> <tr class=\"divider_bottom\"> <td>May have elevated RBC glycogen</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Hepatic phosphorylase (GSD VI)</td> <td class=\"divider_bottom\" rowspan=\"3\">Normal</td> <td class=\"divider_bottom\" rowspan=\"3\">Normal</td> <td class=\"divider_bottom\" rowspan=\"3\">+</td> <td class=\"divider_bottom\" rowspan=\"3\">Normal or &#8593;</td> <td class=\"divider_bottom\" rowspan=\"3\">Usually normal, but variable</td> <td>Hepatomegaly</td> </tr> <tr> <td>Onset in early childhood</td> </tr> <tr class=\"divider_bottom\"> <td>Mild fasting hypoglycemia</td> </tr> <tr> <td rowspan=\"4\">Hepatic phosphorylase b kinase</td> <td rowspan=\"4\">Normal</td> <td rowspan=\"4\">Normal or &#8593;</td> <td rowspan=\"4\">+</td> <td rowspan=\"4\">Normal or &#8593;</td> <td rowspan=\"4\">Normal</td> <td>Hepatomegaly</td> </tr> <tr> <td>Onset in early childhood</td> </tr> <tr> <td>Mild fasting hypoglycemia</td> </tr> <tr> <td>X-linked inheritance</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GSD: glycogen storage disease; CK: creatine kinase; RBC: red blood cell; +: present.<br />* Postprandial.</div><div id=\"graphicVersion\">Graphic 51949 Version 7.0</div></div></div>"},"51950":{"type":"graphic_picture","displayName":"Tuberculosis cutis orificialis","title":"Tuberculosis cutis orificialis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberculosis cutis orificialis</div><div class=\"cntnt\"><img style=\"width:282px; height:306px;\" src=\"images/DERM/51950_Tuber_cutis_orificialis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple nodules are present on the perianal skin.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. M Ramam, New Delhi.</div><div id=\"graphicVersion\">Graphic 51950 Version 1.0</div></div></div>"},"51951":{"type":"graphic_picture","displayName":"Latex allergy - allergic contact dermatitis","title":"Allergic contact dermatitis due to latex allergy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Allergic contact dermatitis due to latex allergy</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ALLRG/51951_Latex_allergy_ACD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An individual was visiting a family member in the hospital who was on isolation. She forgot that she had an allergy to latex and donned latex gloves. She developed local erythema and pruritus (no urticaria), followed by vesicles, which ruptured.</div><div class=\"graphic_reference\">Courtesy of Vaibhav Parekh, MD, MS.</div><div id=\"graphicVersion\">Graphic 51951 Version 3.0</div></div></div>"},"51952":{"type":"graphic_figure","displayName":"Medial ankle ligaments","title":"Medial ankle ligaments","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Medial ankle ligaments</div><div class=\"cntnt\"><img style=\"width:446px; height:427px;\" src=\"images/EM/51952_Mdl_ankl_lgmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The deltoid ligament, located on the medial side of the ankle, is a broad band of connective tissue that has four separate divisions connecting the distal tibia with the talus, calcaneus, and the navicular bones.</div><div id=\"graphicVersion\">Graphic 51952 Version 4.0</div></div></div>"},"51953":{"type":"graphic_table","displayName":"DRI trace elements","title":"Dietary Reference Index (DRIs) of trace elements","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary Reference Index (DRIs) of trace elements</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"16\" width=\"4%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Life stage group</td> <td class=\"subtitle1\" colspan=\"2\">Zinc<br /> (mg/d)</td> <td class=\"subtitle1\" colspan=\"2\">Selenium<br /> (&#181;g/d)</td> <td class=\"subtitle1\" colspan=\"2\">Iodine<br /> (&#181;g/d)</td> <td class=\"subtitle1\" colspan=\"2\">Copper<br /> (&#181;g/d)</td> <td class=\"subtitle1\" colspan=\"2\">Chromium<br /> (&#181;g/d)</td> <td class=\"subtitle1\" colspan=\"2\">Manganese<br /> (mg/d)</td> <td class=\"subtitle1\" colspan=\"2\">Fluoride<br /> (mg/d)</td> <td class=\"subtitle1\" colspan=\"2\">Molybdenum<br /> (&#181;g/d)</td> </tr> <tr> <td class=\"subtitle2\"><strong>RDA*</strong> <strong>AI<sup>&#182;</sup></strong></td> <td class=\"subtitle2\">UL<sup>&#916;</sup></td> <td class=\"subtitle2\"><strong>RDA</strong>/<strong>AI<sup>&#182;</sup></strong></td> <td class=\"subtitle2\">UL</td> <td class=\"subtitle2\"><strong>RDA</strong>/<strong>AI<sup>&#182;</sup></strong></td> <td class=\"subtitle2\">UL</td> <td class=\"subtitle2\"><strong>RDA</strong>/<strong>AI<sup>&#182;</sup></strong></td> <td class=\"subtitle2\">UL</td> <td class=\"subtitle2\"><strong>RDA</strong>/<strong>AI<sup>&#182;</sup></strong></td> <td class=\"subtitle2\">UL</td> <td class=\"subtitle2\"><strong>RDA</strong>/<strong>AI<sup>&#182;</sup></strong></td> <td class=\"subtitle2\">UL</td> <td class=\"subtitle2\"><strong>RDA</strong>/<strong>AI<sup>&#182;</sup></strong></td> <td class=\"subtitle2\">UL</td> <td class=\"subtitle2\"><strong>RDA</strong>/<strong>AI<sup>&#182;</sup></strong></td> <td class=\"subtitle2\">UL</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"17\">Infants</td> </tr> <tr> <td class=\"indent1\">0-6 mo</td> <td><strong>2<sup>&#182;</sup></strong></td> <td>4</td> <td><strong>15<sup>&#182;</sup></strong></td> <td>45</td> <td><strong>110<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>200<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>0.2<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>0.003<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>0.01<sup>&#182;</sup></strong></td> <td>0.7</td> <td><strong>2<sup>&#182;</sup></strong></td> <td>ND</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">7-12 mo</td> <td><strong>3</strong></td> <td>5</td> <td><strong>20<sup>&#182;</sup></strong></td> <td>60</td> <td><strong>130<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>220<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>5.5<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>0.6<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>0.5<sup>&#182;</sup></strong></td> <td>0.9</td> <td><strong>3<sup>&#182;</sup></strong></td> <td>ND</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"17\">Children</td> </tr> <tr> <td class=\"indent1\">1-3 y</td> <td><strong>3</strong></td> <td>7</td> <td><strong>20</strong></td> <td>90</td> <td><strong>90</strong></td> <td>200</td> <td><strong>340</strong></td> <td>1000</td> <td><strong>11<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.2<sup>&#182;</sup></strong></td> <td>2</td> <td><strong>0.7<sup>&#182;</sup></strong></td> <td>1.3</td> <td><strong>17</strong></td> <td>300</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">4-8 y</td> <td><strong>5</strong></td> <td>12</td> <td><strong>30</strong></td> <td>150</td> <td><strong>90</strong></td> <td>300</td> <td><strong>440</strong></td> <td>3000</td> <td><strong>15<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.5<sup>&#182;</sup></strong></td> <td>3</td> <td><strong>1<sup>&#182;</sup></strong></td> <td>2.2</td> <td><strong>22</strong></td> <td>600</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"17\">Males</td> </tr> <tr> <td class=\"indent1\">9-13 y</td> <td><strong>8</strong></td> <td>23</td> <td><strong>40</strong></td> <td>280</td> <td><strong>120</strong></td> <td>600</td> <td><strong>700</strong></td> <td>5000</td> <td><strong>25<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.9<sup>&#182;</sup></strong></td> <td>6</td> <td><strong>2<sup>&#182;</sup></strong></td> <td>10</td> <td><strong>34</strong></td> <td>1100</td> </tr> <tr> <td class=\"indent1\">14-18 y</td> <td><strong>11</strong></td> <td>34</td> <td><strong>55</strong></td> <td>400</td> <td><strong>150</strong></td> <td>900</td> <td><strong>890</strong></td> <td>8000</td> <td><strong>35<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>2.2<sup>&#182;</sup></strong></td> <td>9</td> <td><strong>3<sup>&#182;</sup></strong></td> <td>10</td> <td><strong>43</strong></td> <td>1700</td> </tr> <tr> <td class=\"indent1\">19-30 y</td> <td><strong>11</strong></td> <td>40</td> <td><strong>55</strong></td> <td>400</td> <td><strong>150</strong></td> <td>1100</td> <td><strong>900</strong></td> <td>10,000</td> <td><strong>35<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>2.3<sup>&#182;</sup></strong></td> <td>11</td> <td><strong>4<sup>&#182;</sup></strong></td> <td>10</td> <td><strong>45</strong></td> <td>2000</td> </tr> <tr> <td class=\"indent1\">31-50 y</td> <td><strong>11</strong></td> <td>40</td> <td><strong>55</strong></td> <td>400</td> <td><strong>150</strong></td> <td>1100</td> <td><strong>900</strong></td> <td>10,000</td> <td><strong>35<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>2.3<sup>&#182;</sup></strong></td> <td>11</td> <td><strong>4<sup>&#182;</sup></strong></td> <td>10</td> <td><strong>45</strong></td> <td>2000</td> </tr> <tr> <td class=\"indent1\">51-70 y</td> <td><strong>11</strong></td> <td>40</td> <td><strong>55</strong></td> <td>400</td> <td><strong>150</strong></td> <td>1100</td> <td><strong>900</strong></td> <td>10,000</td> <td><strong>30<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>2.3<sup>&#182;</sup></strong></td> <td>11</td> <td><strong>4<sup>&#182;</sup></strong></td> <td>10</td> <td><strong>45</strong></td> <td>2000</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#62;70 y</td> <td><strong>11</strong></td> <td>40</td> <td><strong>55</strong></td> <td>400</td> <td><strong>150</strong></td> <td>1100</td> <td><strong>900</strong></td> <td>10,000</td> <td><strong>30<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>2.3<sup>&#182;</sup></strong></td> <td>11</td> <td><strong>4<sup>&#182;</sup></strong></td> <td>10</td> <td><strong>45</strong></td> <td>2000</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"17\">Females</td> </tr> <tr> <td class=\"indent1\">9-13 y</td> <td><strong>8</strong></td> <td>23</td> <td><strong>40</strong></td> <td>280</td> <td><strong>120</strong></td> <td>600</td> <td><strong>700</strong></td> <td>5000</td> <td><strong>21<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.6<sup>&#182;</sup></strong></td> <td>6</td> <td><strong>2<sup>&#182;</sup></strong></td> <td>10</td> <td><strong>34</strong></td> <td>1100</td> </tr> <tr> <td class=\"indent1\">14-18 y</td> <td><strong>9</strong></td> <td>34</td> <td><strong>55</strong></td> <td>400</td> <td><strong>150</strong></td> <td>900</td> <td><strong>890</strong></td> <td>8000</td> <td><strong>24<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.6<sup>&#182;</sup></strong></td> <td>9</td> <td><strong>3<sup>&#182;</sup></strong></td> <td>10</td> <td><strong>43</strong></td> <td>1700</td> </tr> <tr> <td class=\"indent1\">19-30 y</td> <td><strong>8</strong></td> <td>40</td> <td><strong>55</strong></td> <td>400</td> <td><strong>150</strong></td> <td>1100</td> <td><strong>900</strong></td> <td>10,000</td> <td><strong>25<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.8<sup>&#182;</sup></strong></td> <td>11</td> <td><strong>3<sup>&#182;</sup></strong></td> <td>10</td> <td><strong>45</strong></td> <td>2000</td> </tr> <tr> <td class=\"indent1\">31-50 y</td> <td><strong>8</strong></td> <td>40</td> <td><strong>55</strong></td> <td>400</td> <td><strong>150</strong></td> <td>1100</td> <td><strong>900</strong></td> <td>10,000</td> <td><strong>25<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.8<sup>&#182;</sup></strong></td> <td>11</td> <td><strong>3<sup>&#182;</sup></strong></td> <td>10</td> <td><strong>45</strong></td> <td>2000</td> </tr> <tr> <td class=\"indent1\">51-70 y</td> <td><strong>8</strong></td> <td>40</td> <td><strong>55</strong></td> <td>400</td> <td><strong>150</strong></td> <td>1100</td> <td><strong>900</strong></td> <td>10,000</td> <td><strong>20<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.8<sup>&#182;</sup></strong></td> <td>11</td> <td><strong>3<sup>&#182;</sup></strong></td> <td>10</td> <td><strong>45</strong></td> <td>2000</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#62;70 y</td> <td><strong>8</strong></td> <td>40</td> <td><strong>55</strong></td> <td>400</td> <td><strong>150</strong></td> <td>1100</td> <td><strong>900</strong></td> <td>10,000</td> <td><strong>20<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>1.8<sup>&#182;</sup></strong></td> <td>11</td> <td><strong>3<sup>&#182;</sup></strong></td> <td>10</td> <td><strong>45</strong></td> <td>2000</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"17\">Pregnancy</td> </tr> <tr> <td class=\"indent1\">14-18 y</td> <td><strong>12</strong></td> <td>34</td> <td><strong>60</strong></td> <td>400</td> <td><strong>220</strong></td> <td>900</td> <td><strong>1000</strong></td> <td>8000</td> <td><strong>29<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>2.0<sup>&#182;</sup></strong></td> <td>9</td> <td><strong>3<sup>&#182;</sup></strong></td> <td>10</td> <td><strong>50</strong></td> <td>1700</td> </tr> <tr> <td class=\"indent1\">19-30 y</td> <td><strong>11</strong></td> <td>40</td> <td><strong>60</strong></td> <td>400</td> <td><strong>220</strong></td> <td>1100</td> <td><strong>1000</strong></td> <td>10,000</td> <td><strong>30<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>2.0<sup>&#182;</sup></strong></td> <td>11</td> <td><strong>3<sup>&#182;</sup></strong></td> <td>10</td> <td><strong>50</strong></td> <td>2000</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">31-50 y</td> <td><strong>11</strong></td> <td>40</td> <td><strong>60</strong></td> <td>400</td> <td><strong>220</strong></td> <td>1100</td> <td><strong>1000</strong></td> <td>10,000</td> <td><strong>30<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>2.0<sup>&#182;</sup></strong></td> <td>11</td> <td><strong>3<sup>&#182;</sup></strong></td> <td>10</td> <td><strong>50</strong></td> <td>2000</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"17\">Lactation</td> </tr> <tr> <td class=\"indent1\">14-18 y</td> <td><strong>13</strong></td> <td>34</td> <td><strong>70</strong></td> <td>400</td> <td><strong>290</strong></td> <td>900</td> <td><strong>1300</strong></td> <td>8000</td> <td><strong>44<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>2.6<sup>&#182;</sup></strong></td> <td>9</td> <td><strong>3<sup>&#182;</sup></strong></td> <td>10</td> <td><strong>50</strong></td> <td>1700</td> </tr> <tr> <td class=\"indent1\">19-30 y</td> <td><strong>12</strong></td> <td>40</td> <td><strong>70</strong></td> <td>400</td> <td><strong>290</strong></td> <td>1100</td> <td><strong>1300</strong></td> <td>10,000</td> <td><strong>45<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>2.6<sup>&#182;</sup></strong></td> <td>11</td> <td><strong>3<sup>&#182;</sup></strong></td> <td>10</td> <td><strong>50</strong></td> <td>2000</td> </tr> <tr> <td class=\"indent1\">31-50 y</td> <td><strong>12</strong></td> <td>40</td> <td><strong>70</strong></td> <td>400</td> <td><strong>290</strong></td> <td>1100</td> <td><strong>1300</strong></td> <td>10,000</td> <td><strong>45<sup>&#182;</sup></strong></td> <td>ND</td> <td><strong>2.6<sup>&#182;</sup></strong></td> <td>11</td> <td><strong>3<sup>&#182;</sup></strong></td> <td>10</td> <td><strong>50</strong></td> <td>2000</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><FONT color=black>RDA: recommended dietary allowance;</FONT><FONT color=black> AI: adequate intake; </FONT>UL: upper tolerable level.<br />* Values in this column represent the RDA, unless otherwise indicated. The RDA is the level of dietary intake that is sufficient to meet the daily nutrient requirements of 97 percent of the individuals in a specific life stage group.<br />¶ These values represent the AI. The AI&nbsp;is an approximation of the average nutrient intake that sustains a defined nutritional state, based on observed or experimentally determined values in a defined population.<br />Δ The UL is the maximum level of daily nutrient intake that is likely to pose no risk of adverse health effects in almost all individuals in the specified life-stage or gender group.</div><div class=\"graphic_reference\">Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. Otten JJ, Hellwig JP, Meyers LD (Eds), The National Academies Press, Washington, DC 2006. pp.530-541. Reprinted with permission from the National Academies Press, Copyright &copy; 2006, National Academy of Sciences.<br />Sources: Dietary reference intakes for Thiamin, Riboflavin, Niacin, Vitamin B<sub>6</sub>, Folate, Vitamin B<sub>12</sub>, Panthothenic acid, Biotin, and Choline (1998); Dietary reference intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids (2000). These reports may be accessed via <a href=\"http://www.nap.edu/\" style=\"font-style: italic;\" target=\"_blank\">www.nap.edu</a>.</div><div id=\"graphicVersion\">Graphic 51953 Version 14.0</div></div></div>"},"51956":{"type":"graphic_figure","displayName":"LV filling dynamics HF","title":"Effects of exercise on left ventricular filling dynamics","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effects of exercise on left ventricular filling dynamics</div><div class=\"cntnt\"><img style=\"width:269px; height:446px;\" src=\"images/CARD/51956_LVfillingdynamicsHF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Changes in left ventricular pressure (LVP), left atrial pressure changes (LAP), and the rate of change of LVP (dV/dt) at rest and during exercise.<br />(Top panel) During exercise in normals, minimal LVP decreases without any change in LAP, leading to an increase in the peak mitral valve gradient and producing a higher peak filling rate (E).<br />(Bottom panel) In heart failure, the peak LV filling rate (E) increases during exercise due to an increase in the early transmitral valve pressure gradient. However, the gradient is produced by an increase in left atrial pressure instead of a reduction in LVP as occurs in normals.</div><div id=\"graphicVersion\">Graphic 51956 Version 5.0</div></div></div>"},"51957":{"type":"graphic_diagnosticimage","displayName":"Bronchiectasis CT II","title":"Bronchiectasis with marked airway dilatation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchiectasis with marked airway dilatation</div><div class=\"cntnt\"><img style=\"width:360px; height:265px;\" src=\"images/PULM/51957_Bronchiectasis_CT_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HRCT shows clustering of markedly dilated airways in both upper lobes (arrow).</div><div class=\"graphic_footnotes\">HRCT: high resolution computed tomography.</div><div class=\"graphic_reference\">Courtesy of Alan Barker, MD.</div><div id=\"graphicVersion\">Graphic 51957 Version 3.0</div></div></div>"},"51959":{"type":"graphic_figure","displayName":"Comparison of WHO and CDC weight-for-age charts 0 to 24 months","title":"Comparison of WHO and CDC weight-for-age measurements for children younger than 24 months","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comparison of WHO and CDC weight-for-age measurements for children younger than 24 months</div><div class=\"cntnt\"><img style=\"width:444px; height:741px;\" src=\"images/PEDS/51959_Comparison_of_weight_for_age.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CDC: Centers for Disease Control and Prevention; WHO: World Health Organization.</div><div class=\"graphic_reference\">Reproduced from: Grummer-Strawn, LM, Reinold, C, Krebs, NF. Use of World Health Organization and CDC growth charts for children aged 0 to 59 months in the United States. MMWR Recomm Rep 2010; 59:1.</div><div id=\"graphicVersion\">Graphic 51959 Version 3.0</div></div></div>"},"51960":{"type":"graphic_figure","displayName":"Changes in appendiceal position during pregnancy","title":"Changes in appendiceal position during pregnancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Changes in appendiceal position during pregnancy</div><div class=\"cntnt\"><img style=\"width:434px; height:452px;\" src=\"images/SURG/51960_Changes_appendiceal_posit.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Harwood-Nuss A, Wolfson AB, et al. The Clinical Practice of Emergency Medicine, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51960 Version 1.0</div></div></div>"},"51962":{"type":"graphic_picture","displayName":"Follicular pattern in KS","title":"Follicular pattern in Kaposi's sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Follicular pattern in Kaposi's sarcoma</div><div class=\"cntnt\"><img style=\"width:252px; height:360px;\" src=\"images/ID/51962_Follicular_pattern_in_KS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This central plaque is formed by a confluence of small lesions surrounded by papules on the thigh.</div><div class=\"graphic_reference\">Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Williams and Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 51962 Version 5.0</div></div></div>"},"51963":{"type":"graphic_movie","displayName":"View through a rigid bronchoscope - epiglottis to trachea","title":"Rigid broncoscopy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rigid broncoscopy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/51963_rgintbiiconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:315px; height:236px;\" src=\"images/CARD/51963_rgintbii.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Video shows the view through a rigid bronchoscope as it is passed from the epiglottis to the trachea.</div><div class=\"graphic_reference\">Courtesy of Henri G Colt, MD and Praveen Mathur, MD.</div><div id=\"graphicVersion\">Graphic 51963 Version 2.0</div></div></div>"},"51965":{"type":"graphic_table","displayName":"ECG disturbances stroke","title":"Rates of ECG abnormalities and arrhythmias following stroke","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rates of ECG abnormalities and arrhythmias following stroke</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody><tr>\n<td colspan=\"1\" rowspan=\"2\" class=\"subtitle1\">Type\nof arrhythmia</td>\n<td colspan=\"2\" class=\"subtitle1\">Rate, percent</td>\n</tr><tr>\n<td class=\"subtitle2\">Goldstein</td>\n<td class=\"subtitle2\">Ramani et al</td>\n</tr><tr>\n<td>Prolonged QT</td>\n<td>37</td>\n<td>28</td>\n</tr><tr>\n<td>U waves/tall U waves</td>\n<td>25</td>\n<td>9</td>\n</tr><tr>\n<td>ST depression/changes</td>\n<td>25</td>\n<td>25</td>\n</tr><tr>\n<td>T wave inversion/changes</td>\n<td>24</td>\n<td>34</td>\n</tr><tr>\n<td>Tachycardia/sinus tachycardia</td>\n<td>22</td>\n<td>15</td>\n</tr><tr>\n<td>Left ventricular hypertrophy</td>\n<td>22</td>\n<td>4</td>\n</tr><tr>\n<td>Q waves</td>\n<td>22</td>\n<td>9</td>\n</tr><tr>\n<td>Atrial fibrillation</td>\n<td>13</td>\n<td>0</td>\n</tr><tr>\n<td>Premature ventricular contractions</td>\n<td>13</td>\n<td>0</td>\n</tr><tr>\n<td>Decreased heart rate/sinus bradycardia</td>\n<td>9</td>\n<td>11</td>\n</tr><tr>\n<td>Right bundle branch block</td>\n<td>7</td>\n<td>NR</td>\n</tr><tr>\n<td>First degree heart block</td>\n<td>6</td>\n<td>2</td>\n</tr><tr>\n<td>Premature atrial contractures</td>\n<td>6</td>\n<td>NR</td>\n</tr><tr>\n<td>Left atrial enlargement/hypertrophy</td>\n<td>3</td>\n<td>2</td>\n</tr><tr>\n<td>ST elevation</td>\n<td>3</td>\n<td>NR</td>\n</tr><tr>\n<td>Left bundle branch block</td>\n<td>0</td>\n<td>NR</td>\n</tr></tbody></table></div><div class=\"graphic_lgnd\">The rates are compared in two studies. The first (Goldstein) evaluated 150 patients with stroke, including those with a history of heart disease. The second (Ramani et al.) evaluated 100 patients with stroke and no prior history of heart disease.</div><div class=\"graphic_footnotes\">NR: not reported.</div><div class=\"graphic_reference\">Data from: Goldstein, DS. The electrocardiogram in stroke: relationship to pathophysiological type and comparison with prior tracings. Strok 1979; 10:253.; and Ramani, A, Shetty, U, Kundaje, GN. Electrocardiographic abnormalities in cerebrovascular accidents. Angiology 1990; 41:681.</div><div id=\"graphicVersion\">Graphic 51965 Version 1.0</div></div></div>"},"51966":{"type":"graphic_figure","displayName":"Breech2","title":"Delivery of the lower limbs","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Delivery of the lower limbs</div><div class=\"cntnt\"><img style=\"width:541px; height:294px;\" src=\"images/OBGYN/51966_Breech2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After spontaneous expulsion to the scalpulae, external rotation of each thigh (A) combined with opposite rotation of the fetal pelvis results in flexion of the knee and delivery of each leg (B)</div><div class=\"graphic_reference\">Reproduced with permission from: Gabbe, SG, Niebyl, JR, Simpson, JL (Eds). Obstetrics: Normal and Problem Pregnancies, 4th ed, Churchill Livingstone New York 2003. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 51966 Version 1.0</div></div></div>"},"51967":{"type":"graphic_picture","displayName":"Patient with SGD","title":"Patient with neutrophil-specific granule deficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patient with neutrophil-specific granule deficiency</div><div class=\"cntnt\"><img style=\"width:333px; height:432px;\" src=\"images/ALLRG/51967_SGD_patient.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A nine-year-old boy with SGD presented for evaluation with severe, large bacterial abscesses of several months duration. This patient was described in detail by Gallin JI, et al. Blood 1982; 59:1317.</div><div class=\"graphic_footnotes\">SGD: specific granule deficiency.</div><div class=\"graphic_reference\">Courtesy of Robert L Roberts, MD, PhD.</div><div id=\"graphicVersion\">Graphic 51967 Version 3.0</div></div></div>"},"51968":{"type":"graphic_picture","displayName":"Colonic adenoma Light","title":"Colonic adenoma","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colonic adenoma</div><div class=\"cntnt\"><img style=\"width:441px; height:288px;\" src=\"images/GAST/51968_Colonic_adenoma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of a colonic tubular adenoma shows mildly dysplastic crypts without invasion of the lamina propria.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 51968 Version 1.0</div></div><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Normal colon</div><div class=\"cntnt\"><img style=\"width:518px; height:172px;\" src=\"images/GAST/81083_Normal_colon_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low (left) and high (right) power views of a biopsy of a normal colon. Low power reveals straight crypts and mild lamina propria mononuclear cell infiltration. High power shows the surface enterocytes with interspersed goblet cells (arrows).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD</div><div id=\"graphicVersion\">Graphic 81083 Version 1.0</div></div></div>"},"51969":{"type":"graphic_table","displayName":"Guidelines after polypectomy II","title":"Additional surveillance considerations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Additional surveillance considerations</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>1. The present recommendations assume that colonoscopy is complete to the cecum and that bowel preparation is adequate; a repeat examination should be performed if the bowel preparation is not adequate before planning a long-term surveillance program</td>\n</tr>\n<tr>\n<td>2. There is clear evidence that the quality of examinations is highly variable; continuous quality improvement process is critical to the effective application of colonoscopy in colorectal cancer prevention</td>\n</tr>\n<tr>\n<td>3. A repeat examination is warranted if there is a concern that the polyp was removed incompletely, particularly if it shows high grade dysplasia</td>\n</tr>\n<tr>\n<td>4. Endoscopists should make clear recommendations to primary care physicians about when the next colonoscopy is indicated</td>\n</tr>\n<tr>\n<td>5. Given the evolving nature of guidelines, it is important that physicians and patients should remain in contact so that surveillance recommendations reflect changes in guidelines</td>\n</tr>\n<tr>\n<td>6. Pending further investigation, performance of FOBT is discouraged in patients undergoing colonoscopic surveillance</td>\n</tr>\n<tr>\n<td>7. Discontinuation of surveillance colonoscopy should be considered in patients with serious comorbidities with less than 10 years of life expectancy, according to the clinician's judgment</td>\n</tr>\n<tr>\n<td>8. Surveillance guidelines are intended for asymptomatic people; new symptoms may need diagnostic work-up</td>\n</tr>\n<tr>\n<td>9. The application of evolving technologies such as chromoendoscopy, magnification endoscopy, narrow band imaging, and computed tomography colonography are not established for postpolypectomy surveillance at this time</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006; 130:1872. Copyright &#169; 2006 American Gastroenterological Association.</div><div id=\"graphicVersion\">Graphic 51969 Version 3.0</div></div></div>"},"51970":{"type":"graphic_table","displayName":"Obstetrical history 2","title":"Obstetrical history","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Obstetrical history</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>History of any pregnancies</td>\n\n    </tr>\n\n    <tr>\n\n      <td>History of miscarriages, terminations, or ectopic pregnancies</td>\n\n    </tr>\n\n    <tr>\n\n      <td>History of assisted reproduction</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">For each pregnancy carried:</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Date of delivery</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Gestational age at delivery</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Mode of delivery with indication for operative delivery</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Maternal complications, such as hypertension or diabetes</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1\">Fetal complications, such as growth restriction, anomalies or stillbirth</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Delivery or operative complications&nbsp;</td>\n\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Neonatal problems</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Current health of children</td>\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 51970 Version 1.0</div></div></div>"},"51971":{"type":"graphic_picture","displayName":"Basophils in CML","title":"Basophils in chronic myeloid leukemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Basophils in chronic myeloid leukemia</div><div class=\"cntnt\"><img style=\"width:365px; height:237px;\" src=\"images/HEME/51971_Basophils.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear from a patient with newly diagnosed chronic myeloid leukemia, showing three normal-appearing basophils. These cells differ from a neutrophil by the presence of coarse, dark blue-black granules. (Wright-Giemsa stain).</div><div class=\"graphic_reference\">From: Brunning RD, McKenna RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 51971 Version 4.0</div></div></div>"},"51972":{"type":"graphic_picture","displayName":"Hypopyon associated with endophthalmitis","title":"Hypopyon associated with endophthalmitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypopyon associated with endophthalmitis</div><div class=\"cntnt\"><img style=\"width:322px; height:216px;\" src=\"images/PC/51972_Endophthalmitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hazy cornea and hypopyon and markedly inflamed conjunctiva.</div><div class=\"graphic_reference\">Reproduced with permission from: Trobe JD, Hackel RE. Field Guide to the Eyes. Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 51972 Version 9.0</div></div></div>"},"51974":{"type":"graphic_table","displayName":"Differential dx COPD","title":"Differential diagnosis of COPD","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of COPD</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Diagnosis </td> <td class=\"subtitle1\">Suggestive Features*</td> </tr> <tr> <td rowspan=\"5\">COPD</td> <td>Onset in mid-life; onset in early adulthood should prompt suspicion for alpha-1 antitrypsin deficiency</td> </tr> <tr> <td>Symptoms slowly progressive</td> </tr> <tr> <td>Long smoking history, although can occur in nonsmokers</td> </tr> <tr> <td>Dyspnea during exercise</td> </tr> <tr> <td>Largely irreversible airflow limitation</td> </tr> <tr> <td rowspan=\"6\">Asthma</td> <td>Onset early in life (often childhood)</td> </tr> <tr> <td>Symptoms vary from day to day</td> </tr> <tr> <td>Symptoms at night/early morning</td> </tr> <tr> <td>Allergy, rhinitis, and/or eczema also present</td> </tr> <tr> <td>Family history of asthma</td> </tr> <tr> <td>Largely reversible airflow limitation</td> </tr> <tr> <td rowspan=\"4\">Central airway obstruction (eg, bronchogenic or metastatic cancer, lymphadenopathy, scarring from&nbsp;endotracheal tube)&nbsp;</td> <td>Monophonic wheeze or stridor</td> </tr> <tr> <td>Variable inspiratory or fixed slowing on flow volume loop</td> </tr> <tr> <td>Chest radiograph often normal&nbsp;</td> </tr> <tr> <td>Airway narrowing on three dimensional reconstruction of HRCT scan</td> </tr> <tr> <td rowspan=\"3\">Heart failure</td> <td>Fine basilar crackles on auscultation</td> </tr> <tr> <td>Chest&nbsp;radiograph shows dilated heart, pulmonary edema</td> </tr> <tr> <td>Pulmonary function tests typically&nbsp;indicate volume restriction,&nbsp;but airflow limitation can sometimes be seen</td> </tr> <tr> <td rowspan=\"4\">Bronchiectasis</td> <td>Large volumes of purulent sputum</td> </tr> <tr> <td>Commonly associated with recurrent or persistent bacterial infection</td> </tr> <tr> <td>Coarse crackles on auscultation, clubbing of digits</td> </tr> <tr> <td>Chest radiograph/HRCT shows bronchial dilation, bronchial wall thickening</td> </tr> <tr> <td rowspan=\"4\">Tuberculosis</td> <td>Onset all ages</td> </tr> <tr> <td>Chest&nbsp;radiograph shows upper lung zone scarring and/or calcified granulomata</td> </tr> <tr> <td>Positive PPD or IGRA</td> </tr> <tr> <td>High local prevalence of tuberculosis</td> </tr> <tr> <td rowspan=\"3\">Obliterative bronchiolitis</td> <td>Onset in younger age, nonsmokers</td> </tr> <tr> <td>May have history of rheumatoid arthritis or fume exposure</td> </tr> <tr> <td>HRCT on expiration shows hypodense areas, mosaic pattern</td> </tr> <tr> <td rowspan=\"4\">Diffuse panbronchiolitis</td> <td>Most patients are male and nonsmokers</td> </tr> <tr> <td>Highest prevalence in East Asia</td> </tr> <tr> <td>Almost all have chronic sinusitis</td> </tr> <tr> <td>Chest&nbsp;radiograph and HRCT show diffuse small centrilobular nodular opacities and hyperinflation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HRCT: high resolution computed tomography; PPD: purified protein derivative; IGRA: interferon gamma release assay.<BR>* These features tend to be characteristic of the respective diseases, but do not occur in every case. For example, a person who has never smoked may develop COPD (especially in the developing world, where other risk factors may be more important than cigarette smoking); asthma may develop in adult and even elderly patients.</div><div class=\"graphic_reference\">Adapted&nbsp;with permission from the Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: Revised 2011. Global Initiative for Chronic Obstructive Lung Disease (GOLD), www.goldcopd.org (Accessed on August 10, 2012).</div><div id=\"graphicVersion\">Graphic 51974 Version 2.0</div></div></div>"},"51976":{"type":"graphic_diagnosticimage","displayName":"AP radiograph intertrochanteric hip fracture","title":"AP radiograph of an intertrochanteric hip fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AP radiograph of an intertrochanteric hip fracture</div><div class=\"cntnt\"><img style=\"width:279px; height:432px;\" src=\"images/EM/51976_Hip_fx_intertroch2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A right intertrochanteric fracture seen on anteroposterior hip radiograph. Note that although the femoral neck is intact, it has lost the normal angle with the femoral shaft.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Reproduced with permission from: Koval KJ, MD and Zuckerman, JD, MD. Atlas of Orthopaedic Surgery: A Multimeidal Reference. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51976 Version 3.0</div></div></div>"},"51977":{"type":"graphic_diagnosticimage","displayName":"Stage I lateral condyle fracture 2","title":"Stage I fracture of the lateral condyle","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Stage I fracture of the lateral condyle</div><div class=\"cntnt\"><img style=\"width:460px; height:597px;\" src=\"images/EM/51977_Stage_I_LC_fx_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Anteroposterior radiograph shows 1-mm fracture line. <br />(B) Lateral view shows 2 mm of displacement with posterolateral Thurston-Holland fragment. <br />(C and D) Anteroposterior and lateral radiographs four weeks later show healed fracture with callus formation.</div><div class=\"graphic_reference\">Reproduced with permission from: Beaty JH, Kasser JR. The elbow: Physeal fractures, apophyseal injuries of the distal humerus, avascular necrosis of the trochlea, and T-condylar fractures. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 51977 Version 12.0</div></div></div>"},"51978":{"type":"graphic_picture","displayName":"Gamma probe for SLN detection","title":"Gamma detector for SLN biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gamma detector for SLN biopsy</div><div class=\"cntnt\"><img style=\"width:291px; height:351px;\" src=\"images/ONC/51978_Gamma_probe_for_SLN_detecti.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hand-held gamma probe that is used intraoperatively to detect a sentinel lymph node (SLN) after local injection of radioactive colloid around the primary tumor.</div><div class=\"graphic_reference\">Courtesy of Kevin Donohoe, MD.</div><div id=\"graphicVersion\">Graphic 51978 Version 2.0</div></div></div>"},"51979":{"type":"graphic_figure","displayName":"Prob PC death PSA doubling time","title":"Probability of dying of prostate cancer according to number of PSA doublings per year","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Probability of dying of prostate cancer according to number of PSA doublings per year</div><div class=\"cntnt\"><img style=\"width:493px; height:408px;\" src=\"images/ONC/51979_Prob_PC_death_PSA_doubling.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Albertsen, PC, Hanley, JA, Penson, DF, Fine, J. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 2004; 171:2223.</div><div id=\"graphicVersion\">Graphic 51979 Version 1.0</div></div></div>"},"51980":{"type":"graphic_table","displayName":"Distal muscular dystrophies/myopathies","title":"Distal muscular dystrophies/myopathies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distal muscular dystrophies/myopathies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Inheritance</td> <td class=\"subtitle1\">Usual age of onset (years)</td> <td class=\"subtitle1\">Initial weakness</td> <td class=\"subtitle1\">Serum creatine kinase</td> <td class=\"subtitle1\"> <p>Muscle</p> <p>biopsy</p> </td> <td class=\"subtitle1\">Locus/gene</td> </tr> <tr> <td>Nonaka distal myopathy (hereditary inclusion body myopathy*)</td> <td>Autosomal recessive or sporadic</td> <td>15 to 20</td> <td>Legs: anterior compartment</td> <td>Slightly to moderately increased, usually &#60;10 times normal</td> <td>Myopathic with rimmed vacuoles</td> <td> <p>9p13.3</p> GNE</td> </tr> <tr> <td>Miyoshi muscular dystrophy 1 (LGMD 2B<sup>&#182;</sup>)</td> <td>Autosomal recessive or sporadic</td> <td>&#60;20</td> <td>Legs: posterior compartment</td> <td>Increased 10 to 100 times normal</td> <td>Myopathic, usually without vacuoles; gastrocnemius often 'end stage'</td> <td> <p>2p13.3</p> DYSF</td> </tr> <tr> <td>Miyoshi muscular dystrophy 3 (LGMD 2L<sup>&#916;</sup>)</td> <td>Autosomal recessive</td> <td>&#62;20</td> <td>Legs: posterior compartment</td> <td>Increased 20 to 50 times normal</td> <td>Myopathic</td> <td> <p>11p14.3</p> ANO5</td> </tr> <tr> <td>Welander distal myopathy</td> <td>Autosomal dominant</td> <td>&#62;40</td> <td>Hands: fingers and wrist extensors</td> <td>Normal or slightly increased</td> <td>Myopathic; rimmed vacuoles in some cases</td> <td> <p>2p13</p> TIA1</td> </tr> <tr> <td>Udd distal myopathy</td> <td>Autosomal dominant</td> <td>&#62;35</td> <td>Legs: anterior compartment</td> <td>Normal or slightly increased</td> <td>Vacuolar myopathy</td> <td> <p>2q31</p> TTN</td> </tr> <tr> <td>Markesbery-Griggs late onset distal myopathy</td> <td>Autosomal dominant</td> <td>&#62;40</td> <td>Legs: anterior compartment</td> <td>Normal or slightly increased</td> <td>Vacuolar and myofibrillar myopathy</td> <td> <p>10q22.3-q23.2</p> LDB3</td> </tr> <tr> <td>Distal myotilinopathy</td> <td>Autosomal dominant</td> <td>&#62;40</td> <td>Legs: posterior &#62; anterior compartment</td> <td>Slightly increased</td> <td>Vacuolar and myofibrillar myopathy</td> <td> <p>5q31</p> MYOT</td> </tr> <tr> <td>Laing distal myopathy (MPD1)</td> <td>Autosomal dominant</td> <td>&#60;20</td> <td>Legs: anterior compartment; neck flexors</td> <td>Slightly increased to &#8804;3 times normal</td> <td>Moderate myopathic changes; no vacuoles</td> <td> <p>14q12</p> MYH7</td> </tr> <tr> <td>Distal myopathy with vocal cord and pharyngeal signs (ALS21<sup>&#9674;</sup>)</td> <td>Autosomal dominant</td> <td>35 to 70</td> <td>Asymmetric lower legs and hands; variable dysphonia and dysphagia</td> <td>1 to 8 times normal</td> <td>Rimmed vacuoles</td> <td> <p>5q31</p> MATR3</td> </tr> <tr> <td>New Finnish distal myopathy (MPD3)</td> <td>Autosomal dominant</td> <td>&#62;30</td> <td>Hands or anterior lower legs</td> <td>1 to 4 times normal</td> <td>Dystrophic; rimmed vacuoles, eosinophilic inclusions</td> <td>8p22-q11</td> </tr> <tr> <td>Williams distal myopathy (MPD4)</td> <td>Autosomal dominant</td> <td>20 to 40</td> <td>Hands</td> <td>Normal to 6 times normal</td> <td>Normal, or myopathic changes</td> <td> <p>7q32.1</p> FLNC</td> </tr> <tr> <td>Distal myopathy with pes cavus and areflexia (vacuolar neuromyopathy)</td> <td>Autosomal dominant</td> <td>15 to 50</td> <td>Legs: lower anterior and posterior; dysphonia and dysphagia</td> <td>2 to 6 times normal</td> <td>Dystrophic, rimmed vacuoles</td> <td>19p13.3</td> </tr> <tr> <td>Distal myopathy with rimmed vacuoles&nbsp;</td> <td>Autosomal dominant</td> <td>&nbsp;35 to 60</td> <td>Anterior lower legs</td> <td>1 to&nbsp;2 times normal</td> <td>Dystrophic, rimmed vacuoles</td> <td> <p>5q35.3</p> <p>SQSTM1</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ANO5: anoctamin 5 gene; DYSF: dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive) gene; FLNC: filamin C, gamma gene; GNE: UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene; LDB3: LIM domain binding 3 gene; MATR3: matrin 3 gene; MPD1: distal myopathy 1; MPD2: distal myopathy 2; MPD3: distal myopathy 3; MPD4: distal myopathy 4; MYH7: myosin heavy chain 7 cardiac muscle beta gene; MYOT: myotilin gene; SQSTM1: sequestosome 1 gene; TIA1: TIA1 cytotoxic granule-associated RNA binding protein gene; TTN: titin gene.<br />* Autosomal recessive hereditary inclusion body myopathy (HIBM or IBM2), also known as quadriceps sparing myopathy, and Nonaka distal myopathy are allelic disorders caused by mutations in the GNE gene.<br />¶ Limb girdle muscular dystrophy type 2B co-localizes with Miyoshi muscular dystrophy 1.<br />Δ Limb girdle muscular dystrophy type 2L co-localizes with Miyoshi muscular dystrophy 3.<br /><FONT class=lozenge>◊</FONT> In some families, MATR3 mutations cause familial amyotrophic lateral sclerosis.</div><div class=\"graphic_reference\">Additional data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Suominen T, Udd B, Hackman P. Udd distal myopathy. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1323/ (Accessed on January 18, 2011).</LI>&#xD;&#xA;<LI>Guergueltcheva V, Peeters K, Baets J, et al. Distal myopathy with upper limb predominance caused by filamin C haploinsufficiency. Neurology 2011; 77:2105.</LI>&#xD;&#xA;<LI>Schessl J, Kress W, Schoser B. Novel ANO5 mutations causing hyper-CK-emia, limb girdle muscular weakness and Miyoshi type of muscular dystrophy. Muscle Nerve 2012; 45:740.</LI>&#xD;&#xA;<LI>Hackman P, Sarparanta J, Lehtinen S, et al. Welander distal myopathy is caused by a mutation in the RNA-binding protein TIA1. Ann Neurol 2012; 73:500.</LI>&#xD;&#xA;<LI>Johnson JO, Pioro EP, Boehringer A, et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci 2014; 17:664.</LI>&#xD;&#xA;<LI>Bucelli RC, Arhzaouy K, Pestronk A, et al. SQSTM1 splice site mutation in distal myopathy with rimmed vacuoles. Neurology 2015; 85:665.</LI>&#xD;&#xA;<LI><A href=\"http://www.ncbi.nlm.nih.gov/omim\" target=_blank>Online Mendelian Inheritance in Man</A>.</LI></OL>Adapted with permission from: Orrell RW, Darras BT, Griggs RC. Facioscapulohumeral dystrophy, scapuloperoneal syndromes, and distal myopathies. In: Neuromuscular disorders in infancy, childhood, and adolescence: A clinician's approach, Jones HR, De Vivo DC, Darras BT (Eds), Butterworth Heinemann, Philadelphia 2003. p.701. Copyright © 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 51980 Version 14.0</div></div></div>"},"51981":{"type":"graphic_table","displayName":"Hydrocarbon containing products","title":"Household products containing hydrocarbon and covered by the poison prevention packaging standard of the consumer product safety commission","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Household products containing hydrocarbon and covered by the poison prevention packaging standard of the consumer product safety commission</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Cosmetics*</td></tr>\n\t\t\t\t\t\t<tr><td>Baby oils</td></tr>\n\t\t\t\t\t\t<tr><td>Hair oils</td></tr>\n\t\t\t\t\t\t<tr><td>Body oils</td></tr>\n\t\t\t\t\t\t<tr><td>Bath oils</td></tr>\n\t\t\t\t\t\t<tr><td>Massage oils</td></tr>\n\t\t\t\t\t\t<tr><td>Sunscreens</td></tr>\n\t\t\t\t\t\t<tr><td>Nail enamel dryers</td></tr>\n\t\t\t\t\t\t<tr><td>Makeup removers</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Automotive chemicals*</td></tr>\n\t\t\t\t\t\t<tr><td>Gasoline additives</td></tr>\n\t\t\t\t\t\t<tr><td>Fuel injection cleaners</td></tr>\n\t\t\t\t\t\t<tr><td>Carburetor cleaners</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Cleaning solvents*</td></tr>\n\t\t\t\t\t\t<tr><td>Wood oil cleaners</td></tr>\n\t\t\t\t\t\t<tr><td>Spot removers</td></tr>\n\t\t\t\t\t\t<tr><td>Metal cleaners</td></tr>\n\t\t\t\t\t\t<tr><td>General-use household oils</td></tr>\n\t\t\t\t\t\t<tr><td>Adhesive removers</td></tr>\n\t\t\t\t\t\t<tr><td>Gun-cleaning solvents containing kerosene</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Other*</td></tr>\n\t\t\t\t\t\t<tr><td>Water repellents containing mineral spirits used for decks, shoes, and sports equipment</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\n\n\n    </tr>\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* CPSC requires child-resistant packaging for low viscosity products that contain &#8805;10 percent hydrocarbon by weight</div><div class=\"graphic_reference\">Adapted from Barone, S. Consumer Product Safety Review. 2002; 6:3. (www.cpsc.gov/cpscpub/pubs/cpsr_nws23.pdf).</div><div id=\"graphicVersion\">Graphic 51981 Version 1.0</div></div></div>"},"51982":{"type":"graphic_table","displayName":"ISHLT cardiac biopsy grades","title":"ISHLT standardized cardiac biopsy grading: Acute cellular rejection*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ISHLT standardized cardiac biopsy grading: Acute cellular rejection*</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">2004</td> </tr> <tr> <td> <p>Grade 0</p> R<sup>&#182;</sup></td> <td>No rejection</td> </tr> <tr> <td> <p>Grade 1</p> R, mild</td> <td>Interstitial and/or perivascular infiltrate with up to 1 focus of myocyte damage</td> </tr> <tr> <td> <p>Grade 2</p> R, moderate</td> <td>Two or more foci of infiltrate with associated myocyte damage</td> </tr> <tr> <td> <p>Grade 3</p> R, severe</td> <td>Diffuse infiltrate with multifocal myocyte damage &#177; edema, &#177; hemorrhage &#177; vasculitis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">1990</td> </tr> <tr> <td>Grade 0</td> <td>No rejection</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Grade 1, mild</td> </tr> <tr> <td class=\"sublist1\">A - Focal</td> <td class=\"sublist_other\">Focal perivascular and/or interstitial infiltrate without myocyte damage</td> </tr> <tr> <td class=\"sublist1\">B - Diffuse</td> <td class=\"sublist_other\">Diffuse infiltrate without myocyte damage</td> </tr> <tr> <td>Grade 2 moderate (focal)</td> <td>One focus of infiltrate with associated myocyte damage</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Grade 3, moderate</td> </tr> <tr> <td class=\"sublist1\">A - Focal</td> <td class=\"sublist_other\">Multifocal infiltrate with myocyte damage</td> </tr> <tr> <td class=\"sublist1\">B - Diffuse</td> <td class=\"sublist_other\">Diffuse infiltrate with myocyte damage</td> </tr> <tr> <td>Grade 4, severe</td> <td>Diffuse, polymorphous infiltrate with extensive myocyte damage &#177; edema, &#177; hemorrhage + vasculitis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The presence or absence of acute antibody-mediated rejection (AMR) may be recorded as AMR 0 or AMR 1, as required.<br />&para; Where \"R\" denotes revised grade to avoid confusion with 1990 scheme.</div><div class=\"graphic_reference\">Reproduced with permission from: Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standard of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24:1710. Copyright &copy;2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 51982 Version 4.0</div></div></div>"},"51984":{"type":"graphic_diagnosticimage","displayName":"Postop CBD stricture","title":"Common hepatic duct stricture after cholecystectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Common hepatic duct stricture after cholecystectomy</div><div class=\"cntnt\"><img style=\"width:227px; height:450px;\" src=\"images/GAST/51984_Postop_CBD_stricture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography&nbsp;reveals a 2 cm long, pinhole, postsurgical common hepatic duct stricture (arrow) presenting at two months post laparoscopic cholecystectomy. The patient was treated by stenting.</div><div class=\"graphic_reference\">Courtesy of Michael J Bourke, MBBS, FRACP.</div><div id=\"graphicVersion\">Graphic 51984 Version 5.0</div></div></div>"},"51986":{"type":"graphic_picture","displayName":"S pneumoniae gram stains","title":"<EM>Streptococcus pneumoniae</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Streptococcus pneumoniae</EM></div><div class=\"cntnt\"><img style=\"width:378px; height:518px;\" src=\"images/ID/51986_S_pneumoniae_gram_stains.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Gram stain of <EM>Streptococcus pneumoniae</EM> in sputum. <br />(B) Gram-positive <EM>Streptococcus pneumoniae</EM> in a Gram-stained smear of a blood culture. Note the pairs of cocci (known as diplococci).</div><div class=\"graphic_reference\">(A) Reproduced with permission from: McClatchey KD M.D., D.D.S. Clinical Laboratory Medicine, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins.<br />(B) Reproduced with permission from: Koneman's Color Atlas and Textbook of Diagnostic Microbiology, 6th ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 51986 Version 4.0</div></div></div>"},"51988":{"type":"graphic_figure","displayName":"Risk factors CV dis transplant","title":"Schematic depiction of risk factors for atherosclerosis in transplant recipients","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Schematic depiction of risk factors for atherosclerosis in transplant recipients</div><div class=\"cntnt\"><img style=\"width:529px; height:359px;\" src=\"images/NEPH/51988_Risk_factors_CV_dis_transpl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The risk factors for cardiovascular disease found in the transplant recipient include hyperlipidemia, hypertension, diabetes mellitus, hyperhomocystenemia, uremia, and others (shaded boxes). Many of these factors are exacerbated by the immunosuppressive drugs (dashed boxes) in current clinical use to prevent rejection.</div><div id=\"graphicVersion\">Graphic 51988 Version 3.0</div></div></div>"},"51990":{"type":"graphic_figure","displayName":"Bones of the hand and wrist","title":"Bones of the hand and wrist","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Bones of the hand and wrist</div><div class=\"cntnt\"><img style=\"width:548px; height:598px;\" src=\"images/EM/51990_Wrist_hand_bones.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palmar view of the wrist and hand bones.</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. Copyright &copy; 2008 Wolters Kluwer Health.</div><div id=\"graphicVersion\">Graphic 51990 Version 3.0</div></div></div>"},"51991":{"type":"graphic_picture","displayName":"Full thickness diabetic foot ulcer","title":"Full thickness diabetic foot ulcer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Full thickness diabetic foot ulcer</div><div class=\"cntnt\"><img style=\"width:377px; height:211px;\" src=\"images/ENDO/51991_Wagner_2_foot_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Foot from a diabetic patient with a penetrating neuropathic ulcer that is not associated with abscess formation or bone involvement.<br />The toes have begun to claw (ie, extension deformity at the metatarsal phalangeal joint and flexion deformity at the proximal interphalangeal joint) because the pull of the extensor digitorum longus, an extrinsic muscle in the anterior compartment of the leg, overpowers the neuropathy-induced weakness of the intrinsic foot muscles. The proximal phalanges will eventually sublux, or even dislocate, dorsally. As the deformities progress, the metatarsal fat pad will migrate distally and the toes will lose the ability to effectively plantarflex and offload the metatarsal heads. The combined effect increases pressure under the metatarsal heads, predisposing to ulcer formation.</div><div class=\"graphic_reference\">Courtesy of David McCulloch, MD.</div><div id=\"graphicVersion\">Graphic 51991 Version 4.0</div></div></div>"},"51992":{"type":"graphic_figure","displayName":"Abciximab in coronary artery stenting","title":"Abciximab improves the outcome with coronary artery stenting","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abciximab improves the outcome with coronary artery stenting</div><div class=\"cntnt\"><img style=\"width:393px; height:484px;\" src=\"images/CARD/51992_Abciximab_in_stenting.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data from the EPISTENT trial of 2399 patients undergoing emergent or elective angioplasty. Top panel: The 30-day incidence of the primary endpoint (death, MI, or need for urgent revascularization) was significantly lower among patients receiving a stent with abciximab compared to those undergoing angioplasty with abciximab therapy or stenting alone (5.3, 6.9, and 10.8 percent, respectively). Bottom panel: The benefit from abciximab primarily reflected a reduced incidence of death and of large non-Q wave MI (shown in blue).</div><div class=\"graphic_reference\">Data from The EPISTENT Investigators. Lancet 1998; 352:87.</div><div id=\"graphicVersion\">Graphic 51992 Version 3.0</div></div></div>"},"51993":{"type":"graphic_picture","displayName":"Infectious colitis Endosc","title":"Infectious colitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infectious colitis</div><div class=\"cntnt\"><img style=\"width:368px; height:183px;\" src=\"images/GAST/51993_Infectious_colitis_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy of infectious colitis can look identical to either Crohn's disease or ulcerative colitis.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 51993 Version 1.0</div></div></div>"},"51994":{"type":"graphic_figure","displayName":"Division of round ligament","title":"Opening the parametrium during a radical hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Opening the parametrium during a radical hysterectomy</div><div class=\"cntnt\"><img style=\"width:425px; height:406px;\" src=\"images/OBGYN/51994_Division_of_round_ligament.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The uterus is placed under tension and the round ligament divided as far laterally as possible. The pelvic peritoneum is then incised lateral to the external iliac artery and vein, and the incision carried cephalad to the corresponding paracolic gutter.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 51994 Version 2.0</div></div></div>"},"51996":{"type":"graphic_figure","displayName":"Rate change AV area progress AS","title":"Rate of change of aortic valve area during ejection predicts progression of aortic stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rate of change of aortic valve area during ejection predicts progression of aortic stenosis</div><div class=\"cntnt\"><img style=\"width:347px; height:328px;\" src=\"images/CARD/51996_Rate_change_AV_area_progres.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The rate of change in aortic valve area (AVA) is established as the ratio of the AVA measured at mid-acceleration and mid-deceleration to the AVA at peak velocity; an individual with a slower rate of change in AVA will have a larger ratio. Among 84 patients with asymptomatic aortic stenosis and an AVA ≥0.9 cm<SUP>2</SUP>, rapid progression of aortic stenosis (≥0.2 cm<SUP>2</SUP>/year) was associated with an AVA ratio ≥1.25 (p = 0,007).</div><div class=\"graphic_reference\">Data from Lester SJ, McElhinney DB, Miller JP, et al. Circulation 2000; 101:1947.</div><div id=\"graphicVersion\">Graphic 51996 Version 2.0</div></div></div>"},"51998":{"type":"graphic_picture","displayName":"Amelanotic melanoma","title":"Amelanotic melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amelanotic melanoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/51998_Amelanotic_melanoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Amelanotic melanoma presenting as a red, nonspecific lesion with slightly elevated borders.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51998 Version 4.0</div></div></div>"},"51999":{"type":"graphic_picture","displayName":"Warfarin-induced skin necrosis on thighs","title":"Warfarin-induced skin necrosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Warfarin-induced skin necrosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/51999_Warfarin_skin_necr_thighs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sharply demarcated, purpuric lesions are present on the thighs.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 51999 Version 4.0</div></div></div>"}};